# EDGAR Filing Document

**Accession Number:** 0002034588
**File Stem:** 0001213900-25-055754
**Filing Date:** 2025-6
**Character Count:** 867771
**Document Hash:** 15d521935b279bf2fe681e3d4f6c4038
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-055754.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001213900-25-055754

**CONFORMED SUBMISSION TYPE**: S-1

**PUBLIC DOCUMENT COUNT**: 20

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neuro Spectrum Insights, Inc.
- **CENTRAL INDEX KEY:** 0002034588
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 831708919
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288157
- **FILM NUMBER:** 251058815

**BUSINESS ADDRESS:**
- **STREET 1:** 376 MAIN STREET
- **STREET 2:** STE. 100
- **CITY:** BEDMINSTER
- **STATE:** NJ
- **ZIP:** 07921
- **BUSINESS PHONE:** 908-304-4858

**MAIL ADDRESS:**
- **STREET 1:** 376 MAIN STREET
- **STREET 2:** STE. 100
- **CITY:** BEDMINSTER
- **STATE:** NJ
- **ZIP:** 07921

#### As filed with the Securities and Exchange Commission on June 18 , 2025.
**No. 333-** 

#### UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549

#### ______________________________

#### FORM S-1 <br> REGISTRATION STATEMENT<br> UNDER <br>THE SECURITIES ACT OF 1933

#### ______________________________

#### NEUROSPECTRUM INSIGHTS, INC.<br> (Exact name of registrant as specified in its charter)

#### ______________________________

---

| | | |
|:---|:---|:---|
|  **Delaware** | **[3841]** | **83-1708919** |
|  (State or other jurisdiction of <br>incorporation or organization) | (Primary Standard Industrial <br>Classification Code Number) | (I.R.S. Employer <br>Identification No.) |

---

#### NeuroSpectrum Insights, Inc. <br> 367 Main Street, Ste. 105<br>Bedminster, NJ 07921<br> 908-304-4858
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

#### ______________________________
**Andrew Stewart<br>Chief Executive Officer<br>NeuroSpectrum Insights, Inc.<br>367 Main Street, Ste. 105<br>Bedminster, NJ 07921<br>908-304-4858<br>(Name, address, including zip code, and telephone number, including area code, of agent for service)**

#### Copies to:

---

| | |
|:---|:---|
|  **Joseph M. Lucosky, Esq.<br>Lawrence Metelitsa, Esq.<br>Lucosky Brookman LLP<br>101 Wood Avenue South, 5**<sup>th</sup> **Floor<br>Iselin, New Jersey 08830<br>Telephone: (732) 395-4400<br>Fax: (732) 395-4401** | **Fang Liu Esq.<br>VCL Law LLP<br>1945 Old Gallows Road, Suite 260<br>Vienna, VA 22182<br>Telephone: +1**-703-919-7285 |

---

#### ______________________________
**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

<u> Large accelerated filer </u>   <u> ☐ </u>   <u> Accelerated filer </u>   <u> ☐ </u> <br> <u> Non-accelerated filer </u>   <u> ☒ </u>   <u> Smaller reporting company </u>   <u> ☒ </u> <br>         <u> Emerging growth company </u>   <u> ☒ </u>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said section 8(a), may determine.**

------

[**Table of Contents**](#TOC001)

#### EXPLANATORY NOTE
This Registration Statement contains two prospectuses as set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Public Offering Prospectus***: A prospectus to be used for the initial public offering by the Company of [•] shares of its common stock through the underwriters named on the cover page, which we refer to as the "Public Offering Prospectus".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Resale Prospectus:*** A prospectus to be used for the potential resale by selling stockholders of up to [•] shares of common stock of the Company, which we refer to as the "Resale Prospectus".

The Resale Prospectus is substantively identical to the Public Offering Prospectus, except for the following principal points:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• they contain different outside and inside front covers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• they contain different Offering sections in the Prospectus Summary section;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• they contain different Use of Proceeds sections;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Capitalization and Dilution sections are deleted from the Resale Prospectus;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a Selling Stockholders section is included in the Resale Prospectus;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Underwriting section from the Public Offering Prospectus is deleted from the Resale Prospectus and a Plan of Distribution is inserted in its place; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Legal Matters section in the Resale Prospectus deletes the reference to counsel for the underwriters.

We have included in this Registration Statement, after the financial statements, a set of alternate pages after the back cover page of the Public Offering Prospectus, which we refer to as the "Alternate Pages", to reflect the foregoing differences in the Resale Prospectus as compared to the Public Offering Prospectus. The Public Offering Prospectus will exclude the Alternate Pages and will be used for the public offering by the registrant. The Resale Prospectus will be substantively identical to the Public Offering Prospectus except for the addition or substitution of the Alternate Pages and will be used for the resale offering by the selling stockholders.

------

[**Table of Contents**](#TOC001)

**The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.**

#### SUBJECT TO COMPLETION, DATED [\*]

#### Shares of Common Stock
This is the initial public offering of shares of common stock par value $0.00001 per share (the "Common Stock") of NeuroSpectrum Insights, Inc. Prior to this offering there has been no public market for our Common Stock. We currently expect the initial public offering price to be between $[•] and $[•] per share.

We intend to apply to list our Common Stock on the New York Stock Exchange, or NYSE, under the symbol "[\*]". No assurance can be given that our application will be approved. If our Common Stock is not approved for listing on the NYSE, we will not consummate this offering.

This Prospectus relates to two distinct offerings: (1) an initial public offering of [•] shares of Common Stock by the Company through underwriters and (2) a potential resale offering of up to [•] shares of Common Stock by selling stockholders. The resale offering will not commence until after the completion of the initial public offering and is expected to remain open for a duration of [•]. We intend to apply to list our Common Stock on the NYSE in connection with this offering.

We are an "emerging growth company" as that term is defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, have elected to take advantage of certain reduced public company reporting requirements for this prospectus and future filings.

**Investing in our Common Stock involves a high degree of risk. Please read "Risk Factors" beginning on page 13 of this prospectus to read about factors you should consider before buying our Common Stock.**

---

| | | |
|:---|:---|:---|
|  | **Per Share** | **Total** |
|  Public offering price | $| $|
|  Underwriting discounts and commissions<sup>(1)</sup> | $| $|
|  Proceeds to us, before expenses | $| $|

---

____________

<sup>(1)</sup> We have also agreed to reimburse the underwriters for certain of their expenses and to issue to [•], underwriter warrants to purchase a number of shares of Common Stock equal to 8% of the number of shares included in this offering at an exercise price equal to 110% of the initial public offering price of the shares. See "Underwriting" beginning on page 82 of this prospectus for more information about these arrangements and other items of value payable to the underwriters.

Additionally, we have granted to the representative of the underwriters an option to purchase up to 15% additional shares of Common Stock at a purchase price of $[•] per share less the underwriting discounts and commissions, for [•] days after the date of this prospectus to cover over-allotments, if any.

**Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

Delivery of the shares is expected to be made on or about, [•], 2025.

*[underwriter]*

#### NETWORK 1 FINANCIAL SECURITIES, Inc.

#### The date of this prospectus is, [•] , 2025

------

[**Table of Contents**](#TOC001)

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
|  [PROSPECTUS SUMMARY](#T99101) | 1 |
|  [RISK FACTORS](#T99102) | 13 |
|  [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY AND MARKET DATA](#T99103) | 42 |
|  [USE OF PROCEEDS](#T99104) | 44 |
|  [DIVIDEND POLICY](#T99105) | 45 |
|  [CAPITALIZATION](#T99106) | 46 |
|  [DILUTION](#T99107) | 47 |
|  [BUSINESS](#T99108) | 55 |
|  [MANAGEMENT](#T99109) | 66 |
|  [EXECUTIVE AND DIRECTOR COMPENSATION](#T99110) | 71 |
|  [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#T99111) | 73 |
|  [CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS](#T99112) | 74 |
|  [DESCRIPTION OF CAPITAL STOCK](#T99113) | 76 |
|  [DESCRIPTION OF SECURITIES WE ARE OFFERING](#T99114) | 78 |
|  [SHARES ELIGIBLE FOR FUTURE SALE](#T99115) | 80 |
|  [UNDERWRITING](#T99116) | 82 |
|  [LEGAL MATTERS](#T99117) | 86 |
|  [EXPERTS](#T99118) | 86 |
|  [WHERE YOU CAN FIND MORE INFORMATION](#T99119) | 86 |
|  [INDEX TO FINANCIAL STATEMENTS](#T99120) | F-1 |

---

We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Shares offered hereby, but only under the circumstances and in the jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our Shares, Common Stock or Warrants. Our business, financial condition, results of operations and prospects may have changed since that date.

For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus or any applicable free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus and any applicable free writing prospectus must inform themselves, and observe any restrictions relating to, the offering of the Shares and the distribution of this prospectus outside the United States.

**Through and including, [\*] 2025 (25 days after the date of this prospectus), all dealers that buy, sell or trade our Common Stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.**

This prospectus includes trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the<sup>®</sup> and™ symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

i

[**Table of Contents**](#TOC001)

#### PROSPECTUS SUMMARY
*This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider before investing in our Common Stock. This summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read this entire prospectus carefully, including the information set forth in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our condensed financial statements and related notes thereto included elsewhere in this prospectus, before making an investment decision. Unless the context requires otherwise, references in this prospectus to "we," "us," "our," "our company," "NSI," or similar terminology refer to NeuroSpectrum Insights, Inc.*

#### Overview
We are a medical device company preparing to commercialize breakthrough computerized analysis technology that enhances clinicians' capabilities in diagnosing neurological and neurodevelopmental disorders. NSI's first product, GyriCalc is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated analysis of MRI images.

NSI's initial market focus will be the United States and Canada. In the U.S., we filed for marketing clearance with the FDA in early March 2025 and anticipate receiving approval during 2025. In Canada, where no regulatory approval is required, we recognize the political nature of the healthcare industry and will prioritize strategic discussions with influential government departments and non-profit organizations to ensure a successful market entry.

Currently, NSI does not generate any revenue. Our primary focus is on successfully launching GyriCalc for autism and establishing a foothold in the U.S. and Canadian markets.

While GyriCalc currently focuses on autism, NSI envisions expanding its applications to support clinicians in diagnosing other conditions, such as dyslexia, ADHD, and schizophrenia. Plans to develop GyriCalc for these additional markets will be considered in Q4 2025 after the successful launch of the product for autism. This phased approach underscores our commitment to delivering high-impact solutions that address critical clinical needs.

The Company was incorporated in 2016 and in 2018 entered into an agreement with the University of Louisville, Kentucky, which awarded the Company an exclusive worldwide license to the technology underlying the Company's product. Thereafter, activities were primarily focused on raising capital and developing the professional resources required for future commercialization. Software engineering efforts began in 2022 and accelerated throughout 2023 and 2024, accompanied by clinical trials in preparation for submission to the FDA. During 2023, 2024 and the first quarter in 2025 we incurred net losses of approximately $788,000, $2,649,000 and $397,000, respectively, due to personnel and professional services expenses and product development costs.

#### Our Product
GyriCalc<sup>TM</sup> is a patented, proprietary computerized algorithm which measures predetermined human brain regions for specific surface characteristics. Images of these brain regions are captured by generally available structural magnetic resonance imagers ("MRI"). The MRI scan typically takes 15 to 20 minutes.

When GyriCalc<sup>TM</sup> is applied to the MRI scan, it conducts an analysis and generates a detailed report, in minutes, of the brain surface characteristics measured and the degree these characteristics correlate to the reference data set for typical (normal) brains. The report is provided directly to the ordering clinician.

The specific regions of the cerebral cortex and their surface characteristics (known as "gyri" and "sulci") correlate to autism as determined through years of research study within the University of Louisville Bioimaging Laboratory, Bioengineering Department in conjunction with the Department of Psychiatry and Behavioral Science and the Norton Children's Autism Center. (sources include: "Reduced Gyral Window and Corpus Callosum Size in Autism: Possible Macroscopic Correlates of a Minicolumnopathy", Casanova, et al, J Autism Dev Discord [January 2009] with corresponding references; and "Spherical Harmonic Analysis of Cortical Complexity in Autism and Dyslexia", Williams, et al, Transl Neurosci, [March 2012] with corresponding references) The algorithm achieved an autism identification rate of 94%<sup>1</sup>. (primary source: "Towards Personalized Autism Diagnosis: Promising Results", ElNakieb, et al, International Conference on Pattern Recognition, [August 2018] with corresponding references)

[**Table of Contents**](#TOC001)

NeuroSpectrum Insights has an exclusive commercialization license with the University of Louisville for this technological advancement.

#### Our Strategy
NeuroSpectrum Insights will market GyriCalc<sup>TM</sup> to clinicians at a predetermined list price per patient MRI scan report. The MRI scan will be ordered by the practitioner and paid for by the patient which in most instances will be covered by medical insurance coverage.

Our business plan foresees the introduction of GyriCalc to the market during the second half of 2025. Revenues are determined by the number of tests ordered by physicians and other clients for evaluation of patients' MRI scans for the presence of certain neurological markers. Our projections consider current data for the prevalence of autism and our assessment of the attractiveness of the introduction of GyriCalc's high degree of objectivity into current diagnostic processes.

The average price for a brain MRI in the United States is ~$1,000<sup>2</sup>. At a projected list price of $1,500 per patient we estimate a 5-Year Revenue Projection *(~35% of annual projected market at 5 years).*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2026** | **2027** | **2028** | **2029** |
|  Number of GyriCalc Test | 415 | 4218 | 12820 | 29815 | 35200 |
|  Total Revenue | 623000 | $6326000 | $19229500 | $44721000 | $52850000 |
|  **Operating Income (Loss)** | $**(1730000)** | $**(1753800)** | $**12369000** | $**34480600** | $**40750000** |
|  **Net Income (Loss)** | $**(1857000)** | $**(1753800)** | $**10390000** | $**25860400** | $**29750000** |

---

*Marketing & Sales*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Marketing Strategy

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Targeted, digital messaging tools (including social media accounts) for calendarized promotional campaigning aligned with professional clinical meetings and advocacy groups for autism events

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinician targeted for sales/ordering *("push")*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Parents/caregivers targeted for awareness/stimulation *("pull")*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Best of breed, branding, key opinion leader ("KOL") endorsements, connecting with subject matter "influencers", and internet presence through new website and customer information support portal, with select use of video messaging (ad hoc and professional)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• KOL support for select, high profile events and annual professional and advocacy meeting presentations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Surveilling the market for success stories and merchandizing same through news outlets (internet and traditional)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sales Strategy

____________

1 *Shape Analysis of the Human Brain by Matthew Joseph Nitzken B.S., University of Louisville, 2009; M. Eng., University of Louisville, 2010.*

*The UCLA database was collected from individuals between the ages of 8 to 17 years of age, with an average age of 13 years. Subjects were evaluated using the WISC, ADOS, and by medical professionals to determine a diagnosis. All scans were acquired using the MP RAGE, three*-dimensional*, T1*-weighted*, gradient*-echo *sequence. The results for the UCLA database showed an overall accuracy of 94.36%. Assuming negative for diagnosing autism and positive for determining neurotypical, the test sensitivity (TPR) is 0.900, the specificity (SPC) is 0.976, the positive predictive value (PPV) is 0.964, and the negative predictive value (NPV) is 0.930.* 

*The method was tested on a large number of subjects spread across multi*-center *databases. The testing confirmed that the software was capable of accurately making a diagnosis of autism in a wide range of individuals. Results for the testing data sets achieved accuracies of 88.89% for the KKI database, 94.36% for the UCLA database, 88.18% for the UM database, 95.65% for the Conturo database, and 97.29% for the IBIS database.*

2 *New Health Choice, Inc. https://www.newchoicehealth.com/procedures/brain*-mri

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An individual with clinical autism diagnosis and intervention experience will lead the sales effort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Directly contact, via email, phone and social media, targeted clinicians trained to diagnose autism to deliver and reinforce product and services information

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Participate in industry specific events presenting appropriate materials and messaging based on the individual events and opportunities

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Coordinate directly with the NSI Clinical Advisory Committee to expand its membership and extend influence into members' professional networks

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sales promotion programs to stimulate repeat ordering and telling of success stories

#### Our Market Opportunity
Developmental pediatricians, pediatric neurologists, child psychiatrists, and neuropsychologists make up the constellation of clinicians trained to diagnose autism. These are NSI's primary target customers. The exact numbers for these clinicians are uncertain. Data on the number of clinicians that represent target customers can be found on the websites of The American Board of Pediatrics, The American Board of Professional Psychology and the American Psychological Association.

According to the American Psychiatric Association (APA) the diagnosis of Autism Spectrum Disorder (ASD) is arrived at by a clinician following the guidelines within the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR); Section: Autism Spectrum Disorder-Diagnostic Criteria — 299.0 (F84.0). Clinicians following these guidelines arrive at what is referred to as a "clinical diagnosis" of this particular neurodevelopment disorder, ASD. Medical insurance carriers require, in most cases, such a diagnostic finding in order to pay for the therapeutic, interventional services needed to support a person with autism.

The clinicians who are trained and qualified to carry out this clinical evaluation include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. First line practitioners:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Developmental-Behavioral Pediatrician (MD)s

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There are ~ 700 of these physicians in the United States according to the American Board of Pediatrics

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Pediatric Neurologists (MDs)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There are between 2,000 and 2,500 of these physicians in the United States according to the Child Neurology Society (CNS)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Pediatric Neuropsychologists (PhDs)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Estimates of the number of specialists vary widely.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Those with the board certification by the American Board of Professional Psychology(ABPP) in clinical neuropsychology represent a notable subsegment recognized for their expertise in diagnostic development disorders such as autism.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• This certification covers all age ranges and includes ~1,400 practitioners

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Secondary practitioners

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Pediatricians (MDs)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There are ~ 35,000 of these physicians in the United States according to the U.S. Bureau of Labor Statistics (BLS)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the American Board of Pediatrics (ABP) has collected survey data from over 42,000 physicians certified in general pediatrics and pediatric subspecialties between 2019 and 2023.

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• General pediatricians are considered the first line of potential professional interaction with a child suspected of having autism. The American Academy of Pediatrics (AAP)recommends that all children be screened for ASD at 18 and 24 months of age using standardized, validated tools.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If a child shows signs of developmental delays or is identified as at increased risk for ASD through screening or surveillance, the AAP advises that the child be referred promptly for a comprehensive diagnostic evaluation and early intervention services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Such referrals typically include: developmental pediatricians, pediatric neurologists, and pediatric neuropsychologists. In some instances, a very experienced pediatrician can make the diagnosis, particularly when the symptoms observed are acute and obvious.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Pediatric Psychiatrists (MDs)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There are ~11,000 of these clinicians in the United States according to the American Academy of Child and Adolescent Psychiatry (AACAP)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Due to the importance of verbal skills, developmental maturity, and recurring interactions over time in the practice of psychiatry, psychiatrists are not viewed by most autism experts as the first line for diagnosing toddlers

This comparatively small number of practitioners, combined with the subjective observational nature of assessment (current standard of care), is another contributing factor to long lead times for diagnosis. Additionally, these practitioners assess a wide range of neurological and neurodevelopmental disorders. Yet, it is these clinicians that are the stage gate for getting insurance coverage needed to support the cost of autism interventional therapies.

The Center for Disease Control and Prevention ("CDC") estimates that one in 36 children, by the age of eight, will be diagnosed with autism. According to the National Center for Health Statistics, between 2020 and 2022, United States annual live births have plateaued at 3.7 million. At a 1/36 rate, the projected number of new cases of autism over the forecast years is approximately 100,000 per year. While the projected number of cases is relatively small compared to the estimated number of diagnosing clinicians, we believe that the crux of the problem is screening 3.7 million candidates each year. As reported by Okoye, et al in "Early Diagnosis of ASD: Review and Analysis of the Risks and Benefits", Cureous (August 9, 2023), "The National Center on Birth Defects and Developmental Disabilities (NCBDD) recommends that children undergo screenings at nine months, 18 months, and 24 or 30 months. The American Association of Pediatrics (AAP) proposes that autism screening be included in standard 18- and 24-month checkups". Additionally, "The CDC's developmental milestones are guidelines for parents and healthcare providers to help track a child's development from birth to five years old".

Additionally, screening isn't diagnosing. It is an essential first step that falls to general pediatricians, parents, caregivers all with highly variable experiences and skills. This too is a significant contributing factor in delayed diagnosis. In a future envisioned market where an objective GyriCalc<sup>TM</sup> "test" would be as common as a blood test, greater screening compliance could be achieved together with greater detection precision.

#### Our Competitive Strengths
For autism, there is no currently available, objective, physiological "test" that can assist the clinician at arriving at a more definitive conclusion regarding autism. We believe that GyriCalc<sup>TM</sup> may be found by the FDA to be the first of its kind objective test bringing to the industry detection precision long sought after.

There are a number of testing protocols currently used involving individual practitioner observational studies. The "gold standard" is considered to be the Autism Diagnostic Observation Schedule™, Second Edition (ADOS<sup>®</sup>-2). Administered by a trained, experienced clinician, this assessment typically takes several hours. However, according to the Child Neurology Foundation, the number of practitioners is at least 20% below national leads, resulting in potentially long lead times for appointments.

[**Table of Contents**](#TOC001)

While the ADOS<sup>®</sup>-2 is highly regarded by researchers because of its sensitivity and specificity, it is not regarded as an ideal instrument. In a publication from the Child Mind Institute, Susan Epstein, PhD and Catherine Lord, PhD address ADOS<sup>®</sup>-2 limitations including: "it can miss individuals with subtle autism symptoms, particularly in high-functioning individuals or females, potentially leading to false negatives; it can also produce false positives in individuals with other mental health conditions, and relies heavily on a single snapshot of behavior during the assessment, not capturing potential developmental changes over time, requiring a comprehensive evaluation alongside other assessments to reach an accurate diagnosis. ADOS<sup>®</sup>-2 results are combined with interviews with parents, and at times other family members and teachers, and medical history (subject, siblings, and parents) to arrive at a finding that may be definitive in certain "clear cut" cases or inconclusive or too early to tell in other cases. The latter leads to increased parental anxiety, "worried waiting", and further extended lead times to a diagnosis and therapeutic intervention. Management conducted a formal opinion research study with 22 pediatric neurologists in 2019. Combined with input from the clinicians making up the company's professional advisor board and on-going informal market sensing discussions with various neuropsychologists, pediatricians, developmental pediatricians, and neurodivergent behavioral therapists, management has become well aware that ADOS-2 is a reflection of the DSM-5TR's diagnostic criteria on the clinical definition of autism spectrum disorder. And as such the ADOS-2 assessment is considered to be the current definitive means for arriving at a "clinical diagnosis" in keeping with the DSM-5 criteria. Additionally, as the DSM-5 defines Autism as a behavioral diagnosis, "gray area" cases (in words of practitioners) are those that don't exhibit clear, obvious, demonstrative behaviors that align with the criteria. And, as such, these cases require further follow up over time to either finally diagnosis autism or perhaps another neurodivergent condition.

It is management's opinion that parental worrying / "worried waiting" is not based on a specific measurement criteria but is instead qualitative, experiential reporting by clinicians who consistently report that parents generally seek the following: a diagnosis as soon as possible, an explanation of what has caused the condition, why can't they get clear answers, why it takes so long to get an appointment with a specialist, what they can do while waiting to either see a specialist or wait for further symptoms or behaviors to emerge, how to avoid the stigma attached to an autism diagnosis, and more. The responses generally available to such questions leave many parents frustrated and somewhat on their own. This can be even more frustrating for parents who have a child already diagnosed with autism. Whether they immediately recognize it or not, parents need early support and reassurance to love and care for their child. Parents who received an early diagnosis of their child's ASD were reported by Grzadzinski et al, "pre-symptomatic intervention for autism spectrum disorder (ASD): defining a research agenda" Journal of Neurodevelopmental Disorders. 2021, to have lower levels of stress and anxiety. The CDC regarding Autism Spectrum Disorder that for families, "daily life is not easy".

The advocacy organization "Autism Speaks", is a preeminent source parents often turn to find answers. The concerns and needs of parents and the support persons with autism require are the propellants that have made Autism Speaks the leading organization it has become. Additionally, parents and other advocates concerns have fueled increasingly visible and expanded federal legislative actions and laws to address the needs of autistic individuals and families.

#### Intellectual Property
NeuroSpectrum Insights, Inc. has an exclusive worldwide license to commercialize the technology, patents, copyrights, and intellectual property rights owned by the University of Louisville Research Foundation Inc. (the "Research Foundation"). The Company was granted an exclusive worldwide license pursuant to an "Exclusive Agreement" dated January 31, 2017 which is valid through the expiration date of the last granted patent which is scheduled to expire on July 29, 2035, unless terminated earlier by the parties pursuant to the terms of the license agreement. The agreement, among other, provides that the Company must: (i) pay royalties on income from the licensed products during the term of the agreement, (ii) pay a 30% fee on non-royalty income from sub-licensing, (iii) reimburse the Research Foundation certain expenses, which have been paid as of September 30, 2019, (iv) adhere to certain milestone criteria for the raising of capital and submission of the product for FDA clearance and (v) comply with ongoing reporting and disclosure requirements.

[**Table of Contents**](#TOC001)

#### Summary of Risk Factors
Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects that you should consider before making a decision to invest in our Common Stock. These risks are discussed more fully in "Risk Factors" beginning on page 13 of this prospectus. These risks include, but are not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Even if this offering is successful, we may need additional funding in order to grow our business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The commercial success of our technology and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, and patients.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations on any guidance we may provide.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including COVID-19, could adversely affect our business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The sizes of the markets for our diagnostic technologies and services and any future diagnostic tests and services may be smaller than we estimate and may decline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services, we could lose customers or market share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our diagnostic technologies and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and negatively impact our sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The timing of any new technology product offerings is uncertain.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may depend on third party distributors for our sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risks Related to our Governmental Regulation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for in-development or future diagnostic tests could limit our ability, and that of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate revenue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We must comply with healthcare fraud and abuse laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The regulatory clearance or approval processes of regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable regulatory approvals or clearances, or if such approvals or clearances are significantly delayed, our business will be substantially harmed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA regulation of our industry generally or our tests specifically could be disruptive to our business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Any product for which we obtain regulatory clearance or approval will be subject to extensive ongoing regulatory requirements, and we may be subject to penalties if we or our partners fail to comply with regulatory requirements or if we experience unanticipated problems with our products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For any of our products that are approved or cleared by the FDA, we will be required to report to the FDA certain information about adverse medical events or malfunctions, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Obtaining and maintaining regulatory authorization of our products in one jurisdiction does not mean that we will be successful in obtaining regulatory authorization of our products in other jurisdictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinical trials may be necessary to support future product submissions to the FDA. These clinical trials are expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any in-development, modified or new diagnostic tests and will adversely affect our business, operating results and prospects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our diagnostic tests and services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The data that we collect may be vulnerable to breach, loss or misuse, and our handling of such data may be impacted by changes in data privacy and protection laws and regulations, which could increase operational costs or result in regulatory penalties, litigation, or reputational harm.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Failure to comply with the HIPAA Privacy, Security and Breach Notification Regulations, as such rules become applicable to our business, may increase our operational costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Information technology ("IT") failures and data security breaches, including as a result of cybersecurity attacks, could negatively impact our results of operations and financial condition, subject us to increased operating costs, and expose us to litigation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risks Related to Our Intellectual Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risks Related to this Offering and Ownership of Our Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There has been no prior public market for our Common Stock and an active trading market may not develop.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect that the price of our Common Stock will fluctuate substantially, and you may not be able to sell the shares you purchase in this offering at or above the offering price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The public price of our common stock may be volatile, and could, following a sale, decline significantly and rapidly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are an "emerging growth company" and a "smaller reporting company," and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our Common Stock less attractive to investors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If you purchase our Shares in this offering, you will incur immediate and substantial dilution in the book value of your shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management. Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

#### Corporate Information
We were incorporated in Delaware on January 20, 2016 under the name of Autism Diagnostic Technologies, Inc. The original Certificate of Incorporation was restated on January 31, 2024 to change the name of the Company to NeuroSpectrum Insights, Inc. Our principal executive offices are located at 376 Main Street, Ste. 105, Bedminster, NJ 07921, and our telephone number is (908) 304-4858. Our corporate website address is *https://neurospectruminsights.com/.* The information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

[**Table of Contents**](#TOC001)

#### THE OFFERING

---

| | |
|:---|:---|
|  Common Stock | shares at $ per share |
|  Over-allotment option to purchase additional shares | We have granted the representative of the underwriters an option for a period of [•] days from the date of this prospectus to purchase an additional 15% of shares of our Common Stock at a price of $[•] per share to cover over-allotments, if any. |
|  Common Stock to be outstanding before this <br>offering<sup>(1)</sup> | <br>10,974,238 shares. |
|  Common Stock to be outstanding after this offering<sup>(2)</sup> | shares. |
|  Representative's Warrants | We have agreed to issue to [•] warrants to purchase up to a total of shares of Common Stock and/or Warrants, (and up to total shares of Common Stock and/or warrants assuming the representative's over-allotment option is exercised in full), which is equal to 8% of the number of Shares included in this offering (the "Representative's Warrants"). We are registering hereby the issuance of the Representative's Warrants and the shares of Common Stock and/or Warrants (and the shares issuable upon exercise thereof) issuable upon exercise of the Representative's Warrants. The Representative's Warrants will be exercisable at any time, and from time to time, in whole or in part, during the five-year period commencing 180 days from the effective date of this offering at an exercise price equal to 110% of the public offering price of the Shares. Please see "Underwriting — Representative's Warrants" for a description of the Representative's Warrants. |
|  Use of proceeds | We estimate that we will receive net proceeds from this offering of approximately $[•] million (or $[•] million if the representative of the underwriters exercise its over-allotment option to purchase additional shares of Common Stock in full), based upon an assumed initial public offering price of $[•] per Share, which is the mid-point of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. |
|  Risk Factors | See "Risk Factors" on page 13 for a discussion of certain of factors to consider carefully before deciding to purchase any shares of our Shares. |

---

____________

(1) The number of shares of our Common Stock to be outstanding after this offering is based on shares of Common Stock outstanding as of June 18, 2025, and excludes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 850,000 shares of our Common Stock issuable upon the exercise of outstanding stock options under the Company's 2019 Stock Plan (the "2019 Plan").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2.150,000 shares of our Common Stock reserved for future issuance under the 2019 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [•] shares issuable upon the automatic conversion of all convertible notes and accrued interest thereon issued in the bridge financings (the "[•] Conversions").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Shares that may be issued upon the exercise of outstanding warrants.

[**Table of Contents**](#TOC001)

---

| | |
|:---|:---|
|  Proposed listing | We intend to apply to list our Common Stock on the NYSE in connection with this offering. If our Common Stock is not approved for listing on the NYSE, we will not consummate this offering. Our transfer agent is Vstock Transfer, LLC. |
|  Proposed NYSE | "[•]". |
|  Capital Market symbol  | We intend to apply to list our Common Stock on the New York Stock Exchange, or the NYSE, under the symbol "[\*]" |
|  Lock Up | We, our officers, directors and our existing beneficial owners of 5% or more of the outstanding shares of our Common Stock have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our Common Stock or securities convertible into Common Stock for a period of six (6) months after the date of this prospectus. See "Underwriting" section on page 82. |

---

Unless otherwise indicated, all information contained in this prospectus assumes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• no exercise by the representative of the underwriters of its over-allotment option to purchase up to additional shares of our Common Stock and/or Warrants;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• No exercise of warrants held by the investors in the bridge financings.

[**Table of Contents**](#TOC001)

#### SUMMARY FINANCIAL DATA
The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. The statements of operations data for the three months ended March 31, 2025 and March 31, 2024 (condensed and unaudited) are derived from the interim financial statements for the periods ended March 31, 2025 and March 31, 2024, and the statements of operations data for the years ended December 31, 2024 and December 31, 2023, and the balance sheet data as of December 31, 2024 and December 31, 2023 are derived from our audited financial statements included elsewhere in this prospectus.

The following summary financial information should be read in connection with, and is qualified by reference to, our financial statements and related notes thereto included elsewhere in this prospectus and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus. Our historical results are not necessarily indicative of results to be expected in any future period.

#### BALANCE SHEET DATA

---

| | | |
|:---|:---|:---|
|  | **December 31,<br>2024** | **December 31,<br>2023** |
|  **ASSETS** |  |  |
|  **CURRENT ASSETS** | $193502 | $325713 |
|  **DEFERRED OFFERING COSTS** | 220811 |  |
|  **INTANGIBLE ASSETS** | 18766 | 20472 |
| &nbsp;&nbsp;&nbsp; **TOTAL ASSETS** | 433079 | 346185 |
|  **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
|  **CURRENT LIABILITIES** | 1536656 | 1133382 |
|  **NON-CURRENT LIABILITIES** | 674558 | 311172 |
| &nbsp;&nbsp;&nbsp; **TOTAL LIABILITIES** | 2211214<br><sup>(1)</sup> | 1444554<br><sup>(2)</sup> |
|  **STOCKHOLDERS' DEFICIT** |  |  |
|  Preferred Stock, $0.00001 par value; 10,000,000 shares authorized, none <br>issued; |  |  |
|  Common stock, $.00001 par value, 90,000,000 shares authorized, 10,973,358 and 9,652,655 shares issued and outstanding | 110 | 96 |
| &nbsp;&nbsp;&nbsp; Additional paid-in-capital | 3528103 | 1401326 |
| &nbsp;&nbsp;&nbsp; Retained deficit | (5306348) | (2499791) |
| &nbsp;&nbsp;&nbsp; **TOTAL STOCKHOLDERS' DEFICIT** | (1778135) | (1098369) |
| &nbsp;&nbsp;&nbsp; **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | $433079 | $346185 |

---

____________

(1) *includes $270,667 compensation accrued for management and $1,066,084 notes convertible into equity issued pursuant to the Bridge Financing transaction (net of debt discount) (see Section Certain Relationships and Related Party Transactions).*

(2) *includes $855,250 compensation accrued for management and key advisors and $311,172 notes convertible into equity issued pursuant to the Bridge Financing transaction (net of debt discount) (see Section Certain Relationships and Related Party Transactions).*

[**Table of Contents**](#TOC001)

#### STATEMENT OF OPERATIONS DATA

---

| | | |
|:---|:---|:---|
|  | **December 31,<br>2024** | **December 31,<br>2023** |
|  **REVENUE** | $— | $— |
|  **COST OF SALES** |  |  |
|  **GROSS MARGIN** |  |  |
|  **OPERATING AND ADMINISTRATIVE EXPENSES** | 2322078 | 780772 |
|  **LOSS FROM OPERATIONS** | (2322078) | (780772) |
|  **TOTAL OTHER EXPENSES** | (327100) | (7233) |
|  **NET LOSS** | (2649178) | (788005) |
|  Implied dividends | 157379 |  |
|  Net loss attributable to common shareholders | (2806557) | (788005) |
|  Net loss per common share – Basic and Diluted | $(0.27) | $(0.08) |
|  Weighted average common shares – Basic and Diluted | 10561751 | 9445792 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months <br>ended <br>March 31, <br>2025** | **Year <br>ended<br>December 31, <br>2024** | **Year <br>ended<br>December 31, <br>2023** |
|  Personnel expenses | $69700 | $1256333 | $304160 |
|  Product development | $72260 | $487332 | $139152 |
|  Outside services and G&A | $196272 | $578413 | $337460 |
|  Loss from Operations | $(338232) | $(2322078) | $(780772) |
|  Net Loss | $(396748) | $(2649178) | $(788005) |

---

[**Table of Contents**](#TOC001)

#### RISK FACTORS
*Investing in our Common Stock involves a high degree of risk. You should consider and carefully read all of the risks and uncertainties described below, as well as other information included in this prospectus, including our condensed financial statements and related notes appearing at the end of this prospectus, before making an investment decision. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition and results of operations. In such case, the trading price of our Common Stock could decline, and you may lose all or part of your investment. This prospectus also contains forward*-looking *statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward*-looking *statements as a result of specific factors, including the risks and uncertainties described below.*

#### Risks Related to our Business and Industry

#### Even if this offering is successful, we may need additional funding in order to grow our business.
To date, we have financed our operations through private placements of our securities. We have devoted substantially all our financial resources and efforts to developing our technology products, workforce, and R&D capabilities. Our long-term growth and success are dependent upon our ability to generate cash from operating activities. There is no assurance that we will be able to generate sufficient cash from operations or access the capital we need to grow our business. Our inability to obtain additional capital could have a material adverse effect on our ability to fully implement our business plan as described herein and grow our business, to a greater extent than we can with our existing financial resources.

#### The commercial success of our technology and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, and patients.
Our commercial success depends, in part, on the acceptance of our diagnostic technologies and services as being safe and relatively simple for medical practitioners to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective. We cannot predict how quickly, if at all, payers, providers, clinics and patients will accept future diagnostic technologies and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over other available alternatives.

The degree of market acceptance of our product depends on a number of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the convenience and ease of use of our diagnostic technologies relative to the currently used on the market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effectiveness of our sales and marketing efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to provide incremental data that show the clinical benefits and cost effectiveness, and operational benefits, of our diagnostic technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the coverage and reimbursement acceptance of our products and services by insurance providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pricing pressure, including from group purchasing organizations ("GPO"), seeking to obtain discounts on our diagnostic technologies based on the collective bargaining power of the GPO members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• negative publicity regarding our or our competitors' diagnostic technologies resulting from defects or errors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the accuracy of our technology relative to that of our competitors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ability to obtain any requisite authorization from FDA prior to commercializing our technology; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• product requirements by other regulatory authorities;

[**Table of Contents**](#TOC001)

Additionally, even if our diagnostic technologies achieve widespread market acceptance, they may not maintain that market acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.

***Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations on any guidance we may provide.***

Our quarterly and annual revenue and operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business.

These fluctuations may occur due to a variety of factors, including, but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the level of demand for our diagnostic technologies, which may vary significantly;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing and cost of developing our diagnostic technologies, which may vary depending on the terms of our agreements with third party developers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenditures that we may incur to acquire, develop or commercialize additional tests and technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unanticipated pricing pressures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• geopolitical instability, economics problems, and other uncertainties in certain foreign countries in which we operate;

#### A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, could adversely affect our business.
If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. Any pandemic has the potential to spread to other countries and throughout the United States. In the past, numerous state and local jurisdictions have imposed, and others in the future may impose, "shelter-in-place" orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of any pandemic. Such orders or restrictions have resulted in reduced operations at our headquarters, work stoppages, slowdowns and delays, travel restrictions and cancellation of events.

Other disruptions or potential disruptions include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruptions in our production schedule and ability to assemble diagnostic tests;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• inventory shortages or obsolescence;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• delays in actions of regulatory bodies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• diversion of or limitations on employee resources that would otherwise be focused on the operations of our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we may conduct business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers' capacity to develop our diagnostic technologies.

[**Table of Contents**](#TOC001)

***The sizes of the markets for our diagnostic technologies and services and any future diagnostic tests and services may be smaller than we estimate and may decline.***

Our estimates of the annual total addressable market for our diagnostic technologies and services are based on a number of internal and third-party estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.

As a result, our estimates of the annual total addressable market for our diagnostic tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them or the annual total addressable market for them is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.

***Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services, we could lose customers or market share.***

Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep pace with evolving standards of care. If we fail to discover new diagnostic applications or update our diagnostic technology to reflect new scientific knowledge, our diagnostic tests could become obsolete and sales of our current diagnostic technologies and any new tests we develop could decline or fail to grow as expected. This failure to make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition and results of operations.

***If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our diagnostic technologies and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and negatively impact sales.***

We face an inherent risk of product liability as a result of the marketing and sale of our diagnostic technologies and services. For example, we may be sued if our diagnostic tests or services are perceived to be unsuitable during marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, strict liability or a breach of warranties. If medical personnel, or care partners are not properly trained, are negligent or use our diagnostic technologies incorrectly, the capabilities of such tests may be diminished. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies for our diagnostic tests.

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic technologies and services. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• decreased demand for our diagnostic technologies and services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• harm to our reputation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• initiation of investigations by regulators;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• costs to defend the related litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a diversion of management's time and our resources;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• substantial monetary awards to trial participants or patients;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• product recalls, withdrawals, marketing or promotional restrictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• loss of revenue;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adverse impact on the market price of our Common Stock; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exhaustion of any available insurance and our capital resources.

We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of our diagnostic tests and services. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.

#### Our insurance policies may not be sufficient to cover all claims.
Our insurance policies may not adequately cover all risks to which we are exposed. A significant claim not covered by our insurance, in full or in part, may result in significant expenditures by us. Moreover, we may not be able to maintain insurance policies in the future at reasonable costs or on acceptable terms, which may adversely affect our business and the trading price of our shares.

***Our software may not operate properly, which could damage its reputation, give rise to claims against the Company, or divert application of our resources from other purposes, any of which could harm its business and operating results.***

Software development is time-consuming, expensive, and complex. Unforeseen difficulties can arise. GyriCalc may encounter technical obstacles, and it is possible that it will discover additional problems that prevent its applications from operating properly. If the Company's systems do not function reliably or fail to achieve client expectations in terms of performance, clients could assert liability claims against us, which could damage the Company's reputation and impair its ability to attract or retain clients.

Software as complex as GyriCalc has in the past contained, and may in the future develop or contain, undetected defects, vulnerabilities, or errors. The Company cannot assure that material performance problems or defects in its services will not arise in the future. Errors may result from sources beyond the Company's control, including the receipt, entry, or interpretation of patient information; interface of the Company's services with legacy systems that it did not develop; or errors in data provided by third parties. It is challenging for the Company to test its software for all potential problems because it is difficult to simulate the wide variety of computing environments or treatment methodologies that its clients may deploy or rely upon. Therefore, despite testing, defects or errors may arise in the Company's existing or new software or service processes following introduction to the market.

In light of this, defects, vulnerabilities, and errors and any failure by the Company to identify and address them could result in loss of revenue or market share; liability to clients, their patients, or others; failure to achieve market acceptance or expansion; diversion of development and management resources; delays in the introduction of new services; injury to the Company's reputation; and increased service and maintenance costs. Defects, vulnerabilities, or errors in the Company's software and service processes might discourage existing or potential clients from purchasing services from the Company. Correction of defects, vulnerabilities, or errors could prove to be impossible or impracticable. The costs incurred in correcting any defects, vulnerabilities, or errors or in responding to resulting claims or liability may be substantial and could adversely affect the Company's operating results.

[**Table of Contents**](#TOC001)

#### We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our operations.
We will need to raise additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increase our sales and marketing efforts to drive market adoption of and address competitive developments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fund development and marketing efforts of our diagnostic tests or any other future diagnostic technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expand our technologies into other types of brain disorder diagnostic tests;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquire, license or invest in new technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquire or invest in complementary businesses or assets; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• finance capital expenditures and general and administrative expenses.

Our present and future funding requirements will depend on many factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to achieve revenue growth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of and reimbursement for our diagnostic technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our rate of progress in, and cost of research and development activities associated with, diagnostic tests in research and early development;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effect of competing technological and market developments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the potential cost of and delays in product development as a result of any regulatory oversight applicable to our diagnostic tests.

The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, our stockholders could experience dilution. Any preferred equity securities issued could also provide for rights, preferences or privileges senior to those of holders of our Common Stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our Common Stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or diagnostic tests, pay a portion of our royalties, or grant licenses on terms that are not favorable to us.

***Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.***

We have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future. As of March 31, 2025, we had an accumulated deficit of $5,703,097. The Company has incurred recurring losses and the Company expects to continue to incur losses as a result of costs and expenses related to product testing, FDA submission and product commercialization. Our financial statements have been prepared assuming that we will continue as a going concern. These factors raise substantial doubt about the Company's ability to continue as a going concern.

This going concern determination could materially limit our ability to raise additional funds through the issuance of equity or debt securities or otherwise. Further financial statements may include an explanatory paragraph with respect to our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through debt or equity financing. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to our products. This raises substantial doubt about our ability to continue as a going concern.

[**Table of Contents**](#TOC001)

#### If we are unable to continue as a going concern, our securities will have little or no value.
Although our audited financial statements for the years ended December 31, 2024 and December 31, 2023 were prepared under the assumption that we would continue our operations as a going concern, the report of our independent registered public accounting firm that accompanies our financial statements for the years ended December 31, 2024 and December 31, 2023 contains a reference to a going concern assessment from our management on the substantial doubt about our ability to continue as a going concern, based on the financial statements at that time. Prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. In addition, continued operations and our ability to continue as a going concern may be dependent on our ability to obtain additional financing in the near future and thereafter, and there are no assurances that such financing will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through sales of our products, financings or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. If we cannot continue as a going concern, our shareholders would likely lose most or all of their investment in us. The ability of the Company to continue as a going concern is dependent upon its ability to successfully execute the business plan and attain profitable operations.

#### The timing of any new technology product offerings is uncertain.
Our product development process involves a high degree of risk and may take several years in some instances. Our product development efforts may fail for many reasons, including, but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure of the technology product at the research or development phase;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulty in accessing samples, especially samples with known clinical results; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• lack of clinical validation data to support the effectiveness of the technology product.

Few research and development projects result in commercial technology products, and success in early clinical trials often is not replicated in later studies. At any point, we may abandon development of a technology product, or we may be required to expend considerable resources repeating clinical trials, which would adversely impact the timing for generating potential revenues from those technology products. In addition, as we develop technology products, we will have to make significant investments in technology product development. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the technology product or product feature that was the subject of the clinical trial, which could harm its business. In addition, our competitors may develop and commercialize competing technologies faster than we are able to do so.

#### We may depend on third party distributors for our sales.
We have limited experience marketing and selling our diagnostic tests. We will rely on our network of licensees and distributors to sell our diagnostic tests globally, and any failure to maintain and grow our distribution network will negatively affect our business, financial condition and results of operations. Our distribution partners are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of our diagnostic tests in their respective territories. The loss of these business partners to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our distributors or replace them with partners of equivalent technical expertise, qualifications, and track-records, it may negatively affect our business, financial condition and results of operations. There are no financial penalties if our distribution partners choose to discontinue our products. Furthermore, our success depends on third-party distribution and these distributors' ability to attract and retain salespeople with extensive experience selling products in the industry, and medical disciplines. We may have difficulties developing sales if we and/or our third-party distributors have difficulty locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our tests.

[**Table of Contents**](#TOC001)

#### Risks Related to our Governmental Regulation
***The insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for in-development or future diagnostic tests could limit our ability, and that of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate revenue.***

The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford the clinical diagnostic tests that we currently or in the future plan to develop and sell. In addition, because our clinical diagnostics and diagnostic tests represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our diagnostic tests, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained, or any potential revenue generated. Sales of our diagnostic tests will depend substantially, both domestically and internationally, on the extent to which the costs of our diagnostic tests are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our diagnostic tests or services. Even if coverage is provided, the available reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our diagnostic tests or services. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our diagnostic tests.

In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by the Centers for Medicare and Medicaid Services ("CMS"), an agency within the Department of Health and Human Services ("HHS"). CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare, although it frequently delegates this authority to local Medicare Administrative Contractors. Private payers tend to follow Medicare to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel diagnostic tests such as ours.

#### Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.
In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our diagnostic tests. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our diagnostic tests.

The effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our diagnostic tests. For example, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"), contains a number of provisions, including those governing enrollments in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs.

There have been judicial challenges to certain aspects of the ACA, as well as efforts by Congress to repeal, replace or alter the implementation of certain aspects of the ACA. Most recently, the Supreme Court of the United States granted certiorari on March 2, 2020, for a Texas District Court case, which invalidated the ACA in its entirety because he concluded that the individual mandate was unconstitutional. Although the Supreme Court of the United States reversed the holding and remanded the case back to the Texas District Court, it is unclear how the Texas District Court will rule, as it is unclear how any future decisions, subsequent appeals, and other efforts to challenge, repeal, or replace, or alter the implementation of the ACA will affect our business, financial condition and results of operations.

Congress may continue to pursue significant changes to the current healthcare laws. We face uncertainties that might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the ACA are likely to have an impact on our results

[**Table of Contents**](#TOC001)

of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations.

The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may harm:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to set a price that we believe is fair for our diagnostic tests;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to generate revenue and achieve or maintain profitability; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the availability of capital.

The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. Future changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt the commercialization of our current and future solutions. Future changes in healthcare policy could also decrease our revenue and impact sales of and reimbursement for our in development and future diagnostic tests.

#### We must comply with healthcare fraud and abuse laws.
Various federal and state laws, as well as the laws of foreign countries, prohibit payments to induce the referral, purchase, order or use of healthcare products or services and require medical device companies to limit prevent, and/or monitor, and report certain payments to third-party payers, health care professionals, and other individuals. These healthcare fraud and abuse anti-kickback, public reporting and aggregate spend laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. In particular, these laws influence, among other things, how we structure our sales offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. These laws prohibit certain marketing initiatives that are commonplace in other industries. If we were to offer or pay inappropriate inducements for the purchase, order or use of our diagnostic tests or our services, or our arrangements are perceived as inappropriate inducements, we could be subject to claims under various healthcare fraud and abuse laws.

Restrictions under applicable United States federal and state healthcare laws and regulations include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the federal Anti-Kickback Statute, a criminal law, prohibits, among other things, persons and entities from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, leasing, ordering, or arranging for, referring, or recommending the purchase, lease, order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Eliminating Kickbacks in Recovery Act, which prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Beneficiary Inducement Statute, which prohibits any person, organization, or entity from giving anything of value to a federal health care program beneficiary that is likely to induce or influence the beneficiary's choice of provider, practitioner, or supplier for covered services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the federal civil False Claims Act, which may be enforced through civil whistleblower or *qui tam* actions and is often used to enforce the federal Anti-Kickback Statute and other healthcare laws and regulations, imposes civil penalties and potential exclusion from federal healthcare programs, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers.

Other federal and state laws, as well as the laws of foreign countries, generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payments to government or commercial payers that are false or fraudulent, or for items or services that were not provided as claimed. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates and medical devices from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If any physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.

Manufacturers can also be held liable under these laws if they are deemed to "cause" the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers, by providing improper financial inducements, or through certain other activities. We attempt to ensure that any billing and coding information we provide for our diagnostic tests emphasizes the need for physicians and other providers to make independent judgments, use accurate and appropriate billing and coding that complies with all applicable payer policies, and document the medical need for their patients as appropriate. Nevertheless, the government may not regard any billing errors that may be made by our customers as inadvertent and may examine our role in providing information to our customers, physicians and patients concerning the benefits and potential coverage.

***The regulatory clearance or approval processes of regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable regulatory approvals or clearances, or if such approvals or clearances are significantly delayed, our business will be substantially harmed.***

The time required and ability to obtain clearance or approval by the FDA or any regulatory authorities is unpredictable, typically takes several years following the commencement of clinical studies, and depends upon numerous factors, including the type, complexity, and novelty of our products. In addition, policies, laws, regulations, or the type and amount of clinical data necessary to gain clearance or approval may change during the course of a test's clinical development and may vary among jurisdictions, which may cause delays in the clearance or approval of, or the decision not to approve, an application. Regulatory authorities have substantial discretion in the premarket review process and may refuse to accept any application, decide that our data are insufficient for clearance or approval, require additional clinical or other data, or determine that our manufacturing and quality systems are insufficient or in violation of applicable requirements. Even if we believe our data are sufficient to support regulatory approval, regulatory authorities may disagree that approval is warranted, or may require the generation and submission of additional data or data analyses and significantly delay approval.

Before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, a company must first submit an application for and receive 510(k) clearance pursuant to a premarket notification submitted under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FDCA), de-novo classification, or "PMA" approval from the FDA, unless an exemption applies. Products that are approved through a PMA application generally need prior FDA approval before modifications can be made that affect

[**Table of Contents**](#TOC001)

safety or effectiveness, and certain modifications to a 510(k)-cleared device may also require FDA premarket review before the modified product can be marketed. We have applied for regulatory clearance and approval for our GyriCalc product, but it is possible that we will never obtain regulatory clearance or approval.

FDA or other regulators can delay, limit, or deny premarket clearance or approval of a product for many reasons, including but not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA or comparable foreign regulatory authorities may disagree with the design, implementation, or results of, or interpretation of the data from, our clinical studies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA or comparable foreign regulatory authorities may determine that our product has not been shown to be safe and effective or has other characteristics that preclude us from obtaining marketing authorization or prevent or limit its commercial use (for example, a narrowed indication for use claim);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the population studied in the clinical program may not be sufficiently broad, generalizable, or representative of the intended target population of our product to assure effectiveness and safety in the population for which we seek authorization or clearance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical studies or may fail to accept data from clinical studies (or clinical sites), including if we fail to establish the integrity of our data;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA or comparable foreign regulatory authorities may determine that our clinical studies otherwise fail to comply with applicable regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• serious or unexpected adverse effects or other performance issues are identified with our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA or comparable foreign regulatory authorities may determine that our manufacturing or quality system fails to comply with applicable regulations or otherwise fails to meet the standards necessary to support approval; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

#### FDA regulation of our industry generally or our tests specifically could be disruptive to our business.
Our operations are subject to extensive federal, state, local and foreign laws and regulations, including FDA laws and regulations, all of which are subject to change. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. We believe that we are in material compliance with all statutory and regulatory requirements applicable to us, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payers.

In the United States, before we can market a new medical device, or a new use of, or claim for, an existing product, we must first receive either 510(k) clearance, PMA approval or approval of a de-novo application from the FDA, unless an exemption applies.

Government regulation of medical devices is meant to assure their safety and effectiveness, and includes regulation of, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• design, development and manufacturing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• testing, labeling, including directions for use, processes, controls, quality assurance, packaging, storage, distribution, installation and servicing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pre-clinical studies and clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• establishment registration and listing;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• test kit safety and effectiveness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• marketing, sales and distribution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• recordkeeping procedures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advertising and promotion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• premarket authorization (510(k), PMA, de-novo, Emergency Use Authorization (EUA));

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• corrections and removals and recalls;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• post-market surveillance, including reporting of deaths or serious injuries, and malfunctions that, if they were to recur, would be likely to cause or contribute to a death or serious injury; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• product import and export.

We can provide no assurances that the FDA will not focus its attention on diagnostic tests, including those that we provide. If this were to happen, it may impact our marketing practices relating to the relevant tests, which in turn may have an adverse impact on our business, financial condition and results of operations.

***Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.***

The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts, including the application of the FDA's Emergency Use Authorization (EUA) authority.

We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.

Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of any certificate and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory's approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.

***Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.***

If premarket review is required for some or all of our products, the FDA may require that we stop selling our products pending clearance or approval, which would negatively impact our business. Even if our products are allowed to remain on the market prior to required clearance or approval, demand or reimbursement for our products may decline if there is uncertainty about our products, if we are required to label our products as investigational by the FDA, or if the FDA limits the labeling claims we are permitted to make for our products. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our products, or from other products now in development.

Finally, if the FDA asserts active regulatory authority over our products (*i.e.,* determines them ineligible for the enforcement discretion), we will need to implement all of the required post-market controls for regulated medical devices including compliance with all applicable provisions of the FDA's Quality System Regulation ("QSR"), medical device reporting, corrections and removals, etc.

[**Table of Contents**](#TOC001)

***Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained.***

In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our diagnostic tests. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future diagnostic tests. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future diagnostic tests could make it more difficult and costly to obtain clearance or approval for new diagnostic tests or to produce, market and distribute existing diagnostic tests. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new diagnostic tests would have an adverse effect on our ability to expand our business.

***Any product for which we obtain regulatory clearance or approval will be subject to extensive ongoing regulatory requirements, and we may be subject to penalties if we or our partners fail to comply with regulatory requirements or if we experience unanticipated problems with our products.***

Any product for which we obtain regulatory clearance or approval from the FDA or other regulators, along with the manufacturing processes, post-market surveillance, labeling, packaging, advertising, and promotion, distribution, storage, import, export, reporting, and recordkeeping for such product, will be subject to continued regulatory review, oversight, requirements, and periodic inspections by the FDA and comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports; registration and listing requirements; requirements relating to quality control, quality assurance, and corresponding maintenance of records and documents; requirements relating to recalls, removals, and corrections; and requirements relating to product labeling, advertising and promotion, and recordkeeping. The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA enforces these regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we will be found compliant in connection with any future regulatory inspections.

Regulatory clearance or approval of a test or device may be subject to limitations by the regulatory body as to the indicated uses for which the product may be marketed or to other conditions of clearance or approval. In addition, clearance or approval may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the test or device. After clearance or approval, discovery of problems with our product, suppliers, vendors, or contract manufacturers, or manufacturing processes (including software validation), and/or failure to comply with regulatory requirements, may result in actions such as:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restrictions on marketing of a product;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• withdrawal or recall of the product from the market or seizure of the product;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• refusal to approve applications or supplements to approved applications that we may submit;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fines, restitution or disgorgement of profits or revenue;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• suspension, limitation or withdrawal of regulatory approvals or clearances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• safety communications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• refusal to permit the import or export of our product;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• injunctions; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Imposition of civil or criminal penalties.

[**Table of Contents**](#TOC001)

***For any of our products that are approved or cleared by the FDA, we will be required to report to the FDA certain information about adverse medical events or malfunctions, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.***

For products for which we obtain FDA clearance or approval, we will be subject to the FDA's medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our products, or delay in clearance or approval of future products.

The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA's authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Depending on the corrective action we take to redress a product's deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.

Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.

***Obtaining and maintaining regulatory authorization of our products in one jurisdiction does not mean that we will be successful in obtaining regulatory authorization of our products in other jurisdictions.***

Obtaining and maintaining regulatory authorization of products in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory authorization in any other jurisdiction, but a failure or delay in obtaining regulatory authorization in one jurisdiction may have a negative effect on the regulatory authorization process in others. For example, even if the FDA or a comparable foreign regulatory authority grants clearance or approval of our products, comparable regulatory authorities in foreign jurisdictions may also need to authorize the products in those countries, which may be a new review process. Premarket authorization processes vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional clinical studies, because clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions or the data may not be considered applicable to the jurisdiction's intended patient population. In some cases, the price that we intend to charge for our products may also be subject to approval.

Obtaining foreign regulatory authorization and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in other jurisdictions, or we fail to receive necessary or desirable marketing authorizations in other jurisdictions, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.

[**Table of Contents**](#TOC001)

***Clinical trials may be necessary to support future product submissions to the FDA. These clinical trials are expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any in-development, modified or new diagnostic tests and will adversely affect our business, operating results and prospects.***

Initiating and completing clinical trials necessary to support any future PMA applications or other regulatory premarket submissions, and additional safety and efficacy data beyond that typically required for a 510(k) clearance for our possible future product candidates, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.

Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance.

Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy is required and we may not adequately develop such protocols to support FDA clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our diagnostic tests or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.

***If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our diagnostic tests and services.***

We may not have the ability to independently conduct our pre-clinical and clinical trials for our future diagnostic tests and services and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated. Additionally, we may not be able to obtain regulatory approval for, or successfully commercialize, our diagnostic tests and services on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.

***The data that we collect may be vulnerable to breach, loss or misuse, and our handling of such data may be impacted by changes in data privacy and protection laws and regulations, which could increase operational costs or result in regulatory penalties, litigation, or reputational harm.***

In connection with our business, we maintain and process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection with our clinical studies and our employees, and may be subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. Despite our efforts to properly handle and protect this information in compliance with all applicable regulatory requirements, our facilities and systems and those of our third-party

[**Table of Contents**](#TOC001)

vendors, collaborators, contractors and consultants may be vulnerable to security breaches, theft, misplaced or lost data, and programming, procedural or human errors that could potentially lead to such information being compromised of handled improperly.

These laws, rules and regulations — both domestic and foreign — evolve frequently, and their scope may continually change, through new legislation, amendments to existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.

We may be subject to numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. For example, the State of California legislature passed the California Consumer Privacy Act of 2018 (the "CCPA"), effective January 1, 2020, which grants certain rights to California residents with respect to their personal information.

***Failure to comply with the HIPAA Privacy, Security and Breach Notification Regulations, as such rules become applicable to our business, may increase our operational costs.***

Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of protected health information ("PHI") and personal identifiable information ("PII"). These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. We are a covered entity under HIPAA when we are conducting our clinical trials. We are a covered entity with regard to our observational studies and clinical trials, and also a business associate under HIPAA for certain other business activities, and we execute business associate agreements with our clients.

HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.

HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $119 per violation and are subject to a cap of $1,785,651 for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suits on behalf of their residents. Courts may award damages, costs and attorneys' fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates. With regard to business associates, those audits assess the business associate's compliance with the HIPAA Privacy and Security Standards. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500 individuals' data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a business associate's reputation.

In addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, which can lead to government imposed fines, orders requiring that we or these third-parties change our or their practices, among others.

[**Table of Contents**](#TOC001)

If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.

***Information technology ("IT") failures and data security breaches, including as a result of cybersecurity attacks, could negatively impact our results of operations and financial condition, subject us to increased operating costs, and expose us to litigation.***

We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, cybersecurity attacks, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, including any third-party vendors that collect, process and store personal data on our behalf, fail to comply with laws requiring the protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.

#### Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA authorities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• CMS regulations, including laws pertaining to clinical laboratory standards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign, federal and state healthcare fraud and abuse laws and regulations; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• laws that require the true, complete and accurate reporting of financial information or data.

In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by the HHS Office of Inspector General could result in penalties, a loss of business from third parties, and severe reputational harm.

In connection with this offering, we will adopt a Code of Business Conduct and Ethics and compliance policies to govern and deter such behaviors, but it is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.

[**Table of Contents**](#TOC001)

***Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.***

Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support clearance and approval of new diagnostic tests and services. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these diagnostic tests and services. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities and notified bodies will agree with our conclusions regarding them. We rely on data collected in foreign countries and we cannot be certain that the FDA accept all of the data collected outside the U.S. as support for our product candidate claims. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon development of our tests and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, may impact our ability to commercialize our tests and generate revenues.

Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.

We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices ("GCPs") which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated.

Many of these factors could be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability.

#### Risks Related to Our Intellectual Property

#### Our success may be impaired if we are unable to obtain, maintain and protect our intellectual property rights.
Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our diagnostic tests, products and services and technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology and prevent others from duplicating our suite of diagnostic tests and products. However, these means may afford only limited protection and may not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• prevent our competitors from gaining access to our proprietary information and technology; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• allow us to gain or maintain a competitive advantage.

[**Table of Contents**](#TOC001)

Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. Consequently, we do not know whether any of our diagnostic tests, products and services will be protectable or remain protected by valid and enforceable patents. We may not prevail if our patents are challenged by competitors or other third parties. Furthermore, competitors may be able to design around our patents by developing similar or alternative technologies or products in a non-infringing manner, or obtain patent protection for more effective technologies, designs or methods. If these developments were to occur, our diagnostic tests and products may become less competitive and sales may decline.

Moreover, some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain or maintain an exclusive license to any such third party co-owners' interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

If we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize diagnostic tests, products and services similar or superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner.

Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our copyrights may be limited.

***If we or any of our current or future licensors, including the University of Louisville Research Foundation Inc. are unable to maintain, obtain or protect intellectual property rights related to our technologies and any future technologies we may develop, or if the scope of any protection obtained is not sufficiently broad, we may not be able to compete effectively in our market.***

Our success depends, in part, on our ability to seek, obtain and maintain intellectual property protection in the United States and other countries with respect to our technologies. We and the University of Louisville Research Foundation Inc. currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Additionally, the University of Louisville Research Foundation Inc. has obtained a United States patent related to its proprietary diagnostic tests. We also intend to protect our proprietary technology and methods by, among other things, filing for and obtaining United States and foreign patent applications related to our proprietary technology, inventions, methods of use, and improvements that are important to the development and implementation of our business.

***Our rights to develop and commercialize our product and future product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, including the University of Louisville Research Foundation Inc., if we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.***

We are heavily reliant upon our license from the University of Louisville Research Foundation Inc. to certain proprietary technology that is important or necessary to the development of GyriCalc and future product candidates. Additionally, further development and commercialization of GyriCalc and future product candidates may require us to enter into additional license or collaboration agreements. For more information regarding our reliance on the University of Louisville Research Foundation Inc. and future collaboration agreements, please see "Risk Factors — Reliance on Third Parties."

[**Table of Contents**](#TOC001)

Our current and any future licenses may not provide us with exclusive rights to use the licensed intellectual property and technology or may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize GyriCalc and future product candidates. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses.

In some circumstances, we may not have the right to control the maintenance, prosecution, preparation, filing, enforcement, defense or litigation of patents and patent applications that we license from or license to third parties and are reliant on our licensors or licensees to do so. We thus cannot be certain that activities such as patent maintenance and prosecution by our licensors have been or will be conducted consistent with our best interests or in compliance with applicable laws and regulations, or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors' infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests. If our licensors fail to maintain such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize future product candidates that are the subject of such licensed rights and our right to exclude third parties from commercializing competing products could be adversely affected. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

In spite of our efforts, our current and future licensors might conclude that we have materially breached our obligations under our license agreements and might therefore terminate such license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. Disputes may arise with respect to our current or future licensing agreements, including disputes relating to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the scope of rights granted under the license agreements and other interpretation-related issues;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our financial or other obligations under the license agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the extent to which GyriCalc and future product candidates infringe on intellectual property of the licensors that is not subject to the licensing agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the sublicensing of patent and other rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our diligence obligations under the license agreements and what activities satisfy those diligence obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the priority of invention of patented technology.

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize GyriCalc and future product candidates. If our licenses are terminated, we may lose our rights to develop and market GyriCalc and future product candidates, lose patent protection for GyriCalc and future product candidates, experience significant delays in the development and commercialization of GyriCalc and future product candidates, or incur liability for damages. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with GyriCalc and future product candidates.

Furthermore, if the licensing Agreement with the University of Louisville Research Foundation Inc. or any future licenses are terminated, or if the underlying patents or other intellectual property rights fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of GyriCalc and future product candidates. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize GyriCalc and future product candidates. In addition, certain of these license

[**Table of Contents**](#TOC001)

agreements may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

Our license agreements are, and future license agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

#### If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.
In addition to seeking patent protection for the patents underlying our diagnostic tests, products and services, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties.

Additionally, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology.

Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property rights we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary, or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our diagnostic tests or products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.

***Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our in-development and future diagnostic tests, products and services.***

Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (the "Leahy-Smith Act") was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law, including the way patent applications are prosecuted and litigated. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.

[**Table of Contents**](#TOC001)

In addition, patent reform legislation and judicial holdings may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.

***If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.***

Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected.

Our efforts to enforce or protect our rights related to trademarks, trade secrets, domain names or other intellectual property rights may be ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations.

***We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time consuming and unsuccessful.***

Competitors or other third parties may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violations. In addition, our patents also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. If securities analysts or investors perceive the litigation developments or proceedings results to be negative, it could have a substantial adverse effect on the price of our Common Stock.

Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Further, any claims we assert against perceived infringers can lead to those parties asserting counterclaims against us alleging infringement from our side. These proceedings can lead to our intellectual property right to be deemed invalid or unenforceable, which have unpredictable outcomes, but may include us losing at least part, or all, of the patent protection on our diagnostic tests, products and services. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.

Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, *inter partes* review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, including opposition proceedings. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our diagnostic tests, products and services or prevent third parties from competing with our diagnostic tests, products and services.

Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

[**Table of Contents**](#TOC001)

***Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.***

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-United States patent agencies. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property rights. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.

***We may not have been the first company to make the inventions covered by our pending patents because publications of discoveries in the scientific literature often lag behind the actual discoveries.***

We may not be aware of all third-party intellectual property rights potentially relating to our current or future diagnostic tests, products or services. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management's attention and resources.

#### Patent terms may be inadequate to protect our competitive position on our in-development and future diagnostic tests, products and services for an adequate amount of time.
Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.

Even if patents covering our diagnostic tests, products and services are obtained, once the patent life has expired, we may be open to competition from competitive diagnostic tests, products and services. Given the amount of time required for the development, testing and regulatory review of potential new diagnostic tests, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests, products or services similar or identical to ours.

#### We may not be able to protect our intellectual property rights throughout the world.
Third parties may attempt to commercialize competitive diagnostic tests, products or services in foreign countries where we do not have any patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.

Filing, prosecuting and defending patents on our diagnostic tests, products and services in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing diagnostic tests or products made using our inventions in and into the United States or other jurisdictions. Competitors may use our diagnostic tests, products, services and technologies in jurisdictions where we have not obtained patent protection to develop their own

[**Table of Contents**](#TOC001)

diagnostic tests and, further, may export otherwise infringing diagnostic tests or products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These diagnostic tests and products may compete with our diagnostic tests, products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many countries, including India, China, and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected.

#### Intellectual property rights do not necessarily address all potential threats.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• it is possible that our current or future pending patent applications will not lead to issued patents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive diagnostic tests, products and services for sale in our major commercial markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may not develop additional proprietary technologies that are patentable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the patents of others may harm our business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property rights.

Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.

#### Risks Related to this Offering and Ownership of Our Common Stock

#### There has been no prior public market for our Common Stock and an active trading market may not develop.
Prior to this offering, there has been no public market for our Common Stock. An active trading market may not develop following completion of this offering or, if developed, may not be sustained. The lack of an active trading market may impair the value of your shares of Common Stock and your ability to sell your shares of Common Stock at the time you wish to sell them. An inactive trading market may also impair our ability to both raise capital by selling shares of Common Stock and acquire other complementary diagnostic tests, technologies or businesses by using our shares of Common Stock as consideration.

Upon closing of this offering, we expect that our Common Stock will be listed on the New York Stock Exchange. If we fail to satisfy the continued listing standards of the New York Stock Exchange, however, we could be de-listed, which would negatively impact the price of our Common Stock. In addition, our board may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A de-listing of our Common Stock from the New York Stock Exchange may materially impair our shareholders' ability to buy and sell

[**Table of Contents**](#TOC001)

our Common Stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our Common Stock. In addition, the delisting of our Common Stock could significantly impair our ability to raise capital in the future.

If we fail to meet the minimum requirements for listing on the New York Stock Exchange, we will not proceed with this offering.

***We expect that the price of our Common Stock will fluctuate substantially, and you may not be able to sell the shares you purchase in this offering at or above the offering price.***

The initial public offering price for the shares of our Common Stock sold in this offering is determined by negotiation between the representatives of the underwriters and us. This price may not reflect the market price of our Common Stock following this offering. In addition, the market price of our Common Stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the introduction of new diagnostic tests or enhancements to such tests by us or others in our industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disputes or other developments with respect to our or others' intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to develop, obtain regulatory clearance or approval for, and market new and enhanced diagnostic tests on a timely basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• product liability claims or other litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• quarterly variations in our results of operations or those of others in our industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• media exposure of our diagnostic tests or of those of others in our industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in governmental regulations or in the status of our regulatory approvals or applications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in earnings estimates or recommendations by securities analysts; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.

In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our Common Stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our Common Stock shortly following this offering. If the market price of shares of our Common Stock after this offering does not ever exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment.

In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management's attention and resources from our business.

#### The purchasers in the resale offering may pay a different price than those in the initial public offering.
The resale offering by the selling stockholders will occur after the completion of the initial public offering, and the offering price for shares sold in the resale offering will depend on prevailing market prices or negotiated prices at the time of sale. As a result, the resale offering price may differ from the offering price in the initial public offering. Purchasers in the resale offering could pay more or less than purchasers in the primary offering, depending on market conditions and other factors at the time of the resale offering. This variability in pricing may create disparities in the costs incurred by investors and could impact on the trading price of our shares on the New York Stock Exchange.

[**Table of Contents**](#TOC001)

#### The public price of our common stock may be volatile, and could, following a sale, decline significantly and rapidly.
The initial public offering price for the shares will be determined by negotiations between us and the underwriters and may not be indicative of prices that will prevail in the open market following this offering. The market price of our common stock may decline below the initial offering price, and you may not be able to sell your shares of our common stock at or above the price you paid in the offering, or at all. Following this offering, the public price of our common stock in the secondary market will be determined by private buy and sell transaction orders collected from broker-dealers.

In addition, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to operating performance of individual companies, particularly following an initial public offering of a company with a small public float. There is the potential for rapid and substantial price volatility of our common stock following this offering. These broad market factors may seriously harm the market price of our common stock, regardless of our actual or expected operating performance and financial condition or prospects, which may make it difficult for investors to assess the rapidly changing value of our common stock. In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted. A class action suit against us could result in significant liabilities and, regardless of the outcome, could result in substantial costs and the diversion of our management's resources and attention.

Stock price run-ups followed by rapid price declines and stock price volatility may also be completely unrelated to company performance. Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our stock. Our common stock may experience extreme stock price volatility unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Common Stock.

***Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.***

If a trading market for our Common Stock develops, the trading market will be influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a new public company, we may be slow to attract research coverage and the analysts who publish information about our Common Stock will have had relatively little experience with us, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.

***We are an "emerging growth company" and a "smaller reporting company," and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our Common Stock less attractive to investors.***

We are an "emerging growth company," as defined in the JOBS Act. We may take advantage of certain exemptions and relief from various public reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). We will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor's report on financial statements; we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.

Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act to comply with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

[**Table of Contents**](#TOC001)

We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.

We will remain an "emerging growth company" until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (ii) the date we qualify as a "large accelerated filer," with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering.

We are also a "smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year's second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by nonaffiliates exceeds $700 million as of the end of that year's second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.

Investors may find our Common Stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and the price of our Common Stock may decline or become more volatile.

***If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. It is possible that interpretation, industry practice and guidance may evolve over time. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.

#### If you purchase our Shares in this offering, you will incur immediate and substantial dilution in the book value of your shares.
Investors purchasing Shares in this offering will pay a price per Share that substantially exceeds the pro forma as adjusted net tangible book value per share. As a result, investors purchasing Shares in this offering will incur immediate dilution of $[•] per Share, based on an assumed initial public offering price of $[•] per Share, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and our pro forma as adjusted net tangible book value per share of Common Stock as of [•]. For more information on the dilution you may suffer as a result of investing in this offering, see the section of this prospectus entitled "Dilution."

This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this offering as compared to the price offered per Share to the public in this offering. It is also due to the conversion of our convertible debt into shares of our Common Stock upon the completion of this offering and the exercise of stock options granted to our employees as the conversion and exercise prices of such securities and options are substantially below the price offered per Share to the public in this offering.

[**Table of Contents**](#TOC001)

***Future sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline, regardless of our operating performance.***

Sales of a substantial number of shares of our common stock in the public market, including the resale of shares held by various holders of our securities registered for resale, could occur at any time (after the expiration of any applicable lock-up period). These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could increase the volatility of the market price of our common stock or result in a significant decline in the public trading price of our common stock.

#### We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve.
Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled "Use of Proceeds." Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the United States government. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline.

***We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and results of operations.***

Upon completion of this offering, we expect to incur costs associated with corporate governance requirements that will become applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended (the Exchange Act), as well as the rules of the New York Stock Exchange. These rules and regulations are expected to significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. We also expect these rules and regulations to make it more expensive for us to maintain directors' and officers' liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors (the "Board of Directors") or as executive officers. Accordingly, increases in costs incurred as a result of becoming a publicly traded company may adversely affect our business, financial condition and results of operations.

***If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our Common Stock.***

As a result of becoming a public company, we will be required, under Section 404 of the Sarbanes-Oxley Act to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ended [\*]. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual and interim financial statements will not be detected or prevented on a timely basis.

We are further enhancing internal controls, processes and related documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• faulty human judgment and simple errors, omissions or mistakes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fraudulent action of an individual or collusion of two or more people;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• inappropriate management override of procedures; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.

When we cease to be an "emerging growth company" under the federal securities laws, our auditors will be required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our Common Stock to decline.

#### Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

***Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.***

Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock, thereby depressing the market price of our Common Stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

***Our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain stockholder litigation matters, which could limit our stockholders' ability to obtain a chosen judicial forum for disputes with our directors, officers, employees, or stockholders.***

Our bylaws require that derivative actions brought on behalf of us be brought in the Court of Chancery in the State of Delaware. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consent to the forum provision in our bylaws. In addition, our bylaws provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act and the Exchange Act. There is uncertainty as to whether a court would enforce this exclusive forum provision for claims arising under the Securities Act or the Exchange Act. Neither the exclusive forum provisions nor the federal securities laws (and the rules and regulations thereunder) may be waived by a stockholder.

The choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, officers, other employees, or stockholders, which may discourage lawsuits with respect to such claims and. If a stockholder were to bring such a claim, the choice of forum provision may result

[**Table of Contents**](#TOC001)

in the stockholder incurring increased costs in connection with bringing such a claim, because such stockholder will be required to bring the claim in the state or federal courts located in the State of Delaware. Alternatively, if a court were to find the choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, operating results, and financial condition.

***Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.***

Our certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Section 145 of the Delaware General Corporate Law.

In addition, as permitted by the Delaware General Corporate Law, our certificate of incorporation and our indemnification agreements that we have entered into with our directors and officers provide that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by applicable law. Such law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person's conduct was unlawful;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the rights conferred in our certificate of incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we may not retroactively amend our certificate of incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents.

[**Table of Contents**](#TOC001)

#### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND IN DUSTRY AND MARKET DATA

#### Special Note Regarding Forward-Looking Statements
This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections titled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business," but are also contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements.

Key factors that could cause actual results to be different than expected or anticipated include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to comply with applicable FDA regulatory requirements or obtain FDA clearance or approval to commercially sell certain of our products in a timely manner or at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the expected growth of our business and our operations, and the capital resources needed to progress our business plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reliance on third party suppliers for certain components of our proposed products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reliance on third parties to commercialize and distribute our proposed products in the United States and internationally;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in external competitive market factors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• uncertainties in generating sustained revenue or achieving profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unanticipated working capital or other cash requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in FDA regulations, including testing procedures, of medical devices and related promotional and marketing activities;]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to obtain and maintain intellectual property protection for our proposed products; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in our business strategy or an inability to execute our strategy due to unanticipated changes in the medical device industry.

You should read this prospectus, including the section titled "Risk Factors," and the documents that we reference elsewhere in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

These forward-looking statements represent our estimates and assumptions only as of the date of this prospectus regardless of the time of delivery of this prospectus or any sale of our Common Stock. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new

[**Table of Contents**](#TOC001)

information, future events or otherwise after the date of this prospectus. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.

#### Industry and Market Data
Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market opportunity and market size, is based on information from various sources, including independent industry publications, such as [\*]. In presenting this information, we have also made assumptions based on such data and other similar sources, and on our knowledge of, and our experience to date in, the markets for our products. This information involves a number of assumptions and limitations. We believe that the information from these industry publications that is included in this prospectus is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in "Risk Factors." These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

[**Table of Contents**](#TOC001)

#### USE OF PROCEEDS
We estimate that the net proceeds to us from our issuance and sale of all of the Shares sold by us in this offering will be approximately $5.9 million (or $6.845 million if the representative of the underwriters exercise its over-allotment option to purchase additional shares of Common Stock in full), based upon an assumed initial public offering price of $[•] per Share, which is the mid-point of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

Each $1.00 increase or decrease in the assumed initial public offering price of $[•] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $[•] million, assuming the number of Shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of Shares we are offering. Each increase or decrease of 1.0 million in the number of Shares we are offering at the assumed initial public offering price of $[•] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $[•] million, assuming the assumed initial public offering price remains the same.

We intend to use the net proceeds from this offering as follows:

Approximately $300,000 to fund our software engineering over the span of two (2) years;

Approximately $1,800,000 to fund clinical trials for new applications of our software;

Approximately $200,000 to fund our marketing;

Approximately $320,000 to fund offering expenses, including but not limited to, legal and promotional services;

Approximately $125,000 to fund our service of debt;

Approximately $600,000 to fund our accounts receivable financing over the span of two (2) years;

Approximately $1,500,000 to fund our operations;

Approximately $1,055,000 to fund our working capital (unassigned).

This expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and results from clinical trials, our sales, marketing and manufacturing efforts, any collaborations that we may enter into with third parties for our products and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.

We believe opportunities may exist from time to time to expand our current business through the acquisition or in-license of complementary products and product candidates. While we have no current agreements or commitments for any specific acquisitions or in-licenses at this time, we may use a portion of the net proceeds for these purposes.

[**Table of Contents**](#TOC001)

#### DIVIDEND POLICY
We have never declared or paid any cash dividends on our capital stock. We do not anticipate paying cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects, the requirements of current or then-existing debt instruments and other factors our Board of Directors may deem relevant.

[**Table of Contents**](#TOC001)

#### CAPITALIZATION
The following table sets forth our cash, cash equivalents and capitalization as of [\*]:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• on an actual basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• on a pro forma as adjusted basis to give further effect to our issuance and sale of Shares in this offering at an assumed initial public offering price of $[•] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

The pro forma and pro forma as adjusted information below is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the initial public offering price of our Shares and other terms of this offering determined at pricing. You should read the following table in conjunction with "Use of Proceeds," "Summary Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Description of Capital Stock" and other financial information contained in this prospectus, including the condensed financial statements and related notes appearing elsewhere in this prospectus.

---

| | | | |
|:---|:---|:---|:---|
|  | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** |
|  | **Actual** | **Pro <br>Forma** | **Pro Forma <br>As Adjusted<sup>(1)</sup>** |
|  Cash | $1847 | $| $|
|  Promissory notes | $125000 |  |  |
|  Convertible debt (net of debt discount) | $1159573 | $| $|
| &nbsp;&nbsp;&nbsp; Common Stock, par value | $110 |  |  |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | $3528983 |  |  |
| &nbsp;&nbsp;&nbsp; Accumulated deficit | $(5703097) |  |  |
|  Total shareholders' deficit | $(2174004) |  |  |
|  Total capitalization | $(889431) | $| $|

---

____________

(1) Each $1.00 increase or decrease in the assumed initial public offering price of $[\*] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of cash and cash equivalents, additional paid-in capital, total shareholders' (deficit) equity and total capitalization by approximately $[\*] million, assuming the number of Shares offered by us, as stated on the cover page of this prospectus, remains unchanged and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 100,000 in the number of Shares we are offering would increase or decrease, as applicable, each of cash and cash equivalents, additional paid-in capital, total shareholders' (deficit) equity and total capitalization by approximately $[\*], assuming the assumed initial public offering price of $[\*] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

The number of shares of our Common Stock to be outstanding after this offering is based on shares of Common Stock outstanding as of [•], 2025, and excludes shares underlying options, warrants and convertible debt.

[**Table of Contents**](#TOC001)

#### DILUTION
If you invest in our Shares in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share of our Common Stock (giving no value to the Warrants) and the pro forma as adjusted net tangible book value per share of our Common Stock immediately after this offering. Net tangible book value per share of Common Stock is determined by dividing our total tangible assets less total liabilities by the number of outstanding shares of our Common Stock.

Our historical net tangible book deficit as of December 31, 2024 was $(2,017,712), or $(0.18) per share of Common Stock.

Our pro forma net tangible book deficit as of March 31, 2025 was $(2,456,532), or $(0.22) per share of our Common Stock.

Pro forma net tangible book value [(deficit)] per share represents the amount of our total tangible assets less our total liabilities. Pro forma net tangible book value (deficit) per share represents pro forma net tangible book value (deficit) divided by the total number of shares outstanding as of December 31, 2024 and March 31, 2025, after giving effect to the pro forma adjustments described above.

Pro forma as adjusted net tangible book value (deficit) is our pro forma net tangible book value, after giving further effect to (i) the sale of shares of our Common Stock in this offering at an assumed initial public offering price of $[•] per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and (ii) the application of the net proceeds from this offering as described in the section of this prospectus entitled "Use of Proceeds." This amount represents an immediate increase in pro forma net tangible book value (deficit) of $[•] per share to our existing shareholders, and an immediate dilution of $[•] per share to new investors participating in this offering.

The following table illustrates this dilution on a per share basis to new investors:

---

| | | |
|:---|:---|:---|
|  Assumed initial public offering price per share |  | $|
|  Historical net tangible book deficit per share as of March 31, 2025 | $(0.22) |  |
| &nbsp;&nbsp;&nbsp; Pro forma net tangible book value (deficit) per share as of [\*], <br>before giving effect to this offering |  |  |
| &nbsp;&nbsp;&nbsp; Increase in pro forma net tangible book value (deficit) per share <br>attributable to new investors participating in this offering |  |  |
| &nbsp;&nbsp;&nbsp; Pro forma as adjusted net tangible book value (deficit) per share <br>after this offering |  |  |
|  Dilution in pro forma net tangible book value (deficit) per share to new investors participating in this offering |  | $|

---

A $1.00 increase or decrease in the assumed initial public offering price of $[•] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted net tangible book value (deficit) per share of Common Stock after this offering by approximately $[•] per share of Common Stock and decrease or increase, as appropriate, the dilution in pro forma net tangible book value (deficit) per share of Common Stock to investors participating in this offering by approximately $[•] per share of Common Stock, assuming that the number of Shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

Similarly, a [1.0 million] Share increase or decrease in the number of Shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as appropriate, the pro forma as adjusted net tangible book value (deficit) per share of Common Stock after this offering by approximately $[•] and decrease or increase, as appropriate, the dilution in pro forma net tangible book value (deficit) per share of Common Stock to investors participating in this offering by approximately $[•], assuming the assumed initial public offering price of $[•] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

[**Table of Contents**](#TOC001)

The pro forma information discussed above is illustrative only and will change based on the actual initial public offering price, number of shares and other terms of this offering determined at pricing.

If the representative of the underwriters exercises its over-allotment option to purchase additional shares of our Common Stock and/or Warrants in this offering in full, the pro forma as adjusted net tangible book value will increase to $[•] per share of Common Stock, representing an immediate increase in pro forma net tangible book value to existing shareholders of $[•] per share and an immediate dilution of $[•] per share to new investors participating in this offering.

The following table sets forth, as of March 31, 2025, on the pro forma as adjusted basis described above, the differences between our existing shareholders and the purchasers of Shares in this offering with respect to the number of Shares purchased from us, the total consideration paid to us and the weighted average price paid per share paid to us, based on an assumed initial public offering price of per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts and commissions and estimated offering expenses payable by us:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Shares <br>Purchased** | **Shares <br>Purchased** | **Total <br>Consideration** | **Weighted <br>Average Price<br>per Share** |
|  | **Number** | **Percent** | **Percent** | **Weighted <br>Average Price<br>per Share** |
|  Existing shareholders |  | % | $% | $|
|  New investors |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Total |  | 100% | $100% |  |

---

If the representative of the underwriters exercises its over-allotment option to purchase additional shares of our Common Stock and/or Warrants in this offering in full, the number of shares held by existing shareholders will be reduced to % of the total number of shares of Common Stock that will be outstanding upon completion of this offering, and the number of shares of Common Stock held by new investors participating in this offering will be further increased to % of the total number of shares of Common Stock that will be outstanding upon completion of the offering.

A $1.00 increase or decrease in the assumed initial public offering price of $[•] per Share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as appropriate, the total consideration paid by new investors by $[•] million, assuming the number of Shares we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Shares we are offering. Similarly, each increase or decrease of 1.0 million shares in the number of Shares offered by us would increase or decrease, as appropriate, the total consideration paid by new investors by $[•] million, assuming that the assumed initial price to the public remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We may choose to raise additional capital through the sale of equity or equity-linked securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that any options are issued under our equity incentive plan or we issue additional shares of Common Stock or equity-linked securities in the future, there will be further dilution to investors purchasing in this offering.

[**Table of Contents**](#TOC001)

#### MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<br>AND RESULTS OF OPERATIONS
*You should read the following discussion of our financial condition and results of operations in conjunction with "Summary Financial Data" and our condensed financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward*-looking *statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these forward*-looking *statements as a result of several factors, including those set forth under "Risk Factors" and elsewhere in this prospectus. You should carefully read the "Risk Factors" section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward*-looking *statements. Please also see the section entitled "Cautionary Note Regarding Forward*-Looking *Statements and Industry and Market Data" in this prospectus.*

#### Overview
The Company is in the business of commercializing a medical diagnostic technology in late-stage development that may have the potential of significantly facilitating, and enhancing the accuracy of, the diagnosis of certain neuro-disabling diseases if approved by the FDA. To that extent, we plan, upon successful conclusion of our current efforts to raise new equity capital and after achieving FDA marketing clearance, to bring to market this new diagnostic technology for early detection of autism.

This technology assists in the diagnosis of neuro-disabling diseases through the use of advanced three-dimensional ("3D") brain mapping technology. Currently, we are focused on developing this technology in order to provide a first of its kind diagnostic tool for autism in order to reduce the time for diagnosis to ensure the earliest possible intervention. Based on the application of the algorithms on more than 1,000 MRI scans conducted by the University of Louisville, our diagnostic software technology can diagnose Autism in infants, some as young as six months old, at 90%+ rate of accuracy. The technology was developed with the help of physicians at the University of Louisville and is compatible with existing MRI scan imagery. Our software measures the thickness of Cerebral White Matter (CWM) gyrification and analyzes and classifies the shape of the brain based on this measurement.

#### Recent Developments
The Company has recently completed a series of clinical trials to validate the efficacy of its software technology in preparation for submission to the FDA which was filed in March 2025.

**Financial Operations Overview**

Our product has not yet been approved by the Food and Drug Administration (FDA) for commercial sale and has not generated revenue to date. We have applied for 510(k) approval on March 5, 2025. We have never been profitable and have incurred net losses in each year since inception. We incurred net losses of $2,649,178 and $788,005 for the years ended December 31, 2024 and 2023, respectively, and a net loss of $396,748 for the first quarter in 2025. As of March 31, 2025, we had an accumulated deficit of $5,703,097. Substantially all of our net losses resulted from expenses incurred in connection with staff expenses, our research and development programs and outside professional services, and from stock-based compensation.

[**Table of Contents**](#TOC001)

#### Results of Operations — Three Months Ended March 31, 2025 and March 31, 2024
The following discussion and analysis of our results of operations includes a comparison of the three months ended March 31, 2025 to the three months ended March 31, 2024:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months ended <br>March 31,** | **For the Three Months ended <br>March 31,** |
|  | **2025** | **2024** |
|  Personnel expenses | $69700 | $168387 |
|  General and administrative expenses | 12386 | 1874 |
|  Outside professional services | 183886 | 135238 |
|  Product development expenses | 72260 | 44132 |
|  Loss from operations | (338232) | (349631) |
|  Other Income (Expense) | (58516) | (106526) |
|  Loss before provision of income taxes | (396748) | (456157) |
|  Provision for income taxes |  |  |
|  Net Loss after income taxes | (396748) | (456157) |
|  Net Loss applicable to common shareholders | $(396748) | $(456157) |

---

*Revenues*

The Company has not yet derived any revenues from the sale or licensing of its products.

*Research and Development*

The Company has to date spent approximately $758,000 on product development expenses.

*Operating Expenses*

Operating expenses for the three months ended March 31, 2025 decreased to $338,232 from $349,631 for the comparable period in 2024. During the first quarter in 2024 we recognized a charge of $118,387 for stock options granted for services whereas no such expense was incurred in the first quarter of 2025. This favorable development, however, was substantially offset by increases in (i) higher product development expenses which increased by approximately $28,000, and (ii) consultancies expenses incurred which increased by approximately $50,000.

*Other Income (Expense)*

Interest expenses for the three months ended March 31, 2025 increased to $78,121 from $31,873 for the comparable period in 2024 due to (i) the increase in 2024 of convertible notes outstanding and (ii) higher charges for the amortization of debt discount. The increase in interest expenses was more than offset by a favorable change for the fair value assessment of warrant and derivative liabilities, amounting to approximately $94,000.

*Net Loss*

Our net losses for the three months ended March 31, 2025 and March 31, 2024 were $396,748 and $456,157, respectively, due to the above-mentioned factors.

#### Results of Operations – Years ended December 31, 2024 and December 31, 2023
*Revenues*

The Company had not derived any revenues from the sale or licensing of its products.

[**Table of Contents**](#TOC001)

*Research and Development*

Our software is intended to be marketed as a distinctive separate product and, pursuant to ASC 985-20, the related costs which arise in the design, configuration and coding performed by third party contractors are expensed. Software development began in 2022. All related work is done by third party contractors. During the two years 2024 and 2023 we incurred product development expenses of $487,332 and 139,152, respectively.

*Operating Expenses*

Operating expenses for 2024 increased to $2,322,078 from $780,772 for the year 2023. The increase in 2024 is primarily attributable to (i) higher product development expenses which increased by $348,180, (ii) increases in outside consultancy, legal, and accounting expenses which increased by $310,267, and (iii) the grant of stock, stock options and warrants to directors and officers, the cost of which was recognized for $863,305 non-cash expense in 2024, up from $104,160 in 2023.

*Other Income (Expense)*

Interest expenses for 2024 increased to $190,174 from $29,808 for 2023 due to the issuance in 2024 of additional convertible notes and related charges for the amortization of debt discount. We also recorded a charge of approximately $137,000 for a negative change in the fair value assessment of warrants and derivative liabilities.

*Net Loss*

Our net losses for the years ended December 31, 2024 and December 31, 2023 were $2,649,178 and $788,005, respectively, due to the above-mentioned factors.

#### Plan of Operations
We anticipate receiving FDA marketing clearance for the U.S. by the end of the second quarter of 2025. This clearance will mark the official launch of our software product in the U.S., with revenues projected to start materializing in the fourth quarter in 2025. In Canada, where regulatory approval is not required, there is potential for sales to begin prior to receiving FDA clearance; however, this is not guaranteed. Our plan projects that operations will become cashflow positive during the first half of 2026. We believe that the net proceeds from this public offering of our stock, which we estimate to be approximately $5,900,000, will be sufficient to satisfy our cash needs until then, and we do not anticipate having to raise additional funds.

#### Liquidity and Capital Resources

#### Sources of Liquidity
Since our inception, we have not generated any revenue and have incurred significant operating losses. Our product is at a late phase of development with respect to product verification and validation through clinical trials, required for an application for approval of commercialization by the FDA. We do not expect to generate significant revenue from product sales until late 2025.

To finance ongoing operations and product development we entered in 2023 into a Placement Agent's Agreement with Network 1 Financial Securities, Inc., a licensed broker/dealer ("Network 1"), for a bridge financing transaction (the Bridge Financing Transaction), for the placement of up to $2,000,000 senior convertible debentures, on a best-efforts basis. The debentures carry interest of 6% per year, mature in 24 months, and will automatically convert into the Company's stock in the event of a public offering of the Company's stock, at a 25% discount to the offering price in such an event (the "Event"). Investors who participate in the debenture offering receive stock purchase warrants at the rate of 0.5 warrants for every share issued upon conversion of the notes. The warrants may be exercised at the debt conversion price in the Event or $2.00 if no Event takes place, and expire 3 years after issuance. At December 31, 2024, a total $1,420,400 of such convertible notes have been placed.

As of March 31, 2025, our cash balance is $1,847, which is not adequate for our current planned level of operations through at least 12 months from the issuance date of this Form S-1.

[**Table of Contents**](#TOC001)

Our cash needs during the remaining three quarters in 2025 and before material revenues are expected to materialize in late 2025 are projected to be between $1.2 million and 1.5 million whereby approximately $200,000 are attributable to the initial three months' timeframe, towards the end of which we expect our public offering to supply needed cash. Those initial three months will be financed through expected additional proceeds from our Bridge Financing Transaction. If our public offering were to be delayed beyond the end of the second quarter in 2025, we expect to raise additional capital through the private placement of equity.

#### Cash Flows
*The following tables summarize our cash flows:*

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2024** | **2023** |
|  **Cash flows used in operating activities** | $(748688) | $(186151) |
|  **Net Cash flows provided by financing activities** | 616477 | 398460 |
|  **Net (decrease) increase in cash** | (132211) | 212309 |
|  Cash at beginning of period | 305713 | 93404 |
|  **Cash at end of period** | $173502 | $305713 |

---

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2025** | **2024** |
|  Net cash used by operating activities | $(195778) | $(185077) |
|  Net cash used by investing activities | (15996) |  |
|  Net cash flows provided by financing activities | 40119 | 262740 |
|  Net (decrease) increase in cash | (171655) | 77663 |
|  Cash at beginning of period | 173502 | 305713 |
|  Cash at end of period | $1847 | $383376 |

---

#### Operating Activities
During the years ended December 31, 2024 and December 31, 2023, net cash used in operating activities was primarily for product development expenses and for outside professional services.

#### Investing Activities
There were no cash flows from investing activities during the years ended December 31, 2024 or December 31, 2023.

#### Financing Activities
During the Years ended December 31, 2024, and December 31, 2023 net cash provided by financing activities was from the bridge financing transaction.

#### Market Capital Expenditure Commitments
We have no material commitment for capital expenditures.

#### Fair value of Common Stock
In order to determine the fair value of shares of our Common Stock, given the absence of a public trading market of our capital stock to date, the Company has exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our Common Stock, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• contemporaneous valuations of our Common Stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our business, financial condition and results of operations, including related industry trends affecting our operations;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company, given prevailing market conditions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the lack of marketability of our Common Stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the market performance of comparable publicly-traded companies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• U.S. and global economic and capital market conditions and outlook; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Common Stock valuation methodology.

In estimating the fair market value of our Common Stock, the Company retained the services of third party consultants which specialize in Section 409A valuation analysis.

#### Revenue Recognition
In accordance with ASC 606, revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The Company has not yet derived revenues from the sale or licensing of its product.

#### Derivative Liability
The Company evaluates its financial instruments to determine if those contracts or embedded components of those contracts qualify as derivatives to be accounted for separately. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other bifurcated embedded derivative instruments in the convertible instrument, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date, with the change in fair value recorded in the statements of operations as other income or expense.

#### Intangible Assets
Intangible assets consist of an exclusive world-wide license granted to the Company by the University of Louisville for the technology underlying the Company's software products and are stated at cost less accumulated amortization. The Company amortizes its intangible assets on a straight line over the estimated useful life of the assets and assesses the valuation of such assets whenever events or circumstances dictate that the carrying value might not be recoverable.

The Company incurs fees related to third party patents, consisting of costs to defend patents, and renew or extend the term of existing patents, which are expensed as incurred.

#### Funding Requirements
We expect that our expenses will continue on the level shown during 2024 and operating losses will be generated. Based on our current plans, we believe our existing cash will not be sufficient to fund our operations requirements through at least 12 months from the issuance date of this Form S-1. We expect to incur substantial additional expenditures in the medium term to support market entry and commercialization of our product. We expect to incur net losses for the foreseeable future. Our ability to fund our product development and commercialization of our product will depend on the amount and timing of cash received from the planned public offering. Our future capital requirements will depend on many factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the costs, timing and outcomes of clinical trials and regulatory reviews associated with our product;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the costs of commercialization activities, including product marketing, sales and distribution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the emergence of competing technologies and products and other adverse marketing developments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effect on our product development activities of actions taken by the FDA, EMA or other regulatory authorities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our degree of success in commercializing our product, if and when approved; and

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the number and types of future products we develop and commercialize.

A change in the outcome of any of these or other variables with respect to the development of our product could significantly change the costs and timing associated with the development of the product. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

#### Off-Balance Sheet Arrangements
We have no other off-balance sheet arrangements that have had, or are reasonably likely to have, a material current or future effect on our consolidated financial statements or changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

#### Recent Accounting Pronouncements
For information on recent accounting pronouncements, see our financial statements and the related notes found elsewhere in this report.

#### The JOBS Act and Emerging Growth Company Status
Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act to comply with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period.

For as long as we remain an "emerging growth company" under the recently enacted JOBS Act, we will, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• be exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act, which requires that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Exchange Act and instead provide a reduced level of disclosure concerning executive compensation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor's report on the financial statements.

Although we are still evaluating the JOBS Act, we currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an "emerging growth company," including the extension of time to comply with new or revised financial accounting standards available under Section 102(b) of the JOBS Act. Among other things, this means that our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an emerging growth company, we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our Common Stock may be materially and adversely affected.

[**Table of Contents**](#TOC001)

#### BUSINESS

#### Overview
NeuroSpectrum Insights (NSI), a startup medical device company, is preparing to commercialize breakthrough computerized analysis technology to enhance clinicians' capabilities in diagnosing various neurological and neurodevelopmental disorders, such as: autism, dyslexia, ADHD, or schizophrenia. GyriCalc, NSI's first product, focuses on autism. The GyriCalc proprietary, patented software technology identifies early human brain structural markers of neurodevelopmental differences by automatically analyzing images taken by magnetic resonance imaging (MRI) machines.

The NSI vision is to unshackle the benefits of early intervention for persons born with neurological and neurodevelopmental disorders. For autism, the average age of diagnosis is 4 – 1/2 years. The American Academy of Pediatrics recommends screening every child for autism between 18 and 24 months old. This resulting 2+ year gap is a function of limited numbers of diagnostic specialists combined with the use of subjective, behavioral, and functional observation assessments. Widely accepted views within the autism care community are that earlier mitigating intervention therapies lead to superior life span outcomes for persons with autism, their caregivers and society overall.

GyriCalc will introduce the first fully objective measure to assist in autism diagnosis. This objective measure can be accomplished in minutes versus the hours, weeks, months, and sometimes years it currently takes for subjective assessments. Our technology provides clinicians expedited guidance for tailoring more precise functional measurements and early interventions.

#### Our Product
GyriCalc is a patented, proprietary computerized algorithm which measures predetermined human brain regions for specific surface characteristics. Images of these brain regions are captured by generally available structural magnetic resonance imagers ("MRI"). The MRI scan typically takes 15 to 20 minutes.

When GyriCalc is applied to the MRI scan, it conducts an analysis and generates a detailed report, in minutes, of the brain surface characteristics measured and the degree these characteristics correlate to the reference data set for typical (normal) brains. The report is provided directly to the ordering clinician.

The specific regions of the cerebral cortex and their surface characteristics (known as "gyri" and "sulci") correlate to autism as determined through years of research study within the University of Louisville Bioimaging Laboratory, Bioengineering Department in conjunction with the Department of Psychiatry and Behavioral Science and the Norton Children's Autism Center. The algorithm achieved an autism identification rate of 94%<sup>3</sup>.

NeuroSpectrum Insights has an exclusive commercialization license with the University of Louisville for this technological advancement.

NeuroSpectrum Insights is currently in the final stages of completing a Clinical Performance Protocol (which is distinct from a clinical trial). In this Clinical Performance Protocol, we analyzed 50 brain scans from children of ages two to three years old, using our proprietary technology, GyriCalc, to generate detailed reports for each scan. The same 50 scans were independently reviewed by three board-certified neurologists. We have compared the findings from GyriCalc to those of the neurologists to assess alignment and performance accuracy and have compiled the data, and have submitted the results to the FDA in early March of 2025.

____________

3 *Shape Analysis of the Human Brain by Matthew Joseph Nitzken B.S., University of Louisville, 2009; M. Eng., University of Louisville, 2010.*

*The UCLA database was collected from individuals between the ages of 8 to 17 years of age, with an average age of 13 years. Subjects were evaluated using the WISC, ADOS, and by medical professionals to determine a diagnosis. All scans were acquired using the MP RAGE, three*-dimensional*, T1*-weighted*, gradient*-echo *sequence. The results for the UCLA database showed an overall accuracy of 94.36%. Assuming negative for diagnosing autism and positive for determining neurotypical, the test sensitivity (TPR) is 0.900, the specificity (SPC) is 0.976, the positive predictive value (PPV) is 0.964, and the negative predictive value (NPV) is 0.930.* 

*The method was tested on a large number of subjects spread across multi*-center *databases. The testing confirmed that the software was capable of accurately making a diagnosis of autism in a wide range of individuals. Results for the testing data sets achieved accuracies of 88.89% for the KKI database, 94.36% for the UCLA database, 88.18% for the UM database, 95.65% for the Conturo database, and 97.29% for the IBIS database.*

[**Table of Contents**](#TOC001)

#### Commercialization Strategy
NeuroSpectrum Insights will market GyriCalc to clinicians at a predetermined list price per patient MRI scan report. The MRI scan will be ordered by the practitioner and paid for by the patient which in most instances will be covered by medical insurance coverage.

The average price for a brain MRI in the United States is ~$1,000<sup>4</sup>. At a projected list price of $1,500 per patient we estimate a 5-Year Revenue Projection *(~35% of annual projected market at 5 years).*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2026** | **2027** | **2028** | **2029** |
|  Number of GyriCalc Test | 415 | 4218 | 12820 | 29815 | 35200 |
|  Total Revenue | 623000 | $6326000 | $19229500 | $44721000 | $52850000 |
|  Operating Income (Loss) | $(1730000) | $(1753800) | $12369000 | $34480600 | $40750000 |
|  Net Income (Loss) | $(1857000) | $(1753800) | $10390000 | $25860400 | $29750000 |

---

*Marketing & Sales*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Marketing Strategy

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Targeted, digital messaging tools (including social media accounts) for calendarized promotional campaigning aligned with professional clinical meetings and advocacy groups for autism events

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinician targeted for sales/ordering *("push")*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Parents/caregivers targeted for awareness/stimulation *("pull")*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Best of breed, branding, key opinion leader ("KOL") endorsements, connecting with subject matter "influencers", and internet presence through new website and customer information support portal, with select use of video messaging (ad hoc and professional)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• KOL support for select, high profile events and annual professional and advocacy meeting presentations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Surveilling the market for success stories and merchandizing same through news outlets (internet and traditional)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sales Strategy

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An individual with clinical autism diagnosis and intervention experience will lead the sales effort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Directly contact, via email, phone and social media, targeted clinicians trained to diagnose autism to deliver and reinforce product and services information

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Participate in industry specific events presenting appropriate materials and messaging based on the individual events and opportunities

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Coordinate directly with the NSI Clinical Advisory Committee to expand its membership and extend influence into members' professional networks

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sales promotion programs to stimulate repeat ordering and telling of success stories

#### Barriers to Entry
Though our industry, broadly speaking, has a number of competitors — large and small — with new entrants appearing regularly, in the Company's opinion, there is one primary barrier to entry in our favor that is coupled with an important ancillary barrier to entry. These barriers to entry include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Intellectual Property and Patents

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Technical Learning Curve

____________

4 *New Health Choice, Inc. https://www.newchoicehealth.com/procedures/brain*-mri

[**Table of Contents**](#TOC001)

*Intellectual Property and Patents*

We have an exclusive license agreement with the University of Louisville Research Foundation ("ULRF"), as the agent for the University of Louisville, for intellectual property owned by the University of Louisville (the "ULRF License Agreement"). Such intellectual property is underlying our software product. The ULRF License Agreement allows us to use certain patents or copyrights (the "Licensed Rights") listed below in the development of our products (the "Licensed Products"). The ULRF License Agreement will continue until the expiration of the last to licensed patents, set to expire July 29, 2035, unless terminated early by the parties pursuant to the terms of the ULRF License Agreement.

Pursuant to the ULRF License Agreement, as amended, we agreed to hit certain progress milestones set out in the exhibits to the agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• By January 1, 2025, we would complete verification and validation of software for implementation of the technology in a Licensed Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• By March 31, 2025, we would submit an application to the United States Food and Drug Administration ("FDA") to obtain 501(k), PMA or other clearance to market and sell Licensed Products in the United States

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Within 12 months of receiving FDA approval and by no later than March 31, 2026, whichever occurs first, we would make a first sale in the United States

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• After the first sale, and throughout the remainder of the length of the license, we would sell at least one product every 6 months.

Under the ULRF License Agreement, in lieu of a license issuance fee, we entered into the Stock Issuance Agreement, pursuant to which we issued shares of our common stock equal to eight percent (8%) of the total equity of our company on the date of the issuance to the ULRF and four individuals, which was equal to 478,261 shares of our common stock. The shares issued pursuant to the Stock Issuance Agreement are restricted and have no registration rights.

Additionally, we will pay ULRF 5% of our Net Sales for all license products sold during the term of the license, and 30% of any sublicensing income. If the total amount paid to ULRF through the sum of the stock issuance and percentage of net sales in any year is less than the agreed upon annual minimum payment, we pay ULRF the difference between the compensation provided and such minimum. For the year in which the first sale of our product occurs (= "Year 1"), the minimum is $25,000, for Years 2 and 3, the annual minimum is $75,000, and for any year thereafter, the annual minimum is $150,000. Furthermore, the amended license agreement calls for milestone payments of $5,000 on December 1, 2024 and on May 21, 2025. We have also reimbursed ULRF in the amount of $34,273 for certain costs incurred prior to entry into the license agreement.

We hold licensed commercialization rights for two method of use utility patents that may provide protection for GyriCalc, supporting its position as a unique and innovative product in the market. We believe that these patents will help to safeguard key aspects of our technology, including a processor-implemented method for classifying a brain. While we cannot guarantee that these patents will fully protect against potential infringement, we believe they provide adequate coverage to deter other companies from attempting to replicate GyriCalc, ensuring its competitive edge in the marketplace.

List of Licensed Patents:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. U.S. Patent No. 9,230,321, "Computer Aided Diagnostic System Incorporating 30 Shape Analysis of the Brain for Identifying Developmental Brain Disorders," issued Jan. 5, 2016 from U.S. Patent App. No. 13/834,231 (ULRF Ref. 11064-02), which claims priority to U.S. Provisional Patent App. No. 61/617,869, filed Mar. 30, 2012 (ULRF Ref. 11064-01, -02), expiration date March 30, 2032.

Title: *Method and System for Automatically Classifying Brain Magnetic Resonance Images*

This Process/Method patent describes a system and method for the automated classification of brain structures using MRI scans. The technology leverages cortical surface analysis, including regional brain volume, surface area, and curvature, to identify neurological patterns associated with neurodevelopmental disorders such as autism.

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. U.S. Patent No. 10,262,414 "Computer Aided Diagnostic System for Mapping of Brain Images," issued from U.S. Patent App. No. 15/223,671, filed Jul. 29, 2016 (ULRF Ref. 13098-03), which claims priority to U.S. Provisional Patent App. No. 62/198,169, filed Jul. 29, 2015 (ULRF Ref. 13098-02, -03), expiration date July 29, 2035.

Title: *Method and System for Predicting Autism Spectrum Disorder*

This Use/Method patent extends the earlier work to a specific application: the use of imaging data to predict autism spectrum disorder in pediatric populations. It describes algorithms that quantify cortical features and use them in machine learning models to forecast ASD diagnosis likelihood.

List of Licensed Copyrights:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. U.S. Copyright Registration No. TX-520-124 for "Mesh Diagnostic Software," registered Apr. 6, 2012 (ULRF Ref. 12063-01)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. U.S. Copyright Office Case No. 1-402120627, "Brain Image Segmentation Software," filed Sep. 23, 2016 (ULRF Ref. 13100-02)

#### Trademark
The Company filed an application to trademark the name "Gyricalc" with the U.S. Patent and Trademark Office ("USPTO") in September 2024 (USPTO Serial Number: 98743213). The application is under review. The review process can take up to one year depending on the number of applications subject to clearance by the USPTO in any given year. The status of this trademark application is still pending.

#### Our Market Opportunity
Developmental pediatricians, pediatric neurologists, child psychiatrists, and neuropsychologists make up the constellation of clinicians trained to diagnose autism. These are NSI's primary target customers. Exact numbers for these clinicians are uncertain. Generally accepted estimates put the combined total number at eight to ten thousand in the Unites States and mainly concentrated in major metro areas. This comparatively small number of practitioners, combined with the subjective observational nature of assessment (current standard of care), is another contributing factor to long lead times for diagnosis. Additionally, these practitioners assess a wide range of neurological and neurodevelopmental disorders. Yet, it's these clinicians that are the stage gate for getting insurance coverage needed to support the cost of autism interventional therapies.

The Centers for Disease Control and Prevention (CDC) estimates that 1 in 36 children, by the age of 8, will be diagnosed with autism. Between 2020 and 2022, United States annual live births have plateaued at 3.7 million. At a 1/36 rate, the projected number of new cases of autism over the forecast years is approximately 100,000/year. While the projected number of cases is relatively small compared to the estimated number of diagnosing clinicians, the crux of the problem is screening 3.7 million candidates each year. Additionally, screening isn't diagnosing. It is an essential first step that falls to general pediatricians, parents, caregivers all with highly variable experiences and skills. This too is a significant contributing factor in delayed diagnosis. In a future envisioned market where an objective GyriCalc "test" would be as common as a blood test, greater screening compliance could be achieved together with greater detection precision.

#### Government Regulation
We will be subject to various healthcare related laws regulating fraud and abuse, pricing and sales and marketing practices and the privacy and security of health information, including the United States federal regulations described below. Many states, foreign countries and supranational bodies have also adopted laws and regulations similar to, and in some cases more stringent than, the federal regulations discussed above and below.

[**Table of Contents**](#TOC001)

#### Regulation of Medical Devices in the United States
Our products and operations are subject to extensive and ongoing regulation by the Food and Drug Administration ("FDA") under the Federal Food, Drug, and Cosmetic Act of 1938 and its implementing regulations, collectively referred to as the FDCA, as well as other federal and state regulatory bodies in the United States. The laws and regulations govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, record keeping and reporting, clearance or approval, marketing, distribution, promotion, import and export and post-marketing surveillance.

The FDA regulates the development, design, pre-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, import, export, adverse event reporting, advertising, promotion, marketing and distribution of medical devices in the United States to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA. Failure to comply with applicable requirements may subject a device and/or its manufacturer to a variety of administrative sanctions, such as FDA refusal to approve pending premarket applications, issuance of warning letters, mandatory product recalls, import detentions, civil monetary penalties, and/or judicial sanctions, such as product seizures, injunctions and criminal prosecution.

*FDA Premarket Clearance and Approval Requirements*

Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, approval of a premarket approval, or PMA, or grant of a de novo request for classification. During public emergencies, the FDA also may grant emergency use authorizations to allow commercial distribution of devices intended to address public health emergency. Under the FDCA, medical devices are classified into one of three classes — Class I, Class II or Class III — depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to provide reasonable assurance of its safety and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to marketing the device.

Class I devices include those with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to the FDA's "general controls" for medical devices, which include compliance with the applicable portions of the FDA's Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events and malfunctions through the submission of Medical Device Reports, or MDRs, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some Class I or low risk devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below.

Class II devices are moderate risk devices subject to the FDA's general controls, and any other "special controls" deemed necessary by the FDA to ensure the safety and effectiveness of the device, such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process, though certain Class II devices are exempt from this premarket review process. When required, the manufacturer must submit to the FDA a premarket notification, or 510(k), submission demonstrating that the device is "substantially equivalent" to a legally marketed predicate device, which in some cases may require submission of clinical data. Unless a specific exemption applies, 510(k) premarket notification submissions are subject to user fees. If the FDA determines that the device, or its intended use, is not substantially equivalent to a legally marketed device, the FDA will place the device, or the particular use of the device, into Class III, and the device sponsor must then fulfill more rigorous premarketing requirements.

Class III devices include devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices and devices deemed not substantially equivalent to a predicate device following a 510(k) submission. The safety and effectiveness of Class III devices cannot be reasonably assured solely by general or special controls. Submission and FDA approval of a PMA application is required before marketing of a Class III device can proceed. As with 510(k) submissions, unless an exemption applies, PMA submissions are subject to user fees. The PMA process is much more demanding than the 510(k) premarket notification process. A PMA application, which is intended to demonstrate that the device is reasonably safe and effective for its intended use and must be supported by extensive data, typically including data from pre-clinical studies and clinical trials.

The FDA also has the authority to allow the commercialization of unapproved medical devices, or new uses of existing devices in times of emergency, such as during a pandemic.

[**Table of Contents**](#TOC001)

*510(k) Clearance Marketing Pathway*

To obtain 510(k) clearance for a medical device, an applicant must submit to the FDA a 510(k) notice demonstrating that the proposed device is "substantially equivalent" to a legally marketed device, known as a "predicate device." A legally marketed predicate device may include a device that was legally marketed prior to May 28, 1976 (a pre-amendment device), a device that has been reclassified from Class III to Class II or Class I, or a device that was found substantially equivalent through the 510(k) process. A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (1) the same technological characteristics, or (2) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise new questions of safety and effectiveness and is at least as safe and effective as the predicate device. A showing of substantial equivalence sometimes, but not always, requires clinical data. Once the 510(k) submission is accepted for review, by regulation, the FDA has 90 calendar days to review and issue a determination. As a practical matter, clearance may take and often takes longer. Upon review, the FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments.

Before the FDA will accept a 510(k) submission for substantive review, the FDA will first assess whether the submission satisfies a minimum threshold of acceptability. If the FDA determines that the 510(k) submission is incomplete, the FDA will issue a "Refuse to Accept" letter which generally outlines the information the FDA believes is necessary to permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information within 180 days before the FDA will proceed with additional review of the submission.

If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is "not substantially equivalent" to a previously cleared device, for example, if the device is deemed to have a new intended use or different technological characteristics that raise different questions of safety or effectiveness when compared to the cited predicate device (and no other predicate can be identified), the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance with the "de novo" process, which is a route to market for novel medical devices that are low to moderate risk and have no suitable predicate device. If the FDA determines that the information provided in a 510(k) submission is insufficient to demonstrate substantial equivalence to the predicate device, the FDA generally identifies the specific information that needs to be provided so that it may complete its evaluation of substantial equivalence, and such information may be provided within the time allotted by the FDA or in a new 510(k) submission should the original one have been withdrawn.

After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval. The determination as to whether or not a modification meets these criteria is initially left to the manufacturer using available FDA guidance. Many minor modifications today are accomplished by a "letter to file" in which the manufacturer documents the rationale for the change and why a new 510(k) submission is not required. However, the FDA may review such letters to file to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.

Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals, including on whether it should consider certain actions that might require new authority. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation.

[**Table of Contents**](#TOC001)

*PMA Approval Pathway*

Class III devices require PMA approval before they can be marketed in the U.S., although some pre-amendment Class III devices for which FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is generally more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is reasonably safe and effective, and the PMA must be supported by extensive data, including data from pre-clinical studies and clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA's review may take and often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel's recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers' or suppliers' manufacturing facility or facilities to ensure compliance with the QSR.

The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical trial that supported PMA approval or requirements to conduct additional clinical trials post-approval. The FDA may also condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.

Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, that affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.

*De novo Classification*

Medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. To market low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, a manufacturer may request a de novo down-classification of its medical device into Class I or Class II, rather than requiring the submission and approval of a PMA application. A medical device may be eligible for de novo classification if the manufacturer first submitted a 510(k) notice and received a determination from the FDA that the device was not substantially equivalent, or a manufacturer may request de novo classification directly without first submitting a 510(k) notice and receiving a not substantially equivalent determination. The FDA is required to classify the device within 120 calendar days following receipt of the de novo application, although in practice, the FDA's review may take significantly longer. During the pendency of the FDA's review, the FDA may issue an additional information letter, which places the de novo request on hold and stops the review clock pending receipt of the additional information requested. If the de novo requestor does not provide the requested information within 180 calendar days, the FDA will consider the de novo request to be withdrawn. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the de novo request if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls

[**Table of Contents**](#TOC001)

would be inadequate to control the risks and special controls cannot be developed. In the event the FDA determines the data and information submitted demonstrate that general controls or general and special controls are adequate to provide reasonable assurance of safety and effectiveness, the FDA will grant the de novo request for classification. When the FDA grants a de novo request for classification, the device is granted marketing authorization and further can serve as a predicate for future devices of that type, through a 510(k) premarket notification.

*Clinical Trials*

Clinical trials are typically required to support a PMA, often required for a de novo request, and sometimes required to support a 510(k) notice. An application for PMA clearance under a 510(k) notice requires the identification of a competitor with the same claims which is already operating with PMA clearance from the FDA. Therefore, for a 510(k) notice to be successful, the interested party must demonstrate that the product is safe and effective under the standards of the competitor. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA's investigational device exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a "significant risk," as defined by the FDA, to human health, the FDA requires the device sponsor to submit an IDE application to the FDA, which must be approved prior to commencing clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, purported or represented to be used in supporting or sustaining human life, is for a use that is substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. A clinical trial may begin 30 days after receipt of the IDE by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. Acceptance of an IDE application for review does not guarantee that the FDA will approve the IDE and, if it is approved, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.

In addition, the clinical trials must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA.

If the device is considered "non-significant risk" ("NSR"), IDE submission to the FDA is not required. Instead, only approval from the IRB overseeing the investigation at each clinical trial site is required. Abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements also apply to NSR device studies.

During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical trial are also subject to the FDA's regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all applicable reporting and record keeping requirements.

Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a clinical trial is completed, there can be no assurance that the data generated during a clinical trial will meet the safety and effectiveness endpoints or otherwise produce results that will lead the FDA to grant marketing clearance or approval.

[**Table of Contents**](#TOC001)

*Post-market Regulation*

After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• establishment registration and device listing with the FDA;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• QSR requirements, which require manufacturers and contract manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• labeling regulations and FDA prohibitions against the promotion of investigational products, or "off-label" uses of cleared or approved products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• requirements related to promotional activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections, product removals or recalls if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the FDA's recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.

Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission ("FTC") and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. In general, if the FDA determines that our promotional materials or training constitute promotion of an unapproved or uncleared use or our products, it could request that we modify these materials or subject us to regulatory or enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our materials to constitute promotion of an unapproved or uncleared use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.

Manufacturing processes for commercial products are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, history file, device history records, and complaint files. As manufacturers, we and our contract manufacturers will be subject to periodic scheduled or unscheduled inspections by the FDA. Failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, manufacturing operations and the recall or seizure of products, which would harm our business. The discovery of previously unknown problems with any of our test kits, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.

[**Table of Contents**](#TOC001)

The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unanticipated expenditures to address or defend such actions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• customer notifications for repair, replacement, refunds;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• recall, withdrawal, administrative detention or seizure of our test kits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operating restrictions or partial suspension or total shutdown of production;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• refusal of or delay in granting our requests for 510(k) clearance or PMA approval of new test kits or modified test kits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operating restrictions, partial suspension or total shutdown of production;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• withdrawing 510(k) clearance or PMA approvals that are already granted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• refusal to grant export approval for our test kits; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• criminal prosecution.

The Federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program, such as Medicare or Medicaid.

The Health Insurance Portability and Accountability Act of 1996 ("HIPAA") prohibits knowingly and willfully (1) executing a scheme to defraud any health care benefit program, including private payers or (2) falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, also restricts the use and disclosure of personal health information, mandates the adoption of standards relating to the privacy and security of individually identifiable health information and requires us to report certain breaches of unsecured, individually identifiable health information.

The Physician Payments Sunshine Act requires manufacturers of medical devices covered under Medicare and Medicaid to record transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosure. Similar reporting requirements have also been enacted on the state level, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals.

The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery.

If we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from participating in government healthcare programs, contractual damages, reputational harm and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could materially adversely affect our ability to operate our business and our financial results.

[**Table of Contents**](#TOC001)

#### Human Capital Resources
As of December 31, 2024, we have two (2) full-time employees and (3) part-time employees, and we use the services of several consultants who are experts in neuroscience related fields. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees.

#### Stock Incentive Plan
On June 7, 2019, the Company issued a stock plan (the "Plan") that is intended to encourage ownership of shares by employees and directors and certain consultants and for them to promote the success of the company. The plan provides for the granting of ISOs, Non-Qualified Options, Stock Grants and Stock-Based awards.

The number of shares which may be issued pursuant to the Plan shall be 3,000,000, or the equivalent of such number of shares after the Administrator has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with the plan.

The administrator of the Plan shall be the Board of Directors, or a committee thereof, and is authorized to (i) interpret the provision of the Plan and all the rights thereto, (ii) determine which employees, directors and consultants shall be granted awards, (iii) determine the number of shares for which an award or awards shall be granted; provided, however, that in no event shall the award be more than 100,000 shares in one fiscal year, (iv) specify the terms and conditions upon which an award may be granted, and (v) adopt any sub-plans applicable to residents of any specified jurisdiction as it deem necessary in order to comply with or take advantage of any tax or other law.

The administrator will, in its sole discretion, name the participants in the Plan, provided, however, that each participant must be an employee, director or consultant of the Company, or of an affiliate at the time the award is granted.

No participant in the Plan to whom an award has been granted shall have rights as a shareholder with respect to any shares covered by such award, except after due exercise of the option or acceptance of the stock grant and tender of the full purchase price, if any, for the shares being purchased pursuant to such exercise or acceptance and registration of the Shares in the Company's share register in the name of the participant.

The Plan shall terminate on June 7, 2029, or at an earlier date voted upon by the shareholder or the Board of Directors of the Company; provided, however, that any such earlier termination shall not affect any agreements executed prior to the effective date of such termination.

#### Properties and Facilities
The Company does not own any real property. We use office space at 376 Main Street, Suite 105, Bedminster, NJ 07921 at $2,000 per month under a month-to-month sublease arrangement.

#### Legal Proceedings
From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are currently not a party to any legal proceedings.

#### Changes in and Disagreements with Accountants
None.

#### Corporation Information
We were incorporated in Delaware on January 19, 2016. Our principal executive offices are located at 376 Main Street, Ste. 105, Bedminster, NJ 07921, and our telephone number is 908-304-4858. Our corporate website address is *https://neurospectruminsights.com/*. The information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

[**Table of Contents**](#TOC001)

#### MANAGEMENT

#### Executive Officers and Directors

---

| | | |
|:---|:---|:---|
|  **Name** | **Age** | **Position(s)** |
|  ***Executive Officers and Directors*** |  |  |
|  Andrew Stewart | 77 | Chief Executive Officer, Director |
|  Joerg Klaube | 83 | Chief Financial Officer |
|  Mark Rosenberg | 71 | Chairman |
|  Boura Ali | 56 | Director |
|  Jason Pottinger | 40 | Director |
|  Corey Park | 52 | Director |

---

#### Executive Officers

#### Andrew Stewart, Chief Executive Officer, Director
Mr. Stewart combines over 40 years of experience in the medical device industry. He has served as CEO of NeuroSpectrum Insights, Inc. (f/k/a Autism Diagnosis Technologies) since May 2017. Previously, he held the position of CEO for Wipe-Rite Technologies, Inc. and Medeject, Inc., both medical device startups. Formerly, from 2006 to 2013, he was CEO of EyeTect, LLC, a startup medical device company focused on eye tracking for diagnosing depth of consciousness monitoring. From 1994 through 2003, Mr. Stewart was the Vice President of Sales and Member of the Management Board for Ethicon, a Division of Johnson and Johnson, Inc., a medical device company focused upon wound closure. From 1986 to 1993 he was Vice President Sales and Marketing, worldwide for Johnson and Johnson Professional, Inc., another Johnson and Johnson Division, focused on neurosurgical and cardiovascular surgical products. He served as Chairman and Vice Chairman of the Board of Directors for Somerset Medical Center from 1994 to 2003. He graduated from Kenyon College with double majors in Economics and Political Science in 1970. He graduated from Harvard Business School with an AMP in General Management in 1993.

#### Joerg H. Klaube, Chief Financial Officer
Mr. Klaube's career encompasses a broad range of appointments in corporate financial management, controllership and administrative functions, in a variety of business environments including publicly held companies. He joined the Company in 2018. From 2013 to 2017 he held the position of Chief Financial Officer at Turnpoint Medical Devices Inc., a designer and marketer of specialized infusion pumps. Prior to that he served as Chief Financial Officer for the telecommunications holding company E. Oliver Capital Group and the software design and computer marketing firms Magnitude Information Systems Inc. and Unitronix Corporation. Before that, he was employed for sixteen years with the U.S. subsidiary of Siemens AG, where he last served as Director of Business Administration in the Telecommunications Division. He graduated from the Banking School in Berlin, Germany, and holds a master's degree in business administration from Rutgers University.

#### Directors

#### Dr. Mark Rosenberg, Chairman of the Board
Dr. Mark Rosenberg came to NeuroSpectrum Insights in October 2023 to assume the role of Chairman of the Board. He brings 45 years of diverse experience which include hospital and clinical leadership, business ventures and innovation and leadership roles within the American College of Emergency Physicians (ACEP). Dr. Rosenberg had the privilege of serving as President of American College of Emergency Physicians during the Covid-19 pandemic representing over 40,000 emergency physicians. Mark Rosenberg is well known for his medical career as an emergency physician and Chairman of Emergency Medicine at a prestigious teaching hospital in New Jersey. He led the development of the nation's first Geriatric emergency department, as well as the Alternative to Opioid Pain Management Program (ALTO), and The Life Sustaining Management and Alternatives Program (LSMA) bringing palliative care to patients in the emergency department. Internationally, Dr. Rosenberg's innovations have changed the face of Emergency Medicine.

[**Table of Contents**](#TOC001)

#### Boura Ali, Director
Mr. Ali combines over 20 years of experience in the pharmacy industry and as an entrepreneur involving work in retail and hospital environments. Mr. Ali advised a Fortune 100 company regarding logistics and international marketing. He advised another Fortune 100 company regarding new technology. Mr. Ali is the managing member of Highlands Harris LLC and has been a partner at Academic Technology Ventures since 2015. Mr. Ali is a co-founder of Autism Diagnostic Technology.

#### Jason Pottinger, Director
Mr. Pottinger combines over 6 years of experience in technology commercialization senior management, following a 9-year career as a real estate investor and professional athlete. Previously, he has been involved in Plasma Stream Technologies and Predictive Aviation Analytics holding positions including Chief Executive Officer and Board Member. From 2009 through 2015, Mr. Pottinger was the President and CEO for Ark Management, Inc., a real estate and property management company. From 2014 to present, he has been CEO of Academic Technology Ventures, Inc., a company involved in technology commercialization. Mr. Pottinger is also currently a Director of Thermo-Flex Technologies, Inc., a company developing cooling systems for large corporations in various industry segments, including the mattress and apparel industries. He has an undergraduate degree from McMaster University and an MBA from The Schulich School of Business at York University in Toronto, Canada.

#### Corey Park, Director
Corey Park has brought value to the world as a serial entrepreneur for over 30 years. He attended the Notre Dame Mendoza School of Business (Leadership & Management) and is a certified hedge fund professional (CHP) with additional (CHP) certifications at the highest levels in portfolio analytics & risk management. He currently serves on several boards and is a highly sought-after advisor and mentor in the tech startup and venture arenas. Corey excels at taking a vision and making it a reality through sound business strategy and team development "bench strength". He intuitively sees the threads of opportunity and the many leverage points that wind through an organization, brings them together into a coherent whole, helps others extend their thinking, and drives material business advantage.

#### Family Relationships
There are no family relationships between our board of directors and any of our executive officers.

#### Legal Proceedings
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

#### Board Composition
Our business and affairs are organized under the direction of our Board of Directors, which currently consists of 5 members.

#### Director Independence
The NYSE Marketplace Rules require a majority of a listed company's Board of Directors to be comprised of independent directors within one year of listing. In addition, the NYSE Marketplace Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act.

Under Rule 5605(a)(2) of the NYSE Marketplace Rules, a director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3 of the Exchange Act, a member of an audit committee of a listed company

[**Table of Contents**](#TOC001)

may not, other than in his or her capacity as a member of the audit committee, the Board of Directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.

Our Board of Directors has reviewed the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family relationships, our Board of Directors has determined that each of Messrs. Rosenberg, Pottinger, Ali and Park is an "independent director" as defined under Rule 5605(a)(2) of the NYSE Marketplace Rules. Our Board of Directors also determined that Jason Pottinger, who comprises our audit committee and Mark Rosenberg who comprises our compensation committee, and Boura Ali and Corey Park, who will be members of our nominating and corporate governance committee following this offering, satisfy the independence standards for such committees established by the SEC and the NYSE Marketplace Rules, as applicable. In making such determinations, our Board of Directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director.

#### Board Committees
The NYSE permits a phase-in period of up to one year for an issuer registering securities in an initial public offering to meet the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee independence requirements. Under the initial public offering phase-in period, only one member of each committee is required to satisfy the heightened independence requirements at the time our registration statement becomes effective, a majority of the members of each committee must satisfy the heightened independence requirements within 90 days following the effectiveness of our registration statement, and all members of each committee must satisfy the heightened independence requirements within one year from the effectiveness of our registration statement.

*Audit Committee*

Our audit committee consists of Jason Pottinger, who is the chair of the committee. Each of the members of our audit committee will satisfy the NYSE Marketplace Rules and SEC independence requirements. The functions of this committee will include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations," and discussing the statements and reports with our independent auditors and management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.

Our Board of Directors has determined that Jason Pottinger qualifies as an "audit committee financial expert" within the meaning of applicable SEC regulations and meets the financial sophistication requirements of the NYSE Marketplace Rules. In making this determination, our board has considered extensive financial experience and business background. Both our independent registered public accounting firm and management periodically meet privately with our audit committee.

[**Table of Contents**](#TOC001)

*Compensation Committee*

Our compensation committee will consist of Mark Rosenberg, who is the chair of the committee, and Jason Pottinger. Our Board of Directors has determined that the members of our compensation committee are independent directors, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, and satisfies the NYSE Marketplace Rules independence requirements. The functions of this committee include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full Board of Directors regarding) our overall compensation strategy and policies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment of our executive officers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving (or if it deems appropriate, making recommendations to the full Board of Directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reviewing with management and approving our disclosures under the caption "Compensation Discussion and Analysis" in our periodic reports or proxy statements to be filed with the SEC; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• preparing the report that the SEC requires in our annual proxy statement.

*Nominating and Corporate Governance Committee*

Our nominating and corporate governance committee will consist of Boura Ali and Corey Park, who is the chair of the committee. Our Board of Directors has determined that each of the members of this committee satisfies the NYSE Marketplace Rules independence requirements. The functions of this committee include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• identifying, reviewing and evaluating candidates to serve on our Board of Directors consistent with criteria approved by our Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• evaluating director performance on the board and applicable committees of the board and determining whether continued service on our board is appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• evaluating, nominating and recommending individuals for membership on our Board of Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• evaluating nominations by stockholders of candidates for election to our Board of Directors.

#### Code of Ethics
Our Board plans to adopt a written code of business conduct and ethics (the "Code of Ethics") that applies to our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. We intend to post on our website a current copy of the Code of Ethics and all disclosures that are required by law in regard to any amendments to, or waivers from, any provision of the Code of Ethics.

#### Board Leadership Structure
Our Board of Directors, as a whole and also at the committee level, plays an active role overseeing the overall management of our risks. Our Audit Committee reviews risks related to financial and operational items with our management and our independent registered public accounting firm. Our Board of Directors is in regular contact with our Chief Executive Officer and Chief Financial Officer, who report directly to the Board of Directors and who supervise day-to-day risk management.

[**Table of Contents**](#TOC001)

#### Role of Board in Risk Oversight Process
We face a number of risks, including those described under the caption "Risk Factors" contained elsewhere in this prospectus. Our Board of Directors believes that risk management is an important part of establishing, updating and executing our business strategy. Our Board of Directors has oversight responsibility relating to risks that could affect the corporate strategy, business objectives, compliance, operations, and the financial condition and performance of our company. Our Board of Directors focuses its oversight on the most significant risks facing us and, on our processes, to identify, prioritize, assess, manage and mitigate those risks. Our Board of Directors receives regular reports from members of our senior management on areas of material risk to us, including strategic, operational, financial, legal and regulatory risks. While our Board of Directors has an oversight role, management is principally tasked with direct responsibility for management and assessment of risks and the implementation of processes and controls to mitigate their effects on us.

[**Table of Contents**](#TOC001)

#### EXECUTIVE AND DIRECTOR COMPENSATION
The following table sets forth total compensation paid to our named executive officers for the years ended 2024 and 2023. Individuals we refer to as our "named executive officers" include our Chief Executive Officer and Chief Financial Officer. Most of the salaries are unpaid and have been accrued.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  **Name and <br>Principal Position** | **Year** | **Salary <br>($)** | **Bonus <br>($)** | **Stock <br>Awards <br>($)** | **Option/Warrants<br>Awards <br>($)** | **All other <br>Compensation <br>($)** | **Totals <br>($)** |
|  **Andrew Stewart** | **2024** | **150000**<br><sup>(1)</sup> | **30000** | **—** | **95295** | **—** | **275295** |
| &nbsp;&nbsp;&nbsp; **CEO** | **2023** | **150000**<br><sup>(1)</sup> | **—** |  | **—** | **—** | **150000** |
|  **Joerg Klaube** | **2024** | **100000**<br><sup>(2)</sup> | **20000** | **192150** | **120400** | **—** | **432550** |
| &nbsp;&nbsp;&nbsp; **CFO** | **2023** | **50000**<br><sup>(2)</sup> | **—** | **—** | **25720** | **—** | **75720** |

---

____________

(1) Mr. Stewart's 2024 and 2023 base annual salary was $150,000 in each year and he received a bonus of $30,000 in 2024, all of which was accrued.

(2) Mr. Klaube's 2024 and 2023 base annual salary was $100,000 and $50,000, respectively, and he received a bonus of $20,000 in 2024, all of which except for $29,167 was accrued. During 2024, Mr. Klaube was awarded 100,000 stock purchase warrants, exercisable at $1.00 per share in connection with the cancellation of 25,000 warrants, exercisable at $0.50 per share, valued at $120,400 using the Black Scholes valuation model. He also received a stock grant of 100,000 shares, valued at $192,150. During 2023, Mr. Klaube was awarded 100,000 stock options, exercisable at $1.00 per share, valued at $25,720 using the Black Scholes valuation model.

#### Employment Agreements
We have entered into employment agreements with two of our executive officers. Set forth below is a summary of the material provisions of such employment agreements, which summaries do not purport to contain all of the material terms and conditions of each such agreement. For purposes of the following employment agreements:

*Andrew Stewart Employment Agreement*

Andrew Stewart entered into an employment agreement with the Company on October 1, 2018 as Chief Executive Officer. The initial term of employment was for 3 years and is to be automatically renewed for successive one-year periods unless either party gives written notice of termination. As part of Mr. Stewart's employment, Mr. Stewart received an initial grant of stock awards for 300,000 shares of restricted Common Stock, of which 75,000 vested immediately, and received a $120,000 annual base salary, since increased to $150,000, may receive bonuses or incentive cash compensation as determined annually by the Board of Directors, and may participate in any company equity incentive plan.

*Joerg Klaube Employment Agreement*

Joerg Klaube entered into an employment agreement with the Company on April 1, 2019 as Chief Financial Officer. The initial term of employment was for 3 years and is automatically renewed for successive one-year periods unless either party gives written notice of termination. As part of Mr. Klaube's employment, Mr. Klaube received an initial grant of stock purchase warrants for 100,000 shares of the Company's common stock at $0.50 per share and carrying a cashless exercise option, of which 75,000 have expired at the time of this submission, with the remaining 25,000 warrants cancelled, which cancelled and expired warrants were replaced by 100,000 new warrants, exercisable at $1.00 per share. He originally received a $50,000 annual base salary, which in March 2024 was increased to $100,000. He may receive bonuses or incentive cash compensation as determined annually by the Board of Directors, and may participate in any company equity incentive plan.

[**Table of Contents**](#TOC001)

#### Director Compensation
The following table sets forth the total compensation for each person who served as a non-employee member of our Board of Directors and received compensation for such service during the fiscal year ended December 31, 2024. Other than as set forth in the table, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our Board of Directors in 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **Name** | **Fees <br>Earned or <br>Paid in <br>Cash** | **Stock <br>Awards** | **Option <br>Awards** | **Total** |
|  **Mark Rosenberg 2024** | **—** | $384300 | **—** | $384300 |
| **2023** |  | **—** | $**120231** | $120231 |
|  **Jason Pottinger 2024** | $**39151** | **—** |  | $39151 |
| **2023** |  | **—** | $**41053** | $41053 |

---

In 2024, Dr. Rosenberg was awarded a stock grant of 200,000 shares, valued at $384,300. In 2023, Dr. Rosenberg and Jason Pottinger were awarded 300,000 and 100,000 stock options, respectively, valued at $120,231 and $41,053.

[**Table of Contents**](#TOC001)

#### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information concerning the ownership of our Common Stock as of March 31, 2025, with respect to: (i) each person, or group of affiliated persons, known to us to be the beneficial owner of more than five percent of our Common Stock; (ii) each of our directors; (iii) each of our named executive officers; and (iv) all of our current directors and executive officers as a group, upon the closing of this offering.

Applicable percentage ownership is based on 10,974,238 shares of Common Stock outstanding as of March 31, 2025. The percentage of beneficial ownership after this offering assumes the sale and issuance of shares of Common Stock in this offering and no exercise by the representative of the underwriters of its over-allotment option to purchase additional shares of Common Stock and/or Warrants and no conversion of notes and exercise of warrants issued pursuant to the Bridge Financing transaction (see section *Certain Relationships and Related Party Transactions*).

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting or investment power with respect to such securities. In addition, pursuant to such rules, we deemed outstanding shares of Common Stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60 days of , [\*]. We did not deem such shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the beneficial owners named in the table below have sole voting and investment power with respect to all shares of our Common Stock that they beneficially own, subject to applicable community property laws.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **Name and Address of Beneficial Owner<sup>(1)</sup>** | **Beneficial Ownership <br>Prior to Offering** | **Beneficial Ownership <br>Prior to Offering** | **Beneficial Ownership <br>After the Offering** | **Beneficial Ownership <br>After the Offering** |
|  **Name and Address of Beneficial Owner<sup>(1)</sup>** | **Number of <br>Shares** | **Percentage** | **Number of <br>Shares** | **Percentage** |
|  **Named Executive Officers and Directors** |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Boura Ali | 2042805 | 18.61% |  |  |
| &nbsp;&nbsp;&nbsp; Joerg Klaube | 529000<br><sup>(1)</sup> | 4.82% |  |  |
| &nbsp;&nbsp;&nbsp; Corey Park | 1993576<br><sup>(2)</sup> | 18.17% |  |  |
| &nbsp;&nbsp;&nbsp; Jason Pottinger | 348666<br><sup>(3)</sup> | 3.18% |  |  |
| &nbsp;&nbsp;&nbsp; Mark Rosenberg | 500000<br><sup>(4)</sup> | 4.56% |  |  |
| &nbsp;&nbsp;&nbsp; Andrew Stewart | 1372500<br><sup>(5)</sup> | 12.51% |  |  |
| &nbsp;&nbsp;&nbsp; All Directors and Officers as a group | 6786547 | 61.84% |  |  |
| &nbsp;&nbsp;&nbsp; Jerry Swon | 1251367<br><sup>(6)</sup> | 11.40% |  |  |
| &nbsp;&nbsp;&nbsp; Damon D. Testaverde | 1104708 | 10.07% |  |  |

---

____________

(1) Includes 100,000 stock options and 100,000 warrants.

(2) Consists of 1,993,576 shares held by Academic Innovation Partners Inc., a company controlled by Corey Park.

(3) Includes 100,000 stock options.

(4) Includes 300,000 stock options.

(5) Includes 300,000 stock options.

(6) Includes 1,029,699 shares held by Strategy Advisors LLC, a company controlled by Jerry Swon, 171,726 shares registered for Jerry Swon Inc. Defined Benefit Plan, 24,334 registered for Jerry Swon 401k Plan and 25,608 shares held by Jerry Swon directly.

[**Table of Contents**](#TOC001)

#### CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
The following is a description of transactions since the last two fiscal years to which we were a party in which (i) the amount involved exceeded or will exceed the lesser of $120,000 or one percent (1%) of our average total assets at yearend for the last two completed fiscal years and (ii) any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, any of the foregoing persons, who had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other similar arrangements, which are described under "Executive and Director Compensation."

During 2023 we granted 500,000 stock options to certain officers and directors of the Company, exercisable for three years (450,000 options) and 5 years (50,000 options). All such options are exercisable at $1.00 per share.

We also converted $401,500 in accrued salaries of certain officers, and $169,750 in accrued consulting fees of a major shareholder into 571,000 common shares.

During 2024 we issued 100,000 warrants to an officer of the Company. We converted accrued liabilities due to certain officers and a major shareholder into 899,750 shares, and issued a combined 300,000 shares as stock awards to an officer and a director of the Company.

Accrued interest on notes payable to an officer and a major shareholder at December 31, 2024 and December 31, 2023 was $24,247 and $14,247, respectively.

The Company rents office space at the rate of $2,000 per month from a company controlled by a major shareholder under a sublease arrangement.

#### Policies and Procedures for Related Party Transactions
All future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.

#### Professional Services
During 2023 we converted accrued salaries and fees of $571,250 into 571,250 shares.

During 2024 we converted accrued salaries and fees of $899,750 into 899,750 shares.

We have contracted Yorktown Advisors LLC, a company controlled by a major shareholder, for management consulting services at a fee of $7,000 per month, changed in April 2024 to $5,000 per month.

#### Notes payable — Related Party
Advances from Related Parties

In March 2022 we issued two promissory notes to the chief executive officer, and a major shareholder of the Company, in the total amount of $100,000. The notes carry interest at the rate of 8% and were originally due on December 31, 2022, and have since been extended to June 30, 2025.

#### Bridge Financing Transaction
On June 12, 2023, we entered into a Placement Agent's Agreement with Network 1 Financial Securities Inc. for a bridge financing transaction, involving the placement of up to $2,000,000 senior convertible debentures, on a best-efforts basis. The debentures carry interest of 6% per year, mature in 24 months, and will automatically convert into the Company's common stock in the event of a public offering of the Company's stock, at a 25% discount to the offering price in such an event (the "Event"). Investors who participate in the debenture offering received stock purchase warrants, the number of which is calculated by dividing one half of the corresponding note amount by the offering price in the Event. The warrants are exercisable at the offering price in the Event and expire 3 years after issuance. As of December 31, 2024, a total $1,420,400 of such convertible notes have been placed. In the process, we paid $59,540 and $125,112 in 2023 and 2024, respectively, in placement fees.

[**Table of Contents**](#TOC001)

#### Indemnification of Officers and Directors
Our certificate of incorporation and bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by Delaware law. Further, we intend to enter into indemnification agreements with each of our directors and officers, and we have purchased a policy of directors' and officers' liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances.

#### Policies and Procedures for Related Party Transactions
All future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel. Our audit committee will approve only those transactions that it determines are fair to and in the best interests of the Company.

To the best of our knowledge, during the past two fiscal years, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds $[•], and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our Common Stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation to our officers and directors in the ordinary course of business).

[**Table of Contents**](#TOC001)

#### DESCRIPTION OF CAPITAL STOCK
The following is a summary of the rights of our Common Stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of the certificate of incorporation and bylaws, copies of which have been filed as exhibits to the registration statement and are incorporated by reference to our registration statement, of which this prospectus forms a part.

#### Authorized Capital Stock
Our authorized capital stock consists of 100,000,000 shares consisting of 90,000,000 shares of Common Stock, par value $0.00001 per share. and 10,000,000 shares of preferred stock, par value $0.00001 per share.

#### Common Stock
As of December 31, 2024, there were 10,973,358 shares of Common Stock issued and outstanding, [•] shares of Common Stock issuable upon exercise of outstanding warrants, and 850,000 shares of Common Stock issuable upon exercise of outstanding stock options. In addition, there were [•] shares of common stock issuable upon conversion of the outstanding convertible notes and interest thereon issued in the Bridge Financing transaction.

Under the terms of our certificate of incorporation, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. The holders of outstanding shares of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as our Board of Directors from time to time may determine. Our Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution to stockholders are distributable ratably among the holders of our Common Stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. The rights, preferences and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

#### Preferred Stock
Our Board of Directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Common Stock. The issuance of our preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action.] As of December 31, 2024, there were no shares of Preferred Stock outstanding.

#### Options
As of December 31, 2024, we had stock options for 850,000 common shares outstanding, exercisable at $1.00 per share.

#### Warrants
As of December 31, 2024, we had common stock purchase warrants for [\*] common shares outstanding, exercisable at $[\*] per share.

[**Table of Contents**](#TOC001)

#### Senior Convertible Notes
As of December 31, 2024, we had $1,420,400 secured convertible notes, convertible into [\*] shares of common stock.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Conversion Rate** | **Denomination** | **Outstanding <br>Principal <br>(in USD)** | **Interest <br>Rate** | **Default <br>Rate** | **Maturity Date** |
|  $[\*] per share | US$ | $1420400 | 6% p.a. | 6% p.a. | Between 8/23/25 and 12/11/26 |

---

On June 12, 2023, we entered into a Placement Agent's Agreement with Network 1 Financial Securities, Inc., a licensed broker/dealer, for a bridge financing transaction, for the placement of up to $2,000,000 senior convertible debentures, on a best-efforts basis. The debentures will carry interest of 6% per year, mature in 24 months, and will be convertible, together with interest accrued thereon, at the option of the holder into the Company's stock in the event of a public offering of the Company's stock, at a 25% discount to the offering price in such an event (the "Event"). Investors who participate in the debenture offering receive stock purchase warrants at the rate of ½ warrant for every Dollar invested, divided by the offering price. The warrants may be exercised at the offering price in the Event and expire 3 years after issuance. At December 31, 2024, a total $1,420,400 of such convertible notes have been placed.

#### Registration Rights
The secured convertible notes and the warrants issued in connection with the convertible notes have registration rights.

[**Table of Contents**](#TOC001)

#### DESCRIPTION OF SECURITIES WE ARE OFFERING

#### Shares Offered Hereby
We are offering Shares. Each Share has an assumed offering price of $[\*].

#### Common Stock
The material terms and provisions of our Common Stock and each other class of our securities which qualifies or limits our Common Stock are described under the caption "Description of Capital Stock" in this prospectus.

#### Anti-Takeover Provisions of Delaware Law and Our Charter Documents

#### Section 203 of the Delaware General Corporation Law ("DGCL")
We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• before such date, the Board of Directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• on or after such date, the business combination is approved by the Board of Directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

In general, Section 203 defines a "business combination" to include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any merger or consolidation involving the corporation and the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.

In general, Section 203 defines an "interested stockholder" as an entity or person who, together with the person's affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

[**Table of Contents**](#TOC001)

The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

#### Exchange Listing
We intend to apply to list our Common Stock on the New York Stock Exchange under the trading symbol "[\*]".

#### Transfer Agent and Registrar
The transfer agent and registrar for our Common Stock is V-Stock Transfer LLC. The transfer agent and registrar's address is 18 Lafayette Place, Woodmere, NY 11598.

[**Table of Contents**](#TOC001)

#### SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, no public market existed for our Common Stock. Future sales of substantial amounts of our Common Stock in the public market following this offering, or the possibility of such sales occurring, could adversely affect prevailing market prices and could impair our ability to raise capital through the offering of equity securities.

Based on the number of shares of Common Stock outstanding as of [•], upon the completion of this offering, we will have a total of shares of Common Stock outstanding, assuming an initial public offering price of $[•] per Share and assuming no exercise by the representative of the underwriters of its over-allotment option to purchase additional shares of Common Stock and/or Warrants and no exercise of outstanding options or warrants to purchase shares of Common Stock and/or Warrants. All of the shares sold in this offering will be freely tradable unless held by our "affiliates", as defined in Rule 144 under the Securities Act.

As a result of contractual restrictions described below and the provisions of Rules 144 and 701 promulgated under the Securities Act, the shares of Common Stock sold in this offering will be available for sale in the public market as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• all the shares of Common Stock sold in this offering will be eligible for immediate sale upon the closing of this offering; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• common shares will be eligible for sale in the public market upon expiration of lock-up agreements 180 days after the date of this prospectus, subject, in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and Rule 701.

#### Rule 144
In general, persons (or persons whose shares are required to be aggregated) who have beneficially owned shares of our Common Stock for at least six months, and any affiliate of ours who owns shares of our Common Stock, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by Rule 144 under the Securities Act.

#### Non-Affiliates
Any person (or persons whose shares are required to be aggregated) who is not deemed to have been an affiliate of ours at any time during the three months preceding a sale, and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell those shares, subject only to the availability of current public information about us and provided that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. If such person has held our shares for at least one year, such person can resell such shares under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the 90-day public company and current public information requirements.

#### Affiliates
Any person (or persons whose shares are required to be aggregated) who is deemed to be an affiliate of ours and who has beneficially owned restricted securities within the meaning of Rule 144 for at least six months would be subject to the restrictions described above. Additionally, such person would be subject to additional restrictions, pursuant to which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be entitled to sell within any three-month period a number of shares that does not exceed the greater of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1% of the number of shares of Common Stock then outstanding, which will equal approximately immediately after this offering, based on the number of shares outstanding as of, [\*] and assuming no exercise by the representative of the underwriters of its over-allotment option to purchase additional shares of Common Stock and/or Warrants and no outstanding options or warrants; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the average weekly trading volume of our shares of Common Stock on the New York Stock Exchange during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.

[**Table of Contents**](#TOC001)

Additionally, persons who are our affiliates at the time of, or any time during the three months preceding, a sale may sell unrestricted securities under the requirements of Rule 144 described above, without regard to the six-month holding period of Rule 144, which does not apply to sales of unrestricted securities.

#### Rule 701
Under Rule 701 under the Securities Act, shares of our Common Stock acquired upon the exercise of currently outstanding options or pursuant to other rights granted under our stock plans may be resold, by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• persons other than affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject only to the manner-of-sale provisions of Rule 144; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject to the manner-of-sale and volume limitations, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144.

Notwithstanding the foregoing, all our Rule 701 shares are subject to lock-up agreements as described below and, in the section, titled "Underwriting" and will become eligible for sale upon the expiration of the restrictions set forth in those agreements.

#### Lock-Up Agreements
The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the underwriter, it will not, for a period of 180 days after the date of this prospectus (the "Lock-Up Period"), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement with the SEC relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.

Furthermore, each of our directors and executive officers, and our existing beneficial owners of 5% or more of the outstanding shares of our Common Stock will enter into a similar lock-up agreement for a period of 180 days from the date of this prospectus, subject to certain exceptions, with respect to our Common Stock and securities that are substantially similar to our common stock. These restrictions also apply to any Common Stock acquired by our directors and executive officers in the offering pursuant to the directed share program, if any.

[**Table of Contents**](#TOC001)

#### UNDERWRITING
Network 1 Financial Securities Inc. is acting as the sole book-running manager of the offering and as representative of the underwriters named below. Subject to the terms and conditions of the underwriting agreement dated the date of this prospectus, the underwriters named below, through the Representative, have severally agreed to purchase, and we have agreed to sell to the underwriters, the following respective number of Shares set forth opposite the underwriter's name.

---

| | |
|:---|:---|
|  **Underwriters** | **Number of <br>Shares** |
| &nbsp;&nbsp;&nbsp; Total: |  |

---

The underwriters and the representative are collectively referred to as the "underwriters" and the "representative" or "Network 1," respectively. The underwriters are offering the Shares subject to their acceptance of the Shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the Shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the Shares offered by this prospectus if any such Shares are taken. However, the underwriters are not required to take or pay for the shares of Common Stock and/or Warrants covered by the representative's over-allotment option described below.

The underwriters initially propose to offer part of the Shares directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $[•] per Share under the public offering price. After the initial offering of the Shares, the offering price and other selling terms may from time to time be varied by the representative.

#### Over-Allotment Option
We have granted the representative an option, exercisable for 45 days from the date of this prospectus, to purchase up to an additional [•] shares of Common Stock at a price of $[•] per share less underwriting discounts and commissions. The representative may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the Shares offered by this prospectus.

#### Discount, Commissions and Reimbursements
The following table shows the per Share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the representative's option to purchase up to additional shares of Common Stock and/or Warrants.

---

| | | | |
|:---|:---|:---|:---|
|  | **Total** | **Total** | **Total** |
|  | **Per Share** | **No Exercise** | **Full Exercise** |
|  Public offering price | $| $| $|
|  Underwriting discounts and commissions to be paid by us | $| $| $|
|  Proceeds, before expenses, to us | $| $| $|

---

We have agreed to pay the representative out-of-pocket accountable expenses, including legal fees and disbursements, up to a maximum amount of $100,000. If the offering is not consummated, then the maximum amount we will pay with respect to [•] external counsel legal costs is $[•]. We have paid $35,000 to the representative as an advance to be applied towards reasonable out-of-pocket expenses (which we refer to as the Advance). Any portion of the Advance shall be returned back to us to the extent not actually incurred in accordance with FINRA Rule 5110(g)(4)(A). Additionally, we agreed to provide 2% of the gross proceeds of the offering to the representative for non-accountable expenses.

We estimate that the total expenses of the offering payable by us, not including the underwriting discount, will be approximately $300,000.

[**Table of Contents**](#TOC001)

#### Representative's Warrants
In addition, we have agreed to issue warrants to the representative or its designees, upon the closing of this offering, which entitle it to purchase 8% of the total number of Shares being sold in this offering, including Shares issued upon exercise of representative's over-allotment option (the "Representative's Warrants"). The exercise price of the warrants is equal to 110% of the offering price of the Shares offered hereby. The Representative's Warrants will be exercisable at any time and from time to time, in whole or in part, during the five-year period after the date of the closing. The Representative's Warrants and the shares of Common Stock underlying the Representative's Warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA. The Representative's Warrants may not be sold, transferred, assigned, pledged or hypothecated or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities for a period of 180 days following the effective date of the registration for this offering, except that they may be assigned, in whole or in part, to any officer or partner of the representative, and to members of the underwriting syndicate or selling group (or to officers or partners thereof), or as otherwise permitted, in compliance with FINRA Rule 5110(e)(2). The Representative's Warrants will provide for cashless exercise and contain provisions for one demand registration of the sale of the underlying shares of Common Stock at our expense and unlimited "piggyback" registration rights for a period of five (5) years after the closing at our expense. We will bear all fees and expenses attendant to registering the shares issuable upon exercise of the Representative's Warrants, other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances, including in the event of a stock dividend, extraordinary cash dividend, or our recapitalization, reorganization, merger, or consolidation. The warrant exercise price and/or underlying shares may also be adjusted for issuances of shares at a price below the warrant exercise price.

Other than the underwriting agreement, the underwriters have had no material relationship with us or any of our affiliates and have not owned any of our securities prior to this offering.

#### Determination of Offering Price
Before this offering, there has been no public market for our Common Stock. Accordingly, the public offering price will be negotiated between us and the Representative. Among the factors to be considered in these negotiations are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the information set forth in this prospectus and otherwise available to the underwriters;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the prospects for our Company and the industry in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an assessment of our management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our past and present financial and operating performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our prospects for future earnings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• financial and operating information and market valuations of publicly traded companies engaged in activities similar to ours;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the prevailing conditions of United States securities markets at the time of this offering; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other factors deemed relevant.

Neither we nor [\*] can assure investors that an active trading market will develop for shares of our Common Stock, or that the shares will trade in the public market at or above the initial public offering price.

#### Lock-up Agreements
The Company, on behalf of itself and any successor entity and each of our officers, directors, and significant shareholders, agrees that, without the prior written consent of the underwriter, it will not, for a period of 180 days after the date of this prospectus (the "Lock-Up Period"), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or

[**Table of Contents**](#TOC001)

caused to be filed any registration statement with the SEC relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.

Furthermore, each of our directors and executive officers, and our existing beneficial owners of 5% or more of the outstanding shares of our Common Stock will enter into a similar lock-up agreement for a period of 180 days from the date of this prospectus, subject to certain exceptions, with respect to our Common Stock and securities that are substantially similar to our common stock. These restrictions also apply to any Common Stock acquired by our directors and executive officers in the offering pursuant to the directed share program, if any.

#### Tail Period
In the event that this offering is not consummated by the underwriters as contemplated herein, the Company agrees to pay to [\*] a cash fee equal to [\*]% of the gross proceeds received by the Company from the sale of securities by any investor actually introduced by [\*]to the Company during the period beginning on [\*]and ending on the earlier of (i) [\*], or (ii) the final closing, if any, of the Offering (the "Engagement Period") (a "Tail Financing") and such Tail Financing is consummated during the Engagement Period or within twelve (12) month period following the expiration of the Engagement Period, provided that such financing is by a party actually introduced to the Company in an offering in which we have direct knowledge of such party's participation.

#### Right of First Refusal
Until [twelve (12) months] from the closing date of this offering, the representative shall have an irrevocable right of first refusal, in its sole discretion, to act as sole investment banker, sole book-runner, and/or sole placement agent, for all each and every future public and private equity and debt offerings, including all equity-linked financings (each, a "Subject Transaction"). The representative will have the sole right to determine whether or not any other broker-dealer will have the right to participate in any such offering and the economic terms of any such participation. We agreed not to retain, engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a subject transaction without the express written consent of the representative. The Company has a right of termination for cause, and the exercise of its right of termination for cause eliminates any obligations with respect to the payment of any termination fee or provision of any right of first refusal.

#### Stabilization, Short Positions, and Penalty Bids
The underwriters may engage in stabilizing transactions for the purpose of pegging, fixing, or maintaining the price of our Common Stock. Stabilizing transactions permit bids to purchase the underlying Common Stock so long as the stabilizing bids do not exceed a specific maximum. These stabilizing transactions may have the effect of raising or maintaining the market prices of our securities or preventing or retarding a decline in the market prices of our securities. As a result, the price of our Common Stock may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriters make any representation or prediction as to the effect that stabilizing transactions may have on the price of our Common Stock. These transactions may be effected on the New York Stock Exchange, in the over-the-counter market, or on any other trading market and, if commenced, may be discontinued at any time.

In connection with this offering, the underwriters also may engage in passive market-making transactions in accordance with Regulation M. In general, a passive market maker must display its bid at a price, not in excess of the highest independent bid for that security. However, if all independent bids are lowered below the passive market maker's bid that bid must then be lowered when specific purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

[**Table of Contents**](#TOC001)

Neither we nor the underwriters make any representations or predictions as to the direction or magnitude of any effect that the transactions described above may have on the prices of our securities. In addition, neither we nor the underwriters make any representations that the underwriters will engage in these transactions or that any transactions, once commenced will not be discontinued without notice.

#### Electronic Offer, Sale, and Distribution of Shares
A prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members, if any, participating in this offering. The underwriters may agree to allocate a number of our Shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representative to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters' websites and any information contained in any other website maintained by the underwriters is not part of this prospectus or the registration statement of which this prospectus forms a part.

The underwriters do not expect to sell more than [\*]% of the shares in the aggregate to accounts over which they exercise discretionary authority.

#### Other Relationships
Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.

#### New York Stock Exchange Listing
We plan to apply to have our shares of our Common Stock approved for listing on the New York Stock Exchange under the symbol ''[\*]". We will not proceed with this offering in the event our Common Stock are not approved for listing on the New York Stock Exchange.

#### Indemnification
We have agreed to indemnify the underwriters against certain liabilities, including certain civil liabilities arising under the Securities Act or to contribute to payments that the underwriters may be required to make for these liabilities.

#### Offer Restrictions Outside the United States
Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

[**Table of Contents**](#TOC001)

#### LEGAL MATTERS
Certain legal matters with respect to the validity of the securities being offered by this prospectus will be passed upon by Lucosky Brookman LLP. VCL Law LLP is acting as counsel for the underwriters with respect to the offering.

#### EXPERTS
The financial statements of NeuroSpectrum Insights, Inc. (f/k/a Autism Diagnostic Technologies, Inc.) as of December 31, 2024 and December 31, 2023 and for each of the years then ended have been audited by Rosenberg Rich Baker Berman, P.A., an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are included in this prospectus and registration statement in reliance upon the report (which includes an explanatory paragraph relating to our ability to continue as a going concern) appearing elsewhere herein, and upon the authority of such firm as experts in accounting and auditing.

#### WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities offered in this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement and its exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. For further information about us and our securities, we refer you to the registration statement and to its exhibits and schedules. Statements in this prospectus about the contents of any contract, agreement or other document are not necessarily complete and, in each instance, we refer you to the copy of such contract, agreement or document filed as an exhibit to the registration statement, with each such statement being qualified in all respects by reference to the document to which it refers. You may inspect the registration statement and its exhibits and schedules and other information without charge at the website maintained by the SEC. The address of this site is *www.sec.gov*.

As a result of this offering, we will become subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, will be required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available for inspection and copying at the SEC's public reference facilities and the website of the SEC referred to above. We also maintain a website at [\*]. Upon completion of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f / k / a Autism Diagnostic Technologies, Inc.

#### INDEX TO THE FINANCIAL STATEMENTS

---

| | |
|:---|:---|
|  | **Page <br>Number** |
|  [Report of Independent Registered Public Accounting Firm (PCAOBID 089)](#T501) | F-2 |
|  [Balance Sheets – December 31, 2024 and December 31, 2023](#T502) | F-4 |
|  [Statements of Operations – For the years ended December 31, 2024 and December 31, 2023](#T503) | F-5 |
|  [Statements of Stockholders' Equity – For the years ended December 31, 2023 and <br>December 31, 2024](#T504) | F-6 |
|  [Statements of Cash Flows – For the years ended December 31, 2024 and December 31, 2023](#T505) | F-7 |
|  [Notes to Financial Statements](#T506) | F-8 |

---

---

| | |
|:---|:---|
|  [Balance Sheets – March 31, 2025 (Unaudited) and December 31, 2024](#T3001) | F-22 |
|  [Statements of Operations (Unaudited) – For the three months ended March 31, 2025 and March 31, 2024](#T3002) | F-23 |
|  [Statements of Stockholders' Equity (Unaudited) – For the three months ended March 31, 2024 and March 31, 2025](#T3003) | F-24 |
|  [Statements of Cash Flows (Unaudited) – For the three months ended March 31, 2025 and March 31, 2024](#T3004) | F-25 |
|  [Notes to Financial Statements](#T3005) | F-26 |

---

[**Table of Contents**](#TOC001)

#### REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and

Stockholders of NeuroSpectrum Insights, Inc.

#### Opinion on the Financial Statements
We have audited the accompanying balance sheets of NeuroSpectrum Insights, Inc. (f/k/a Autism Diagnostic Technologies, Inc., or the "Company") as of December 31, 2024 and 2023, and the related statements of operations, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

#### Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has not yet derived any revenue and has negative working capital. Management's evaluation of the events and conditions and management's plans regarding those matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter.

#### Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

#### Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,

"RRBB" is the brand name under which Rosenberg Rich Baker Berman, P.A. and RRBB Advisors, LLC, and its subsidiary entities, including CFO Financial Partners LLC, provide professional services. Rosenberg Rich Baker Berman, P.A. and RRBB Advisors, LLC (and its subsidiary entities) practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations, and professional standards. Rosenberg Rich Baker Berman, P.A. is a licensed independent CPA firm that provides attest services to its clients, and RRBB Advisors, LLC, and its subsidiary entities provide tax and business consulting services to their clients. RRBB Advisors, LLC, and its subsidiary entities are not licensed CPA firms.<br>

[**Table of Contents**](#TOC001)

subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

*Stock-Based Compensation*

We identified the audit of stock-based compensation as a critical audit matter due to significance of the assumptions underlying the 409A valuation in determining the value of the Company's common stock, including management judgments involved in estimating discounted cash flows, evaluation of market conditions and volatility, discounts for lack of marketability, and other valuation assumptions including Black-Scholes model inputs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We obtained an understanding and evaluated the design of the controls over the valuation of common stock and stock-based compensation, including the assessment of the expertise and independence of the Company's outside specialist.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We performed a detailed analysis of the 409A valuation performed by the Company's outside specialist, and critically evaluated valuation assumptions related to expected cash flows, discounts utilized, consideration of comparable companies and historical volatilities of those entities and other market indicators.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the mathematical accuracy of the calculations and evaluated significant assumptions and the underlying data used by the Company by performing procedures to test the valuation computations, including the methodology for determining estimated common stock values between the 409A valuation dates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We used experienced personnel with extensive and specific knowledge in this area perform audit procedures and to evaluate the expertise, valuation assumptions and methodologies utilized by professionals engaged by the Company with specialized skills and knowledge, and critically evaluated management's accounting compliance and assumptions used in the valuations.

*Warrants and Embedded Derivatives*

We identified the audit of warrants and embedded derivatives as a critical audit matter due to the complexity of the accounting involved, management's significant assumptions in estimating fair value, and other valuation assumptions including Black-Scholes model inputs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We evaluated the Company's accounting for complex debt and accounting instruments, including the consistency and relevance of the application of the accounting standards that govern such instruments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We critically evaluated significant fair value estimates and related valuation assumptions related to management's assumptions, particularly those related to the 409A valuation, exercise price contingencies, discount rates utilized for determining present value, and expectations of timing and value for a future initial public offering price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested the mathematical accuracy of the fair value calculations based on the significant assumptions and the underlying data used by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We used experienced personnel with extensive and specific knowledge in complex debt and equity instruments as well as valuation assumptions and methodologies to perform audit procedures and critically evaluate management's accounting compliance and appropriateness of assumptions and data used in the valuations.

/s/ Rosenberg Rich Baker Berman, P.A.

We have served as the Company's auditor since 2019.

Somerset, New Jersey

June 18, 2025

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f / k / a Autism Diagnostic Technologies, Inc.

#### BALANCE SHEETS

---

| | | |
|:---|:---|:---|
|  | **December 31, <br>2024** | **December 31, <br>2023** |
|  Assets |  |  |
|  Current Assets |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $173502 | $305713 |
| &nbsp;&nbsp;&nbsp; Prepaid expenses | 20000 | 20000 |
| &nbsp;&nbsp;&nbsp; Total Current Assets | 193502 | 325713 |
|  Other Assets |  |  |
| &nbsp;&nbsp;&nbsp; Deferring offering costs | 220811 |  |
| &nbsp;&nbsp;&nbsp; Intangible assets, net of $11,942 and $10,236 accumulated amortization | 18766 | 20472 |
|  Total Assets | $433079 | $346185 |
|  Liabilities and Stockholders' Equity |  |  |
| &nbsp;&nbsp;&nbsp; Accounts payable | $135577 | $9458 |
| &nbsp;&nbsp;&nbsp; Accrued expenses – Related Parties | 285466 | 855250 |
| &nbsp;&nbsp;&nbsp; Accrued expenses – Other | 80579 | 18500 |
| &nbsp;&nbsp;&nbsp; Accrued interest – Related Parties | 22247 | 12458 |
| &nbsp;&nbsp;&nbsp; Accrued interest – Other | 71657 | 10137 |
| &nbsp;&nbsp;&nbsp; Liability for stock to be issued | 6933 | 23075 |
| &nbsp;&nbsp;&nbsp; Liability for warrants issued | 184793 | 26510 |
| &nbsp;&nbsp;&nbsp; Derivative liability for note conversion feature | 232878 | 52994 |
| &nbsp;&nbsp;&nbsp; Convertible notes payable (net of debt discount), current portion | 391526 |  |
| &nbsp;&nbsp;&nbsp; Notes payable | 125000 | 125000 |
|  Total Current Liabilities | 1536656 | 1133382 |
|  Convertible notes payable (net of debt discount) | 674558 | 311172 |
|  Total Liabilities | 2211214 | 1444554 |
|  Commitments and Contingencies (Notes 4 and 8) |  |  |
|  Stockholders' Equity |  |  |
| &nbsp;&nbsp;&nbsp; Preferred Stock, par value $0.00001, 10,000,000 shares authorized, none issued |  |  |
| &nbsp;&nbsp;&nbsp; Common Stock, par value $0.00001, 90,000,000 shares authorized, <br>10,973,358 and 9,652,655 shares issued and outstanding | 110 | 96 |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | 3528103 | 1401326 |
| &nbsp;&nbsp;&nbsp; Retained Deficit | (5306348) | (2499791) |
|  Total Stockholders' Equity | (1778135) | (1098369) |
|  Total Liabilities and Stockholders' Equity | $433079 | $346185 |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f / k / a Autism Diagnostic Technologies, Inc.

#### STATEMENTS OF OPERATIONS

---

| | | |
|:---|:---|:---|
|  | **For the <br>Year Ended<br>December 31,<br>2024** | **For the <br>Year Ended<br>December 31,<br>2023** |
|  Operating Expenses |  |  |
| &nbsp;&nbsp;&nbsp; Personnel expenses | $1161038 | $304160 |
| &nbsp;&nbsp;&nbsp; Professional and outside services | 630096 | 319829 |
| &nbsp;&nbsp;&nbsp; General and administrative expenses – other | 43612 | 17631 |
| &nbsp;&nbsp;&nbsp; Product development expenses | 487332 | 139152 |
|  Total Operating Expenses | 2322078 | 780772 |
|  Loss from Operations | (2322078) | (780772) |
|  Other Income (Expense)  |  |  |
| &nbsp;&nbsp;&nbsp; Interest expense | (190174) | (29808) |
| &nbsp;&nbsp;&nbsp; Change in fair value of derivative and warrant liabilities | (136926) | 22575 |
|  Total Other Income (Expense) | (327100) | (7233) |
|  Loss before provision of income taxes | (2649178) | (788005) |
|  Provision for income taxes |  |  |
|  Net Loss | $(2649178) | $(788005) |
|  Implied dividends | 157379 |  |
|  Net loss attributable to common shareholders | $(2806557) | $(788005) |
|  Loss per share, basic and diluted | $(0.27) | $(0.08) |
|  Weighted average number of shares outstanding during the period | 10561751 | 9445792 |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f / k / a Autism Diagnostic Technologies, Inc.

#### STATEMENTS OF STOCKHOLDERS' EQUITY

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Additional<br>Paid-in <br>Capital** | **Accumulated<br>Deficit** | **Total<br>Equity** |
|  | **Shares** | **Amount** | **Additional<br>Paid-in <br>Capital** | **Accumulated<br>Deficit** | **Total<br>Equity** |
|  Balances at December 31, 2023 | 8945905 | $89 | $545707 | $(1711786) | $(1165990) |
|  Issuance of common stock for services | 135500 | 1 | 125065 |  | 125066 |
|  Stock options issued for services |  |  | 159310 |  | 159310 |
|  Accrued salaries and fees converted into common shares | 571250 | 6 | 571244 |  | 571250 |
|  Net Loss for the year ended December 31, 2023 |  |  |  | (788005) | (788005) |
|  Balances at December 31, 2023 | 9652655 | $96 | $1401326 | $(2499791) | $(1098369) |
|  Issuance of common stock for services | 367953 | 4 | 731728 |  | 731732 |
|  Stock issued to settle liabilities | 53000 |  | 51075 |  | 51075 |
|  Stock options issued for services |  |  | 166455 |  | 166455 |
|  Warrant issued for services |  |  | 120400 |  | 120400 |
|  Accrued salaries and fees converted into common shares | 899750 | 10 | 899740 |  | 899750 |
|  Implied dividends from warrant extensions |  |  | 157379 | (157379) |  |
|  Net Loss for the year ended December 31, 2024 |  |  |  | (2649178) | (2649178) |
|  Balances at December 31, 2024 | 10973358 | $110 | $3528103 | $(5306348) | $(1778135) |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f / k / a Autism Diagnostic Technologies, Inc.

#### STATEMENTS OF CASH FLOWS

---

| | | |
|:---|:---|:---|
|  | **For the <br>Year Ended<br>December 31,<br>2024** | **For the <br>Year Ended <br>December 31, <br>2023** |
|  Cash Flows from Operating Activities |  |  |
|  Net Loss | $(2649178) | $(788005) |
|  Adjustments to reconcile net loss to net cash used by operating activities |  |  |
| &nbsp;&nbsp;&nbsp; Amortization of intangible assets | 1706 | 1706 |
| &nbsp;&nbsp;&nbsp; Amortization of debt discount | 118865 | 14791 |
| &nbsp;&nbsp;&nbsp; Securities-based compensation | 1018587 | 284376 |
| &nbsp;&nbsp;&nbsp; Change in fair value derivative liabilities | 136926 | (22575) |
|  Increase in prepaid expenses | —  | (20000) |
|  Increase in liability for stock to be issued | 34933 | 23075 |
|  Increase in accounts payable and accruals | 589473 | 320481 |
|  Net Cash Used by Operating Activities | (748688) | (186151) |
|  Cash Flows from Financing Activities |  |  |
|  Proceeds from issuance of promissory notes | 962400 | 458000 |
|  Deferred offering costs | (220811) |  |
|  Cash paid for debt financing | (125112) | (59540) |
|  Net Cash provided by Financing Activities | 616477 | 398460 |
|  Net Increase in Cash and Cash Equivalents | (132211) | 212309 |
|  Cash and Cash Equivalents at Beginning of Year | 305713 | 93404 |
|  Cash and Cash Equivalents at End of Year | $173502 | $305713 |
|  Supplemental Disclosure of Cash Flow Information: |  |  |
|  Cash Paid for: |  |  |
| &nbsp;&nbsp;&nbsp; Interest | $— | $— |
| &nbsp;&nbsp;&nbsp; Income Taxes | $— | $— |
|  Non-cash Financing Activities: |  |  |
| &nbsp;&nbsp;&nbsp; Warrants issued as debt discount | $103701 | $42513 |
| &nbsp;&nbsp;&nbsp; Derivative conversion feature | $97540 | $59566 |
| &nbsp;&nbsp;&nbsp; Stock issued in settlement of liabilities | $950825 | $571250 |
| &nbsp;&nbsp;&nbsp; Implied dividends from warrant modifications | $157379 | $— |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
1. DESCRIPTION OF BUSINESS

*Nature of Organization*

NeuroSpectrum Insights, Inc. (the "Company", "We", or "Us") was incorporated as a Delaware corporation on January 20, 2016 as Autism Diagnostic Technologies, Inc. On January 31, 2024 we changed the Company's name to NeuroSpectrum Insights, Inc.

*Business*

We are in the business of commercializing a medical diagnostic technology that may have the potential of significantly facilitating, and enhancing the accuracy of, the diagnosis of certain neuro-disabling diseases, if approved by the FDA. To that extent we plan, upon successful conclusion of our current efforts to raise new equity capital, to finalize the preparation of our application for FDA clearance, and bring to market this new diagnostic technology for early detection of autism.

This technology assists in the diagnosis of neuro-disabling diseases through the use of advanced three-dimensional ("3D") brain mapping technology.

*Going Concern*

The Company has not yet derived any revenues, and at December 31, 2024 had a working capital deficit of $1,343,154. In view of these conditions there is substantial doubt about the ability of the Company to continue as a going concern through at least April 2026. Realization of the Company's business plans is dependent upon the successful conclusion of currently planned public offering of its stock. Should the Company be unable to raise the desired amount of capital with such offering or through alternate funding sources, its operating plans will be limited to the amount of capital that it can access which may not be enough to continue as a going concern. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

*Basis of Presentation*

These audited financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP") and applicable rules and regulations of the U.S. Securities and Exchange Commission ("SEC") regarding financial reporting.

*Cash Equivalents*

Cash and all highly liquid investments with an original maturity of three months or less from the date of purchase, including money market mutual funds, short-term time deposits, and certain government agency and corporate obligations, are classified as cash and cash equivalents. The Company had no cash equivalents at December 31, 2024 or December 31, 2023. At December 31, 2023 an amount of $55,713 was in excess of FDIC covered insurance and therefore at risk.

*Long-Lived Assets*

The Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

*Intangible Assets*

The Company amortizes its intangible assets on a straight line over the estimated useful life of the assets and assesses the valuation of such assets whenever events or circumstances dictate that the carrying value might not be recoverable. At December 31, 2024, the Company's only intangible asset is a license for the use of certain proprietary technology (see Note 2). The expected future cash flows associated with this asset are dependent on the Company's ability to reimburse the technology owner for prosecution and/or maintenance costs under the license arrangement, which the Company has been able to accomplish since inception.

*Research and Development Expenses*

Our software is intended to be marketed as a distinctive separate product and our related development costs, incurred to establish the technological feasibility pursuant to ASC 985-20, which arise in the design, configuration and coding that are performed by third party contractors, are charged to expense as incurred as required by Subtopic 730-10. The costs for the license to the technology underlying our product were capitalized in accordance with ASC 730-10-25-2(c).

Software development began in 2022. Product development costs for the years ended December 31, 2024 and 2023 were $487,332 and $139,152, respectively, and were charged to operations as incurred since technological feasibility for our product had not yet been established. Once that has been achieved such costs will be capitalized in accordance with ASC 985-20.

*Contingent Liabilities*

We will pay the Research Foundation 5% of our Net Sales for all license products sold during the term of the license, and 30% of any sublicensing income. We are facing a contingent liability in so far as we must pay the Research Foundation the difference between the 5% royalties paid during a given year and agreed upon annual minimum amounts.

All royalty payments to the Research Foundation are being expensed. Liabilities for potential payments to reach the agreed upon annual minimum amounts are being recognized when their probability has been established and their amount can reasonably be estimated. We are expensing these costs rather than capitalizing them because they do not bestow additional IP rights on us.

*Derivative Liabilities*

The Company issued convertible notes accompanied by stock purchase warrants.

Accounting treatment of the Warrants:

We determined that the Warrants should be classified as a liability instrument in accordance with ASC 480 since they contain a potentially applicable put option which, if exercised would oblige the Company to redeem the warrants at their fair value as measured at the time of a defined future event. As such we measure them at their fair value on the issuance date, which we chose to be determined by applying a probability-weighted Black Scholes valuation model.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Accounting treatment of the conversion feature of the Convertible Notes:

We separated the conversion feature from the notes as a separate liability in accordance with ASC 815 (bifurcation of an embedded derivative conversion feature due to the indeterminate number of shares upon conversion), measured at their fair value on the issuance date of the notes, and determined by probability-weighted present value of share-settled redemption feature derivative liability.

*Stock-based Compensation*

The Company records stock-based compensation in accordance with ASC 718, Compensation — Stock Compensation ("ASC 718"). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the employees required service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.

*Fair Value Measurements*

Financial Accounting Standards Board ("FASB") *ASC Topic 820, Fair Value Measurements and Disclosures* ("ASC 820"), provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows:

---

| | |
|:---|:---|
| Level 1 — | Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices. |
| Level 2 — | Pricing inputs are other than quoted prices in active markets but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts or priced with models using highly observable inputs. |
| Level 3 — | Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights. |

---

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

*Income Taxes*

The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss carryforwards. The carrying amounts of deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed periodically based

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

on the more-likely-than-not recognition threshold. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses, the duration of statutory carryforward periods, and tax planning alternatives. The Company assesses the likelihood that uncertain tax positions will be accepted by the applicable taxing authority based on the technical merits of the position. Tax positions meeting the more-likely-than-not recognition threshold are measured and recognized in the financial statements at the largest amount of benefit that has a greater than 50% likelihood of being realized upon measurement of a tax position taken in a prior annual period, including interest and penalties, and are recognized during the period in which the change occurs. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. For the years ended December 31, 2024 and 2023, we did not have any interest and penalties or any significant unrecognized uncertain tax positions. The Company's tax years since 2020 are subject to examination. The Company recognizes accrued interest and penalties related to the unrecognized tax benefits in operating expenses.

*Recently Issued Accounting Pronouncements*

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's financial statements.

From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position.

In November 2023 the FASB issued ASU 2023-07, (Segment Reporting). The accounting standard requires companies to disclose significant expense categories within business segments. The Company has adopted this guidance as of January 1, 2024 (see Note 10).

In March 2024, the FASB issued ASU 2024-01, (Compensation-Stock Compensation (Topic 718). ASU 2024-01 shows examples how an entity should apply the guidance in ASC 718-10-15-3 to determine whether a profits interest award is within the scope of ASC 718. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. The pronouncement is effective for public business entities that are SEC filers in fiscal years beginning after December 15, 2024, and for other entities in fiscal years beginning after December 15, 2025 including interim periods within those fiscal years. The adoption of this standard is not expected to result in any material changes in the Company's financial statements from our reports for 2024 and the prior years.

In November 2024 the FASB has released ASU 2024-03, (Disaggregation of Income Statement Expenses). The ASU's purpose is "to improve the disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development). During the same month the FASB issued ASU 2024-04, (Induced Conversions of Convertible Debt Instruments). This new guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The ASU is effective for annual periods beginning after December 15, 2026. The Company will evaluate the potential effects on our financial reporting at that time.

*Income (loss) per share*

Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the respective period presented in our accompanying financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Common shares related to warrants, stock options, and convertible debt which, if exercised, would have an anti-dilutive effect on earnings per share, but in view of the Company's net loss position with respect to the reporting periods have not been included in computing diluted earnings per share. Anti-dilutive securities not included in net loss per share calculations for the periods presented include:

---

| | | |
|:---|:---|:---|
|  | **December 31, <br>2024** | **December 31, <br>2023** |
|  Warrants issued to Officer | 100000 | 50000 |
|  Warrants issued with private equity placements | 286313 | 314091 |
|  Warrants issuable with Debt Financing (computed per ASC 260) based on the value of the Company's common stock | 375767 | 330805 |
|  Stock Options | 850000 | 875000 |
|  Shares issuable upon conversion of convertible debt (computed based on the offering price)\* | [\*] | [\*] |

---

____________

\* Issuance of these shares is contingent upon consummation of the public offering.

The number of shares issuable upon automatic conversion of convertible debt in the case of a public offering is linked to the offering price and cannot at this time be determined. The number of shares to be issued is derived by dividing the amount of the convertible debt by 75% of the offering price.

*Use of Estimates*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

*Reclassifications*

Certain reclassifications have been made to 2023 information to conform to the current year presentation. Specifically, the inclusion of position "Security-based compensation" within positions "Personnel expenses" and "Professional and outside services", respectively.

*Subsequent Events Evaluation Date*

The Company evaluated the events and transactions subsequent to its December 31, 2024 balance sheet date and, in accordance with FASB ASC 855-10-50, "Subsequent Events" through June 18, 2025, which is the date the financial statements were issued.

3. INTANGIBLE ASSETS

The patents, copyrights, and intellectual property rights to the technology that we seek to commercialize are owned by the University of Louisville Research Foundation Inc. (the "Research Foundation" or "ULRF"). The Company was granted an exclusive worldwide license pursuant to an "Exclusive Agreement" dated January 31, 2017 which is valid through the expiration date of the last granted patent and can be terminated only upon occurrence of an uncured violation by the Company of the contract terms. The agreement, among other, obliges the Company to (1) pay royalties on income from the licensed products during the term of the agreement, (2) a 30% fee on non-royalty income from sub-licensing, (3) reimbursement of certain expenses originally aggregating $34,273, of which $4,500 were subsequently waived, payable in installments until October 2019 (the entire amount has been paid as of September 30, 2019), (4) adherence to certain milestone criteria for

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
3. INTANGIBLE ASSETS (cont.)

the raising of capital and submission of the product for FDA clearance and (5) imposes ongoing reporting and disclosure requirements. The agreement furthermore called for issuance of a total 478,262 common shares (the "Foundation Shares") to the Research Foundation and the four inventors of the patented technology.

The costs of the license for the technology underlying our product were capitalized as intangible assets in accordance with ASC 730-10-25-2(c) since the licensed technology has alternative future uses, for example in potential applications that seek to analyze brain structures for indicators of Alzheimer's disease. Our software is intended to be marketed as a distinctive separate product and our related development costs, pursuant to ASC 985-20, which arise in the design, configuration and coding that are performed by third party contractors, are expensed.

The capitalized costs were $30,708 consisting of the above $29,773 net expenses plus the value assigned to the Foundation Shares, to be amortized over the estimated remaining life of the license, presently calculated at 18 years, on a straight-line basis. For the year ended December 31, 2023 we recognized $1,706 in amortization expense. For the year ended December 31, 2024 we recognized $1,706 in amortization expense. Future payments to the Research Foundation are for maintenance and upkeep of the license and are being expensed as period expenses.

Scheduled amortization over the next five years and thereafter is as follows:

---

| | |
|:---|:---|
|  **For the periods ending December 31,** | |
| 2025 | $1706 |
| 2026 | 1706 |
| 2027 | 1706 |
| 2028 | 1706 |
| 2029 | 1706 |
|  Thereafter | 10236 |
|  Total | $18766 |

---

Licensed Patents:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. U.S. Patent No. 9,230,321, "Computer Aided Diagnostic System Incorporating 3D Shape Analysis of the Brain for Identifying Developmental Brain Disorders," issued Jan. 5, 2016 from U.S. Patent App. No. 13/834,231 (ULRF Ref. 11064-02), which claims priority to U.S.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Provisional Patent App. No. 61/617,869, filed Mar. 30, 2012 (ULRF Ref. 11064-01, -02) 2. U.S. Patent App. No. 15/233,671, "Computer Aided Diagnostic System for Mapping of Brain Images," filed Jul. 29, 2016 (ULRF Ref. 13098-03), which claims priority to U.S. Provisional Patent App. No. 62/198,169, filed Jul. 29, 2015 (ULRF Ref. 13098-02, -03). On October 31, 2018 we received a Notice of Allowance from the U.S. Patent and Trademark Office on the U.S. Patent App No. 15/233,671. On April 16, 2019, the U.S. Patent and Trademark Office issued Patent No. 10262414.

Royalties and License Payments:

Pursuant to the Research Foundation License Agreement, as amended, we agreed to hit certain progress milestones set out in the exhibits to the agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• During the first quarter in 2025, we would complete verification and validation of software for implementation of the technology in a Licensed Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• By March 31, 2025, we would submit an application to the United States Food and Drug Administration ("FDA") to obtain 501(k), PMA or other clearance to market and sell Licensed Products in the United States

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
3. INTANGIBLE ASSETS (cont.)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Within 12 months of receiving FDA approval and by no later than March 31, 2026, whichever occurs first, we would make a first sale in the United States

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• After the first sale, and throughout the remainder of the length of the license, we would sell at least one product every 6 months.

Additionally, we will pay ULRF 5% of our Net Sales for all license products sold during the term of the license, and 30% of any sublicensing income. If the total amount paid to ULRF through the sum of the stock issuance and percentage of net sales in any year is less than the agreed upon annual minimum payment, we pay ULRF the difference between the compensation provided and such minimum. For the year in which the first sale of our product occurs (= "Year 1"), the minimum is $25,000, for Years 2 and 3, the annual minimum is $75,000, and for any year thereafter, the annual minimum is $150,000.

Furthermore, the amended license agreement calls for milestone payments of $5,000 on December 1, 2024, which were paid in November 2024, and on May 21, 2025.

4. DEBT TRANSACTIONS

In March 2022 we issued three promissory notes to the chief executive officer and a director of the Company and a major shareholder, in exchange of $125,000 in cash. The notes carry interest at the rate of 8% and were originally due on December 31, 2022, and have since been extended to June 30, 2025.

On June 12, 2023 we entered into a Placement Agent's Agreement with Network 1 Financial Securities, Inc. ("Network 1"), a licensed broker/dealer ("Network 1"), for a bridge financing transaction, for the placement of up to $600,000 senior convertible debentures, on a best-efforts basis (amended in February 2024 to increase the financing limit to $1,000,000). The debentures carry interest of 6% per year, mature in 24 months, and will automatically convert into the Company's stock in the event of a public offering of the Company's stock, at a 25% discount to the offering price in such an event (the "Event"). Investors who participate in the debenture offering receive stock purchase warrants at the rate of 0.5 warrants for every share issued upon conversion of the notes. The warrants may be exercised at the debt conversion price in the Event and expire 3 years after issuance. At December 31, 2024, a total $1,420,400 of such convertible notes have been placed.

Debt:

---

| | | | |
|:---|:---|:---|:---|
|  | **Maturities** | **Interest <br>Rate** | **Total Face<br>Value as of <br>December 31, <br>2024** |
|  Promissory notes | 2025 | 8% | $125000 |
|  Convertible notes | 2025 | 6% | $458000 |
|  | 2026 | 6% | $962400 |

---

<u><u>Convertible notes payable</u></u>

During the year 2024 the Company issued $962,400 secured convertible notes, bearing interest at the annualized rate of 6% and mature 2 years after issuance.

The convertible notes carry a conversion feature by which upon successful conclusion of an IPO the notes and accrued interest automatically convert into common shares at a conversion price at a 25% discount to the IPO offering price.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
4. DEBT TRANSACTIONS (cont.)

In connection with the issuance of the convertible notes the Company issued stock purchase warrants, the terms of which call for one half warrant to be issued for every share issued upon conversion of the convertible notes. The warrants are exercisable during three years at the conversion price.

The warrants have been accounted for as liabilities in accordance with ASC 480 due to the contingent put option. The conversion feature has been accounted for as a derivative liability in accordance with ASC 815. In conjunction with the issuance of the convertible notes, the Company incurred placement fees at 13% of the financing or $59,540 in 2023, and $125,112 in 2024. The Company recognized these debt issuance costs, as well as the fair value of the warrants and derivative conversion feature as a debt discount valued at $161,619 in 2023 and $326,353 in 2024.

Convertible notes consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Maturities <br>(calendar year)** | **Interest <br>Rate** | **December 31,** | **December 31,** |
| | **Maturities <br>(calendar year)** | **Interest <br>Rate** | **2024** | **2023** |
|  2023 issuances, total face value | 2025 | 6% | $458000 | $458000 |
|  2024 issuances, total face value | 2026 | 6% | 962400 |  |
|  Unamortized debt discount |  |  | (354316) | (146828) |
|  Carrying value |  |  | $1066084 | $311172 |

---

Interest incurred for the years ended December 31, 2024 and 2023 was $190,174 and $29,808, respectively (including $118,865 and $14,791, respectively, from amortization of debt discount).

<u><u>Derivative and Warrant Liabilities</u></u>

ASC 480 and ASC 815 require us to assess the fair value of the liabilities at the end of each accounting period and recognize the change in the fair market value as income or expense. The Company determined our derivative and warrant liabilities to be a Level 3 fair value measurement and to calculate the fair value at issuance date, at December 31, 2023 and December 31, 2024.

Because the number of shares issuable upon conversion of the notes and the number of warrants will not finally be determined until the liquidation event takes place the Company used assumed data for the event for the calculations (see below).

The following table summarizes the assumptions utilized in the probability-weighted Black Scholes model in measuring the warrant liability during the years ended December 31, 2023 and December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Warrants** | **Warrants** | **Conversion Feature** | **Conversion Feature** |
|  | **Initial Date** | **December 31, <br>2023** | **Initial Date** | **December 31, <br>2024** |
|  Estimated stock price | $0.923 | $0.923 | $1.32 – $2.52 | $2.52 |
|  Expected exercise price | $1.50 – $2.00 | $1.50 – $2.00 | $1.50 – $3.00 | $2.00 – $4.00 |
|  Weighted probability to occur | 50/50% | 50/50% | 50/50% | 70/30% |
|  Expected term | 3 years | 0.75 – 2.83 years | 0.37 – 3 years | 0.5 – 1.83 years |
|  Volatility | 65% | 65% | 74.8% – 83.5% | 74.8% – 86.2% |
|  Dividend yield | 0% | 0% | 0% | 0% |
|  Risk-free interest rate | 4.02% | 4.23% – 4.25% | 3.58% – 5.47% | 4.24% – 4.27% |
|  Expected IPO price | $1.50 | $1.50 | $1.50 – $4.00 | $4.00 |

---

The stock price was based on a 409A valuation of our stock (see Note 5); volatility used was determined in conjunction with the 409A valuation based on comparable companies in the industry.

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

4. DEBT TRANSACTIONS (cont.)

The following table summarizes the assumptions used in measuring the probability-weighted PV of share-settled redemption measuring the derivative liability during the year ended December 31, 2023 and December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Initial Date** | **December 31, <br>2023** | **Initial Date** | **December 31, <br>2024** |
|  Face value | $458000 | $458000 | $962400 | $1420400 |
|  Accrued interest (6%) |  | 20629 |  | 42262 |
|  Face and interest | 458000 | 478629 | 962400 | 1462662 |
|  Conversion price | 75% | 75% | 75% | 75% |
|  Discount value | 114500 | 119657 | 240600 | 365665 |
|  Expected Term | 0.92 | 0.75 | 0.35 – 0.58 | 0.50 |
|  Estimated equity rate of return | 21% | 21% | 21% | 21% |
|  Present | 96112 | 103703 | 218092 | 332684 |
|  Settlement probability |  |  |  |  |
|  Convert on IPO | 50% | 50% | 50% | 70% |
|  Convert no IPO | 0% | 0% | 0% | 0% |
|  Prepayment | 5% | 5% | 5% | 5% |
|  Default | 40% | 40% | 40% | 20% |
|  Maturity | 5% | 5% | 5% | 5% |

---

The stock price was based on a 409A valuation of our stock and linear interpolation of values between 409A valuations (see Note 5); volatility used was determined in conjunction with the 409A valuations based on comparable companies in the industry.

<u><u>Fair Value Measurements</u></u>

Set out below are the Company's financial instruments that are required to remeasured at fair value on a recurring basis, and their fair value hierarchy as of December 31, 2023, and December 31, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **December 31, 2023** | **Level 1** | **Level 2** | **Level 3** | **Carrying Value** |
|  Liabilities |  |  |  |  |
|  Liability – Warrants | $— | $— | $26510 | $26510 |
|  Derivative Liability – Conversion Feature |  |  | 52994 | 52994 |
|  Total Liabilities | $— | $— | $79504 | $79504 |

---

For the year ended December 31, 2023 the estimated fair value of the liabilities are as follows (fair value measured using significant unobservable inputs (Level 3):

---

| | |
|:---|:---|
|  Balance December 31, 2022 | $— |
|  Addition of new liability recognized as debt discount – warrants | 42513 |
|  Addition of new derivatives recognized as debt discount – conversion feature | 59566 |
|  Gain on change of fair value of the liabilities | (22575) |
|  Balance December 31, 2023 | $79504 |

---

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
4. DEBT TRANSACTIONS (cont.)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **December 31, 2024** | **Level 1** | **Level 2** | **Level 3** | **Carrying Value** |
|  Liabilities |  |  |  |  |
|  Liability – Warrants | $— | $— | $184793 | $184793 |
|  Derivative Liability – Conversion Feature |  |  | 232878 | 232878 |
|  Total Liabilities | $— | $— | $417671 | $417671 |

---

For the year ended December 31, 2024 the estimated fair value of the liabilities are as follows (fair value measured using significant unobservable inputs (Level 3):

---

| | |
|:---|:---|
|  Balance December 31, 2023 | $79504 |
|  Addition of new liability recognized as debt discount – warrants | 103701 |
|  Addition of new derivatives recognized as debt discount – conversion feature | 97540 |
|  Loss on change of fair value of the liabilities | 136926 |
|  Balance December 31, 2024 | $417671 |

---

5. EQUITY TRANSACTIONS

In 2023 we performed a 409A valuation to derive an estimate of common share value which yielded a common share value of $0.923 per share. The valuation was based on two approaches — (1) an income approach based on a discounted cash flow method utilizing a discount rate of 24% , and (2) a market approach based on a market calibration method from the valuation date to the most recent stock sale transaction (back solve date). Then, a discount for lack of marketability of 17.5% was incorporated to arrive at the estimated enterprise value and derive the per share value.

During 2023 we issued 571,250 shares in an agreed-upon conversion at $1 per common share of $401,500 in accrued salaries of certain officers, and $169,750 in accrued consulting fees due a major shareholder. We also issued 135,500 shares to five consultants for services rendered at the 409A valuation per share of $0.923.

In 2024 we performed a 409A valuation to derive an estimate of common share value which yielded a common share value of $2.52 per share as of December 31, 2024. The valuation was based on two approaches — (1) an income approach based on a discounted cash flow method utilizing a discount rate of 24%, and (2) a market approach based on market data of S&P Global Market Intelligence as of December 31, 2024, using expected IPO pricing and probability of occurrence. Then, a discount for lack of marketability of 12% at December 31, 2024 was incorporated to arrive at the estimated enterprise value and derive the per share value.

During 2024 we issued 931,250 shares in conversion at an agreed-upon price of $1 per common share of $580,000 in accrued salaries due certain officers, $319,750 in accrued consulting fees due a major shareholder and $31,500 due to another consultant. We also issued 89,453 shares to four consultants for services rendered, valued at a total $174,857 using a linear interpolation framework to estimate the fair value between the per share 409A valuations of $0.923 at December 31, 2023 and $2.52 at December 31, 2024. The Company furthermore awarded stock grants of 300,000 shares to two executives of the Company, valued at $576,450. We also cancelled warrants for 25,000 shares, exercisable at $0.50 per share and issued new warrants for 100,000 shares, exercisable at $1.00 per share, to an officer of the Company. This transaction was an equity warrant modification with the incremental value recognized as additional compensation.

During 2024 we extended the exercise period of 212,313 warrants previously issued to investors in a 2019 private offering which warrants expired or will expire during 2024, until 2026. We accounted for the extension as a modification of the 212,313 warrants, exercisable during two years at the old exercise price of $1.20 per share, using the Black Scholes valuation model, and recognized the value of $157,379 as implied dividends.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
6. RELATED PARTY TRANSACTIONS

During 2023 we granted 500,000 stock options to certain officers and directors of the Company, exercisable during 3 years (450,000 options) and 5 years (50,000 options). All such options are exercisable at $1.00 per share. During the year we converted $401,500 in accrued salaries of certain officers, and $169,750 in accrued consulting fees of a major shareholder into 571,000 common shares. During that year we paid $46,540 in placement fees to Network 1 in connection with the bridge financing transaction (see Note 4). Network 1 is controlled by a major shareholder.

During 2024 we issued 100,000 warrants to an officer of the Company (see Note 5). We converted accrued liabilities due to certain officers and a major shareholder into 899,750 shares, and issued 300,000 shares in form of stock awards to certain executives of the Company (see Note 5). We also extended the exercise period of 300,000 options issued in 2020 to an officer of the Company by two years, recognizing $95,295 as additional expense.

During that year we paid Network 1 $137,712 in placement fees in connection with the bridge financing transaction and $120,000 in advisory fees. We also paid $18,000 for office rent to a company controlled by a major shareholder under a sublease arrangement.

Accrued interest on notes payable to an officer and a major shareholder at December 31, 2024 and December 31, 2023 was $24,247 and $14,247, respectively.

7. INCOME TAXES AND DEFERRED TAX ASSETS

The Company's total deferred tax asset and valuation allowance as of December 31, 2024 and December 31, 2023 are as follows:

---

| | | |
|:---|:---|:---|
|  | **2024** | **2023** |
|  Loss per financial statements | $2649178 | $788005 |
|  Differences in financial statement and tax accounting for: |  |  |
| &nbsp;&nbsp;&nbsp; Amortization of intangibles | 341 | 341 |
| &nbsp;&nbsp;&nbsp; Amortization of debt discount | (118865) | (14791) |
| &nbsp;&nbsp;&nbsp; Change in fair value of derivative liabilities | (136926) | (22575) |
| &nbsp;&nbsp;&nbsp; Stock-based compensation | (1018587) | (282452) |
|  Loss adjusted for tax treatment | 1375141 | 468528 |
|  Deferred tax benefit (fully reserved) | 385039 | 131188 |
|  Deferred tax asset | 939052 | 554013 |
|  Less valuation allowance | (939052) | (554013) |
|  Total deferred tax asset, net of valuation allowance | $— | $— |

---

As of December 31, 2024, the Company had an aggregate net operating loss carryforward(s) to offset future taxable income of approximately $3,453,000. The amount and availability of any net operating loss carryforward(s) will be subject to the limitations set forth in the Internal Revenue Code.

At December 31, 2024, the Company had approximately $937,642 of U.S. federal net operating tax loss carryforward. There is no expiration date, however, a company can only offset up to 80% of taxable profits in a given year. The Company is currently subject to the general three-year statute of limitations for federal tax. Under this general rule, the earliest period subject to potential audit is 2021. For years in which the Company may utilize its net operating losses, the IRS has the ability to examine the tax year that generated those losses and propose adjustments up to the amount of losses utilized.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
7. INCOME TAXES AND DEFERRED TAX ASSETS (cont.)

The Company applies the ASC 740 provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense. Management believes that the company has no uncertain tax positions.

The reconciliation of the effective income tax rate to the Federal statutory rate is as follows:

---

| | | |
|:---|:---|:---|
|  | **2024** | **2023** |
|  Federal statutory rate on pre-tax book loss | (21)% | (21)% |
|  State tax benefit | (7)% | (7)% |
|  Issuance of equity for services | 8% | 8% |
|  Change in Valuation Allowance | 20% | 20% |
|  Effective Income Tax Rate | 0% | 0% |

---

The Company believes that all its positions taken in tax filings are more likely than not to be sustained upon examination by tax authorities.

8. RISKS AND UNCERTAINTIES

In order to finalize development of the licensed technology for commercial purpose, submit and obtain FDA clearance for the product, and commence marketing and distribution efforts the Company needed a substantial infusion of working capital. To that extent the Company undertook an offering of convertible debt (see Note 4) to raise sufficient capital to finance ongoing operations, product development, and preparations for FDA submission of our proprietary technology. The latter has been effected in March 2025. Furthermore, the Company plans to undertake a public offering (the "Offering") of its stock with the goal of raising up to $7,000,000 in equity capital. There can be no assurance that the Offering will be successful in terms of gaining investor acceptance, and that a sufficient amount of new capital will be raised in the process. If we fail to receive a significant portion of the targeted amount and cannot cover any shortfall from other sources we would experience delays in getting our product to market or could even be forced to ultimately abandon our business plan which would potentially render the license to the technology worthless.

9. WARRANTS AND OPTIONS

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Weighted Average** | **Weighted Average** | **Weighted Average** | **Weighted Average** | **Weighted Average** | **Weighted Average** |
|  | **Shares** | **Exercise <br>Price** | **Remaining <br>Life** | **Shares** | **Exercise <br>Price** | **Remaining <br>Life** |
|  Warrants outstanding at beginning of period | 389091 | $1.12 | 1.5 years | 488980 | $1.50 | 1.4 years |
|  Warrants expired or cancelled | (52778) | $0.87 |  | (50000) | $0.50 |  |
|  Warrants granted (net of recalculations) | 152667 | $1.50 |  | 184066 | $1.77 |  |
|  Warrants outstanding at end of period | 488980 | $1.22 | 1.4 years | 623046 | $1.85 | 1.7 years |

---

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
9. WARRANTS AND OPTIONS (cont.)

The warrants granted in 2023 were granted in connection with the convertible note transactions (see Note 4 "DEBT TRANSACTIONS"). For purpose of calculating the quantity of warrants we used 50% of the quantity of shares issuable upon conversion of the convertible notes which conversion price is based on 75% of the expected IPO price of $2.00.

The warrants granted in 2024 included 100,000 warrants issued to an officer of the Company (see Note 5), with a simultaneous cancellation of 25,000 warrants outstanding for the same officer. Both the cancelled old and the new warrants were valued using the Black-Scholes model, with the incremental value of $120,400 recognized as additional compensation. During the year we also issued 320,800 warrants in connection with the convertible note transactions (see Note 4 "DEBT TRANSACTIONS"). For purpose of calculating the quantity of warrants we used 50% of the quantity of shares issuable upon conversion of the convertible notes which conversion price is based on 75% of the expected IPO price of $4.00.

The 2019 Stock Plan provides for the granting of ISOs, Non-Qualified Options, Stock Grants and Stock-Based Awards. The number of Shares which may be issued from time to time pursuant to this Plan shall be 3,000,000, or the equivalent of such number of Shares after the Administrator, in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction. The Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to interpret the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable for the administration of the Plan, and to determine which employees, directors and consultants shall be granted Stock Rights. At December 31, 2024, there were 2,150,000 options available to be granted under the Plan.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2023** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Weighted Average** | **Weighted Average** | **Weighted Average** | **Weighted Average** |
|  | **Shares** | **Shares** | **Exercise <br>Price** | **Remaining <br>Life** |
|  Options outstanding at beginning of period | 325000 | 875000 | $1.00 | 2.9 years |
|  Options expired |  | $(25000) | $1.00 |  |
|  Options granted | 550000 |  | $— |  |
|  Options outstanding at end of period | 875000 | 850000 | $1.00 | 1.9 years |
|  Options vested and exercisable | 650000 | 650000 | $1.00 |  |

---

The options were granted for services and were valued utilizing a Black-Scholes valuation model with the following assumptions: share price — $0.923 based on the 409A valuation as of the grant date; volatility — per below; dividends — none; risk-free rate — 3.76% to 4.85%; expected life — 3 to 5 years.

Volatility assumptions used in 2023 were determined in conjunction with the 409A valuation.

10. SEGMENT REPORTING

We evaluated segment reporting in accordance with Accounting Standards Codification ("ASC") 280, Segment Reporting ("ASC 280") and concluded that the Company is comprised of one operating segment. We report segment information based on the operating results regularly reviewed by the chief operating decision maker to make decisions about resource allocation and the performance of the business.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### NOTES TO FINANCIAL STATEMENTS
10. SEGMENT REPORTING (cont.)

The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the balance sheets as total assets.

---

| | | |
|:---|:---|:---|
|  **EXPENSES** | **Year ended<br>December 31, <br>2024** | **Year ended<br>December 31, <br>2023** |
|  Salaries and benefits | $297733 | $200000 |
|  Stock-based compensation | 884348 | 282451 |
|  Legal and accounting expenses | 114446 | 26000 |
|  Product development expenses | 487332 | 139152 |
|  Consultancies | 492635 | 114250 |
|  Miscellaneous general operating expenses | 45584 | 18919 |
|  Change in fair value- warrants and derivative liabilities | 136926 | (22575) |
|  Interest expense | 190174 | 29808 |
|  TOTAL | $2649178 | $788005 |

---

11. DEFERRED OFFERING COSTS

The Company complies with the requirement of the ASC 340-10-S99-1 and SAB Topic 5A "Expenses of Offering". Deferred offering costs consist of underwriting, legal and other expenses incurred through the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders' equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations. As of December 31, 2024 the Company capitalized $220,811 of deferred offering costs. Such costs will be deferred until the closing of the IPO, at which time the deferred costs will be offset against the offering proceeds.

12. SUBSEQUENT EVENTS

During 2025 we issued additional $231,000 in convertible notes pursuant to the Network 1 financing transactions (see Note 4 "DEBT TRANSACTIONS") which included warrants issued under the same terms as shown in Note 4.

During March of 2025 we filed a 510K application with the Food and Drug Administration.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### BALANCE SHEETS

---

| | | |
|:---|:---|:---|
|  | (Unaudited) | |
|  | **March 31,<br> 2025** | **December 31,<br> 2024** |
|  Assets |  |  |
|  Current Assets |  |  |
| &nbsp;&nbsp;&nbsp; Cash | $1847 | $173502 |
| &nbsp;&nbsp;&nbsp; Prepaid expenses |  | 20000 |
| &nbsp;&nbsp;&nbsp; Total Current Assets | 1847 | 193502 |
|  Other Assets |  |  |
| &nbsp;&nbsp;&nbsp; Deferred offering costs | 248192 | 220811 |
| &nbsp;&nbsp;&nbsp; Capitalized software development costs | 15996 |  |
| &nbsp;&nbsp;&nbsp; Intangible assets, net of $12,368 and $11,942 accumulated amortization | 18340 | 18766 |
|  Total Assets | $284375 | $433079 |
|  Liabilities and Stockholders' Equity |  |  |
| &nbsp;&nbsp;&nbsp; Accounts payable | $194660 | $135577 |
| &nbsp;&nbsp;&nbsp; Accrued expenses – Related Parties | 378042 | 285466 |
| &nbsp;&nbsp;&nbsp; Accrued expenses – Other | 39658 | 80579 |
| &nbsp;&nbsp;&nbsp; Accrued interest – Related Parties | 24219 | 22247 |
| &nbsp;&nbsp;&nbsp; Accrued interest – Other | 93692 | 71657 |
| &nbsp;&nbsp;&nbsp; Liability for stock to be issued | 26118 | 6933 |
| &nbsp;&nbsp;&nbsp; Liability for warrants granted | 163481 | 184793 |
| &nbsp;&nbsp;&nbsp; Derivative liability for note conversion feature | 253936 | 232878 |
| &nbsp;&nbsp;&nbsp; Convertible notes payable (net of debt discount), current portion | 692934 | 391526 |
| &nbsp;&nbsp;&nbsp; Notes payable | 125000 | 125000 |
|  Total Current Liabilities | 1991740 | 1536656 |
|  Convertible notes payable (net of debt discount) | 466639 | 674558 |
|  Total Liabilities | 2458379 | 2211214 |
|  Commitments and Contingencies (Notes 4 and 8) |  |  |
|  Stockholders' Equity |  |  |
| &nbsp;&nbsp;&nbsp; Preferred Stock, par value $0.00001, 10,000,000 shares authorized, none issued |  |  |
| &nbsp;&nbsp;&nbsp; Common Stock, par value $0.00001, 90,000,000 shares authorized, 10,974,238 and 10,973,358 shares issued and outstanding | 110 | 110 |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | 3528983 | 3528103 |
| &nbsp;&nbsp;&nbsp; Retained Deficit | (5703097) | (5306348) |
|  Total Stockholders' Equity | (2174004) | (1778135) |
|  Total Liabilities and Stockholders' Equity | $284375 | $433079 |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### STATEMENTS OF OPERATIONS<br>(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,<br> 2025** | **March 31,<br> 2024** |
|  Operating Expenses |  |  |
| &nbsp;&nbsp;&nbsp; Personnel expenses | $69700 | $168387 |
| &nbsp;&nbsp;&nbsp; Professional and outside services | 183886 | 135238 |
| &nbsp;&nbsp;&nbsp; General and administrative expenses – other | 12386 | 1874 |
| &nbsp;&nbsp;&nbsp; Product development expenses | 72260 | 44132 |
|  Total Operating Expenses | 338232 | 349631 |
|  Loss from Operations | (338232) | (349631) |
|  Other Income (Expense) |  |  |
| &nbsp;&nbsp;&nbsp; Interest expense | (78120) | (31873) |
| &nbsp;&nbsp;&nbsp; Change in fair value of warrants and derivative liabilities . | 19604 | (74653) |
|  Total Other Income (Expense) | (58516) | (106526) |
|  Loss before provision of income taxes | (396748) | (456157) |
|  Provision for income taxes |  |  |
|  Net Loss | $(396748) | $(456157) |
|  Loss per share, basic and diluted | $(0.04) | $(0.04) |
|  Weighted average number of shares outstanding during the period | 10973436 | 10222766 |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### STATEMENTS OF STOCKHOLDERS' EQUITY<br>(Unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **<br>Common Stock** | **<br>Common Stock** | **Additional<br>Paid-in<br> Capital** | **Accumulated<br>Deficit** | **Total<br>Equity** |
|  | **Shares** | **Amount** | **Additional<br>Paid-in<br> Capital** | **Accumulated<br>Deficit** | **Total<br>Equity** |
|  Balances at January 1, 2024 | 9652655 | $96 | $1401326 | $(2499791) | $(1098369) |
|  Issuance of common stock to settle liabilities | 25000 |  | 23075 |  | 23075 |
|  Stock options issued for services |  |  | 118387 |  | 118387 |
|  Accrued salaries and fees converted into common shares | 854750 | 9 | 854741 |  | 854750 |
|  Net Loss for the three months ended March 31, 2024 |  |  |  | (456157) | (456157) |
|  Balances at March 31, 2024 | 10532405 | $105 | $2397529 | $(2955948) | $(558314) |
|  Balances at January 1, 2025 | 10973358 | $110 | $3528103 | $(5306349) | $(1778136) |
|  Issuance of common stock to settle liabilities | 880 |  | 880 |  | 880 |
|  Net Loss for the three months ended March 31, 2025 |  |  |  | (396748) | (396748) |
|  Balances at March 31, 2025 | 10974238 | $110 | $3528983 | $(5703097) | $(2174004) |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

#### NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.

#### STATEMENTS OF CASH FLOWS<br>(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,<br> 2025** | **March 31,<br> 2024** |
|  Cash Flows from Operating Activities |  |  |
|  Net Loss | $(396748) | $(456157) |
|  Adjustments to reconcile net loss to net cash used by operating activities |  |  |
| &nbsp;&nbsp;&nbsp; Amortization of intangible assets | 426 | 426 |
| &nbsp;&nbsp;&nbsp; Amortization of debt discount | 54114 | 18940 |
| &nbsp;&nbsp;&nbsp; Securities-based compensation |  | 118387 |
| &nbsp;&nbsp;&nbsp; Change in fair value warrants and derivative liabilities | (19604) | 74653 |
|  Decrease in prepaid expenses | 20000 |  |
|  Increase in liability for stock to be issued | 20065 |  |
|  Increase in accounts payable and accruals | 125969 | 58675 |
|  Net Cash Used by Operating Activities | (195778) | (185076) |
|  Cash Flows from Investing Activities |  |  |
|  Capitalized software development costs | (15996) |  |
|  Net Cash Used by Investing Activities | (15996) |  |
|  Cash Flows from Financing Activities |  |  |
|  Proceeds from issuance of promissory notes | 67500 | 302000 |
|  Cash outlay – Deferred offering costs | (27381) |  |
|  Cash paid for debt financing |  | (39260) |
|  Net Cash provided by Financing Activities | 40119 | 262740 |
|  Net Increase (Decrease) in Cash | (171655) | 77664 |
|  Cash at Beginning of Year | 173502 | 305712 |
|  Cash at end of first quarter | $1847 | $383376 |
|  Supplemental Disclosure of Cash Flow Information: |  |  |
|  Cash Paid for: |  |  |
| &nbsp;&nbsp;&nbsp; Interest | $— | $— |
| &nbsp;&nbsp;&nbsp; Income Taxes | $— | $— |
|  Non-cash Financing Activities: |  |  |
| &nbsp;&nbsp;&nbsp; Debt discount from new warrants and derivative liabilities | $28125 | $56472 |
| &nbsp;&nbsp;&nbsp; Liabilities converted to stock | $— | $854750 |
| &nbsp;&nbsp;&nbsp; Debt issuance costs incurred, but unpaid | $8775 | $— |
| &nbsp;&nbsp;&nbsp; Stock issued in settlement of liabilities | $880 | $23075 |

---

The accompanying notes are an integral part of the financial statements.

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

1. DESCRIPTION OF BUSINESS

*Nature of Organization*

NeuroSpectrum Insights, Inc. (the "Company", "We", or "Us") was incorporated as a Delaware corporation on January 20, 2016 as Autism Diagnostic Technologies, Inc. On January 31, 2024 we changed the Company's name to NeuroSpectrum Insights, Inc.

*Business*

We are in the business of commercializing a medical diagnostic technology that may have the potential of significantly facilitating, and enhancing the accuracy of, the diagnosis of certain neuro-disabling diseases, if approved by the FDA. To that extent we plan, upon successful conclusion of our current efforts to raise new equity capital, to finalize the preparation of our application for FDA clearance, and bring to market this new diagnostic technology for early detection of autism.

This technology assists in the diagnosis of neuro-disabling diseases through the use of advanced three-dimensional ("3D") brain mapping technology.

*Going Concern*

The Company has not yet derived any revenues, and at March 31, 2025 had a working capital deficit of $1,989,893. In view of these conditions there is substantial doubt about the ability of the Company to continue as a going concern through at least June 2026. Realization of the Company's business plans is dependent upon the successful conclusion of currently planned public offering of its stock. Should the Company be unable to raise the desired amount of capital with such offering or through alternate funding sources, its operating plans will be limited to the amount of capital that it can access which may not be enough to continue as a going concern. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

*Basis of Presentation*

These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP") and applicable rules and regulations of the U.S. Securities and Exchange Commission ("SEC") regarding financial reporting.

*Cash Equivalents*

Cash and all highly liquid investments with an original maturity of three months or less from the date of purchase, including money market mutual funds, short-term time deposits, and certain government agency and corporate obligations, are classified as cash and cash equivalents. The Company had no cash equivalents at March 31, 2025 or December 31, 2024.

*Long-Lived Assets*

The Company assesses the valuation of components of its long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

*Intangible Assets*

The Company amortizes its intangible assets on a straight line over the estimated useful life of the assets and assesses the valuation of such assets whenever events or circumstances dictate that the carrying value might not be recoverable. At March 31, 2025, the Company's only intangible asset is a license for the use of certain proprietary technology (see Note 2). The expected future cash flows associated with this asset are dependent on the Company's ability to reimburse the technology owner for prosecution and/or maintenance costs under the license arrangement, which the Company has been able to accomplish since inception.

*Research and Development Expenses*

Our software is intended to be marketed as a distinctive separate product and our related development costs, incurred to establish the technological feasibility pursuant to ASC 985-20, which arise in the design, configuration and coding that are performed by third party contractors, are charged to expense as incurred as required by Subtopic 730-10. The costs for the license to the technology underlying our product were capitalized in accordance with ASC 730-10-25-2(c).

Software development began in 2022. Product development costs for the three months ended March 31, 2025 and March 31, 2024 were $88,255 and $44,132, respectively, of which $72,260 and $44,132, respectively, were charged to operations as incurred since technological feasibility for our product had not yet been established. That had been achieved at the time of our filing for a 510K application with the FDA in early March 2025, and $15,996 of development costs were capitalized in accordance with ASC 985-20.

*Contingent Liabilities*

We will pay the Research Foundation 5% of our Net Sales for all license products sold during the term of the license, and 30% of any sublicensing income. We are facing a contingent liability in so far as we must pay the Research Foundation the difference between the 5% royalties paid during a given year and agreed upon annual minimum amounts.

All royalty payments to the Research Foundation are being expensed. Liabilities for potential payments to reach the agreed upon annual minimum amounts are being recognized when their probability has been established and their amount can reasonably be estimated. We are expensing these costs rather than capitalizing them because they do not bestow additional IP rights on us.

*Derivative Liabilities*

The Company issued convertible notes accompanied by stock purchase warrants.

Accounting treatment of the Warrants:

We determined that the Warrants should be classified as a liability instrument in accordance with ASC 480 since they contain a potentially applicable put option which, if exercised would oblige the Company to redeem the warrants at their fair value as measured at the time of a defined future event. As such we measure them at their fair value on the issuance date, which we chose to be determined by applying a probability-weighted Black Scholes valuation model.

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Accounting treatment of the conversion feature of the Convertible Notes:

We separated the conversion feature from the notes as a separate liability in accordance with ASC 815 (bifurcation of an embedded derivative conversion feature due to the indeterminate number of shares upon conversion), measured at their fair value on the issuance date of the notes, and determined by probability-weighted present value of share-settled redemption feature derivative liability.

*Stock-based Compensation*

The Company records stock-based compensation in accordance with ASC 718, Compensation — Stock Compensation ("ASC 718"). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the employees required service period, which is generally the vesting period. The Company recognizes forfeitures as they occur.

*Fair Value Measurements*

Financial Accounting Standards Board ("FASB") *ASC Topic 820, Fair Value Measurements and Disclosures* ("ASC 820"), provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows:

---

| | |
|:---|:---|
| Level 1 — | Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices. |
| Level 2 — | Pricing inputs are other than quoted prices in active markets but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts or priced with models using highly observable inputs. |
| Level 3 — | Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights. |

---

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

*Income Taxes*

The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss carryforwards. The carrying amounts of deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed periodically based on the more-likely-than-not recognition threshold. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses, the duration of statutory carryforward periods, and

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

tax planning alternatives. The Company assesses the likelihood that uncertain tax positions will be accepted by the applicable taxing authority based on the technical merits of the position. Tax positions meeting the more-likely-than-not recognition threshold are measured and recognized in the financial statements at the largest amount of benefit that has a greater than 50% likelihood of being realized upon measurement of a tax position taken in a prior annual period, including interest and penalties, and are recognized during the period in which the change occurs. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes. For the three months ended March 31, 2025 and March 31, 2024, we did not have any interest and penalties or any significant unrecognized uncertain tax positions. The Company's tax years since 2020 are subject to examination. The Company recognizes accrued interest and penalties related to the unrecognized tax benefits in operating expenses.

*Recently Issued Accounting Pronouncements*

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's financial statements.

From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position.

In November 2023 the FASB issued ASU 2023-07, (Segment Reporting). The accounting standard requires companies to disclose significant expense categories within business segments. The Company has adopted this guidance as of January 1, 2024 (see Note 10).

In March 2024, the FASB issued ASU 2024-01, (Compensation-Stock Compensation (Topic 718). ASU 2024-01 shows examples how an entity should apply the guidance in ASC 718-10-15-3 to determine whether a profits interest award is within the scope of ASC 718. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. The pronouncement is effective for public business entities that are SEC filers in fiscal years beginning after December 15, 2024, and for other entities in fiscal years beginning after December 15, 2025 including interim periods within those fiscal years. The adoption of this standard is not expected to result in any material changes in the Company's financial statements from our reports for 2024 and the prior years.

In November 2024 the FASB has released ASU 2024-03, (Disaggregation of Income Statement Expenses). The ASU's purpose is "to improve the disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development). During the same month the FASB issued ASU 2024-04, (Induced Conversions of Convertible Debt Instruments). This new guidance clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. The ASU is effective for annual periods beginning after December 15, 2026. The Company will evaluate the potential effects on our financial reporting at that time.

*Income (loss) per share*

Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the respective period presented in our accompanying financial statements.

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Common shares related to warrants, stock options, and convertible debt which, if exercised, would have an anti-dilutive effect on earnings per share, but in view of the Company's net loss position with respect to the reporting periods have not been included in computing diluted earnings per share. Anti-dilutive securities not included in net loss per share calculations for the periods presented include:

---

| | | |
|:---|:---|:---|
|  | **March 31, <br>2025** | **March 31, <br>2024** |
|  Warrants issued to Officer | 100000 | 75000 |
|  Warrants issued with private equity placements | 222313 | 286313 |
|  Warrants issuable with Debt Financing (computed per ASC 260 based on the value of the Company's common stock at March 31, 2024, ($0.923) and March 31, 2025 ($2.52) | 393624 | 548935 |
|  Stock Options | 850000 | 875000 |
|  Shares issuable upon conversion of convertible debt (computed based on the offering price)\* | [\*] | [\*] |

---

____________

\* Issuance of these shares is contingent upon consummation of the public offering.

The number of shares issuable upon automatic conversion of convertible debt in the case of a public offering is linked to the offering price and cannot at this time be determined. The number of shares to be issued is derived by dividing the amount of the convertible debt by 75% of the offering price.

*Use of Estimates*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Subsequent Events Evaluation Date

The Company evaluated the events and transactions subsequent to its March 31, 2025 balance sheet date and, in accordance with FASB ASC 855-10-50, "Subsequent Events" through June 18, 2025, which is the date these financial statements were issued.

3. INTANGIBLE ASSETS

The patents, copyrights, and intellectual property rights to the technology that we seek to commercialize are owned by the University of Louisville Research Foundation Inc. (the "Research Foundation" or "ULRF"). The Company was granted an exclusive worldwide license pursuant to an "Exclusive Agreement" dated January 31, 2017 which is valid through the expiration date of the last granted patent and can be terminated only upon occurrence of an uncured violation by the Company of the contract terms. The agreement, among other, obliges the Company to (1) pay royalties on income from the licensed products during the term of the agreement, (2) a 30% fee on non-royalty income from sub-licensing, (3) reimbursement of certain expenses originally aggregating $34,273, of which $4,500 were subsequently waived, payable in installments until October 2019 (the entire amount has been paid as of September 30, 2019), (4) adherence to certain milestone criteria for the raising of capital and submission of the product for FDA clearance and (5) imposes ongoing reporting and disclosure requirements. The agreement furthermore called for issuance of a total 478,262 common shares (the "Foundation Shares") to the Research Foundation and the four inventors of the patented technology.

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

3. INTANGIBLE ASSETS (cont.)

The costs of the license for the technology underlying our product were capitalized as intangible assets in accordance with ASC 730-10-25-2(c) since the licensed technology has alternative future uses, for example in potential applications that seek to analyze brain structures for indicators of Alzheimer's disease. Our software is intended to be marketed as a distinctive separate product and our related development costs, pursuant to ASC 985-20, which arise in the design, configuration and coding that are performed by third party contractors, are expensed.

The capitalized costs were $30,708 consisting of the above $29,773 net expenses plus the value assigned to the Foundation Shares, to be amortized over the estimated remaining life of the license, presently calculated at 18 years, on a straight-line basis. For the three months periods ended March 31, 2025 and March 31, 2024 we recognized $426 each in amortization expense. For the year ended December 31, 2024 we recognized $1,706 in amortization expense. Future payments to the Research Foundation are for maintenance and upkeep of the license and are being expensed as period expenses.

Scheduled amortization over the next five years and thereafter is as follows:

---

| | |
|:---|:---|
|  **For the periods ending December 31,** | |
| 2025 | $1279 |
| 2026 | 1706 |
| 2027 | 1706 |
| 2028 | 1706 |
| 2029 | 1706 |
|  Thereafter | 10237 |
|  Total | $18340 |

---

4. DEBT TRANSACTIONS

In March 2022 we issued three promissory notes to the chief executive officer and a director of the Company and a major shareholder, in exchange of $125,000 in cash. The notes carry interest at the rate of 8% and were originally due on December 31, 2022, and have since been extended to June 30, 2025.

On June 12, 2023 we entered into a Placement Agent's Agreement with Network 1 Financial Securities, Inc. ("Network 1"), a licensed broker/dealer ("Network 1"), for a bridge financing transaction, for the placement of up to $600,000 senior convertible debentures, on a best-efforts basis (amended in February 2024 to increase the financing limit to $1,000,000). The debentures carry interest of 6% per year, mature in 24 months, and will automatically convert into the Company's stock in the event of a public offering of the Company's stock, at a 25% discount to the offering price in such an event (the "Event"). Investors who participate in the debenture offering receive stock purchase warrants at the rate of 0.5 warrants for every share issued upon conversion of the notes. The warrants may be exercised at the debt conversion price in the Event and expire 3 years after issuance. At March 31, 2025, a total $1,487,900 of such convertible notes have been placed.

Debt:

---

| | | | |
|:---|:---|:---|:---|
|  | **Maturities** | **Interest <br>Rate** | **Total Face <br>Value as of <br>March 31, <br>2025** |
|  Promissory notes | 2025 | 8% | $125000 |
|  Convertible notes | 2025 | 6% | $458000 |
|  | 2026 | 6% | $962400 |
|  | 2027 | 6% | $67500 |

---

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

4. DEBT TRANSACTIONS (cont.)

<u><u>Convertible notes payable</u></u>

During the year 2024 and the first three months in 2025 the Company issued $962,400 and $67,500, respectively, secured convertible notes, bearing interest at the annualized rate of 6% and maturing 2 years after issuance.

The convertible notes carry a conversion feature by which upon successful conclusion of an IPO the notes and accrued interest automatically convert into common shares at a conversion price at a 25% discount to the IPO offering price.

In connection with the issuance of the convertible notes the Company issued stock purchase warrants, the terms of which call for one half warrant to be issued for every share issued upon conversion of the convertible notes. The warrants are exercisable during three years at the conversion price or at $2.00 in the event the IPO does not occur.

The warrants have been accounted for as liabilities in accordance with ASC 480 due to the contingent put option. The conversion feature has been accounted for as a derivative liability in accordance with ASC 815. In conjunction with the issuance of the convertible notes, the Company incurred placement fees at 13% of the financing or $39,260 in the first quarter of 2024, and $8,775 in the first quarter of 2025. The Company recognized these debt issuance costs, as well as the fair value of the warrants and derivative conversion feature as a debt discount valued at $28,124 and $97,498 during the three months ended 2025 and 2024, respectively.

Convertible notes consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Maturities <br>(calendar year)** | **Interest <br>Rate** | **March 31, <br>2025** | **December 31, <br>2024** |
|  2023 issuances, total face value | 2025 | 6% | $458000 | $458000 |
|  2024 issuances, total face value | 2026 | 6% | $962400 | $962400 |
|  2025 issuances, total face value | 2027 | 6% | $67500 |  |
|  Unamortized debt discount |  |  | $(328327) | $(354316) |
|  Carrying value |  |  | $1159573 | $1066084 |

---

Interest incurred for the three months ended March 31, 2025 and 2024 was $78,120 and $31,873, respectively (including $54,114 and $18,940, respectively, from amortization of debt discount).

<u><u>Derivative and Warrant Liabilities</u></u>

ASC 480 and ASC 815 require us to assess the fair value of the liabilities at the end of each accounting period and recognize the change in the fair market value as income or expense. The Company determined our derivative and warrant liabilities to be a Level 3 fair value measurement and to calculate the fair value at issuance date, at March 31, 2025 and December 31, 2024.

Because the number of shares issuable upon conversion of the notes and the number of warrants will not finally be determined until the liquidation event takes place the Company used assumed data for the event for the calculations (see below).

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

4. DEBT TRANSACTIONS (cont.)

The following table summarizes the assumptions utilized in the probability-weighted Black Scholes model in measuring the warrant liability during the three months periods ended March 31, 2024 and March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Initial Date** | **March 31, <br>2024** | **Initial Date** | **March 31, <br>2025** |
|  Estimated stock price | $1.12 | $1.32 | $2.52 | $2.52 |
|  Expected exercise price | $1.50 – $1.50 | $1.50 – $2.00 | $2.00 – $4.00 | $2.00 – $4.00 |
|  Weighted probability to occur | 50% – 50% | 50/50% | 70/30% | 70/30% |
|  Expected term | 0.56 years | 0.37 – 2.8 years | 0.38 – 3 years | 0.25 – 2.87 years |
|  Volatility | 74.8% – 79.8% | 74.8% – 79.8% | 74.8% – 79.8% | 74.8% – 79.8% |
|  Dividend yield | 0% | 0% | 0% | 0% |
|  Risk-free interest rate | 4.18% – 5.21% | 4.33% – 4.37% | 4.33% – 4.37% | 3.89% – 4.32% |
|  Expected IPO price | $1.50 | $1.50 | $4.00 | $4.00 |

---

The following table summarizes the assumptions used in measuring the probability-weighted PV of share-settled redemption measuring the derivative liability during the three months ended March 31, 2024 and March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Initial Date** | **March 31, <br>2024** | **Initial Date** | **March 31, <br>2025** |
|  Face value | $302000 | $760000 | $67500 | $1487900 |
|  Accrued interest (6%) |  | 37370 |  | 87867 |
|  Face and interest | 302000 | 797370 | 67500 | 1575767 |
|  Conversion price | 75% | 75% | 75% | 75% |
|  Discount value | 75500 | 199352 | 16875 | 393942 |
|  Expected term | 0.56 | 0.37 | 0.38 | 0.25 |
|  Estimated equity rate of return | 21% | 21% | 21% | 21% |
|  Present value | 67799 | 176912 | 15702 | 358408 |
|  Settlement probability |  |  |  |  |
|  Convert on IPO | 50% | 50% | 70% | 70% |
|  Convert no IPO | 0% | 0% | 0% | 0% |
|  Prepayment | 5% | 5% | 5% | 5% |
|  Default | 40% | 40% | 20% | 20% |
|  Maturity | 5% | 5% | 5% | 5% |

---

The stock price was based on a 409A valuation of our stock and linear interpolation of values between 409A valuations (see Note 5); volatility used was determined in conjunction with the 409A valuations based on comparable companies in the industry.

<u><u>Fair Value Measurements</u></u>

Set out below are the are the Company's financial instruments that are required to remeasured at fair value on a recurring basis, and their fair value hierarchy as of March 31, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Carrying Value** |
|  Liabilities |  |  |  |  |
|  Liability – Warrants | $— | $— | $163481 | $163481 |
|  Derivative Liability – Conversion Feature |  |  | 253936 | 253936 |
|  Total Liabilities | $— | $— | $417417 | $417417 |

---

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

4. DEBT TRANSACTIONS (cont.)

For the three months ended March 31, 2025 the estimated fair value of the liabilities are as follows (fair value measured using significant unobservable inputs (Level 3):

---

| | |
|:---|:---|
|  Balance December 31, 2024 | $417671 |
|  Addition of new liability recognized as debt discount – warrants | 8358 |
|  Addition of new derivatives recognized as debt discount – conversion feature | 10992 |
|  Gain on change of fair value of the liabilities | (19604) |
|  Balance March 31, 2025 | $417417 |

---

5. EQUITY TRANSACTIONS

In 2024 we performed a 409A valuation to derive an estimate of common share value which yielded a common share value of $2.52 per share as of December 31, 2024. The valuation was based on two approaches - (1) an income approach based on a discounted cash flow method utilizing a discount rate of 24%, and (2) a market approach based on market data of S&P Global Market Intelligence as of December 31, 2024, using expected IPO pricing and probability of occurrence. Then, a discount for lack of marketability of 12% at December 31, 2024 was incorporated to arrive at the estimated enterprise value and derive the per share value.

During the first three months in 2024 we issued 580,000 shares and 274,750 shares to certain officers and a major shareholder, respectively, in conversion — at an agreed-upon price of $1 per share — of $580,000 in accrued salaries due, and of $274,750 in accrued consulting fees. We also issued 25,000 shares to a consultant for services rendered, valued at $23,075 using the fair value per share from a 409A valuations of $0.923 at December 31, 2023.

During the three months ended March 31, 2025 we issued 880 shares to a consultant for services rendered.

6. RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2024 we extended the exercise period of 300,000 options issued in 2020 to an officer of the Company by two years, recognizing $95,295 as additional expense.

During the three months ended March 31, 2025 we accrued $8,775 for Network 1 in placement fees in connection with the bridge financing transaction and paid Network 1 $20,000 in advisory fees. Members of Network 1's executive management are significant shareholders of the Company.

We also paid $6,000 in the first quarter in 2025 for office rent to a company controlled by a significant shareholder under a sublease arrangement.

Accrued interest on notes payable to an officer and a major shareholder at March 31, 2025 and at December 31, 2024 was $24,219 and $22,247, respectively.

7. RISKS AND UNCERTAINTIES

In order to finalize development of the licensed technology for commercial purpose, submit and obtain FDA clearance for the product, and commence marketing and distribution efforts the Company needed a substantial infusion of working capital. To that extent the Company undertook an offering of convertible debt (see Note 4) to raise sufficient capital to finance ongoing operations, product development, and preparations for FDA submission of our proprietary technology. The latter has been effected in March 2025. Furthermore, the Company plans to undertake a public offering (the "Offering") of its stock with the goal of raising up to $7,000,000 in equity capital. There can be no assurance that the Offering will be successful in terms of gaining investor acceptance, and that a sufficient amount of new capital will be raised in the process. If we fail to receive a significant portion of the targeted amount and cannot cover any shortfall from other sources we would experience delays in getting our product to market or could even be forced to ultimately abandon our business plan which would potentially render the license to the technology worthless.

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

8. WARRANTS AND OPTIONS

During the first three months in 2024 and 2025 we granted 50,333 and 11,250 new warrants, respectively, in connection with the convertible note transactions (see Note 4 "DEBT TRANSACTIONS"). For purpose of calculating the quantity of warrants we used 50% of the quantity of shares issuable upon conversion of the convertible notes which conversion price is based on 75% of the expected IPO price of $4.00. We did not grant any new options during these periods.

The 2019 Stock Plan provides for the granting of ISOs, Non-Qualified Options, Stock Grants and Stock-Based Awards. The number of Shares which may be issued from time to time pursuant to this Plan shall be 3,000,000, or the equivalent of such number of Shares after the Administrator, in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction. The Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to interpret the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable for the administration of the Plan, and to determine which employees, directors and consultants shall be granted Stock Rights. At December 31, 2024, there were 2,150,000 options available to be granted under the Plan.

9. SEGMENT REPORTING

We evaluated segment reporting in accordance with Accounting Standards Codification ("ASC") 280, Segment Reporting ("ASC 280") and concluded that the Company is comprised of one operating segment. We report segment information based on the operating results regularly reviewed by the chief operating decision maker to make decisions about resource allocation and the performance of the business.

The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.

---

| | | |
|:---|:---|:---|
|  | **Three Months <br>ended<br>March 31, <br>2024** | **Three Months <br>ended<br>March 31,<br> 2025** |
|  Salaries and benefits | $50000 | $69700 |
|  Stock-based compensation | $118387 | $— |
|  Legal and Accounting expenses | $63000 | $64139 |
|  Product development expenses | $44132 | $72260 |
|  Consultancies | $71941 | $117.820 |
|  Miscellaneous general operating expenses | $2171 | $14313 |
|  Change in fair value - warrants and derivative liability | $74653 | $(19604) |
|  Interest expense | $31873 | $78120 |
|  TOTAL | $456157 | $396748 |

---

[**Table of Contents**](#TOC001)

**NEUROSPECTRUM INSIGHTS, INC.<br>f/k/a Autism Diagnostic Technologies, Inc.**

**NOTES TO FINANCIAL STATEMENTS**

10. DEFERRED OFFERING COSTS

The Company complies with the requirement of the ASC 340-10-S99-1 and SAB Topic 5A "Expenses of Offering". Deferred offering costs consist of underwriting, legal and other expenses incurred through the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders' equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations. As of March 31, 2025 and December 31, 2024, the Company's deferred offering costs amounted to $248,192 and $220,811, respectively. Such costs will be deferred until the closing of the IPO, at which time the deferred costs will be offset against the offering proceeds.

11. SUBSEQUENT EVENTS

After March 31, 2025 we issued additional $163,500 in convertible notes pursuant to the Network 1 financing transactions (see Note 4 "DEBT TRANSACTIONS") which included warrants issued under the same terms as shown in Note 4.

[**Table of Contents**](#TOC001)

 **_________________________________**

#### PROSPECTUS

#### , 2025
**_________________________________**

**No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of these securities.**

**Through and including,** [\*] **(25 days after the date of this prospectus), all dealers that buy, sell or trade shares of our Common Stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.**

------

[**Table of Contents**](#TOC001)

[Alternate Page for Resale Prospectus]

**The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell, and it is not soliciting an offer to buy, these securities in any state where the offer or sale is not permitted.**

Subject to completion, dated , 2025

#### PROSPECTUS

#### [•] Shares

#### of Common Stock

#### NEUROSPECTRUM INSIGHTS, INC.
This prospectus relates to the resale of [•] shares of common stock, no par value, of NeuroSpectrum Insights, Inc., which consists of (i) [•] shares of common stock issued to the selling stockholders named in this prospectus, and (ii) [•] shares of common stock issuable upon the exercise of warrants held by the selling stockholders named in this prospectus, that may be sold from time to time by such selling stockholders.

No sales of the common stock covered by this prospectus shall occur until after the closing of our initial public offering. The selling stockholders may sell shares from time to time in the open market, through privately negotiated transactions or a combination of these methods, at market prices prevailing at the time of sale or at negotiated prices. The selling stockholders may offer shares to or through underwriters, dealers or other agents, directly to investors or through any other manner permitted by law, on a continued or delayed basis. We will not receive any of the proceeds from the sale of the common stock by the selling stockholders named in this prospectus. We will bear all costs, expenses and fees in connection with the registration of the shares offered by this prospectus, and the selling stockholders will bear all incremental selling expenses, including commissions and discounts, brokerage fees and other similar selling expenses they incur in sale of the shares. See "Plan of Distribution".

By separate prospectus (the "IPO Prospectus"), we have registered an aggregate of [•] shares of common stock which we are offering for sale to the public through our underwriters, excluding any shares issuable upon exercise by the underwriters' of their over-allotment option.

The [•] shares of common stock offered by the selling stockholders is defined herein as the "Resale Shares."

We intend to apply to list our shares of common stock for trading on the New York Stock Exchange, subject to official notice of issuance, under the symbol "[\*]". No assurance can be given that our application will be approved. The consummation of this offering is conditioned on obtaining the NYSE approval. The Resale Shares offered by the selling stockholders are part of and conditioned on the closing of our initial public offering.

We are an "emerging growth company" as defined in the federal securities laws, and, as such, are subject to reduced public company reporting requirements. See "Prospectus Summary — Implications of Being an Emerging Growth Company".

**Investing in our securities is highly speculative and involves a significant degree of risk. See "*Risk Factors*" beginning on page 13 of this prospectus for a discussion of information that should be considered before making a decision to purchase our securities.**

Sales of the shares of our common stock registered in this prospectus and the IPO Prospectus will result in two offerings taking place concurrently, which might affect price, demand, and liquidity of our common stock.

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus is , 2025.

------

[**Table of Contents**](#TOC001)

**[Alternate Page for Resale Prospectus]**

**THE OFFERING**

---

| | |
|:---|:---|
|  Common Stock offered by the selling stockholders | <br> shares at $ per share |
|  Over-allotment option to purchase additional shares | <br>We have granted the representative of the underwriters an option for a period of [•] days from the date of this prospectus to purchase an additional 15% of shares of our Common Stock at a price of $[•] per share to cover over-allotments, if any. |
|  Common Stock to be outstanding before the IPO<sup>(1)</sup> | <br>10,974,238 shares. |
|  Common Stock to be outstanding after the IPO pursuant to the Public Offering Prospectus | <br>shares. |
|  Use of proceeds | We are not selling any Common Stock covered by this Resale Prospectus. As such, we will not receive any of the proceeds from the sale of the Common Stock by the selling stockholders named in this prospectus. |
|  Risk Factors | See "Risk Factors" on page 13 for a discussion of certain of factors to consider carefully before deciding to purchase any shares of our Shares. |
|  Proposed listing | We intend to apply to list our Common Stock on the NYSE in connection with this offering. If our Common Stock is not approved for listing on the NYSE, we will not consummate this offering. Our transfer agent is V-Stock Transfer, LLC. |
|  Proposed NYSE | "[•]". |
|  Capital Market symbol  | We intend to apply to list our Common Stock on the New York Stock Exchange, or the NYSE, under the symbol "[\*]" |
|  Terms of the Offering | The selling stockholders will determine when and how they will sell the securities in this prospectus. |

---

____________

(1) The number of shares of our Common Stock to be outstanding after this offering is based on shares of Common Stock outstanding as of [•], 2024, and excludes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 850,000 shares of our Common Stock issuable upon the exercise of outstanding stock options under the Company's 2019 Stock Plan (the "2019 Plan").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2,150,000 shares of our Common Stock reserved for future issuance under the 2019 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [•] shares issuable upon the automatic conversion of all convertible notes and accrued interest thereon issued in the bridge financings (the "[•] Conversions").

[**Table of Contents**](#TOC001)

**[Alternate Page for Resale Prospectus]**

#### USE OF PROCEEDS
We will not receive any of the proceeds from the sale of the Resale Shares. In addition, the underwriter will not receive any compensation from the sale of the Resale Shares.

The selling stockholders will pay any underwriting discounts and commissions and expenses incurred by them for brokerage, accounting, tax or legal services or any other expenses incurred by them in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees and fees and expenses of our counsel and our accountants.

[**Table of Contents**](#TOC001)

#### [Alternate Page for Resale Prospectus]

#### SELLING STOCKHOLDERS
This prospectus covers the possible resale by the selling stockholders identified in the table below of up to [•] shares of our common stock (the "Resale Shares"). The transactions by which the selling stockholders acquired their securities from us were exempt under the registration provisions of the Securities Act.

The selling stockholders may sell some, all, or none of the Resale Shares. Unless otherwise indicated in the footnotes to the table below, no selling stockholder has had any material relationship with us or any of our affiliates within the past three years other than as a security holder.

We have prepared the following table based on written representations and information furnished to us by or on behalf of the selling stockholders. Unless otherwise indicated in the footnotes to the table below, we believe that (i) none of the selling stockholders are broker-dealers or affiliates of broker-dealers, and (ii) no selling stockholder has direct or indirect agreements or understandings with any person to distribute their Resale Shares. To the extent any selling stockholder identified below is, or is affiliated with, a broker-dealer, it could be deemed, individually, but not severally, to be an "underwriter" within the meaning of the Securities Act. Information about the selling stockholders may change over time.

The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of Resale Shares as of , 2024.

The third column lists the shares of common stock being offered by this prospectus by the selling stockholders.

The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **Selling Stockholder** | **Number of <br>Shares <br>Beneficially <br>Owned Before <br>Offering** | **Percentage <br>of Shares <br>Beneficially <br>Owned Before <br>this Offering** | **Number of <br>Shares Being <br>Offered** | **Number of <br>Shares <br>Beneficially <br>Owned After <br>Offering** |
|  [•] | [•] | [•]% | [•] | —<br> \* |
|  [•] | [•] | [•]% | [•] | —<br> \* |
|  [•] | [•] | [•]% | [•] | —<br> \* |
|  [•] | [•] | [•]% | [•] | —<br> \* |
|  [•] | [•] | [•]% | [•] | —<br> **\*** |

---

____________

\* Less than 1%

(1) Applicable percentage ownership after to this offering is based on [•] shares of common stock deemed to be outstanding as of , 2024.

[**Table of Contents**](#TOC001)

#### [Alternate Page for Resale Prospectus]

#### SELLING STOCKHOLDERS PLAN OF DISTRIBUTION
We are registering the Resale Shares to permit the resale of the Resale Shares by the selling stockholders from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale of the Resale Shares. We will pay all expenses (other than discounts, commissions, and transfer taxes, if any) relating to the registration of the Resale Shares in the registration statement of which this prospectus forms a part.

The selling stockholders may, from time to time, after the effective date of the IPO Prospectus, sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers, or agents. If the Resale Shares are sold through underwriters or broker-dealers, the selling stockholders will be responsible for any underwriter discounts or commissions and any applicable transfer taxes. The Resale Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in the over-the-counter market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in transactions otherwise than on these exchanges or systems or in the over-the-counter market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an exchange distribution in accordance with the rules of the applicable exchange;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• privately negotiated transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• short sales;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated price per security;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a combination of any such methods of sale; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any other method permitted pursuant to applicable law

The selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. The selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders may also sell securities short and deliver

[**Table of Contents**](#TOC001)

these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

[**Table of Contents**](#TOC001)

#### [Alternate Page for Resale Prospectus]

#### LEGAL MATTERS
The validity of the common stock covered by this prospectus will be passed upon by Lucosky Brookman LLP.

[**Table of Contents**](#TOC001)

 **[\*] Shares of Common Stock**

**[\*]**

**NeuroSpectrum Insights, Inc.**

**____________________________**

**RESALE PRELIMINARY PROSPECTUS**

**____________________________**

**You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or the sale of these securities.**

**Prospectus dated ______________, 2025**

------

[**Table of Contents**](#TOC001)

#### PART II

#### INFORMATION NOT REQUIRED IN PROSPECTUS

#### Item 13. Other Expenses of Issuance and Distribution.
The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA filing.

---

| | |
|:---|:---|
|  | **Amount to be <br>paid** |
|  SEC registration fee | $|
|  FINRA filing fee | $|
|  NYSE initial listing fee | $\* |
|  Blue sky qualification fees and expenses | $\* |
|  Transfer agent and registrar fees | $\* |
|  Accounting fees and expenses | $\* |
|  Legal fees and expenses | $\* |
|  Printing and engraving expenses | $\* |
|  Miscellaneous | $\* |
|  Total | $\* |

---

____________

\* To be filed by amendment

#### [Item 14. Indemnification of Directors and Officers.]
Section 102 of the General Corporation Law of the State of Delaware (the "DGCL") permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that none of our directors shall be personally liable to us or our shareholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, agent of the corporation or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability.

Our Certificate of Incorporation and our Bylaws provide for indemnification of our directors and officers. Our Bylaws provide that we will indemnify any person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a legal representative, director, officer or employee or agent of the Company, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed

[**Table of Contents**](#TOC001)

to the best interests of the Company, and with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent will not, without more, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful.

#### Item 15. Recent Sales of Unregistered Securities.
The following sets forth information regarding all unregistered securities sold by us in the last three years in transactions that were exempt from the requirements of the Securities Act as provided for by Section 4(a)(2) thereof for transactions not involving a public offering, to the extent an exemption from such registration was required or exempt from registration either under Rule 701 promulgated under the Securities Act, in that the transactions were under compensatory benefit plans and contracts relating to compensation.

During 2021 we received $10,000 against issuance of 10,000 common shares and stock purchase warrants for 10,000 shares, exercisable during 5 years at $1.50 per share.

During 2023 we received $458,000 against placement of $458,000 convertible notes, accompanied by stock purchase warrants, pursuant to our bridge financing offering (see description elsewhere in this document).

During the first three quarters in 2024 we received $747,400 against placement of $747,400 convertible notes, accompanied by stock purchase warrants, pursuant to our bridge financing offering (see description elsewhere in this document).

#### Item 16. Exhibits and Financial Statement Schedules.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) ***Exhibits***: Reference is made to the Exhibit Index following the signature pages hereto, which Exhibit Index is hereby incorporated into this Item.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) ***Financial Statement Schedules***: All schedules are omitted because the required information is inapplicable or the information is presented in the financial statements and the related notes.

#### Item 17. Undertakings.
The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. For the purposes of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. For the purpose of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. For the purposes of determining liability under the Securities Act of 1933 to any purchaser in the initial distributions of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the provisions above, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities, other than the payment by us of expenses incurred or paid by one of our directors, officers, or controlling persons in the successful defense of any action, suit or proceeding, is asserted by one of our directors, officers, or controlling persons in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification is against public policy as expressed in the Securities Act, and we will be governed by the final adjudication of such issue.

[**Table of Contents**](#TOC001)

#### EXHIBIT INDEX

---

| | |
|:---|:---|
|  **Exhibit No.** | **Description** |
|  1.1\* | Form of Underwriting Agreement. |
|  3.1\*\* | [Certificate of Incorporation of the Registrant.](ea021224802ex3-1_neuro.htm) |
|  3.2\*\* | [Bylaws of the Registrant.](ea021224802ex3-2_neuro.htm) |
|  3.3\*\* | [Amendment to Certificate of Incorporation of October 24, 2018 (reverse split)](ea021224802ex3-3_neuro.htm) |
|  3.4\*\* | [Amendment to Certificate of Incorporation of January 30, 2024 (name change)](ea021224802ex3-4_neuro.htm) |
|  4.1\* | Form of Underwriter Warrant. |
|  4.2\*\* | [Placement Agent Agreement Network 1 Financial Securities Inc.](ea021224802ex4-2_neuro.htm) |
|  4.3\*\* | [Placement Agent Agreement Network 1 Financial Securities Inc. (extension)](ea021224802ex4-3_neuro.htm) |
|  5.1\* | Opinion of Lucosky Brookman LLP. |
|  10.1\*\* | [Employment Agreement with Andrew Stewart.](ea021224802ex10-1_neuro.htm) |
|  10.2\*\* | [Employment Agreement with Joerg Klaube](ea021224802ex10-2_neuro.htm) |
|  10.3\*\* | [Lease Agreement dated April 1, 2024](ea021224802ex10-3_neuro.htm) |
|  10.4\*\* | [License Agreement dated January 31, 2017.](ea021224802ex10-4_neuro.htm) |
|  23.1\*\* | [Consent of Rosenberg Rich Baker Berman, P.A.](ea021224802ex23-1_neuro.htm) |
|  23.2\* | Consent of Lucosky Brookman LLP (included in Exhibit 5.1) |
|  24.1\*\* | [Power of Attorney (included on signature page).](#T301) |
|  107\*\* | [Filing Fee Table](ea021224802ex-fee_neuro.htm) |

---

____________

\* To be filed by an amendment to this registration statement.

\*\* Filed herewith.

[**Table of Contents**](#TOC001)

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedminster, New Jersey on June 18, 2025

---

| |
|:---|
|  **NEUROSPECTRUM INSIGHTS, INC.** |
|  /s/ Andrew Stewart |
|  Name: Andrew Stewart |
|  Title: Chief Executive Officer |

---

#### POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joerg Klaube, his true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by the registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, his, hers or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
|  **Name** | **Position** | **Date** |
|  /s/ Andrew Stewart | Chief Executive Officer, Director | June 18, 2025 |
|  Andrew Stewart |  |  |
|  /s/ Joerg Klaube | Chief Financial Officer | June 18, 2025 |
|  Joerg Klaube |  |  |
|  /s/ Mark Rosenberg | Chairman of the Board, Director | June 18, 2025 |
|  Mark Rosenberg |  |  |
|  /s/ Boura Ali | Director | June 18, 2025 |
|  Boura Ali |  |  |
|  /s/ Jason Pottinger | Director | June 18, 2025 |
|  Jason Pottinger |  |  |
|  /s/ Corey Park | Director | June 18, 2025 |
|  Corey Park |  |  |

---

## Exhibit 3.1

**Exhibit 3.1**

---

| |
|:---|
| State of Delaware |
| Secretary of State |
| Division of Corporations |
| Delivered 12:16 PM 01/20/2016 |
| FILED 12:16 PM 01/20/2016 |
| SR 2016030126 - File Number 5942310 |

---

CERTIFICATE OF INCORPORATION

of

Autism Diagnostic Technologies, Inc.

FIRST: The name of this corporation is: Autism Diagnostic Technologies, Inc.

SECOND: The address of its registered office in the State of Delaware and the name of its registered agent is Agents and Corporations, Inc., 1201 Orange Street, Suite 600, Wilmington, New Castle County, Delaware 19801.

THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

FOURTH: The corporation is authorized to issue 90,000,000 shares of Common Stock with a par value of $0.00001 and 10,000,000 shares of Preferred Stock with a par value of $0.00001. The voting powers, designations, preferences, rights and qualifications, limitations or restrictions of such stock are stated in resolutions adopted by the Board of Directors.

FIFTH: The name and mailing address of the incorporator is: John L. Williams, 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.

SIXTH: The corporation is to have perpetual existence.

SEVENTH: The directors shall have concurrent power with the stockholders to make, alter, amend, change, add to or repeal the By-Laws of the corporation.

EIGHTH: No director shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Notwithstanding the foregoing sentence, a director shall be liable to the extent provided by applicable law, (i) for breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the General Corporation Law of Delaware; or (iv) for any transaction from which the director derived and improper personal benefit. This Article Eighth shall not eliminate or limit the liability of a director for any act or omission occurring prior to the date when this Article Eighth became effective.

I, the undersigned, being the incorporator hereinbefore named, for the purpose of forming a corporation pursuant to the General Corporation Law of the State of Delaware, do make this Certificate, hereby declaring and certifying that this is my act and deed, and the facts therein stated are true and, accordingly, I have hereunto set my hand and seal this 19<sup>th</sup> day of January, 2016.

---

| |
|:---|
| /s/ John L. Williams |
| John L. Williams, Incorporator |

---

## Exhibit 3.2

**Exhibit 3.2**

**BY LAWS OF**

**AUTISM DIAGNOSTIC TECHNOLOGIES, INC.**

**(a Delaware corporation)**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| Section 1.01. | Annual Meetings | 4 |
| Section 1.02. | Special Meetings | 4 |
| Section 1.03. | Notice of Meetings | 4 |
| Section 1.04. | Adjournments | 4 |
| Section 1.05. | Quorum | 4 |
| Section 1.06. | Organization | 5 |
| Section 1.07. | Voting; Proxies | 5 |
| Section 1.08. | Fixing Date For Determination of Stockholders of Record | 5 |
| Section 1.09. | List of Stockholders Entitled To Vote | 6 |
| Section 1.10. | Action By Consent of Stockholders | 6 |
| Section 1.11. | Nominations and Stockholder Business | 6 |
| Section 2.01. | Number; Qualifications | 9 |
| Section 2.02. | Election; Resignation; Removal; Vacancies | 9 |
| Section 2.03. | Regular Meetings | 9 |
| Section 2.04. | Special Meetings | 9 |
| Section 2.05. | Telephonic Meetings Permitted. | 9 |
| Section 2.06. | Quorum; Vote Required For Action | 9 |
| Section 2.07. | Organization | 9 |
| Section 2.08. | Written Action By Directors | 10 |
| Section 2.09. | Powers | 10 |
| Section 2.10. | Compensation of Directors | 10 |
| Section 3.01. | Committees | 10 |
| Section 3.02. | Committee Rules | 11 |
| Section 4.01. | Generally | 11 |
| Section 4.02. | Chief Executive Officer (CEO) | 11 |
| Section 4.03. | President | 11 |
| Section 4.04. | Vice President | 11 |
| Section 4.05. | Chief Financial Officer (CFO) | 11 |
| Section 4.06. | Treasurer | 12 |
| Section 4.07. | Secretary | 12 |
| Section 4.08. | Delegation of Authority | 12 |
| Section 4.09. | Removal | 12 |
| Section 5.01. | Certificates | 12 |
| Section 5.02. | Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates | 12 |
| Section 5.03. | Other Regulations | 12 |

---

i

---

| | | |
|:---|:---|:---|
| Section 6.01. | Indemnification of Officers and Directors | 13 |
| Section 6.02. | Advance of Expenses | 13 |
| Section 6.03. | Non-exclusivity of Rights | 13 |
| Section 6.04. | Indemnification of Contracts | 13 |
| Section 6.05. | Insurance | 14 |
| Section 6.06. | Effect of Amendment | 14 |
| Section 7.01. | Notice | 14 |
| Section 7.02. | Waiver of Notice | 14 |
| Section 8.01. | Interest and Directors; Quorum | 15 |
| Section 9.01. | Fiscal Year | 15 |
| Section 9.02. | Seal | 15 |
| Section 9.03. | Form of Records | 15 |
| Section 9.04. | Reliance Upon Books and Records | 16 |
| Section 9.05. | Certificate of Incorporation Governs | 16 |
| Section 9.06. | Severability | 16 |
| Section 9.07. | Derivative Action | 16 |
| Section 10.01. | Amendments | 16 |

---

ii

BYLAWS

OF

AUTISM DIAGNOSTIC TECHNOLOGIES, INC.

(a Delaware corporation)

ARTICLE 1

STOCKHOLDERS

**Section 1.01. Annual Meetings.** An annual meeting of stockholders shall be held for the election of directors at such date, time and place, either within or without the State of Delaware, as the Board of Directors shall each year fix. Any other proper business may be transacted at the annual meeting.

**Section 1.02. Special Meetings.** Special meetings of stockholders for any purpose or purposes may be called at any time by the Chairman of the Board, the CEO, the Board of Directors or stockholders holding shares representing not less than twenty percent of the outstanding votes entitled to vote at the meeting. Special meetings may not be called by any other person or persons.

**Section 1.03. Notice of Meetings.** Notice of all meetings of stockholders shall be given in writing or by electronic transmission stating the place, date and time of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Certificate of Incorporation of the Corporation, such notice shall be given not less than ten (10) or more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting.

**Section 1.04. Adjournments.** Any meeting of stockholders may adjourn from time to time to reconvene at the same or another place, and notice need not be given of any such adjourned meeting if the time, date and place thereof are announced at the meeting at which the adjournment is taken; provided, however, that if the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting the Corporation may transact any business that might have been transacted at the original meeting.

**Section 1.05. Quorum.** At each meeting of stockholders the holders of a majority of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum, except where otherwise required by law. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting may adjourn the meeting. Shares of the Corporation's stock belonging to the Corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation or any other corporation to vote any of the Corporation's stock held by it in a fiduciary capacity.

**Section 1.06. Organization.** Meetings of stockholders shall be presided over by such person as the Board of Directors may designate, or, in the absence of such a person, the Chairman of the Board, or, in the absence of such person, the CEO of the Corporation, or, in the absence of such person, such person as may be chosen by the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting. Such person shall be chairman of the meeting and shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The Secretary of the corporation shall act as secretary of the meeting, but in his or her absence the chairman of the meeting may appoint any person to act as secretary of the meeting.

**Section 1.07. Voting; Proxies***.* Unless otherwise provided by law, and subject to the provisions of Section 1.06 of these Bylaws, each stockholder shall be entitled to one vote for each share of stock held by such stockholder. Each stockholder entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy. Voting at meetings of stockholders need not be by written ballot and need not be conducted by inspectors unless such is demanded by a stockholder or stockholders holding shares representing at least one percent of the votes entitled to vote at such meeting, or by such stockholder's or stockholders' proxy. If a vote is to be taken by written ballot, each such ballot shall state the name of the stockholder or proxy voting and such other information as the chairman of the meeting deems appropriate, and the ballots shall be counted by one or more inspectors appointed by the chairman of the meeting. At all meetings of stockholders for the election of directors a plurality of the votes cast shall be sufficient to elect. All other elections and questions, unless otherwise provided by law or these Bylaws, shall be decided by the vote of the holders of a majority of the shares of stock entitled to vote thereon present in person or by proxy at the meeting.

**Section 1.08. Fixing Date for Determination of Stockholders of Record.** In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting, nor more than sixty (60) days prior to any other action. If no record date is fixed by the Board of Directors, then the record date shall be as provided by law.

A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the Secretary, request the Board of Directors to fix a record date for such consent. Such request shall include a brief description of the action proposed to be taken.

The Board of Directors shall, within ten (10) days after the date on which such a request is received, adopt a resolution fixing the record date. Such record date shall not proceed the date upon which the resolution fixing the record date is adopted by the Board of Directors, and shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors within ten (10) days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the corporation by delivery to its registered office in the State of Delaware, its principal place of business, or any officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.

**Section 1.09. List of Stockholders Entitled To Vote.** A complete list of stockholders entitled to vote at any meeting of stockholders, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present.

**Section 1.10. Action by Consent of Stockholders.** Unless otherwise restricted by the Certificate of Incorporation, and except as set forth in Section 1.08 above, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

**Section 1.11. Nominations and Stockholder Business.** (a) Nominations of persons for election to the Board of Directors of the Corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders only (i) pursuant to the Corporation's notice of meeting (or any supplement thereto), (ii) by or at the direction of the Board of Directors or any committee thereto, or (iii) by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice provided for in this Section 1.11, who is entitled to vote at the meeting and who complied with the notice procedures set forth in this Section 1.11.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to this Section 1.11, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, and such business other than the nominations of persons for election to the Board of Directors must be a proper subject for stockholder action under the Delaware General Corporation Law. To be timely, a stockholder's written notice shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation, not less than ninety (90) days nor more than one hundred twenty (120) days prior to the date on which the Corporation first mailed its proxy materials for the prior year's annual meeting of stockholders; provided, however, that in the event that the date of the annual meeting is advanced by more than thirty (30) days or delayed (other than as a result of adjournment) by more than thirty (30) days from the anniversary of the previous year's annual meeting, notice by the stockholder to be timely must be delivered not later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made. In no event shall the public announcement of any adjournment or postponement of an annual meeting commence a new time period (or extend any time period) for the giving of a stockholder's notice as described above. Such stockholder's notice shall set forth (i) as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including such person's written consent to being named in the proxy statement as a nominee and to serving as a director if elected); (ii) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and (iii) as to the stockholder giving the notice and the beneficial owners if any on whose behalf the nomination or proposal is made (A) the name and address of such stockholder, as they appear on the Corporation's books, and of such beneficial owner, (B) the class and number of shares of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner and (C) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination, and (D) a representation whether the stockholder or the beneficial owner, if any, intends or is part of a group which intends (i) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation's outstanding capital stock required to approve or adopt the proposal or elect the nominee and/or (ii) otherwise to solicit proxies from stockholders in support of such proposal or nomination. The foregoing notice requirements of this Section 1.11 shall be deemed satisfied by a stockholder if the stockholder has notified the Corporation of his, her or its intention to present a proposal or nomination at an annual meeting in compliance with applicable rules and regulations promulgated<sup>7</sup>under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and such stockholder's proposal or nomination has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting. The Corporation may require any proposed nominee to furnish such other information as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder's understanding of the independence, or lack thereof, of such nominee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation's notice of meeting. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation's notice of meeting (i) by or at the direction of the Board of Directors or any committee thereof or (ii) by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice provided for in this Section 1.11, who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 1.11. Nominations by stockholders of persons for election to the Board of Directors may be made at such a special meeting of stockholders if the stockholder's written notice required by this Section 1.11 shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation, not earlier than the one hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such special meeting or the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. In no event shall the public announcement of an adjournment or postponement of a special meeting commence a new time period (or extend any time period) for the giving of a stockholder's notice as described above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Only those persons who are nominated in accordance with the procedures set forth in this Section 1.11 shall be eligible for election as directors at any meeting of stockholders.

Only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 1.11. The chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the procedures set forth in this Section 1.11 and, if any proposed nomination or business is not in compliance with this Section 1.11, to declare that such defective proposal shall be disregarded. Notwithstanding the foregoing provisions of this Section 1.11, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 1.11, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) For purposes of this Section 1.11, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press, Reuters, Business Wire or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 9, 13, 14 or 15(d) of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Notwithstanding the foregoing provisions of this Section 1.11, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this section. Nothing in this section shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursuant to Rule 14a-8 under the Exchange Act or of the holders of any series of Preferred Stock to elect directors pursuant to any applicable provisions of the Certificate of Incorporation.

ARTICLE 2

BOARD OF DIRECTORS

**Section 2.01. Number; Qualifications.** The Board of Directors shall consist of one or more members, the number thereof to be determined from time to time by resolution of the Board of Directors. Directors need not be stockholders.

**Section 2.02. Election; Resignation; Removal; Vacancies.** Each director shall hold office until the next annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier resignation or removal. Any director may resign at any time upon notice in writing or by electronic transmission to the Corporation. Subject to the rights of any holders of Preferred Stock then outstanding, (i) any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, and (ii) any vacancy occurring in the Board of Directors for any cause, and any newly created directorship resulting from any increase in the authorized number of directors to be elected by all stockholders having the right to vote as a single class, may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, or by the stockholders. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

**Section 2.03. Regular Meetings.** Regular meetings of the Board of Directors may be held at such places, within or without the State of Delaware, and at such times as the Board of Directors may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board of Directors.

**Section 2.04. Special Meetings.** Special meetings of the Board of Directors may be called by the Chairman of the Board, the President, the CEO or the Board of Directors and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix. Notice of the time, date and place of such meeting shall be given by the person or persons calling the meeting to all directors at least four (4) days before the meeting if the notice is mailed, or at least two (2) days before the meeting if such notice is given by telephone, hand delivery, electronic transmission, facsimile or similar communication method. Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.

**Section 2.05. Telephonic Meetings Permitted.** Members of the Board of Directors, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or similar communications equipment shall constitute presence in person at such meeting.

**Section 2.06. Quorum; Vote Required For Action.** At all meetings of the Board of Directors a majority of the total number of authorized directors shall constitute a quorum for the transaction of business. Except as otherwise provided herein or required by law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.

**Section 2.07. Organization.** Meetings of the Board of Directors shall be presided over by the Chairman of the Board, or in his or her absence by the President or in his absence the CEO, or in his or her absence by a chairman chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the chairman of the meeting may appoint any person to act as secretary of the meeting.

**Section 2.08. Written Action by Directors.** Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

**Section 2.09. Powers.** The Board of Directors may, except as otherwise required by law, exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.

**Section 2.10. Compensation of Directors.** Directors, as such, may receive, pursuant to a resolution of the Board of Directors, fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the Board of Directors.

ARTICLE 3

COMMITTEES

**Section 3.01. Committees.** The Board of Directors may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meetings and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to amending the Certificate of Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board of Directors as provided in subsection (a) of Section 151 of the Delaware General Corporation Law, fix the designations and any of the preferences or rights of such shares relating to dividends, redemption, dissolution and distribution of assets of the Corporation, or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the Corporation, or fix the number of shares of any series of stock or authorize the increase or decrease of the shares of any series), adopting an agreement of merger or consolidation under Sections 251 or 252 of the Delaware General Corporation Law, recommending to the stockholders the sale, lease or exchange of all or substantially all of the Corporation's property and assets, recommending to the stockholders a dissolution of the Corporation or a revocation of a dissolution, or amending the Bylaws of the Corporation; and unless the resolution of the Board of Directors expressly so provides, no such committee shall have the power or authority to declare a dividend, authorize the issuance of stock or adopt a certificate of ownership and merger pursuant to Section 253 of the Delaware General Corporation Law.

**Section 3.02. Committee Rules.** Unless the Board of Directors otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to Article 2 of these Bylaws.

ARTICLE 4

OFFICERS

**Section 4.01. Generally.** The officers of the Corporation shall consist of a Chief Executive Officer, one or more Presidents, one or more Vice Presidents, a Treasurer, a Secretary and such other officers, including a Chairman of the Board of Directors, as may from time to time be appointed by the Board of Directors. Officers shall be elected by the Board of Directors. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any number of offices may be held by the same person. Any officer may resign at any time upon notice in writing or by electronic transmission to the Corporation. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board of Directors.

**Section 4.02 Chief Executive Officer (CEO).** Subject to the provisions of these Bylaws and to the direction of the Board of Directors, the CEO of the Corporation shall have the responsibility for the general management and control of the business and affairs of the Corporation and shall perform all duties and have all powers that are commonly incident to the office of chief executive or that are delegated to him or her by the Board of Directors.

**Section 4.03. President.** Each President shall have such powers and duties as may be delegated to him or her by the Board of Directors. A President may be designated by the Board to perform the duties and exercise the powers of the CEO in the event of the CEO's absence or disability.

**Section 4.04. Vice President.** Each Vice President shall have such powers and duties as may be delegated to him or her by the Board of Directors. A Vice President may be designated by the Board to perform the duties and exercise the powers of the President in the event of the President's absence or disability.

**Section 4.05. Treasurer.** The Treasurer shall have custody of all monies and securities of the Corporation. He or she shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions. The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.

**Section 4.06. Secretary.** The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of, all meetings of the stockholders and the Board of Directors. He or she shall have charge of the corporate books and shall perform such other duties as the Board of Directors may from time to time prescribe.

**Section 4.07. Delegation of Authority.** The Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.

**Section 4.08. Removal.** Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.

ARTICLE 5

STOCK

**Section 5.01. Certificates.** The shares of the Corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Every holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairman of the Board of Directors, or the President (or CEO) or a Vice President, and by the Treasurer (or CFO) or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation. Any or all of the signatures on the certificate may be a facsimile.

**Section 5.02. Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates.** The Corporation may issue a new certificate of stock in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner's legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.

**Section 5.03. Other Regulations.** The issue, transfer, conversion and registration of stock certificates shall be governed by such other regulations as the Board of Directors may establish.

ARTICLE 6

INDEMNIFICATION

**Section 6.01. Indemnification of Officers and Directors.** Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "proceeding"), by reason of the fact that he or she or a person of whom he or she is the legal representative, is or was a director or officer of the Corporation (including any constituent corporation absorbed in a merger) or, while a director or officer of the Corporation, is or was serving at the request of the Corporation (including any such constituent corporation) as a director, officer or employee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the Delaware General Corporation Law, as the same exists or may hereafter be amended, against all expenses, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that the Corporation shall indemnify any such person seeking indemnity in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.

**Section 6.02. Advance of Expenses***.* The Corporation shall pay all expenses incurred by such a director or officer in defending any such proceeding as they are incurred in advance of its final disposition; provided, however, that if the Delaware General Corporation Law then so requires, the payment of such expenses incurred by a director or officer in advance of the final disposition of such proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it should be determined ultimately that such director or officer is not entitled to be indemnified under this Article 6 or otherwise; and provided further that the Corporation shall not be required to advance any expenses to a person against whom the Corporation brings a claim, in a proceeding, for breach of the duty of loyalty to the Corporation, for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law or for any transaction from which such person derived an improper personal benefit.

**Section 6.03. Non-exclusivity of Rights.** The rights conferred on any person in this Article 6 shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaw, agreement, vote or consent of stockholders or disinterested directors or otherwise.

**Section 6.04. Indemnification of Contracts.** The Board of Directors is authorized to cause the Corporation to enter into a contract with any director, officer or employee of the Corporation, or any person serving at the request of the Corporation as a director, officer or employee of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing for indemnification rights equivalent to or, if the Board of Directors so determines, greater than, those provided for in this Article 6.

**Section 6.05. Insurance.** The Corporation may maintain insurance, at its expense, to the extent it determines such to be reasonably available, to protect itself, its officers and directors and any other persons the Board of Directors may select, against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.

**Section 6.06. Effect of Amendment.** Any amendment, repeal or modification of any provision of this Article 6 by the stockholders or the Directors of the Corporation shall be prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article 6 and existing at the time of such amendment, repeal or modification.

ARTICLE 7

NOTICES

**Section 7.01. Notice.** Except as otherwise specifically provided herein or required by law, all notices required to be given pursuant to these Bylaws shall be in writing and may in every instance be effectively given by hand delivery (including use of a courier service), by depositing such notice in the mail, postage prepaid, or by sending such notice by electronic transmission or facsimile. Any such notice shall be addressed to the person to whom notice is to be given at such persons address as it appears on the records of the Corporation. The notice shall be deemed given (i) in the case of hand delivery, when received by the person to whom notice is to be given or by any person accepting such notice on behalf of such person, (ii) in the case of delivery by mail, when deposited in the mail, and (iii) in the case of delivery via electronic delivery or facsimile, when dispatched.

**Section 7.02. Waiver of Notice***.* Any written waiver of notice, signed by the person entitled to notice or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any written waiver of notice.

ARTICLE 8

INTERESTED DIRECTORS

**Section 8.01. Interest and Directors; Quorum***.* No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the contract or transaction, or solely because his, her or their votes are counted for such purpose if: (i) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (ii) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof, or the stockholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction.

ARTICLE 9

MISCELLANEOUS

**Section 9.01. Fiscal Year.** The fiscal year of the Corporation shall be determined by resolution of the Board of Directors.

**Section 9.02. Seal.** The Board of Directors may provide for a corporate seal, which shall have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board of Directors.

**Section 9.03. Form of Records.** Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept in electronic form or any other information storage device, provided that the records so kept can be converted into clearly legible form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect the same.

**Section 9.04. Reliance Upon Books and Records.** A member of the Board of Directors of the Corporation, or a member of any committee designated by the Board of Directors, shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or reports made to the Corporation by any of its officers, or by an independent certified public accountant, or by an appraiser selected with reasonable care by the Board of Directors or by any such committee, or in relying in good faith upon other records of the Corporation.

**Section 9.05. Certificate of Incorporation Governs.** In the event of any conflict between the provisions of the Corporation's Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.

**Section 9.06. Severability.** If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Corporation's Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation shall remain in full force and effect.

**Section 9.07. Derivative Action.** The sole and exclusive forum for any actual or purported derivative action brought on behalf of the Corporation shall be the Court of Chancery in the State of Delaware.

ARTICLE 10

AMENDMENT

**Section 10.01. Amendments.** The stockholders of the Corporation shall have the power to adopt, amend or repeal Bylaws. The Board of Directors of the Corporation shall also have the power to adopt, amend or repeal Bylaws of the Corporation, except Bylaws adopted by the stockholders that specify that they cannot be amended or repealed by the Board of Directors.

## Exhibit 3.3

**Exhibit 3.3**

---

| |
|:---|
| **State of Delaware** |
| **Secretary of State** |
| **Division of Corporations** |
| **Delivered 11:08 AM 10/24/2018** |
| **FILED 11:08 AM 10/24/2018** |
| **SR 20187294713 - File Number 5942310** |

---

**CERTIFICATE OF AMENDMENT OF**

**CERTIFICATE OF INCORPORATION**

**OF**

**AUTISM DIAGNOSTIC TECHNOLOGIES, INC.**

**Autism Diagnostic Technologies, Inc..,** a corporation organized and existing under the laws of the State of Delaware, herby certifies as follows:

**FIRST:** The name of this corporation is Autism Diagnostic Technologies, Inc. (the "Company'').

**SECOND:** The date on which the Company's Certificate of Incorporation was originally filed with the Secretary of State of the State of Delaware is January 20, 2016.

**THIRD:** The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Certificate of Incorporation, as heretofore amended (the "Certificate of Incorporation"), by adding the following at the end of Section IV.A of the Amended and Restated Certificate of Incorporation:

Effective as of the effective time of 5:00 p.m., Eastern time, on September 18, 2018 (the "Effective Time"), each ten (10) shares of the Company's Common Stock, par value $0.00001 per share, issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of the Company or the respective holders thereof, be combined into one (1) share of Common Stock without increasing or decreasing the par value of each share of Common Stock (the "Reverse Split'"); *provided, however,* no fractional shares of Common Stock shall be issued as a result of the Reverse Split and, in lieu thereof, shall be rounded up to the nearest whole share of Common Stock. Each stock certificate that, immediately prior to the Effective Time, represented shares of pre-Reverse Split Common Stock shall, from and after the Effective Time, automatically and without any action on the part of the Company or the respective holders thereof, represent that number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common Stock represented by such certificate shall have been combined *(provided, however,* that each holder of record of a certificate that represented shares of pre-Reverse Split Common Stock shall receive, upon surrender of such certificate, a new certificate representing the number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common Stock represented by such certificate shall have been combined pursuant to the Reverse Split). The Reverse Split shall be effected on a record holder-by-record holder basis, such that any fractional shares of post-Reverse Split Common Stock resulting from the Reverse Split and held by a single record holder shall be aggregated.

**FOURTH:** The foregoing amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware and shall be effective as of 5:00 p.m., Eastern time, on September 18, 2018.

**IN WITNESS WHEREOF, AUTISM DIAGNOSTIC TECHNOLOGIES, INC.** has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 17th day of October, 2018.

---

| | |
|:---|:---|
| **AUTISM DIAGNOSTIC TECHNOLOGIES, INC.** | **AUTISM DIAGNOSTIC TECHNOLOGIES, INC.** |
| By: | */s/ Andrew Stewart* |
|  | Andrew Stewart |
|  | Chief Executive Officer |

---

## Exhibit 3.4

**Exhibit 3.4**

CERTIFICATE OF AMENDMENT

OF

CERTIFICATE OF INCORPORATION

OF

**<u>Autism Diagnostic Technologies, Inc.</u>**

Autism Diagnostic Technologies, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware.

DOES HEREBY CERTIFY:

FIRST: That at a meeting of the Board of Directors of Autism Diagnostic Technologies, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows:

RESOLVED, that the Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered "FIRST" so that, as amended said Article shall be and read as follows:

FIRST: The name of the corporation is: NeuroSpectrum Insights, Inc.

SECOND: That thereafter, pursuant to resolution of its Board of Directors, a special meeting of the stockholders of said corporation was duly called and held, upon notice in accordance with Section 222 of the General Corporation law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

THIRD: That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, said Autism Diagnostic Technologies, Inc. has caused this certificate to be signed by its Authorized Officer.

---

| | |
|:---|:---|
| BY: | /s/ Joerg Klaube |
| Name: | Joerg Klaube |
|  | Authorized Officer |
| Date: | 1/30/24 |

---

## Exhibit 4.2

**Exhibit 4.2**

![](ex4-2_001.jpg)

June 12, 2023

Autism Diagnostic Technologies, Inc.

Andrew Stewart, CEO

1 Vanderveer Drive

Basking Ridge, NJ 07920

**Re: Placement Agent's Agreement**

Dear Mr. Stewart:

 ****

***Autism Diagnostic Technologies, Inc.,*** a Delaware corporation, (hereinafter referred to as the "Company" or "You"), *proposes* to offer for sale, in a private placement ("Offering") the Company's security, as follows: a maximum of $600,000 of Senior Convertible Debentures, (the "Offering") on a best-efforts basis. The Notes will bear 6% interest and will mature 24 months from issuance. The debentures will be convertible into shares of Common stock automatically upon closing of an Initial public offering (IPO) at a 25% discount to the offering price. Any accrued interest may be paid in common shares at the discretion of the Company. In addition, investors will receive common stock purchase warrants equal to 50% of their converted shares, exercisable at the same IPO 25% discount conversion price. The Debentures, Common stock and Warrants, are hereinafter occasionally referred to as the Securities.

The undersigned, ***Network 1 Financial Securities, Inc.,*** a Texas Corporation and broker/dealer registered with the U.S. Securities & Exchange Commission ("SEC") and member of the Financial Industry Regulatory Authority ("FINRA"), hereinafter referred to as "Placement Agent", "Network l" or "We" or "Our") hereby offers its services to the Company as Placement Agent for the aforementioned *proposed* private placement offering.

The terms and conditions of this Placement Agent's Agreement ("Agreement") are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Appointment of Placement Agent; The Offering Period.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Appointment of Placement Agent</u>. You hereby appoint Network 1 Financial Securities as exclusive Placement Agent of the Company during the Private Offering Period herein specified for the purpose of assisting the Company in placing its Securities with purchasers who are qualified accredited investors ("Subscribers"). Placement Agent hereby accepts such agency and agrees to assist the Company in placing this Private Offering ("Offering") with the Subscribers. Placement Agent's agency hereunder is not terminable by the Company except upon termination of the Private Offering or upon breach by the Placement Agent of its material obligations hereunder.

**NETWORK 1 FINANCIAL SECURITIES, Inc.**

Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse

2 Bridge Avenue ● Red Bank, New Jersey 07701-1106 ● (732) 758-9001

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 2 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Private Offering Period</u>. The Offering Period shall commence on the day that the Company's offering documents ("Offering Documents") are first made available to Placement Agent by the Company and will continue until the final Closing (as hereinafter defined) of the maximum offering or the 30th day of September 30, 2023 (The "Termination Date"), unless extended by the Company for a period of up to ninety (90) days from such date without notice to any Subscriber (the "Offering Period"). After the Initial Closing, subsequent closings with respect to accepted subscriptions may take place at any time during the Offering Period as may be mutually determined by the Company and the Placement Agent (such subsequent closings and the Initial Closing will each be referred to herein as a "Closing").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>Offering Documents</u>. The Company will provide the Placement Agent with a sufficient number of copies of the Offering Documents for delivery to potential Subscribers and such other information, documents and instruments which the Placement Agent deems reasonably necessary to act as Placement Agent hereunder and to comply with the rules, regulations and judicial and administrative interpretations respecting compliance with applicable state and federal statutes related to the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Compliance with Securities Laws</u>.

Each of the Company and the Placement Agent agrees to conduct the Offering in a manner intended (a) to qualify as a private placement of the Securities in any jurisdiction in which the Securities are offered (including the U.S.), and (b) to comply with the requirements of Rule 506 of Regulation D under the Securities Act. Assuming the accuracy of the representations and warranties given to the Company by each investor to the extent relevant for such determination, the Offering will be exempt from the registration requirements of the Securities Act. The Company agrees (i) to limit offers to sell, and solicitations of offers to buy, the Securities to persons reasonably believed by it to be "accredited investors" within the meaning of Rule 501(a) under the Securities Act, and (ii) not to engage in any form of general solicitation or general advertising in connection with the Offering within the meaning of Rule 502 under the Securities Act. The Company agrees to conduct the Offering in a manner intended to comply with the registration or qualification requirements, or available exemptions therefrom, under applicable state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Form D and State Blue Sky Filings</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1 <u>SEC Form D Filing Requirements</u>. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. SEC rules require the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering based on a claim of exemption under Rule 504 or 506 of Regulation or Section 4(5) of that statute. SEC rules further require the notice to be filed within 15 days after the first sale of securities in the offering (although some States have different requirements). For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. If the due date falls on a Saturday, Sunday or holiday, it is moved to the next business day. The SEC does not charge any filing fee for a Form D notice or amendment. The Company shall be solely responsible for compliance with SEC Form D filing requirements.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 3 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.2 <u>Online Filing of Form D is Required by SEC</u>. Companies must file their Form D notices and amendments with the SEC online, through the Internet, using the SEC's EDGAR (electronic gathering, analysis and retrieval) system. To file online using the EDGAR system, a company must have its own filer identification number (called a "Central Index Key" or "CIK" number) and a set of password-like "access codes." The Company must submit basic information about the filer to the SEC online at its Filer Management page and also submit a copy of a notarized paper document containing the same information on Form ID. The paper document is called an "authenticating document" which the Company prepares by printing out and completing a copy of Form ID and having that document notarized. Once the document is notarized, the Company is required to scan and attach it to its Form ID submission as a PDF file. Accordingly, the Company agrees, as a material term to this Agreement, to set up its Form D filing in accordance with the details set forth in this Section 2 above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.3 <u>State Form D Notice Filing Requirements</u>. Many states also require the filing of Form D notices and amendments, and most of them charge a filing fee. Most states allow for either electronic or paper Form D filing, with the majority of states accepting and a few states mandating the electronic filing of Form D. Electronic filing of the Form D can be made through the Electronic Filing Depository (EFD), which is programmed with each state's filing requirements. As an alternative to electronic filing, in those States that do not mandate electronic filing, a filer may be able to satisfy the state Form D filing requirement by submitting either a printout of the SEC online Form D filing (retrieved from the EDGAR Company Search page) or a completed paper version of Form D, along with the appropriate fee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.4 <u>Party Obliged to Filing</u>. The Company shall, as a material term to this Agreement, be solely responsible for compliance, as set forth in Sections 2.1.2. and 2.1.3, with the filing requirements of the securities laws of the United States and all applicable States of the United States, and with any and all applicable foreign jurisdictions in which offerings of the Company's securities are made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.5 <u>Placement Agent Obligations</u>. The Placement Agent shall advise the Company of those States of the U.S., and other jurisdictions, in which the Placement Agent intends to offer the Securities ("Intended States") in order that the Company's counsel, can ensure that the Offering has been qualified, or exempted, under the appropriate laws and regulations. In the event that the Company, or Company's counsel, identifies that an Intended State requires pre-sale qualification this will be communicated to Placement Agent. The company will notify the placement agent upon filing in each state that the offering has been qualified. It is the company's responsibility to assure that each subscription accepted is qualified according to the investor's residence.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 4 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Due Diligence</u>. Current regulations in the securities industry require placement agents to conduct "due diligence" on any issuer that seeks to offer its securities to qualified accredited investors. In the event that Placement Agent is unable to complete "due diligence" either (1) because of lack of cooperation on the part of the Company (for instance, but not limited to, the Company not providing Placement Agent with information or documents requested by the Placement Agent) or (2) because the Placement Agent uncovers "red flags" about the Company that cause Placement Agent to be not satisfied that Placement Agent can in good faith recommend the Company's securities to investors, Placement Agent may terminate this Agreement (1) without further obligation on the part of Placement Agent to proceed with this Offering *and* (2) without any obligation on the part of the Placement Agent to reimburse to Company any monies advanced by Company to Placement Agent. In short, Placement Agent's obligations under this Agreement are expressly conditioned upon "due diligence" on the Company that is both complete in the opinion of and satisfactory to the Placement Agent. Placement Agent's right of termination under this Section 2.2 is not adversely affected in any way by the termination provisions in Section 8.1 and 8.2, below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. <u>Representations and Warranties of the Company</u>**. The Company represents and warrants to the Placement Agent and the Subscribers as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Disclosure in Offering Documents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1.1 <u>Disclosure of Contracts</u>. The descriptions in the Offering Documents of all material contracts, agreements, instruments, indentures, mortgages, loans, leases, licenses, arrangements or undertakings of any nature, written or oral, of the Company which involve future payments, performance or services, development of products, or delivery of goods or materials to or by the Company of an aggregate amount or value in excess of $250,000, or which otherwise are material to the business or prospects of the Company (collectively, "Contracts") are accurate in all material respects and present fairly the information required to be disclosed therein and there are no contracts or other documents required to be described in the Offering Documents which have not been so described. The Company has furnished the Placement Agent, when and if requested, with true, correct and complete copies (or where oral, written descriptions) of all Contracts, including all exhibits, schedules, amendments, supplements, modifications and waivers thereto. Except as otherwise stated in the Offering Documents, each of the Contracts is in full force and effect, the Company has performed in all material respects all of its obligations thereunder and is not in default thereunder, and no party to a Contract has made a claim to the effect that the Company has failed to perform any obligations thereunder. To the best knowledge of the Company, the Company has not received any written notification from any contracting party to a Contract to terminate, cancel or modify such Contract or to reduce or otherwise change its activity thereunder so as to adversely affect in any material respect the benefits derived or expected to be derived therefrom by the Company.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 5 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Changes after Dates in Offering Documents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.1 <u>No Material Adverse Change</u>. Except as otherwise stated in the Offering Documents, since the Balance Sheet Date, as hereinafter defined, (i) there has been no material adverse change in the condition, financial or otherwise, or in the results of operations, business or business prospects of the Company, including, but not limited to a material loss or interference with its business from fire, storm, explosion, flood or other casualty, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, whether or not arising in the ordinary course of business, (ii) the Company has not become a party to, and neither the business nor the property of the Company has become the subject of, any litigation which, if adversely determined, would have a material adverse effect on the business, properties, assets, condition (financial or otherwise) of the Company, whether or not in the ordinary course of business (a "Material Adverse Effect"), and (iii) there have been no transactions entered into by the Company, other than those in the ordinary course of business or reflected in the Offering Documents, which are material with respect to the condition, financial or otherwise, or to the results of operations, or business of the Company. The Balance Sheet Date is defined as the 30<sup>th</sup> of June 2022

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.2 <u>Recent Securities Transactions. Etc</u>. Since the most recent Balance Sheet date, and except as otherwise specifically stated in the Offering Documents or on Schedule A (if any) hereto, the Company has not (i) issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money; (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock; or (iii) issued any options, warrants or other rights to purchase the capital stock of the Company, or any security or other instrument which by its terms is convertible into, exercisable for or exchangeable for capital stock of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>No Preemptive Rights; Options; Registration Rights</u>. Except as set forth in the Offering Documents, there are no preemptive or other rights to subscribe for or purchase, or any restriction upon the voting or transfer of, any shares of Common Stock, or other securities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <u>Financial Statements</u>. The financial statements ("Financials") of the Company, including any notes thereto and supporting schedules, included or incorporated by reference in the Offering Documents, fairly present the financial position and results of operations of the Company at the dates thereof and for the periods covered thereby, subject, in the case of interim periods, to year-end adjustments and normal recurring accruals. The Company has no material liabilities or obligations, contingent, direct, indirect or otherwise except (i) as set forth in the balance sheet for the Balance Sheet Date included in the Financials or the footnotes thereto, (ii) those incurred in the ordinary course of business since the Balance Sheet Date, and (iii) otherwise as set forth in the Offering Documents. The Offering Documents also set forth all material outstanding amounts due to any employees, officers, directors or stockholders of the Company, or to any of their respective affiliates, including, but not limited to, accrued salaries, loans, etc.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 6 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <u>Authorized Capital; Options; Etc</u>. The Company had, at the date or dates indicated in the Offering Documents, such duly authorized, issued and outstanding capitalization as set forth in the Offering Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 <u>Valid Issuance of Securities: Etc</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6.1 <u>Outstanding Securities</u>. All issued and outstanding securities of the Company have been duly authorized and validly issued and are fully paid and non assessable; the holders thereof have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. All outstanding options and warrants to purchase shares of capital stock constitute the valid and binding obligations of the Company, enforceable in accordance with their terms. The authorized capital stock and outstanding options and warrants conform to all statements relating thereto contained in the Offering Documents. The offers and sales of the outstanding capital stock, options and warrants to purchase shares of capital stock were at all relevant times either registered under the Act and the applicable state securities or Blue Sky laws or exempt from such registration requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6.2 <u>Debentures, Common shares and Warrants</u>. The securities have been duly and validly authorized and, when issued and delivered in accordance with the terms of the Subscription Agreements, will be duly and validly issued, fully paid and non-assessable. The holders of the shares will not be subject to personal liability by reason of being such holders and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. All corporate action required to be taken for the authorization, issuance and sale of the shares has been duly and validly taken.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 <u>Registration Rights of Third Parties</u>. Except as set forth in the Offering Documents or on Schedule B (if any) hereto, no holders of any securities of the Company or of any options or warrants of the Company exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register any such securities of the Company under the Act or to include any such securities in a registration statement to be filed by the Company.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 7 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 <u>Due Authorization</u>. The Company has full right, power and authority to enter into this Agreement and the Subscription Agreements, to issue the securities and to perform all of its obligations hereunder and thereunder and to consummate the transactions contemplated by the Offering Documents. This Agreement has been, and the Subscription Agreements, when executed and delivered, will have been, duly and validly authorized by all necessary corporate action and no further corporate action or approval is or will be required for their respective execution, delivery and performance. This Agreement constitutes and each Subscription Agreement (assuming the due authorization, execution and delivery by each subscriber) to be entered into by the Company with respect to the purchase and sale of the securities, will constitute, when executed and delivered by the Company, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms (except (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws now or hereafter in effect relating to or affecting creditors' rights generally, (ii) that the enforceability of the indemnification and contribution provisions of the respective agreements may be limited by the federal and state securities laws and public policy, and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 <u>No Conflicts</u>. The Company's execution, delivery, and performance of this Agreement and the Subscription Agreements, the consummation by the Company of the transactions contemplated herein and therein and the compliance by the Company with the provisions of this Agreement and the Subscription Agreements have been duly authorized by all necessary corporate action and do not and will not, with or without the giving of notice or the lapse of time or both (i) result in a breach of, or conflict with any of the terms and provisions of, or constitute a default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any indenture, mortgage, deed of trust, note, loan or credit agreement or any other agreement or instrument evidencing an obligation for borrowed money, or any other agreement or instrument to which the Company is a party or by which the Company may be bound or to which any of the property or assets of the Company is subject; (ii) result in any violation of the provisions of the Certificate of Incorporation or the By-laws of the Company; (iii) to the best of the Company's knowledge, violate any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its material properties or material businesses; or (iv) have any material adverse effect on any permit, license, certificate, registration, approval, consent, license or franchise necessary for the Company to own or lease and operate any of its properties or to conduct its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 <u>No Defaults</u>. Except as described in the Offering Documents, no material default exists in the due performance and observance of any term, covenant or condition of any permit, license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for borrowed money, or any other agreement or instrument to which the Company is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject the effect of which would have a Material Adverse Effect. Except as described in the Offering Documents, the Company is not in violation of any material term or provision of its Certificate of Incorporation or By-Laws or in material violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its properties or business.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 8 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 <u>Corporate Power; Licenses; Consents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11.1 <u>Conduct of Business</u>. To the best of its knowledge, the Company has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from all governmental regulatory officials, agencies, authorities and bodies to own or lease its properties and conduct its business as described in the Offering Documents. The Company is and has been doing business in material compliance with all such authorizations, approvals, orders, licenses, certificates and permits and all federal, state and local laws, rules and regulations. The disclosures in the Offering Documents concerning the effects of federal, state and local regulation on the Company's business as currently conducted or contemplated to be conducted are correct in all material respects and do not omit to state a material fact.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11.2 <u>Transactions Contemplated Herein; Consents</u>. The Company has all corporate power and authority to enter into this Agreement, and the Subscription Agreements to carry out the provisions and conditions hereof and thereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained. Except as set forth in the Offering Documents, no consent, approval, authorization, order of, or filing with, any court, governmental agency, authority or other body is required to consummate the transactions contemplated by this Agreement and the Subscription Agreements, and the issuance of the securities, except that the offer and sale of the securities in certain jurisdictions may be subject to the provisions of the securities or Blue Sky laws of such jurisdictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 <u>Title to Property; Insurance</u>. Except as set forth in the Offering Documents, the Company has good and marketable title to, or valid and enforceable leasehold estates in, all items of real and personal property (tangible and intangible) owned or leased by it, free and clear of all liens, encumbrances, claims, security interests, defects and restrictions of any material nature whatsoever. The Company has adequately insured its properties against loss or damage by fire or other casualty and maintains such insurance in adequate amounts that are adequate to protect its financial condition against the risks involved in the conduct of its businesses.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 9 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13 <u>No Pending Actions</u>. Except as set forth in the Offering Documents, there are no actions, suits, proceedings, claims, or hearings of any kind or nature existing or pending (or, to the best knowledge of the Company, threatened) or, to the best knowledge of the Company, any investigations or inquiries, before or by any court, or other governmental authority, tribunal or instrumentality (or, the Company's best knowledge, any state of facts which would give rise thereto), pending or threatened against the Company, or involving the properties of the Company, which might result in any Material Adverse Effect or which might materially adversely affect the transactions or other acts contemplated by this Agreement or the validity or enforceability of this Agreement. Except as described in the Offering Documents, there are no outstanding orders, judgments or decrees of any court, governmental agency or other tribunal naming the Company and enjoining the Company from taking, or requiring the Company to take, any action, or to which the Company, its properties or business, is bound or subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14 <u>Due Incorporation, Qualification and Good Standing</u>. The Company has been duly incorporated, validly exists as a corporation and is in good standing under the laws of its state of incorporation. The Company is duly qualified and licensed and in good standing as a foreign corporation for the transaction of business and is in good standing in each jurisdiction in which the ownership or leasing of its properties or the conduct of its business requires such qualification or licensing, except where the failure to qualify would not have a Material Adverse Effect. The Company has all requisite corporate power and authority necessary to own or hold its properties and conduct its business as described in the Offering Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15 <u>Taxes</u>. Except as set forth in the Offering Documents or as set forth on Schedule 3.15 hereto, the Company has filed all federal tax returns and all state and municipal and local tax returns (whether relating to income, sales, franchise, withholding, real or personal property or other types of taxes) required to be filed under the laws of the United States and applicable states, and has paid in full all taxes which have become due pursuant to such returns or claimed to be due by any taxing authority or otherwise due and owing; provided, however, that the Company has not paid any tax, assessment, charge, levy or license fee that it is contesting in good faith and by proper proceedings and adequate reserves for the accrual of same are maintained if required by generally accepted accounting principles. Each of the tax returns heretofore filed by the Company correctly and accurately reflects the amount of its tax liability thereunder. Except as set forth in the Offering Documents, the Company has withheld, collected and paid all levies, assessments, license fees and taxes to the extent required. As used herein, "tax" or "taxes" include all taxes, charges, fees, levies or other assessments imposed by any Federal, state, local, or foreign taxing authority, including, without limitation, income, premium, recapture, credit, excise, property, sales, use, occupation, service, service use, leasing, leasing use, value added, transfer, payroll, employment, license, stamp, franchise or similar taxes (including any interest earned thereon or penalties or additions attributable thereto). The term "returns" means all returns, declarations, reports, statements, and other documents required to be filed in respect of taxes.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 10 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.16 <u>Non-Circumvent</u>. The Company hereby irrevocably agrees not to circumvent, avoid, bypass, or obviate, directly or indirectly, the intent of this Agreement through any transaction, transfer, pledge, agreement, recapitalization, loan, lease, assignment, or otherwise. The Company (including affiliates of such parties) agrees that it will not attempt, directly or indirectly, to contact parties introduced to the Company by the Placement Agent on matters described in this Agreement or contact or negotiate with any confidential source provided by Network 1, except through Network 1 or with the expressed written consent of Network 1 as to each such contact. The Company shall not contact, deal with, or otherwise become involved in any transaction with any corporation, partnership, individual, any banks, trust or lending institutions introduced by or through Network 1 without the permission of Network 1. Any violation of this provision shall be deemed an attempt to circumvent this provision, and the Company shall be liable for damages in favor of the circumvented party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17 <u>Transactions Affecting Disclosure to FINRA</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17.1 <u>Finder's Fees</u>. The Company is not obligated to pay a finder's fee to anyone in connection with the introduction of the Company to the Placement Agent, or the consummation of the Offering contemplated hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.17.2 <u>Use of Proceeds</u>. None of the net proceeds of the Offering will be paid by the Company to any FINRA member or its affiliate or associates, except as specifically authorized herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.18 <u>Foreign Corrupt Practices Act</u>

Neither the Company nor any of its subsidiaries has, nor any director, officer, agent, employee or other person acting on behalf of the Company or any subsidiary has in the course of his actions for or on behalf of the Company, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. Without limiting the generality of the foregoing, the Company and its subsidiaries have not directly or indirectly made or agreed to make (whether or not said payment is lawful) any payment to obtain, or with respect to, sales other than usual and regular compensation to its or their employees and sales representatives with respect to such sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19 <u>Intangibles</u>. The Company owns or possesses the requisite licenses or rights to use all material trademarks, service marks, service names, trade names, patents and patent applications, copyrights and other rights (collectively, "Intangibles") used by the Company in its business or relating to products sold by the Company, and all such Intangibles are stated in the Offering Documents. Any of the Company's Intangibles which have been registered in the United States Patent and Trademark Office have been fully maintained and are in full force and effect, except where the failure to do so would not result in a Material Adverse Effect. There is no claim or action by any person pertaining to, or proceeding pending or to the Company's knowledge, threatened and the Company has not received any notice of conflict with the asserted rights of others which challenges the exclusive right of the Company with respect to any Intangibles used in the conduct of the Company's business except as described in the Offering Documents or except where such challenge, even if successful, would not result in a Material Adverse Effect. To the best of Company's knowledge, the Intangibles and the Company's current products, services and processes do not infringe on any intangibles held by any third party. To the best of the Company's knowledge, no others have infringed upon the Intangibles of the Company.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 11 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19 <u>Relations With Employees</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19.1 <u>Employee Matters</u>. The Company has generally enjoyed a satisfactory employer-employee relationship with its employees and is in compliance in all material respects with all federal, state and local laws and regulations respecting the employment of its employees and employment practices, terms and conditions of employment and wages and hours relating thereto. There are no pending investigations involving the Company by the U.S. Department of Labor, or any other governmental agency responsible for the enforcement of such federal, state or local laws and employment laws and regulations. There is no unfair labor practice charge or complaint against the Company pending before a Labor Relations Board or any strike, picketing, boycott, dispute, slowdown or stoppage pending or threatened against or involving the Company or any predecessor entity. No questions concerning representation exist respecting the employees of the Company and no collective bargaining agreement or modification thereof is currently being negotiated by the Company. No grievance or arbitration proceeding is pending under any expired or existing collective bargaining agreements of the Company, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.19.2 <u>Employee Benefit Plans</u>. Except as disclosed in the Offering Documents, the Company neither maintains, sponsors nor contributes to, nor is it required to contribute to, any program or arrangement that is an "employee pension benefit plan, an employee welfare benefit plan," or a "multi-employer plan" as such terms are defined in Sections 3(2), 3(1) and 3(37), respectively, of the Employee Retirement Income Security Act of 1974, as amended ("ERISA") ("ERISA Plans"). Other than as disclosed in the Offering Documents, the Company does not, and has at no time, maintained or contributed to a defined benefit plan, as defined in Section 3(35) of ERISA. Except as disclosed in the Offering Documents, there are no unfunded benefits under any ERISA Plan which is subject to the funding standards of ERISA. Other than claims for benefits in the ordinary course, there are no pending claims, litigation, arbitration or any other legal proceeding involving any ERISA Plan which may result in material liability on the part of the Company or any ERISA Plan under ERISA or any other law, nor, is there any reasonable basis for such a claim. The Company has no bonus, incentive or deferred compensation plans which constitute a continuing liability of the Company, except individual arrangements of the Company with employees relating to their employment. There are no employees of the Company who, in connection with their employment by the Company, are receiving any pension or retirement payments or are entitled to receive any unfunded pensions not covered by a pension plan to which the Company is a party.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 12 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.20 <u>Environmental Matters</u>. The Company and each of its subsidiaries is in compliance in all material respects with all Environmental and Safety Requirements, and there are no proceedings pending or, to the knowledge of the Company, threatened against the Company or any of its subsidiaries alleging any failure to so comply or involving any of its past operations or any real property currently used by the Company or any of its subsidiaries. Neither the Company nor any of its subsidiaries has received any written or oral notice or report with respect to it or its facilities regarding any (A) actual or alleged violation of environmental and safety requirements or (B) actual or potential liability arising under Environmental and Safety Requirements, including, without limitation, any investigatory, remedial or corrective obligation. Neither the Company nor any of its subsidiaries has expressly assumed or undertaken any liability of any other person under any Environmental and Safety Requirements. Neither the Company nor any of its subsidiaries has treated, stored, disposed of, arranged for or permitted the disposal of, transported, handled or released any substance, or owned or operated any real property in a manner that has given rise to liabilities pursuant to CERCLA, SWDA or any other Environmental and Safety Requirement, including any liability for response costs, corrective action costs, personal injury, property damage, natural resources damage or attorney fees, or any investigative, corrective or remedial obligations. <u>"Environmental and Safety Requirements"</u> means all laws, orders, contractual obligations and all common law concerning public health and safety, worker health and safety, and pollution or protection of the environment, including, without limitation, all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, disposal, distribution, labeling, testing, processing, discharge, release, threatened release, control or cleanup of any hazardous materials, substances or wastes, chemical substances or mixtures, pesticides, pollutants, contaminants, toxic chemicals, petroleum products or byproducts, asbestos, polychlorinated biphenyls, noise or radiation, including, but not limited to, the SWDA, the Clean Air Act, as amended, 42 U.S.C. §§ 7401 et seq., the Federal Water Pollution Control Act, as amended, 33 U.S.C. §§ 1251 et seq., the Emergency Planning and Community Right-to-Know Act, as amended, 42 U.S.C. §§ 11001 et seq., CERCLA, the Hazardous Materials Transportation Uniform Safety Act, as amended, 49 U.S.C. §§ 5101 et seq., the Occupational Safety and Health Act of 1970, as amended, and the rules and regulations promulgated thereunder. "<u>CERCLA</u>" means the Comprehensive Environmental Response, Compensation, and Liability Act, as amended, and the rules and regulations promulgated thereunder. "SWDA" means the Solid Waste Disposal Act, as amended, and the rules and regulations promulgated thereunder.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 13 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.21 <u>No Regulatory Problems</u>. The Company (i) has not filed a registration statement which is the subject of any pending proceeding or examination under Section 8 of the Securities Act, and is not and has not been the subject of any refusal order or stop order thereunder; (ii) is not subject to any pending proceeding under Rule 258 of the Securities Act or any similar rule adopted under Section 3(b) of the Securities Act, or to an order entered thereunder; (iii) has not been convicted of any felony or misdemeanor in connection with the purchase or sale of any security or involving the making of any false filing with the Commission; (iv) is not subject to any order, judgment, or decree of any court of competent jurisdiction temporarily or preliminarily restraining or enjoining, or any order, judgment, or decree of any court of competent jurisdiction permanently restraining or enjoining, the Company from engaging in or continuing any conduct or practice in connection with the purchase or sale of any security or involving the making of any false filing with the Commission; and (v) is not subject to a United States Postal Service false representation order entered under Section 3005 of Title 39, United States Code; or a temporary restraining order or preliminary injunction entered under Section 3007 of Title 39, United States Code, with respect to conduct alleged to have violated Section 3005 of Title 39, United States Code.

To the Company's knowledge, none of the Company's directors, officers, or beneficial owners of five (5%) percent or more of any class of its equity securities (i) has been convicted of any felony or misdemeanor in connection with the purchase or sale of any security, involving the making of a false filing with the Commission, or arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, or investment advisor; (ii) is subject to any order, judgment, or decree of any court of competent jurisdiction temporarily or preliminarily enjoining or restraining, or is subject to any order, judgment, or decree of any court of competent jurisdiction, permanently enjoining or restraining such person from engaging in or continuing any conduct or practice in connection with the purchase or sale of any security, or involving the making of a false filing with the Commission, or arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, or investment adviser; (iii) is subject to an order of the Commission entered pursuant to Section 15(b), 15B(a) or 15B(c) of the Exchange Act, or is subject to an order of the Commission entered pursuant to Section 203(e) or (f) of the Investment Advisers Act of 1940; (iv) is suspended or expelled from membership in, or suspended or barred from association with a member of, an exchange registered as a national securities exchange pursuant to Section 6 of the Exchange Act, an association registered as a national securities association under Section 15A of the Exchange Act, or a Canadian securities exchange or association for any act or omission to act constituting conduct inconsistent with just and equitable principles of trade; or (v) is subject to a United States Postal Service false representation order entered under Section 3005 of Title 39, United States Code, or is subject to a restraining order or preliminary injunction entered under Section 3007 of Title 39, United States Code, with respect to conduct alleged to have violated Section 3005 of Title 39, United States Code.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 14 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.22 <u>Stock Collateral</u>. None of the Company's obligations to any third party are secured by any of the Company's outstanding securities other then the Security Agreement as it relates to this offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.23 <u>Reaffirmation</u>. All of the representations, warranties and covenants of the Company set forth in this Agreement or in any letter or certificate furnished to Placement Agent pursuant hereto, each of which is incorporated herein by reference and made a part hereof, shall be true in all material respects upon the execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. <u>Representations and Warranties of the Placement Agent</u>**. The Placement Agent represents and warrants as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Due Incorporation</u>. The Placement Agent is duly incorporated and validly existing and in good standing under the laws of its state of incorporation and is duly qualified as a foreign corporation for the transaction of business and is in good standing in each jurisdiction where the failure to be so qualified would have a materially adverse effect on the business of the Placement Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Broker/Dealer Registration</u>. The Placement Agent is registered as a broker-dealer under Section 15 of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>Good Standing with FINRA</u>. The Placement Agent is a member in good standing of the FINRA and no proceedings are pending or to the Placement Agent's knowledge, threatened, to revoke or limit such status.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <u>Sale in Certain Jurisdictions</u>. Sales of Shares by the Placement Agent will be made only in such jurisdictions in which (i) the Placement Agent is a registered broker-dealer or where an applicable exemption from such registration exists and (ii) the Offering and sale of the securities is registered under, or is exempt from, applicable registration requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <u>Compliance with Laws</u>. Offers and sales of Shares by the Placement Agent will be made in compliance with the provisions of Rule 506 of Regulation D and/or Section 4(2) of the Act, and the Placement Agent will furnish to each investor a copy of the Offering Documents prior to accepting any payments for Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5.1 <u>Sale to Accredited Investors, No General Solicitation</u>.

The Placement Agent understands that the securities have not been registered under the Securities Act or any Blue Sky law of any state and may not be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and such Blue Sky laws. The Placement Agent agrees that it will not solicit offers for, or offer or sell, the securities by any form of general solicitation or general advertising within the meaning of Section 4(2) of the Securities Act, and Rule 506 thereunder. The Placement Agent further agrees to not offer or sell or arrange for the offer or sale of the securities except (i) to those the Placement Agent reasonably believes are "accredited investors" (as defined in Rule 501 of Regulation D), or (ii) in any other manner that does not require registration of the securities under the Securities Act.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 15 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <u>Due Authorization</u>.

The Placement Agent has all requisite power and authority to execute, deliver and perform its obligations under this Agreement between the Company and the Placement Agent, and this Agreement will be duly authorized and validly executed and delivered by the Placement Agent and constitutes a legal, valid and binding agreement of the Placement Agent enforceable against the Placement Agent in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Closing</u>.

At or prior to each closing, and as a condition of the Placement Agent's obligations hereunder, the following shall have been satisfied: (i) the Company shall have delivered to the Placement Agent at the closing (a) a certificate of the Company, signed by two executive officers thereof, stating the representations and warranties contained herein are true and correct as of the date of such closing as if, and to the same effect, the warranties and representations were made on such date; (b) Subscription Agreements signed by the Company; (c) Consents of any party required to consummate this Offering and the transactions contemplated thereby; and (d) such other closing documents as shall be reasonably requested by the Placement Agent and/or its counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.1 <u>Placement Agent's Fees and Expenses</u>.

At the Initial Closing, and at each subsequent Closing, the Company shall pay to the Placement Agent a commission equal to ten (10%) percent of the aggregate purchase price of the securities sold by the Placement Agent. In addition, the company will also pay the placement agent 3% of the aggregate purchase price of the securities sold by the Placement Agent for unaccountable allowance expenses.

The Company will also issue to Network 1, or its designees, warrants equal to ten percent (10%) of the shares issued from the debenture conversions at the same discounted price exercisable for 3 years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.2 <u>Finder's Fee</u>.

In the event that at any time prior to the third (3rd) anniversary of the final Closing (as defined in the Placement Agent Agreement) the Company or any of its affiliates shall enter into any transaction (including, without limitation, any merger, consolidation, acquisition, financing, joint venture or other arrangement) with any party introduced to the Company by the Placement Agent, directly or indirectly, during such period, the Placement Agent will be paid a transaction fee, payable at the closing thereof, equal to a percentage of the consideration or value received by the Company and/or its stockholders as follows:

(a) 5% of the first $1,000,000,

(b) 4% of the next $1,000,000,

(c) 3% of the next $1,000,000,

(d) 2% of the next $1,000,000, and

(e) 1% of all amounts in excess of$4,000,000.

The Company agrees to pay to the Placement Agent the aforementioned finder's fee during the aforementioned time period, even in situations where the consummation of the transaction at issue culminated *not directly from the finder's initial introduction but indirectly from a chain of introductions initiated by the finder's introduction.* In no event shall the fees payable pursuant to this paragraph shall exceed the maximum finder's fee allowed by the Financial Industry Regulatory Authority ("FINRA") at the time of such transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Right of First Refusal</u>.

If the Company's Board of Directors authorizes the Company to pursue a merger/acquisition opportunity involving the sale of all or substantially all of the Company's assets during the period after the Memorandum has been distributed by the Placement Agent, the Placement Agent shall have the right of first refusal to act as the Company's investment banker or financial advisor in connection with any such merger/acquisition, rendering such services as are customary in connection therewith in consideration for a fee which is considered customary for such services.

For the 2 year period commencing on the date of the Closing, Placement Agent shall have the right of first refusal (on terms at least as favorable as can be obtained from other sources) to act as lead manager, co-manager, placement agent, or investment banker with respect to any proposed underwritten public distribution or private placement of the Company's securities or any merger, acquisition, or disposition of assets of the Company, if the Company uses a lead manager, co-manager, placement agent, investment banker, or other person performing such functions for a fee. Placement Agent will advise the Company promptly, but in no event later than fifteen (15) days following the submission to Placement Agent writing of any such proposed transaction(s), of Placement Agent's election to exercise said right. If any such proposal is not accepted by Placement Agent but later modified, the Company will re-submit such proposal to Placement Agent. Should Placement Agent elect, at any time not to exercise said right this will not affect preferential rights for future financings.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 16 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. <u>Covenants</u>**. The Company covenants and agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Expenses of Offering and Other Expenses</u>. The Company shall be responsible for, and shall pay, all fees, disbursements and expenses incurred in connection with the Offering, including, but not limited to, the Company's legal and accounting fees and disbursements, the costs of preparing, printing, mailing and delivering, and filing, where necessary, the Offering Documents and all amendments and supplements thereto (in such quantities as the Placement Agent may reasonably require), the costs of any "due diligence" meeting held by the Company as requested by the Placement Agent, the fees and disbursements of the Placement Agent counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Further Assurances</u>. The Company will take such actions as may be reasonably required or desirable to carry out the provisions of this Agreement and the transaction contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Indemnification and Contribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <u>Indemnification by the Company</u>. The Company agrees to indemnify and hold harmless the Placement Agent and each person, if any, who controls the Placement Agent within the meaning of the Securities Act and/or the Exchange Act against any losses, claims, damages or liabilities, joint or several, to which the Placement Agent or such controlling person may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained (A) in the Offering Documents, or (B) in any blue sky application or other document executed by the Company specifically for blue sky purposes or based upon any other written information furnished by the Company or on its behalf to any state or other jurisdiction in order to qualify any or all of the securities under the securities laws thereof (any such application, document or information being hereinafter called a "Blue Sky Application"), (ii) any breach by the Company of any of its representations, warranties or covenants contained herein or in any of the Subscription Agreements, or (iii) the omission or alleged omission by the Company to state in the Offering Documents or in any Blue Sky Application a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; and will reimburse the Placement Agent and each such controlling person for any legal or other expenses reasonably incurred by the Placement Agent or such controlling person in connection with investigating or defending any such loss, claim, damage, liability or action, whether arising out of an action between the Placement Agent and a third party; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon (i) an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information regarding the Placement Agent which is furnished to the Company by the Placement Agent specifically for inclusion in the Offering Documents or any such Blue Sky Application or (ii) any breach by the Placement Agent of the representations, warranties or covenants contained herein (together, (i) and (ii) above are referred to as the ''Non-indemnity Events").

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 17 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <u>Indemnification by the Placement Agent</u>. The Placement Agent agrees to indemnify and hold harmless the Company and each person, if any, who controls the Company within the meaning of the Securities Act and/or the Exchange Act against any losses, claims, damages or liabilities, joint or several, to which the Company or such controlling person may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any Non-Indemnity Event; and will reimburse the Company and each such controlling person for any legal or other expenses reasonably incurred by the Company or such controlling person in connection with investigating or defending any such loss, claim, damage, liability or action provided that such loss, claim, damage or liability is found ultimately to arise out of or be based upon any Non Indemnity Event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <u>Procedure</u>. Promptly after receipt by an indemnified party under this Section 7 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 7, notify in writing the indemnifying party of the commencement thereof; and the omission so to notify the indemnifying *party* will relieve the indemnifying party from any liability under this Section 7 as to the particular item for which indemnification is then being sought, but not from any other liability which it may have to any indemnified party. In case any such action is brought against any indemnified party, and it notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein, and to the extent that it may wish, jointly with any other indemnifying party, similarly notified, to assume the defense thereof, with counsel who shall be to the reasonable satisfaction of such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section 7 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof. Any such indemnifying party shall not be liable to any such indemnified party on account of any settlement of any claim or action effected without the consent of such indemnifying party.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 18 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3.1 <u>Notice</u>. Any notices required or permitted to be given hereunder shall be given in writing and shall be delivered (a) in person, (b) by certified mail, postage prepaid, return receipt requested, (c) by facsimile, or (d) by a commercial overnight courier that guarantees next day delivery and provides a receipt, and such notices shall be addressed as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**If to Network 1 Financial Securities:** | **The Galleria Building**<br> **2 Bridge Avenue, Suite 241**<br> **Red Bank, New Jersey 07701**<br> **Attention: Damon Testaverde**<br> **Ddtestaverde@Netwl .com** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**If to Autism Diagnostic Technologies, Inc.:** | **Mr. Andrew Stewart, CEO**<br> **1 Vanderveer Drive**<br> **Basking Ridge, NJ 07920**<br> **Astewar3.as@gmail.com** |

---

Or to such other address as either party may from time to time specify in writing to the other party. Any notice shall be effective only upon delivery, which for any notice given by facsimile shall mean notice that has been received by the party to whom it is sent as evidenced by confirmation slip.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <u>Contribution</u>. If the indemnification provided for in this Section 7 is unavailable to any indemnified party (other than as a result of the failure to notify the indemnifying party as provided in Section 7.3 hereof) in respect to any losses, claims, damages, liabilities or expenses referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party, will contribute to the amount paid or payable by such indemnified party, as a result of such losses, claims, damages, liabilities or expenses (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand, and the Placement Agent, on the other hand, from the Offering, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above, but also the relative fault of the Company, on the one hand, and of the Placement Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Placement Agent, on the other hand, shall be deemed to be in the same proportion as the total proceeds from the Offering (net of sales commissions, but before deducting other expenses) received by the Company bear to the commissions received by the Placement Agent. The relative fault of the Company, on the one hand, and the Placement Agent, on the other hand, will be determined with reference to, among other things, whether the untrue or alleged untrue statement of a material fact of the omission to state a material fact relates to information supplied by the Company, on the one hand, and the Placement Agent, on the other hand, and their relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 19 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <u>Equitable Considerations</u>. The Company and the Placement Agent agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation or by any method of allocation which does not take into account the equitable consideration referred to in the immediately preceding paragraph. No person guilty of fraudulent misrepresentation (within the meaning of Section 11 (f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <u>Attorneys' Fees</u>. The amount payable by a party under this Section 7 as a result of the losses, claims, damages, liabilities or expenses referred to above will be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim (including, without limitation, fees and disbursements of counsel incurred by an indemnified party in any action or proceeding between the indemnifying party and indemnified party or between the indemnified party and any third party or otherwise).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <u>Prior to Completion of Offering Documents and Commencement of Offering</u>. Prior to the completion of the Offering Documents and the commencement of the Offering, either party may terminate this Agreement by giving written notice to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <u>Following Completion of Offering Documents and Commencement of Offering</u>. Following the completion of the Offering Documents and the commencement of the Offering, each of the Company and the Placement Agent will have the right to terminate this Agreement by giving written notice as herein specified, at any time, at or prior to the Initial Closing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if the other party shall have failed, refused, or been unable to perform any of its obligations hereunder, or breached any of its representations or warranties hereunder; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if, in the Placement Agent's or the Company's reasonable opinion, there has occurred an event materially affecting the value of the securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. <u>Competing Claims</u>**. The Company acknowledges and agrees that the Placement Agent will not proceed to perform hereunder until it receives assurances, in form and substance satisfactory to the Placement Agent and their counsel, that as of the first date that the Offering Documents are presented to potential purchasers of the securities, there will be no claims or payments for services in the nature of a finder's fee with respect to the Offering or any other arrangements, agreements, payments, issuances or understandings that may affect the Placement Agent's compensation hereunder other than any claims that may be made by the Placement Agent's own personnel. The Placement Agent shall compensate any of its personnel who may have acted in such capacities, as it shall determine.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 20 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. <u>Miscellaneous</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Governing Law</u>. This Agreement will be deemed to have been made and delivered in the State of New York and will be governed as to validity, interpretation, construction, effect and in all other respects by the internal law of the State of New York, without regard to principles of conflicts of law. The Company (i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement shall be instituted exclusively in the Supreme Court of New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection to the venue of any such suit, action or proceeding, and the right to assert that such forum is an inconvenient forum, and (iii) irrevocably consents to the jurisdiction of the Supreme Court of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. The Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the Supreme Court of New York or the United States District Court for the Southern District of New York and agrees that service of process upon it mailed by certified mail to its address shall be deemed in every respect effective service of process upon it in any such suit, action or proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Counterparts</u>. This Agreement may be executed in any number of counterparts each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Parties</u>. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns. Neither party may assign this Agreement or its obligations hereunder without the prior written consent of the other party. This Agreement is intended to be, and is, for the sole and exclusive benefit of the parties hereto and the persons described in Section 7 hereof and their respective successors and assigns, and for the benefit of no other person, and no other person will have any legal or equitable right, remedy or claim under, or in respect of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Amendment and/or Modification</u>. Neither this Agreement, nor any term or provision hereof, may not be changed, waived, discharged, amended, modified or terminated orally, or in any manner other than by an instrument in writing signed by each of the parties hereto.

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 21 of 22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Validity</u>. In case any term of this Agreement will be held invalid, illegal or unenforceable, in whole or in part, the validity of any of the other terms of this Agreement will not in any way be affected thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Waiver of Breach</u>. The failure of any party hereto to insist upon strict performance of any of the covenants and agreements herein contained, or to exercise any option or right herein conferred in any one or more instances, will not be construed to be a waiver or relinquishment of any such option or right, or of any other covenants or agreements, and the same will be and remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Further Assurances</u>. Each party to this Agreement will perform any and all acts and execute any and all documents as may be necessary and proper under the circumstances in order to accomplish the intents and purposes of this Agreement and to carry out its provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. <u>Entire Agreement</u>**. This Agreement contains the entire agreement and understanding of the parties with respect to the subject matter hereof and thereof, respectively, and there are no representations, inducements, promises or agreements, oral or otherwise, not embodied in this Agreement. Any and all prior discussions, negotiations, commitments and understanding relating to the subject matter of these agreements are superseded by them.

**[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]**

ã 2011 Network 1 Financial Securities, Inc.

Network 1 Financial Securities, Inc.

Private Placement Agent's Agreement-Private Offering

Page 22 of 22

If ***Autism Diagnostic Technologies, Inc*** finds the foregoing is in accordance with its understanding with ***Network 1 Financial Securities, Inc.,*** kindly sign and return to Network 1 Financial Securities, Inc. a counterpart hereof, whereupon this instrument along with all counterparts will become a binding agreement between ***Autism Diagnostic Technologies Inc.*** and ***Network 1 Financial Securities, Inc.***

 ****

---

| | |
|:---|:---|
| **Network 1 Financial Securities, Inc.** | **Network 1 Financial Securities, Inc.** |
| By | /s/ Damon D. Testaverde |
|  | **Damon D. Testaverde** |
|  | **Managing Director** |

---

**AGREED TO BY *Autism Diagnostic Technologies Inc.;*** this the 12th of June 2023.

---

| | |
|:---|:---|
| ***Autism Diagnostic Technologies Inc.*** | ***Autism Diagnostic Technologies Inc.*** |
| By | /s/ **Andrew Stewart** |
|  | **Andrew Stewart** |
|  | **CEO** |

---

ã 2011 Network 1 Financial Securities, Inc.

## Exhibit 4.3

**Exhibit 4.3**

![](ex10-7_001.jpg)

June 20, 2024

Neurospectrum Insights, Inc.

Andrew Stewart, CEO

367 Main Street, Suite 105

Bedminster, NJ 07921

Re: <u>Initial Public Offering</u>

Dear Mr. Stewart:

The terms of our agreement in principle are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Company hereby engages Network 1 Financial Securities, Inc., hereinafter referred to as "**Network 1**," for the period beginning on the date hereof and ending on December 31, 2024 (the "**Engagement Period**"), to act as the Company's lead or managing underwriter and/or book runner and investment banker in connection with the proposed firm commitment public Offering (as defined below), except as otherwise provided in this Paragraph 1. During the Engagement Period or until the consummation of the Offering, and as long as Network 1 is reasonably proceeding in good faith with preparations for the Offering, the Company agrees not to solicit, negotiate with or enter into any agreement with any other source of financing (whether equity, debt or otherwise), any underwriter, potential underwriter, placement agent, financial advisor or any other person or entity in connection with an offering of the Company's securities or any other financing by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The "**Offering**" shall be a firm-commitment public offering consisting of the sale of approximately Seven million dollars ($7,000,000) worth of common stock, of the Company, (the "**Common Stock**"), or such other amount as the Company and Network 1 shall mutually agree. The final valuation, and offering price, of each common share, shall be mutually agreed upon by the parties to this agreement and will be dependent on the Company's performance for the fiscal year 2024, and market conditions. The securities will trade immediately after the Closing (as such term is defined below). Network 1 will act as the lead, or managing underwriter, for firm commitment Offering, subject to, among other things, completion of Network 1's due diligence examination of the Company and its affiliates and the execution of a definitive underwriting agreement between the Company and Network 1 and the other members of the underwriting syndicate in connection with the Offering (the "**Underwriting Agreement**") and other customary documentation. Except as expressly provided herein, this engagement letter is not intended to be a binding document, as the agreement between the parties relating to the Offering will be embodied in the Underwriting Agreement, which the Company shall enter into with Network 1 and the other members of the underwriting syndicate at such time that the Company and Network 1 are mutually satisfied that it is appropriate to commence the Offering.

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The approximate numbers set forth in Paragraph 2 are based on the parties' current projections of the pre-money valuation of the Company. The actual size of the Offering, the precise number of shares to be offered by the Company, and the Offering price per share shall be the subject of continuing negotiations between the Company and Network 1 and will depend upon the capitalization of the Company being acceptable to Network 1 and the Company, general market and economic conditions, a review and finalization of audited financial statements and formal financial projections of the Company, as well as other factors which Network 1 and the Company deem to be relevant. Network 1 may, with the Company's approval (not to be unreasonably withheld, conditioned, or delayed), (i) create an underwriting syndicate for the Offering comprised of broker-dealers who are members of FINRA, (ii) rely on soliciting dealers who are FINRA members in good standing to participate in placing a portion of the Offering and/or (iii) offer shares to such dealers at less than the public Offering price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Underwriting Agreement will provide that the Company will grant to Network 1 an option, exercisable within 45 days after the closing of the Offering (the "**Closing**"), to acquire up to an additional 15% of the total number of shares to be offered by the Company, solely for the purpose of covering over-allotments (the "**Over-allotment Shares**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. An underwriting discount or spread of 8% of the public Offering price for the Shares and the Over-allotment shares shall be provided to Network 1. Network 1 shall also be entitled to a corporate finance fee equal to 2% of the gross proceeds of the Offering (including proceeds from the sale of the Over-allotment shares) (the "Non-accountable Expense Allowance"). Network 1 will also receive an accountable expense allowance of up to $100,000 ("Accountable Expense Allowance") Upon the execution of this engagement letter, the Company shall deliver to Network 1, $35,000 (by check or wire transfer of immediately available funds) as an advance to be applied towards the Accountable Expense Allowance (the "**Advance**"). Upon the first public filing of the registration statement (defined below) with the SEC, Network 1 shall receive the second payment of $25,000. Upon the successful closing of the offering Network 1 shall receive the final payment of $40,000. In the event the offering is terminated, the Advance received against reasonable out-of-pocket expenses incurred in connection with the offering will be returned to the issuer to the extent not actually incurred in accordance with FINRA Rule 5110(f)(2)(C).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. In the event that at any time prior to the Second (2nd) anniversary of the final Closing (as defined in the Underwriting Agreement) the Company, or any of its affiliates, shall enter into any transaction (including, without limitation, any merger, consolidation, acquisition, financing, joint venture or other arrangement) with any party introduced to the Company by the Underwriter, directly or indirectly, during such period, the Underwriter will be paid a transaction fee, payable at the closing thereof, equal to a percentage of the consideration or value received by the Company and/or its stockholders as follows:

5% of the first $1,000,000,

4% of the next $1,000,000,

3% of the next $1,000,000,

2% of the next $1,000,000, and

1% of all amounts in excess of $4,000,000.

The Company agrees to pay to the Underwriter the finder's fee during the aforementioned time period, even in situations where the consummation of the transaction at issue culminated not directly from the finder's initial introduction but indirectly from a chain of introductions initiated by the finder's introduction.

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. The Company shall, as soon as practicable following the date hereof, prepare and file with the Securities and Exchange Commission (the "**Commission**"), a Registration Statement on Form S-1 (the "**Registration Statement**") under the Securities Act of 1933, as amended (the "**Act**"), and a prospectus included therein (the "**Prospectus**") covering the shares to be sold in the Offering, the Over- allotment shares, and the Underwriter's Warrants (as defined below). The Registration Statement (including the Prospectus therein), and all amendments and supplements thereto, will be in form satisfactory to Network 1 and counsel to Network 1 and will contain audited financial statements for the fiscal years ended December 31, 2022, and December 31, 2023 and such interim and other financial statements and schedules as may be required by the Act and rules and regulations of the Commission thereunder. Network 1 and its counsel shall be given the opportunity to make such review and investigation in connection with the Registration Statement and the Company as they deem desirable. Network 1 and the Company shall mutually agree on the use of proceeds of the Offering, which shall be described in detail within the Prospectus, it being further understood and agreed that, except as may expressly be approved by Network 1, no proceeds from the Offering will be used to pay outstanding loans owed by the Company to any Company officers, directors or stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. The Registration Statement filing will include as an exhibit a proposed form of Underwriting Agreement. The final Underwriting Agreement will be in form satisfactory to the Company and Network 1 and will include indemnification provisions and other terms and conditions customarily found in underwriting agreements for initial public offerings. Without limiting the generality of the foregoing, the Underwriting Agreement shall contain customary representations and warranties of the Company and shall further provide that the Company, and the Company's directors and officers, shall enter into customary "lock-up" agreements in favor of Network 1 pursuant to which such persons and entities shall agree, for a period of 180 days after the effective date ("**Effective Date**") of the Registration Statement to neither offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any securities of the Company without Network 1's prior written consent. The foregoing sentence shall not apply to (i) Shares to be sold in the Offering; (ii) any Over-allotment shares, (iii) any shares of Common Stock issued or options to purchase Common Stock or other Common Stock-based awards granted pursuant to any stock incentive plan, stock purchase plan, stock ownership plan or dividend reinvestment plan of the Company in effect at the Effective Date; (iii) issuance of Common Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options, in each case outstanding at the Effective Date; (iv) issuance of Common Stock in connection with strategic acquisitions; or (v) transfers by a stockholder (A) by bona fide gift, (B) by will or intestacy to the spouse, parents, siblings, first cousins or any lineal descendant of such stockholder or such stockholder's spouse, including step relationships and relationships by adoption (each a, "**family member**"), (C) to any trust for the benefit of such stockholder or a family member of such stockholder, (D) to the estate of such stockholder , or (E) to any affiliate of such stockholder or by distribution to any partners, members or stockholders of such stockholder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. The Company will bear all fees, disbursements and expenses in connection with the proposed Offering, including, without limitation: the Company's legal and accounting fees and disbursements; the costs of preparing, printing, mailing and delivering the Registration Statement, the preliminary and final prospectus contained therein and amendments thereto, post-effective amendments and supplements thereto, the Underwriting Agreement and related documents (all in such quantities as Network 1 may reasonably require); preparing and printing stock certificates and warrant certificates. In addition, the Company will bear all fees and expenses incurred by Network 1 ("Accountable Expenses") including: the costs of any "due diligence" meetings; all reasonable and documented fees and expenses for conducting a road show presentation; all filing fees (FINRA, DTC & SEC) and communication expenses relating to the registration of the shares to be sold in the Offering; the reasonable and documented fees and disbursements of Network 1's counsel; background checks of the Company's officers and directors; preparation of bound volumes and Lucite cube mementos; transfer taxes, if any, payable upon the transfer of securities from the Company to Network 1; and the fees and expenses of the transfer agent, clearing firm and registrar for the shares; provided that the actual accountable expenses of the underwriter shall not exceed $100,000.

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. While the Commission is reviewing the Registration Statement, Network 1 may plan and arrange one or more "road show" marketing trips for the Company's management to meet with prospective investors. Such trips will include visits to a number of prospective institutional and retail investors. The Company shall pay for all of its own expenses, including, without limitation, travel and lodging expenses, associated with such trips. During the 45-day period prior to the filing of the Registration Statement with the Commission, and at all times thereafter prior and following to the effectiveness of the Registration Statement, the Company and its officers, directors and related parties will abide by all rules and regulations of the Commission, including, without limitation, those relating to public statements (i.e., "gun jumping") and disclosures of material non-public information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. At such time as the Company and Network 1 are mutually satisfied that it is appropriate to commence the Offering, the final terms of the Underwriting Agreement will be negotiated and the Company and Network 1 will request the Commission to make the Registration Statement effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. The Underwriting Agreement shall provide that, at the Closing, the Company shall grant to Network 1 (or its designated affiliates) share purchase warrants (the "**Underwriter's Warrants**") equal to 8% of the total number of shares of Common Stock sold in the Offering, including any over- allotment shares. The Underwriters Warrants will expire five years after the date of Closing and will be exercisable at a price equal to 110% of the public offering price of the common shares sold in the Offering. The Underwriter's Warrants shall not be redeemable. The Company will register the shares of Common Stock underlying the Underwriter's Warrants under the Act and will file all necessary undertakings in connection therewith. The Underwriter's Warrants may not be transferred, assigned, or hypothecated for a period of six (6) months following the Closing, (the, "**Lock-Up Period**") except that they may be assigned, in whole or in part, to any successor, officer, manager, member or partner of Network 1 (or to officers, managers or members of any such successor, member or partner), and to members of the underwriting syndicate or selling group and their respective officers, managers, members or partners.

The Underwriter's warrants will be exercisable at any time upon issuance, provided that the underlying shares are not sold, or transferred, during the lock-up period; the 180-day lock period will remain on these underlying shares. The Underwriter's Warrants may be exercised as to all, or a lesser number of shares of Common Stock, and will provide for cashless exercise and will contain provisions for one demand registration of the sale of the underlying shares of Common Stock at the Company's expense, an additional demand registration at the warrant holders' expense, and unlimited "piggyback" registration rights for a period of five (5) years after the Closing at the Company's expense. The Underwriter's Warrants shall further provide for adjustment in the number and price of such warrants (and the shares of Common Stock underlying such warrants) in the event of recapitalization, merger, or other structural transaction to prevent dilution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. Upon the closing of the Offering the Company will grant Network 1 the right of first refusal to manage any public underwriting, or private placement of debt or equity securities, (excluding (i) shares issued under any compensation or stock option plan approved by the stockholders of the Company, (ii) shares issued in payment of the consideration for an acquisition or as part of strategic partnerships and transactions and (iii) conventional banking arrangements and commercial debt financing) of the Company or any subsidiary or successor of the Company, with Network 1 receiving the right to underwrite or place a number of the securities to be sold therein having an aggregate purchase price therein equal to a minimum of the aggregate purchase price of the Base Shares in the Offering, until twelve (12) months after completion of the Offering. If Network 1 fails to accept in writing any such proposal for such public or private sale within ten (10) days after receipt of a written notice from the Company containing such proposal, then Network 1 will have no claim or right with respect to any such sale contained in any such notice. If, thereafter, such proposal is modified in any material respect, the Company will adopt the same procedure as with respect to the original proposed public or private sale, and Network 1 shall have the right of first negotiation with respect to such revised proposal in accordance with the terms of this Section 14.

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14. The Offering shall be conditioned upon, among other things, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Satisfactory completion by Network 1 of its due diligence investigation and analysis of the Company's arrangements with its officers, directors, employees, affiliates, customers, and suppliers, (ii) the audited historical financial statements of the Company for the fiscal years ended December 31, 2022 and 2023, and (iii) the Company's projected financial results for the fiscal years ending December 31, 2024 through 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The execution by the Company and Network 1 of a definitive Underwriting Agreement containing all applicable terms and conditions provided for in this engagement letter; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company's registration of the shares under the provisions of Section 12(b) or (g), as applicable, of the Securities Exchange Act of 1934 on or prior to the effective date of the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. Except as provided in Paragraph 1 hereof, this Paragraph 16 and Paragraphs 17 through 20 hereof and Exhibit A hereto (which Paragraphs are intended be legally binding and enforceable on and against the Company and Network 1), this engagement letter is not intended to be a binding legal document, as the agreement between the parties hereto on these matters will be embodied in the Underwriting Agreement. Until the Underwriting Agreement has been finally negotiated and signed, (i) the Company or Network 1 may at any time terminate its further participation in the proposed transactions for any reason whatsoever or (ii) the Company may at any time terminate its further participation in the proposed transactions if Network 1 fails to promptly and diligently prosecute the proposed transactions, and the party so terminating shall have no liability to the other on account of any matters provided for herein, except that if the Company elects to terminate pursuant to clause (i) above, the Company agrees to reimburse Network 1 for, or otherwise pay and bear, the expenses and fees to be paid and borne by the Company as provided for in Paragraph 9 above and to reimburse Network 1 for the full amount of its actual reasonable accountable out of pocket expenses (up to a maximum of $100,000) incurred to such date (which shall include, but shall not be limited to, all reasonable and documented fees and disbursements of Network 1's counsel, travel, lodging and other Network 1 "road show" expenses, mailing, printing and reproduction expenses, and any reasonable expenses incurred by Network 1 in conducting its due diligence, including background checks of the Company's officers and directors), less any Advance and amounts previously paid to Network 1 in reimbursement for such expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. The Company represents and warrants to Network 1 that the entry into this engagement letter or the any other action of the Company in connection with the proposed Offering will not violate any agreement between the Company and any other underwriter. This engagement letter contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and there are no representations, inducements, promises or agreements, oral or otherwise, not embodied in this engagement letter. Any and all prior discussions, negotiations, agreements, commitments and understanding relating to the subject matter hereof are hereby superseded and terminated, effective immediately.

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. The Company agrees that it will not issue press releases or engage in any other publicity (except any necessary investor contact in connection with the Private Financing or the other financings referred to in clauses (ii) or (iii) of Paragraph 1 hereof), without Network 1's prior written consent, commencing on the date hereof and continuing for a period of twenty-five (25) days from Closing of the Offering, other than normal and customary releases issued in the ordinary course of the Company's business. The Company covenants to adhere to all "gun jumping" and "quiet period" rules and regulations of the Commission prior to, during and following the filing of the Registration Statement and the consummation of the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. During the Engagement Period or until the Closing, the Company agrees to cooperate with Network 1 and to furnish, or cause to be furnished, to Network 1, any and all information and data concerning the Company, its subsidiaries and the Offering that Network 1 deems appropriate, including, without limitation, the Company's acquisition plans and plans for raising capital or additional financing (the "**Information**"). The Company shall provide Network 1 reasonable access during normal business hours from and after the date of execution of this Agreement until the date of the Closing to all of the Company's and its subsidiaries assets, properties, books, contracts, commitments and records and to the Company's and its subsidiaries officers, directors, employees, appraisers, independent accountants, legal counsel and other consultants and advisors. The Company represents and warrants to Network 1 that all Information: (i) made available by the Company to Network 1 or its agents, representatives and any potential syndicate or selling group member, (ii) contained in any preliminary or final Prospectus prepared by the Company in connection with the Offering, and (iii) contained in any filing by the Company with any court or governmental regulatory agency, commission or instrumentality, will, as of the date made available or filed, be complete and correct in all material respects and will not, as of the date made available or filed, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in the light of the circumstances under which such statements are made, provided that the Company will update any such information as required prior to the Closing. The Company further represents and warrants to Network 1 that all such Information will have been prepared by the Company in good faith and will be based upon assumptions which, in light of the circumstances under which they were made, are reasonable. The Company acknowledges and agrees that in rendering its services hereunder, Network 1 will be using and relying on such information without independent verification thereof by Network 1 or independent appraisal by Network 1 of any of the Company's assets. The Company acknowledges and agrees that this engagement letter and the terms hereof are confidential and will not be disclosed to anyone other than the officers and directors of the Company and the Company's accountants and legal counsel. Except as contemplated by the terms hereof or as required by applicable law, the Company and Network 1 shall keep strictly confidential all non-public Information concerning the Company provided to Network 1. No obligation of confidentiality shall apply to Information that: (a) is in the public domain as of the date hereof or hereafter enters the public domain without a breach by Network 1, (b) was known or became known by Network 1 prior to the Company's disclosure thereof to Network 1, (c) becomes known to Network 1 from a source other than the Company, and other than by the breach of an obligation of confidentiality owed to the Company, (d) is disclosed by the Company to a third party without restrictions on its disclosure or (e) is independently developed by Network 1, in each case as demonstrated by contemporaneous written evidence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. This engagement letter shall be deemed to have been made and delivered in New York City and both this engagement letter and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York, without regard to the conflict of laws principles thereof.

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. Each of Network 1 and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this engagement letter and/or the transactions contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Underwriter and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified mail to the Company's address shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon Network 1 mailed by certified mail to Network 1's address shall be deemed in every respect effective service process upon Network 1, in any such suit, action or proceeding. Notwithstanding any provision of this engagement letter to the contrary, the Company agrees that neither Network 1 nor its affiliates, and the respective officers, directors, employees, agents and representatives of Network 1, its affiliates and each other person, if any, controlling Network 1 or any of its affiliates, shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction described herein except for any such liability for losses, claims, damages or liabilities incurred by the Company that are finally judicially determined to have resulted from the bad faith or gross negligence of such individuals or entities. Network 1 will act under this engagement letter as an independent contractor with duties to the Company. Because Network 1 will be acting on the Company's behalf in this capacity, it is Network 1's practice to receive indemnification and therefore, as a condition to Network 1's participation with the Company in the Offering process, the Company agrees to indemnify Network 1 in accordance with the indemnification provisions set forth on <u>Exhibit A</u> hereto, which provisions are incorporated by reference into and are made a binding part of this engagement letter.

[Signature Page Follows]

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

Neurospectrum Insights, Inc

June 20, 2024

We are delighted at the prospect of continuing our working relationship with you and look forward to a successful offering. If you agree with the foregoing, please execute and return this engagement letter to the undersigned together with payment for the initial Advance in the amount of $35,000. This engagement letter may be executed in counterparts and by facsimile transmission.

---

| | |
|:---|:---|
| Yours truly, | Yours truly, |
| Network 1 Financial Securities Inc. | Network 1 Financial Securities Inc. |
| By: |  |
|  | Damon Testaverde |
|  | Managing Director |

---

---

| | |
|:---|:---|
| ACCEPTED AND AGREED TO | ACCEPTED AND AGREED TO |
| AS OF THE DATE FIRST | AS OF THE DATE FIRST |
| ABOVE WRITTEN: | ABOVE WRITTEN: |
| Neurospectrum Insights, Inc. | Neurospectrum Insights, Inc. |
| By: | /s/ Mr. Andrew Stewart |
|  | Mr. Andrew Stewart |
|  | CEO |

---

**NETWORK 1 FINANCIAL SECURITIES, Inc.** Member FINRA, SIPC

The Galleria ● Building 2 ● Penthouse 2 Bridge Avenue ●

Red Bank, New Jersey 07701-1106 ● (732) 758 – 9001

**Exhibit A**

Indemnification Provisions

In connection with the engagement letter to which this Exhibit A is attached, (the "**Engagement Letter**"), Neurospectrum Insights, Inc. (the "**Indemnitor**") agrees to indemnify and hold harmless Network 1 Financial Securities Inc. ("**Network 1**") and its affiliates, and the respective officers, directors, employees, agents and representatives of Network 1, its affiliates and each other person, if any, controlling Network 1 or any of its affiliates (Network 1 and each such other person being an "**Indemnified Person**") from and against any losses, claims, damages or liabilities related to, arising out of or in connection with the engagement (the "**Engagement**") under the Engagement Letter, and will reimburse each Indemnified Person for all expenses (including reasonable fees and expenses of counsel) incurred in connection with investigating, preparing, pursuing or defending any action, claim, suit, investigation or proceeding related to, arising out of or in connection with the Engagement, whether or not pending or threatened and whether or not any Indemnified Person is a party. The Indemnitor will not however, be responsible for any losses, claims, damages or liabilities (or expenses relating thereto) that are finally judicially determined to have resulted from the willful misconduct, acts of bad faith or gross negligence of any Indemnified Person or which result from a material breach of contract of any Indemnified Person.

The Indemnitor will not, without Network 1's prior written consent, settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any action, claim, suit or proceeding to which any Indemnified Person is a party and in respect of which indemnification may be sought hereunder unless such settlement, compromise, consent or termination includes a release of each Indemnified Person party thereto from any liabilities arising out of such action, claim, suit or proceeding. No Indemnified Person seeking indemnification, reimbursement or contribution under this agreement will, without the Indemnitor's prior written consent, settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any action, claim, suit, investigation or proceeding referred to in the preceding paragraph.

If the indemnification provided for in the first paragraph of this agreement is judicially determined to be unavailable (other than in accordance with the second sentence of the first paragraph hereof) to an Indemnified Person in respect of any losses, claims, damages or liabilities referred to herein, then, in lieu of indemnifying such Indemnified Person hereunder, the Indemnitor shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (and reasonable expense relating thereto) (i) in such proportion as is appropriate to reflect the relative benefits to the applicable Indemnified Person, on the one hand, and the Indemnitor, on the other hand, of the Engagement or (ii) if the allocation provided by clause (i) above is not available, in such proportion as is appropriate to reflect not only the relative benefits referred to in such clause (i) but also the relative fault of each of the applicable Indemnified Person and us, as well as any other relevant equitable considerations; *provided, however,* that in no event shall any Indemnified Person's aggregate contribution to the amount paid or payable exceed the aggregate amount of fees actually received by Network 1 in connection with the transactions contemplated by the Engagement Letter. For the purposes of this agreement, the relative benefits to the Indemnitor and the applicable Indemnified Person of the Engagement shall be deemed to be in the same proportion as (a) the total value paid or contemplated to be paid or received or contemplated to be received by the Indemnitor or its shareholders, as the case may be, in the transaction or transactions that are the subject of the Engagement, whether or not any such transaction is consummated, bears to (b) the fees paid to Network 1 in connection with the transactions contemplated by the Engagement Letter.

*Procedure*. Upon obtaining knowledge of any claim which may give rise to indemnification not involving a Third Party Claim, the Indemnified Person shall, as promptly as practicable following the date the Indemnified Person has obtained such knowledge, give written notice (which may be delivered by facsimile transmission, with confirmation of receipt by the receiving party) of such claim for which indemnification is sought (each, a "**Claim**") to the Indemnitor, but no failure to give such notice shall relieve the Indemnitor of any liability hereunder (except to the extent the Indemnitor has suffered actual, irreversible and material economic prejudice thereby). The Indemnified Person, at its cost, shall furnish to the Indemnitor in good faith and in reasonable detail such information as the Indemnified Person may have with respect to such Claim.

Promptly after receipt by an Indemnified Person of notice of the commencement of any action, suit or proceeding involving a Claim by a third party (each, a "**Third Party Claim**") against it, such Indemnified Person will give written notice to the Indemnitor of the commencement of such Third Party Claim, and shall give the Indemnitor such information with respect thereto as the Indemnitor may reasonably request, but no failure to give such notice shall relieve the Indemnitor of any liability hereunder (except to the extent the Indemnitor has suffered actual, irreversible and material economic prejudice thereby). The Indemnitor shall have the right, but not the obligation, to assume the defense and control the settlement of such Third Party Claim, at the Indemnitor's cost and expense (and not as a reduction in the amount of indemnification available hereunder), using counsel selected by the Indemnitor and reasonably acceptable to the Indemnified Person. If the Indemnitor satisfies the requirements of this agreement and desires to exercise its right to assume the defense and control the settlement of such Third Party Claim, the Indemnitor shall give written notice (the "**Notice**") to the Indemnified Person within fourteen (14) calendar days of receipt of notice from the Indemnified Person of the commencement of or assertion of any Third Party Claim stating that the Indemnitor shall be responsible for such Third Party Claim. Notwithstanding the foregoing, the Indemnified Person shall have the right: (i) to assume the defense and control the settlement of a Third Party Claim and (ii) to employ separate counsel at the Indemnitor's reasonable expense (provided that the Indemnitor shall not be required to reimburse the expenses and costs of more than one law firm) and control its own defense of a Third Party Claim if (x) the named parties to any such action (including any impleaded parties) include both the Indemnified Person and the Indemnitor , and the Indemnified Person shall have been advised by counsel that there are one or more legal or equitable defenses available to the Indemnified Person that are different from those available to the Indemnitor, (y) such Third Party Claim involves equitable or other non-monetary damages or in the reasonable judgment of the Indemnified Person, such settlement would have a continuing material adverse effect on the Indemnified Person's business (including any material impairment of its relationships with customers and suppliers) or (z) in the reasonable judgment of the Indemnified Person, the Indemnitor may not be able to satisfy fully such Third Party Claim. In addition, if the Indemnitor fails to give the Indemnified Person the Notice in accordance with the terms hereof, the Indemnified Person shall have the right to assume control of the defense of and settle the Third Party Claim and all costs incurred in connection therewith shall constitute damages of the Indemnified Person. For the avoidance of doubt, if the Indemnified Party assumes the defense of the Third Party Claim in accordance herewith, the Indemnitor acknowledges that the Indemnitor will advance any retainer fees required by legal counsel to an Indemnified Person simultaneously with the engagement by such Indemnified Person of such counsel, it being understood and agreed that the amount of such retainer shall not exceed $20,000 and that such retainer shall be credited to fees incurred with the balance (if any) refundable to the Indemnitor.

If at any time after the Indemnitor assumes the defense of a Third Party Claim, any of the conditions set forth in the paragraph above are no longer satisfied, the Indemnified Person shall have the same rights as set forth above as if the Indemnitor never assumed the defense of such claim.

Notwithstanding the foregoing, the Indemnitor or the Indemnified Person, as the case may be, shall have the right to participate, at its own expense, in the defense of any Third Party Claim that the other party is defending.

If the Indemnitor assumes the defense of any Third Party Claim in accordance with the terms hereof, the Indemnitor shall have the right, upon 30 calendar days' prior written notice to the Indemnified Person, to consent to the entry of judgment with respect to, or otherwise settle such Third Party Claim; provided, however, that with respect to such consent to the entry of judgment or settlement, the Indemnified Person will not have any liability and will be fully indemnified with respect to all Third Party Claims. Notwithstanding the foregoing, the Indemnitor shall not have the right to consent to the entry of judgment with respect to, or otherwise settle a Third Party Claim if: (i) the consent to judgment or settlement of such Third Party Claim involves equitable or other non-monetary damages against the Indemnified Person, or (ii) in the reasonable judgment of the Indemnified Person, such settlement would have a continuing effect on the Indemnified Person's business (including any material impairment of its relationships with customers and suppliers), without the prior written consent of the Indemnified Person. In addition, the Indemnified Person shall have the sole and exclusive right to settle any Third Party Claim on such terms and conditions as it deems reasonably appropriate, (x) if the Indemnitor fails to assume the defense in accordance with the terms hereof, or (y) to the extent such Third Party Claim involves only equitable or other non-monetary relief, and shall have the right to settle any Third Party Claim involving monetary damages with the Indemnitor's consent, which consent shall not be unreasonably withheld.

The provisions of this Exhibit A shall apply to the Engagement and any modification thereof and shall remain in full force and effect regardless of any termination or the completion of Network 1's services under the Engagement Letter.

## Exhibit 10.1

**Exhibit 10.1**

**EMPLOYMENT AGREEMENT**

This Agreement (the **"Agreement"),** dated as of October 1, 2018, is by and between Autism Diagnostic Technologies, Inc. (the **"Company")** and Andrew Stewart (the **"Executive").**

**Introduction**

The Company desires to retain the services of the Executive pursuant to the terms and conditions set forth herein and the Executive wishes to be employed by the Company on such terms and conditions. The Executive will be a key employee of the Company, with significant access to information concerning the Company and its business. The disclosure or misuse of such information or the engaging in competitive activities by the Executive would cause substantial harm to the Company.

**Agreement**

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Effective Date; Term.** This Agreement shall become effective on October 1, 2018 (the **"Effective Date").**

Executive's term of employment under this Agreement (such term of employment, as it may be extended or terminated, is herein referred to as the "Employment Term") shall be for a term commencing on the Effective Date and, unless terminated earlier as provided in Section 10 hereof, ending on the third anniversary of the Effective Date (the "Original Employment Term"); provided that the Employment Term shall be automatically extended, subject to earlier termination as provided in Section 10 hereof, for successive additional one (1) year periods (the "Additional Terms"), unless, at least 30 days prior to the end of the Original Employment Term or the then Additional Term, the Company or Executive has notified the other in writing that the Employment Term shall terminate at the end of the then current term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Duties.** The Executive shall serve as the Chief Executive Officer (CEO) of the Company and shall have such duties of an executive nature as the Board shall determine from time to time which are customary and appropriate for the position of Chief Executive Officer, and for companies of similar size. The Executive will report to the Chief Executive Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Full Time; Best Efforts.** The Executive shall use his best efforts to promote the interests of the Company and shall devote the Executive's full business time and best efforts to the performance of his duties and responsibilities hereunder. The Executive may engage in charitable, personal or civic endeavors and may serve on the boards and advisory boards of the entities set forth on **<u>Exhibit</u>** <u>A</u>, so long as such activities do not interfere with the performance of the Executive's duties and responsibilities hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Compensation and Benefits.** During the Executive's employment with the Company under this Agreement, the Executive shall be entitled to compensation and benefits as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Base Salary.** The Executive will receive a salary at the rate of $120,000.00 annually (the **"Base Salary"),** payable in equal increments pursuant to the Company's normal payroll practices. The Board shall, in good faith, review the amount of the Executive's Base Salary and Bonus target on an annual basis. The amount of the Base Salary may not be decreased at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Annual Bonus.** The Executive will be eligible for an annual bonus as determined by the Board for each full fiscal (calendar) year based upon the Company achieving financial and operating objectives established annually for such fiscal year by the Board inconsultation with the Executive (the **"Bonus").** The payment of Bonus for the 2018 year shall be prorated based upon the number of days of employment. The Board shall determine the amount of the Bonus, and such determination shall be binding and conclusive on the Executive, subject to the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Additional Bonuses.** In the sole discretion of the Board, the Executive may receive additional bonuses for extraordinary performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Stock Award.** The Board shall award Executive as of the Effective Date 3,000,000 restricted common shares of the Company (the "Stock Award)", subject to vesting as follows: The Stock Award shall vest in four (4) equal amounts, starting with 25% of the Stock Award vesting upon the Effective Date of this agreement, and 25% upon each on the first, second and third anniversaries of the Effective Date, provided that Executive is employed on each vesting date. As a condition to receiving the Stock Award, Executive shall, if requested, execute and deliver a letter in a form approved by the Company's underwriters agreeing not to sell any shares of Company common stock during a customary period following the completion of an initial public offering of the Company's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e) Option Award.** Executive shall be entitled to participate in any Company Equity Incentive Plan (the "Stock Plan") that provides for the issuance of stock options to employees of the Company, to the extent determined by the Board of the Company. Such option award shall be granted pursuant to and shall be subject to all of the terms and conditions imposed upon such awards granted under the Stock Plan and shall be evidenced by an Incentive Stock Option Agreement in the form approved by the Board or Committee appointed by the Board. As a condition to receiving such options award, Executive shall, if requested, also execute and deliver a letter in a form approved by the Company's underwriters agreeing not to sell any shares of Company common stock during a customary period following the completion of an initial public offering of the Company's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(t) Change in Control.** Notwithstanding any other provision, in the event of a change in control, all equity awards (including, but not limited to, any options or stock grants made subsequent to the date of this Agreement) shall fully vest and be immediately exercisable. A change in control means the consummation after the date hereof of a transaction or series of related transactions that results in any person or group (other than any person or group owned by or affiliated with Point Medical Inc.) ("group" as defined in the rules and regulations promulgated under the Securities Exchange Act of 1934, as amended) acquiring (i) directly or indirectly by merger or otherwise more than 50% of the Company's securities entitled to vote in the election of directors, (ii) all or substantially all of the assets of the Company or (iii) the right to elect a majority of the members of the Company's Board of Directors

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(f) Option to Have Company Repurchase Stock and Options.** If Executive dies while employed, the Company shall, subject to any restrictions contained in any credit or similar agreements or that exist under the Law, offer to purchase all of Executive's stock and any outstanding options which are vested at the time of death. If the representative of the Executive's estate wishes to accept such offer, he or she shall request, within six (6) months of death, that the Board determine the fair market value of Executive's interest in the Company. This value shall be communicated in writing to the representative, and the representative shall have thirty (30) days to accept or reject the valuation. If the valuation is rejected, the representative shall have no further rights to have the interest repurchased by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(h) Benefits.** The Executive shall be entitled to participate in Company benefit plans that are generally available to the Company's executive employees in accordance with and subject to the then existing terms and conditions of such plans; including but not limited to equity, pension, thrift, profit sharing, medical coverage, education, or other retirement or welfare benefits that the Company has adopted or may adopt, maintain or contribute to for the benefit of its executives at a level commensurate with the position, subject to satisfying any applicable eligibility requirements. For example, included in these executive benefits shall be:

&nbsp;&nbsp;&nbsp;&nbsp;(i) Automobile allowance: as determined by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) Life, long term disability, long term care insurance(s).

&nbsp;&nbsp;&nbsp;&nbsp;(iii) Other.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(i) Vacation/Paid time off.** The Executive shall be entitled to paid time off in accordance to Company policies applicable to its senior executives, to include Company paidholidays and no less than 20 days of paid vacation time per year in accordance with Company policies, which paid time off may be taken at such times as Executive elects with due regard to the needs of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(j)** **Perquisites.** The Company shall provide to Executive all perquisites which other senior executives of the Company are generally entitled to receive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(k) Business and Entertainment Expenses.** The Executive will be entitled to reimbursement of all reasonable expenses incurred in the ordinary course of business on behalf of the Company, subject to compliance with the Company's reimbursement policy then ineffect from time to time. All such reimbursements shall be made promptly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(I)** **Withholding.** The Company may withhold from compensation payable to the Executive all applicable federal, state and local withholding taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. Confidentiality; Intellectual Property.** The Executive agrees that during the Executive's employment with the Company, whether or not under this Agreement, and at all times thereafter:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** The Executive will not at any time, directly or indirectly, disclose or divulge any Confidential Information (as hereinafter defined), except as required in connection with the performance of the Executive's duties for the Company, and except to the extent required by law, subpoena or court order (but only after the Executive has provided the Company with reasonable notice and opportunity to take action against any legally required disclosure). As used herein, **"Confidential Information"** means all trade secrets and all other information of a business, financial, marketing, technical or other nature relating to the business of the Company including, without limitation, any customer or vendor lists, financial statements and projections, know-how, pricing policies, operational methods, methods of doing business, technical processes, formulae, designs and design projects, inventions, computer hardware, software programs, business plans and projects pertaining to the Company and including any information of others that the Company has agreed to keep confidential; <u>provided</u>, that Confidential Information shall not include any information that has entered or enters the public domain through no fault of the Executive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** The Executive shall make no use whatsoever, directly or indirectly, of any Confidential Information at any time, except as required in connection with the performance of the Executive's duties for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** Upon the Company's request at any time and for any reason, the Executive shall immediately deliver to the Company all materials (including all soft and hard copies) in the Executive's possession that contain or relate to Confidential Information and all other Company property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** All Developments made by the Executive, either alone or in conjunction with others, at any time or at any place during the Executive's employment with the Company, whether or not reduced to writing or practice during such period of employment, shall be and hereby are the exclusive property of the Company without any further compensation to the Executive. In addition, without limiting the generality of the prior sentence, all Developments which are copyrightable work by the Executive are intended to be "work made for hire" as defined in Section 101 of the Copyright Act of 1976, as amended, and shall be and hereby are the property of the Company. **"Developments"** means any and all inventions, modifications, discoveries, designs, developments, improvements, processes, software programs, works of authorship, documentation, formulae, data, techniques, know-how, secrets or intellectual property rights or any interest therein that (i) relate to the business in which the Company is engaged or in which the Company intends to engage during Executive's employment with the Company (as evidenced by meaningful efforts by the Company with respect thereto), (ii) are created or improved in whole or in part by using any Company resources, data, facilities or equipment, or (iii) are created or improved within the scope of Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** Within a reasonable time after the Executive becoming aware of any Developments, the Executive shall disclose the Developments to the Company. If any Development is not the property of the Company by operation of law, this Agreement or otherwise, the Executive will, and hereby does, assign to the Company all right, title and interest in such Development, without further consideration, and will assist the Company and its nominees in every reasonable way, at the Company's expense, to secure, maintain and defend the Company's rights in such Development; <u>provided</u>, however that following the termination of employment, the foregoing shall not be deemed to require the Executive to travel. The Executive shall sign all instruments necessary for the filing and prosecution of any applications for, or extension or renewals of, letters patent (or other intellectual property registrations or filings) of the United States or any foreign country which the Company desires to file and relates to any Development. The Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Executive's agent and attorney-in-fact (which designation and appointment shall be deemed coupled with an interest and shall survive the Executive's death or incapacity), to act for and in the Executive's behalf to execute and file any such applications, extensions or renewals and to do all other lawfully permitted acts to further the prosecution and issuance of such letters patent, other intellectual property registrations or filings or such other similar documents with the same legal force and effect as if executed by the Executive. Executive waives all claims to moral rights in the Developments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. Restrictive Covenants.** The Executive agrees that during the Executive's employment with the Company, whether or not under this Agreement, and thereafter for eighteen (18) months:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** the Executive will not, directly or indirectly, individually or as a consultant to, or an employee, officer, director, manager, stockholder, partner, member, investor, lender or other owner or participant in any business entity, other than the Company, engage in or assist any other person or entity to engage in any business which competes with any business in which the Company is engaging or in which the Company actively plans to engage (as evidenced by meaningful efforts by the Company with respect thereto), during or at the time of termination of the Executive's employment, anywhere in the United States or anywhere else in the world where the Company does business or actively plans to do business during the Executive's employment (as evidenced by meaningful efforts by the Company with respect thereto); <u>provided</u>, that, this Section 6(a) shall not prohibit the Executive from acquiring, solely as a passive investment, up to 1% of the securities of any publicly traded company whose activities may be in breach of the foregoing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** the Executive will not, directly or indirectly, (i) solicit in competition with the Company, divert or take away, or attempt to solicit in competition with the Company, divert or take away, the business or relationship of Company with any of its customers, clients, distributors, dealers, referral sources, business partners, suppliers, vendors, service providers, consultants, lenders, investors, landlords, licensors or attorneys or any other person or entity with whom the Company does business (collectively, **"Business Partners"),** or (ii) otherwise interfere with the Company's business relationship with any of its Business Partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** the Executive will not, directly or indirectly, solicit, recruit, hire or engage, or otherwise interfere with the business relationship of the Company with, any current or former employee of the Company, other than any person who ceased to be employed by the Company for a period of at least six (6) months; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** Nondisparagment. Neither Executive nor the Company (for purposes hereof, the Company shall mean the Company together with its executive officers and directors and not any other employees) shall make any public statements that disparage the other party, or in the case of the Company, its respective subsidiaries, affiliates, employees, officers, directors, products or services. Notwithstanding the foregoing, statements made in the course of sworn testimony in administrative, judicial or arbitral proceedings (including, without limitation, depositions in connection with such proceedings) shall not be subject to this Section 6(d).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** the Executive will not, directly or indirectly, intentionally assist any person or entity in performing any activity prohibited by Sections 6(a), 6(b), 6(c) or 6(d).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. Remedies.** Without limiting the remedies available to the Company, the Executive acknowledges that a breach of any of the covenants contained in Sections 5 or 6 herein could result in irreparable injury to the Company for which there might be no adequate remedy at law, and that, in the event of such a breach or threat thereof, the Company shall be entitled to obtain a temporary restraining order and/or a preliminary injunction and a permanent injunction restraining the Executive from engaging in any activities prohibited by Sections 5 or 6 herein or such other equitable relief as may be required to enforce specifically any of the covenants of Sections 5 or 6 herein. The Company shall also be entitled to recover from the Executive all reasonable attorneys' fees and costs incurred by it in connection with such breach. If Executive violates Section 6 of this Agreement, the temporal period applicable to that Section shall be extended by the period of time during which such violation occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. Applicability to Related Companies.** For purposes of Sections 5, 6 and 7 of this Agreement and the definitions of Cause and Good Reason, the term "Company" shall include the Company, each of its affiliated companies, subsidiaries and parent companies, whether now existing or hereinafter created, and their respective successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. Review of Agreement; Reasonable Restrictions.** The Executive (a) has carefully read and understands all of the provisions of this Agreement and has had the opportunity for this Agreement to be reviewed by counsel, (b) acknowledges that the duration, geographical scope and subject matter of Sections 5, 6 and 7 of this Agreement are reasonable and necessary to protect the goodwill, customer relationships, legitimate business interests and Confidential Information of the Company and its affiliates, and (c) will be able to earn a satisfactory livelihood without violating this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. Termination.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) General.** The Executive's employment with the Company may be terminated at any time by the Company with Cause or without Cause or in the event of the death or Disability of the Executive. The Executive's employment with the Company may also be terminated by the Executive for Good Reason or, after at least 60 days written notice, without Good Reason.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Definitions.** As used herein, the following terms shall have the following meanings:

**"Cause"** means that the Executive has (i) breached any fiduciary duty or material legal or contractual obligation that he has to the Company, which specific breach, if curable, is not cured within 20 days after written notice to the Executive thereof or, if cured, recurs in the 6-month period following such cure; (ii) intentionally and knowingly failed to follow any reasonable written directive of the Board which is otherwise consistent with the Executive's position and responsibilities, which specific failure, if curable, is not cured within 20 days after written notice to the Executive thereof or, if cured, recurs in the 6- month period following such cure; (iii) engaged in willful misconduct, willful violation of any law, fraud, embezzlement or material acts of dishonesty relating to the affairs of the Company; (iv) been convicted of or pleaded nolo contendere to any felony or other crime of moral turpitude; or (v) willfully and intentionally failed to comply with any material written Company rule, policy or procedure, which specific failure, if curable, is not cured within 20 days after written notice thereof or, if cured, recurs in the 6-month period following such cure.

**"Disability"** means illness (mental or physical) or accident of the Executive that results in the Executive being unable to perform the Executive's duties as an employee of the Company for a period of 180 days, whether or not consecutive, in any twelve-month period.

**"Good Reason"** means (i) a material breach by the Company of this Agreement or under any other material agreement entered into by and between the Company and the Executive; (ii) a material adverse change in Executive's title, duties or responsibilities, <u>provided</u> that any allocation of duties or responsibilities to another employee who reports to the [Chief Executive Officer] of the Company shall not constitute a basis for Executive to resign for Good Reason; or (iii) the relocation of the Executive (other than the Relocation), without the Executive's prior consent, by the Company to a work location more than 50 miles from the Executive's current work location (unless, as a result of such relocation, the Executive's work location is closer to his or her place of residence); <u>provided</u> that in each case, the Company shall have been given written notice from the Executive describing in reasonable detail the occurrence of the event or circumstance for which Executive believes he may resign for Good Reason within 30 days of the date that the Executive has knowledge of the first occurrence thereof and the Company shall not have cured such event or circumstance within 30 days after the Company's receipt of such notice.

**"Severance"** means (i) continuation of payments of Base Salary (at the rate in effect on the date of termination) for the Severance Period (as defined below), payable in accordance with the Company's regular payroll schedule; (ii) payment of a pro-rated amount of the Executive's Bonus (to the extent the financial and operating objectives for such Bonus have been achieved) for the fiscal year in which the termination occurs, which pro-rated amount shall be based upon the number of days Executive was employed with the Company during such year and shall be payable in accordance with Section 4(b); (iii) payments of the Company's and the Executive's share of the Executive's medical and dental and any other health-related insurance premiums in accordance with the terms of the then-existing Company benefit plans (but only to the extent the Executive is allowed by such benefit plans and by law to continue participating in such benefit plans) for the Severance Period. In order to be eligible for the payments under clause (iii) of the prior sentence, the Executive may need to elect for coverage under COBRA.

**"Severance Period"** means a period of 12 months from the date of termination of employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Effects of Termination.** If the Executive's employment is terminated during the term of this Agreement, the Company shall have no further obligation to make any payments or provide any benefits to the Executive hereunder after the date of termination except for (i) payments of Base Salary through the date of termination, accrued and unpaid Bonus, employee benefits and other employment perquisites, and expense reimbursement that had accrued but had not been paid prior to the date of termination, (ii) payments for any accrued but unused vacation time, and (iii) if the Executive's employment with the Company is terminated by the Company without Cause (other than as a result of death or Disability of the Executive) or by the Executive for Good Reason, payments of the Severance. Amounts due under Sections l0 (c)(i) and (ii) hereof shall be payable in accordance with the Company's regular payroll schedule or such earlier date as required by applicable law.

a) Disability. Upon such termination, the Company shall pay or provide Executive (i) any unpaid Base Salary through the date of termination and any accrued vacation in accordance with Company policy; (ii) any unpaid bonus earned with respect to any fiscal year ending on or preceding the date of termination; (iii) reimbursement for any unreimbursed expenses incurred through the date of termination; and (iv) all other payments, benefits or fringe benefits to which Executive may be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant or this Agreement (collectively, "Accrued Amounts").

b) Death. In the event the Employment Term ends on account of Executive's death, Executive's estate shall be entitled to any Accrued Amounts.

c) Termination for Cause or Without Good Reason. If Executive's employment should be terminated (i) by the Company for Cause, or (ii) by Executive without Good Reason, the Company shall pay to Executive any Accrued Amounts.

d) Termination Without Cause or for Good Reason. If Executive's employment by the Company is terminated by the Company other than for Cause (other than atermination for Disability) or by Executive for Good Reason, the Company shall pay or provide Executive with (i) Accrued Amounts; (ii) a pro-rata portion (determined by multiplying the amount Executive would have received had employment continued through the end of the performance year by a fraction, the numerator of which is the number of days during the performance year of termination that Executive is employed by the Company and the denominator of which is 365 of Executive's Annual Bonus for the performance year in which Executive's termination occurs at the time that annual bonuses are paid to other senior executives; provided that the Board determines that the Company was on plan for Executive to earn such bonus at the time of termination; (iii) continue his then current Base Salary as if his employment continued for a period of twelve (12) months from the date of termination, subject to the mitigation provisions set forth below; and (iv) subject to Executive's continued copayment of premiums, continued participation for twelve (12) months in all health and welfare plans which cover Executive (and eligible dependents) upon the same terms and conditions (except for the requirements of Executive's continued employment) in effect on the date of termination. If at any time after Executive's termination while the Company is obligated hereunder to make such payments of Base Salary or continue such benefits, Executive receives compensation for providing services as an employee or as an independent contractor from any person or entity, then Executive shall immediately notify the Company of such event and the Company's obligation to continue to make such payments to Executive shall be reduced by the gross amount of any such payments and the obligation to continue to provide benefits shall cease at such time as Executive is eligible for health insurance coverage by any successor employer or person or entity, prompt notice of which Executive shall furnish to the Company. Executive shall use good faith and reasonable efforts to find and secure new employment after any such termination. To the extent such coverage cannot be provided under the Company's health or welfare plans without jeopardizing the tax status of such plans, for underwriting reasons or because of the tax impact on Executive, the Company shall pay Executive an amount equal to the amount the Company would have paid for such benefits on behalf of Executive if the benefits were provided to him as an employee. The continuation of health benefits under this subsection shall reduce and count against Executive's rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA").

e) Amounts Payable. The Company reserves the right to set off against amounts payable to Executive hereunder any amounts owed by Executive to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Conditions and Limitations to Severance.** Notwithstanding the foregoing, the Company's obligation to make Severance payments to the Executive shall be subject to the following provisions and conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(i) Release of Claims.** The Company shall commence payment of Severance 30 days after the date of the Executive's termination of employment, <u>provided</u> that the Executive has signed and not revoked a general release and separation agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(ii) Consequences of Breach.** If the Executive materially breaches the Executive's obligations under Section 6 of this Agreement, which specific breach, if curable, is not cured within 20 days after written notice to the Executive thereof or, if cured, recurs in the 6-month period following such cure, the Company may immediately cease payments of Severance and may recover all Severance paid to the Executive after the date of such breach. The cessation and recovery of these payments shall be in addition to, and not as an alternative to, any other remedies at law or in equity available to the Company, including without limitation the right to seek specific performance or an injunction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. Survival.** The provisions of Sections 5 through 24 of this Agreement shall survive the term of this Agreement and the termination of the Executive's employment with the Company, and shall continue thereafter in full force and effect in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12. Enforceability.** This Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision hereof shall be prohibited or invalid under any such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating or nullifying the remainder of such provision or any other provisions of this Agreement. If any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, such provisions shall be construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13. Notices.** All notices, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered in person, by e-mail or fax, by United States mail, certified or registered with return receipt requested, or by a nationally recognized overnight courier service, or otherwise actually delivered: (a) if to the Executive, to the address set forth on the signature page hereof; (b) if to the Company, Chairman, Point Medical Inc., 665 Martinsville Road, Suite 219, Basking Ridge, NJ 07920, with copies (which shall not constitute notice) to CEO, Point Medical Inc. 665 Martinsville Road, Suite 219, Basking Ridge, NJ 07920; or (c) or at such other address as may have been furnished by such person in writing to the other parties. Any such notice, demand or communication shall be deemed given on the date given, if delivered in person, e-mailed or faxed, on the date received, if given by registered or certified mail, return receipt requested or given by overnight delivery service, or three days after the date mailed, if otherwise given by first class mail, postage prepaid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14. Severability.** The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15. Indemnification.** The Company hereby agrees to indemnify Executive and hold him harmless to the fullest extent permitted by law and under the bylaws of the Company against and in respect to any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorney's fees), losses, and damages resulting from Executive's good faith performance of his duties and obligations with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16. Governing Law; Consent to Jurisdiction.** This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its choice of law provisions. Any proceeding arising out of or relating to this Agreement shall be brought in the courts of the State of Delaware, or, if it has or can acquire jurisdiction, in the United States District Court for the District of Delaware. This provision may be filed with any court as written evidence of the knowing and voluntary irrevocable agreement between parties to waive any objections to jurisdiction, venue or convenience of forum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17. Arbitration.** Any dispute or controversy arising under or in connection with this Agreement shall be submitted to arbitration in accordance with the rules of the American Arbitration Association then in effect in Delaware before a panel of three (3) arbitrators who shall be knowledgeable in executive employment law, who shall be independent of, and have no ex parte communications with, the parties or their representatives, and who shall render written findings of fact, conclusions of law and order. In addition to any other inherent powers, arbitrators shall have the express powers to order a party to comply with or desist from breaching any of the terms of this Agreement. The determination of the arbitrators shall be final and binding upon the parties and may be entered as a final judgment in any court of competent jurisdiction. The parties shall equally share the costs of arbitration. Nothing herein, however, shall deprive a party of the right to seek equitable relief from the courts to restrain or enjoin the other from a breach this Agreement pending the empanelling of the arbitrators or their final determination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18. Amendments and Waivers.** This Agreement may be amended or modified only by a written instrument signed by the Company and the Executive. No waiver of this Agreement or any provision hereof shall be binding upon the party against whom enforcement of such waiver is sought unless it is made in writing and signed by or on behalf of such party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19. No Waivers.** The waiver of a breach of any provision of this Agreement shall not be construed as a waiver or a continuing waiver of the same or any subsequent breach of any provision of this Agreement. No delay or omission in exercising any right under this Agreement shall operate as a waiver of that or any other right.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20. Binding Effect.** This Agreement shall be binding on and inure to the benefit of the parties hereto and their respective heirs, executors and administrators, successors and assigns, except that the rights and obligations of the Executive here under are personal and may not be assigned without the Company's prior written consent. Any assignment of this Agreement by the Company shall not be considered a termination of the Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21. Entire Agreement.** This Agreement constitutes the final and entire agreement of the parties with respect to the matters covered hereby and replaces and supersedes all other agreements and understandings relating hereto and to the Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22. Counterparts.** This Agreement may be executed in any number of counterparts, including counterpart signature pages or counterpart facsimile signature pages, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23. No Conflicting Agreements.** The Executive represents and warrants to the Company that the Executive is not a party to or bound by any confidentiality, noncompetition, nonsolicitation, employment, consulting or other agreement or restriction that could conflict with, or be violated by, the performance of the Executive's duties to the Company or obligations under this Agreement. Executive will not use or misappropriate any intellectual property, trade secrets or confidential information belonging to former employers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24. Interpretation.** The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises under any provision of this Agreement, this Agreement shall be construed as if drafted jointly by the parties thereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authoring any of the provisions of this Agreement. The parties intend for this Agreement to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the**"Code"),** and all provisions of this Agreement will be interpreted and applied accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25. Notification of New Employer.** In the event that the Executive is no longer an employee of the Company, the Executive consents to notification by the Company to the Executive's new employer or its agents regarding the Executive's rights and obligations under Section 6 of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26. Reimbursement of Executive's Legal Expenses.** The Company shall upon presentation of an invoice promptly reimburse the Executive for legal expenses not to exceed $1,000 incurred in connection with the negotiation and drafting of this Agreement and other agreements entered into in connection herewith.

*[Remainder of this page intentionally left blank.]*

This Agreement has been executed and delivered as a sealed instrument as of the date first above written.

COMPANY

---

| | |
|:---|:---|
| By: | /s/ Jason Pottinger |
| Print Name: | Jason Pottinger |
| Title: | Director |

---

EXECUTIVE

---

| |
|:---|
| ![](ex10-1_001.jpg) |
| Address: |
| 1 Vanderveer Drive |
| Basking Ridge, NJ 07920 |

---

Exhibit A

To Employment Agreement

between Autism Diagnostic Technologies Inc. and Andrew Stewart

<u>Boards and Advisory Boards</u>

## Exhibit 10.2

**Exhibit 10.2**

**EMPLOYMENT AGREEMENT**

This Agreement (the **"Agreement"),** dated as of April 1, 2019, is by and between Autism Diagnostic Technologies, Inc. (the **"Company")** and Joerg Klaube (the **"Executive").**

**Introduction**

The Company desires to retain the services of the Executive pursuant to the terms and conditions set forth herein and the Executive wishes to be employed by the Company on such terms and conditions. The Executive will be a key employee of the Company, with significant access to information concerning the Company and its business. The disclosure or misuse of such information or the engaging in competitive activities by the Executive would cause substantial harm to the Company.

**Agreement**

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Effective Date; Term.** This Agreement shall become effective on April 1, 2019 (the **"Effective Date").**

Executive's term of employment under this Agreement (such term of employment, as it may be extended or terminated, is herein referred to as the "Employment Term") shall be for a term commencing on the Effective Date and, unless terminated earlier as provided in Section 10 hereof, ending on the third anniversary of the Effective Date (the "Original Employment Term"); provided that the Employment Term shall be automatically extended, subject to earlier termination as provided in Section 10 hereof, for successive additional one (1) year periods (the "Additional Terms"), unless, at least 30 days prior to the end of the Original Employment Term or the then Additional Term, the Company or Executive has notified the other in writing that the Employment Term shall terminate at the end of the then current term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Duties.** The Executive shall serve as the Chief Financial Officer (CFO) of the Company and shall have such duties of an executive nature as the Board shall determine from time to time which are customary and appropriate for the position of Chief Financial Officer, and for companies of similar size. The Executive will report to the Chief Executive Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Time; Best Efforts.** The Executive shall use his best efforts to promote the interests of the Company and shall devote a substantial part, sufficient to meet his responsibilities hereunder, of the Executive's business time, and invest best efforts to the performance of his duties and responsibilities hereunder. The Executive may engage in charitable, personal, business, or civic endeavors and may serve on the boards and advisory boards of the entities set forth on **<u>Exhibit</u>**<u>**A**</u>, so long as such activities do not interfere with the performance of the Executive's duties and responsibilities hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Compensation and Benefits.** During the Executive's employment with the Company under this Agreement, the Executive shall be entitled to compensation and benefits as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Base Salary.** The Executive will receive a salary at the rate of $50,000.00 annually (the **"Base Salary"**) until the Company has raised a minimum of $1 million in equity capital, after which time the Base Salary shall increase to $75,000.00 annually, payable in equal increments pursuant to the Company's normal payroll practices. The aforesaid shall be adjusted when Executive's duties require dedication of his full business time to the Company. The Board shall, in good faith, review the amount of the Executive's Base Salary and Bonus target on an annual basis. The amount of the Base Salary may not be decreased at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Annual Bonus.** The Executive will be eligible for an annual bonus as determined by the Board for each full fiscal (calendar) year based upon the Company achieving financial and operating objectives established annually for such fiscal year by the Board inconsultation with the Executive (the **"Bonus"**). The payment of Bonus for the 2019 year shall beprorated based upon the number of days of employment. The Board shall determine the amount of the Bonus, and such determination shall be binding and conclusive on the Executive, subject to the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Additional Bonuses.** In the sole discretion of the Board, the Executive may receive additional bonuses for extraordinary performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Equity Award.** Executive shall be entitled to participate in any Company Equity Incentive Plan (the "Stock Plan") that provides for the issuance of stock options to employees of the Company, to the extent determined by the Board of the Company. The Board shall award Executive as of the Effective Date, stock purchase warrants for one hundred thousand (100,000) shares of the Company's common stock, $0.00001 par value per share, exercisable during three years starting with the Vesting Date, at $0.50 per share, and carrying a cashless exercise option (the "Warrant Award"), which options shall be subject to certain restrictions. The Warrant Award shall vest in four (4) equal amounts, starting with 25% of the Warrant Award vesting upon the signing of this agreement, and 25% upon each of the first, second and third anniversaries of the Effective Date, provided that Executive is employed with the Company on each Vesting Date. The Warrant Award shall be granted pursuant to and shall be subject to all of the terms and conditions imposed upon such awards granted under the Stock Plan and shall be evidenced by a Warrant Certificate in the form approved by the Board or Committee. As a condition to receiving the Warrant Award, Executive shall become party to the Stockholders Agreement dated<u> </u>, as amended from time to time, by and among the Company and certain holders of the Company's securities, and, if requested, Executive shall also execute and deliver a letter in a form approved by the Company's underwriters agreeing not to sell any shares of Company common stock during a customary period following the completion of an initial public offering of the Company's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e) Change in Control.** Notwithstanding any other provision, in the event of a change in control, all equity awards (including, but not limited to, any options or stock grants made subsequent to the date of this Agreement) shall fully vest and be immediately exercisable. A change in control means the consummation after the date hereof of a transaction or series of related transactions that results in any person or group (other than any person or group owned by or affiliated with Point Medical Inc.) ("group" as defined in the rules and regulations promulgated under the Securities Exchange Act of 1934, as amended) acquiring (i) directly or indirectly by merger or otherwise more than 50% of the Company's securities entitled to vote in the election of directors, (ii) all or substantially all of the assets of the Company or (iii) the right to elect a majority of the members of the Company's Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(f) Option to Have Company Repurchase Options and Warrants.** If Executive dies while employed, the Company shall, subject to any restrictions contained in any credit or similar agreements or that exist under the Law, offer to purchase all of Executive's outstanding options or warrants which are vested at the time of death. If the representative of the Executive's estate wishes to accept such offer, he or she shall request, within six (6) months of death, that the Board determine the fair market value of Executive's interest in the Company. This value shall be communicated in writing to the representative, and the representative shall have thirty (30) days to accept or reject the valuation. If the valuation is rejected, the representative shall have no further rights to have the interest repurchased by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(g) Benefits.** The Executive shall be entitled to participate in Company benefit plans that are generally available to the Company's executive employees in accordance with and subject to the then existing terms and conditions of such plans; including but not limited to equity, pension, thrift, profit sharing, medical coverage, education, or other retirement or welfare benefits that the Company has adopted or may adopt, maintain or contribute to for the benefit of its executives at a level commensurate with the position, subject to satisfying any applicable eligibility requirements. For example, included in these executive benefits shall be:

(i) Automobile allowance: as determined by the Board.

(ii) Life, long term disability, long term care insurance(s).

(iii) Other.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(h) Vacation/Paid time off.** The Executive shall be entitled to paid time off in accordance to Company policies applicable to its senior executives, to include Company paid holidays and no less than 10 days of paid vacation time per year in accordance with Company policies, which paid time off may be taken at such times as Executive elects with due regard to the needs of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(i) Perquisites.** The Company shall provide to Executive all perquisites which other senior executives of the Company are generally entitled to receive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(j) Business and Entertainment Expenses.** The Executive will be entitled to reimbursement of all reasonable expenses incurred in the ordinary course of business on behalf of the Company, subject to compliance with the Company's reimbursement policy then ineffect from time to time. All such reimbursements shall be made promptly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(k) Withholding.** The Company may withhold from compensation payable to the Executive all applicable federal, state and local withholding taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. Confidentiality; Intellectual Property.** The Executive agrees that during the Executive's employment with the Company, whether or not under this Agreement, and at all times thereafter:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** The Executive will not at any time, directly or indirectly, disclose or divulge any Confidential Information (as hereinafter defined), except as required in connection with the performance of the Executive's duties for the Company, and except to the extent required by law, subpoena or court order (but only after the Executive has provided the Company with reasonable notice and opportunity to take action against any legally required disclosure). As used herein, **"Confidential Information"** means all trade secrets and all other information of a business, financial, marketing, technical or other nature relating to the business of the Company including, without limitation, any customer or vendor lists, financial statements and projections, know-how, pricing policies, operational methods, methods of doing business, technical processes, formulae, designs and design projects, inventions, computer hardware, software programs, business plans and projects pertaining to the Company and including any information of others that the Company has agreed to keep confidential; <u>provided,</u> that Confidential Information shall not include any information that has entered or enters the public domain through no fault of the Executive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** The Executive shall make no use whatsoever, directly or indirectly, of any Confidential Information at any time, except as required in connection with the performance of the Executive's duties for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** Upon the Company's request at any time and for any reason, the Executive shall immediately deliver to the Company all materials (including all soft and hard copies) in the Executive's possession that contain or relate to Confidential Information and all other Company property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** All Developments made by the Executive, either alone or in conjunction with others, at any time or at any place during the Executive's employment with the Company, whether or not reduced to writing or practice during such period of employment, shall be and hereby are the exclusive property of the Company without any further compensation to the Executive. In addition, without limiting the generality of the prior sentence, all Developments which are copyrightable work by the Executive are intended to be "work made for hire" as defined in Section 101 of the Copyright Act of 1976, as amended, and shall be and hereby are the property of the Company. **"Developments"** means any and all inventions, modifications, discoveries, designs, developments, improvements, processes, software programs, works of authorship, documentation, formulae, data, techniques, know-how, secrets or intellectual property rights or any interest therein that (i) relate to the business in which the Company is engaged or in which the Company intends to engage during Executive's employment with the Company (as evidenced by meaningful efforts by the Company with respect thereto), (ii) are created or improved in whole or in part by using any Company resources, data, facilities or equipment, or (iii) are created or improved within the scope of Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** Within a reasonable time after the Executive becoming aware of any Developments, the Executive shall disclose the Developments to the Company. If any Development is not the property of the Company by operation of law, this Agreement or otherwise, the Executive will, and hereby does, assign to the Company all right, title and interest in such Development, without further consideration, and will assist the Company and its nominees in every reasonable way, at the Company's expense, to secure, maintain and defend the Company's rights in such Development; <u>provided,</u> however that following the termination of employment, the foregoing shall not be deemed to require the Executive to travel. The Executive shall sign all instruments necessary for the filing and prosecution of any applications for, or extension or renewals of, letters patent (or other intellectual property registrations or filings) of the United States or any foreign country which the Company desires to file and relates to any Development. The Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Executive's agent and attorney-in-fact (which designation and appointment shall be deemed coupled with an interest and shall survive the Executive's death or incapacity), to act for and in the Executive's behalf to execute and file any such applications, extensions or renewals and to do all other lawfully permitted acts to further the prosecution and issuance of such letters patent, other intellectual property registrations or filings or such other similar documents with the same legal force and effect as if executed by the Executive. Executive waives all claims to moral rights in the Developments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. Restrictive Covenants.** The Executive agrees that during the Executive's employment with the Company, whether or not under this Agreement, and thereafter for eighteen (18) months:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** the Executive will not, directly or indirectly, individually or as a consultant to, or an employee, officer, director, manager, stockholder, partner, member, investor, lender or other owner or participant in any business entity, other than the Company, engage in or assist any other person or entity to engage in any business which competes with any business in which the Company is engaging or in which the Company actively plans to engage (as evidenced by meaningful efforts by the Company with respect thereto), during or at the time of termination of the Executive's employment, anywhere in the United States or anywhere else in the world where the Company does business or actively plans to do business during the Executive's employment (as evidenced by meaningful efforts by the Company with respect thereto); <u>provided,</u> that, this Section 6(a) shall not prohibit the Executive from acquiring, solely as a passive investment, up to 1% of the securities of any publicly traded company whose activities may be in breach of the foregoing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** the Executive will not, directly or indirectly, (i) solicit in competition with the Company, divert or take away, or attempt to solicit in competition with the Company, divert or take away, the business or relationship of Company with any of its customers, clients, distributors, dealers, referral sources, business partners, suppliers, vendors, service providers, consultants, lenders, investors, landlords, licensors or attorneys or any other person or entity with whom the Company does business (collectively, **"Business Partners"),** or (ii) otherwise interfere with the Company's business relationship with any of its Business Partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** the Executive will not, directly or indirectly, solicit, recruit, hire or engage, or otherwise interfere with the business relationship of the Company with, any current or former employee of the Company, other than any person who ceased to be employed by the Company for a period of at least six (6) months; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** Nondisparagment. Neither Executive nor the Company (for purposes hereof, the Company shall mean the Company together with its executive officers and directors and not any other employees) shall make any public statements that disparage the other party, or in the case of the Company, its respective subsidiaries, affiliates, employees, officers, directors, products or services. Notwithstanding the foregoing, statements made in the course of sworn testimony in administrative, judicial or arbitral proceedings (including, without limitation, depositions in connection with such proceedings) shall not be subject to this Section 6(d).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** the Executive will not, directly or indirectly, intentionally assist any person or entity in performing any activity prohibited by Sections 6(a), 6(b), 6(c) or 6(d).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. Remedies.** Without limiting the remedies available to the Company, the Executive acknowledges that a breach of any of the covenants contained in Sections 5 or 6 herein could result in irreparable injury to the Company for which there might be no adequate remedy at law, and that, in the event of such a breach or threat thereof, the Company shall be entitled to obtain a temporary restraining order and/or a preliminary injunction and a permanent injunction restraining the Executive from engaging in any activities prohibited by Sections 5 or 6 herein or such other equitable relief as may be required to enforce specifically any of the covenants of Sections 5 or 6 herein. The Company shall also be entitled to recover from the Executive all reasonable attorneys' fees and costs incurred by it in connection with such breach. If Executive violates Section 6 of this Agreement, the temporal period applicable to that Section shall be extended by the period of time during which such violation occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. Applicability to Related Companies.** For purposes of Sections 5, 6 and 7 of this Agreement and the definitions of Cause and Good Reason, the term "Company" shall include the Company, each of its affiliated companies, subsidiaries and parent companies, whether now existing or hereinafter created, and their respective successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. Review of Agreement; Reasonable Restrictions.** The Executive (a) has carefully read and understands all of the provisions of this Agreement and has had the opportunity for this Agreement to be reviewed by counsel, (b) acknowledges that the duration, geographical scope and subject matter of Sections 5, 6 and 7 of this Agreement are reasonable and necessary to protect the goodwill, customer relationships, legitimate business interests and Confidential Information of the Company and its affiliates, and (c) will be able to earn a satisfactory livelihood without violating this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **10. Termination.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) General.** The Executive's employment with the Company may be terminated at any time by the Company with Cause or without Cause or in the event of the death or Disability of the Executive. The Executive's employment with the Company may also be terminated by the Executive for Good Reason or, after at least 60 days written notice, without Good Reason.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Definitions.** As used herein, the following terms shall have the following meanings:

**"Cause"** means that the Executive has (i) breached any fiduciary duty or material legal or contractual obligation that he has to the Company, which specific breach, if curable, is not cured within 20 days after written notice to the Executive thereof or, if cured, recurs in the 6-month period following such cure; (ii) intentionally and knowingly failed to follow any reasonable written directive of the Board which is otherwise consistent with the Executive's position and responsibilities, which specific failure, if curable, is not cured within 20 days after written notice to the Executive thereof or, if cured, recurs in the 6-month period following such cure; (iii) engaged in willful misconduct, willful violation of any law, fraud, embezzlement or material acts of dishonesty relating to the affairs of the Company; (iv) been convicted of or pleaded nolo contendere to any felony or other crime of moral turpitude; or (v) willfully and intentionally failed to comply with any material written Company rule, policy or procedure, which specific failure, if curable, is not cured within 20 days after written notice thereof or, if cured, recurs in the 6-month period following such cure.

**"Disability"** means illness (mental or physical) or accident of the Executive that results in the Executive being unable to perform the Executive's duties as an employee of the Company for a period of 180 days, whether or not consecutive, in any twelve-month period.

**"Good Reason"** means (i) a material breach by the Company of this Agreement or under any other material agreement entered into by and between the Company and the Executive; (ii) a material adverse change in Executive's title, duties or responsibilities, <u>provided</u> that any allocation of duties or responsibilities to another employee who reports to the [Chief Executive Officer] of the Company shall not constitute a basis for Executive to resign for Good Reason; or (iii) the relocation of the Executive (other than the Relocation), without the Executive's prior consent, by the Company to a work location more than 50 miles from the Executive's current work location (unless, as a result of such relocation, the Executive's work location is closer to his or her place of residence); <u>provided</u> that in each case, the Company shall have been given written notice from the Executive describing in reasonable detail the occurrence of the event or circumstance for which Executive believes he may resign for Good Reason within 30 days of the date that the Executive has knowledge of the first occurrence thereof and the Company shall not have cured such event or circumstance within 30 days after the Company's receipt of such notice.

**"Severance"** means (i) continuation of payments of Base Salary (at the rate in effect on the date of termination) for the Severance Period (as defined below), payable in accordance with the Company's regular payroll schedule; (ii) payment of a pro-rated amount of the Executive's Bonus (to the extent the financial and operating objectives for such Bonus have been achieved) for the fiscal year in which the termination occurs, which pro-rated amount shall be based upon the number of days Executive was employed with the Company during such year and shall be payable in accordance with Section 4(b); (iii) payments of the Company's and the Executive's share of the Executive's medical and dental and any other health-related insurance premiums in accordance with the terms of the then-existing Company benefit plans (but only to the extent the Executive is allowed by such benefit plans and by law to continue participating in such benefit plans) for the Severance Period. In order to be eligible for the payments under clause (iii) of the prior sentence, the Executive may need to elect for coverage under COBRA.

**"Severance Period"** means a period of 12 months from the date of termination of employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Effects of Termination. If** the Executive's employment is terminated during the term of this Agreement, the Company shall have no further obligation to make any payments or provide any benefits to the Executive hereunder after the date of termination except for (i) payments of Base Salary through the date of termination, accrued and unpaid Bonus, employee benefits and other employment perquisites, and expense reimbursement that had accrued but had not been paid prior to the date of termination, (ii) payments for any accrued but unused vacation time, and (iii) if the Executive's employment with the Company is terminated by the Company without Cause (other than as a result of death or Disability of the Executive) or by the Executive for Good Reason, payments of the Severance. Amounts due under Sections 10 (c)(i) and (ii) hereof shall be payable in accordance with the Company's regular payroll schedule or such earlier date as required by applicable law.

a) Disability. Upon such termination, the Company shall pay or provide Executive (i) any unpaid Base Salary through the date of termination and any accrued vacation in accordance with Company policy; (ii) any unpaid bonus earned with respect to any fiscal year ending on or preceding the date of termination; (iii) reimbursement for any unreimbursed expenses incurred through the date of termination; and (iv) all other payments, benefits or fringe benefits to which Executive may be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant or this Agreement (collectively, "Accrued Amounts").

b) Death. In the event the Employment Term ends on account of Executive's death, Executive's estate shall be entitled to any Accrued Amounts.

c) Termination for Cause or Without Good Reason. If Executive's employment should be terminated (i) by the Company for Cause, or (ii) by Executive without Good Reason, the Company shall pay to Executive any Accrued Amounts.

d) Termination Without Cause or for Good Reason. If Executive's employment by the Company is terminated by the Company other than for Cause (other than atermination for Disability) or by Executive for Good Reason, the Company shall pay or provide Executive with (i) Accrued Amounts; (ii) a pro-rata portion (determined by multiplying the amount Executive would have received had employment continued through the end of the performance year by a fraction, the numerator of which is the number of days during the performance year of termination that Executive is employed by the Company and the denominator of which is 365 of Executive's Annual Bonus for the performance year in which Executive's termination occurs at the time that annual bonuses are paid to other senior executives; provided that the Board determines that the Company was on plan for Executive to earn such bonus at the time of termination; (iii) continue his then current Base Salary as if his employment continued for a period of twelve (12) months from the date of termination, subject to the mitigation provisions set forth below; and (iv) subject to Executive's continued copayment of premiums, continued participation for twelve (12) months in all health and welfare plans which cover Executive (and eligible dependents) upon the same terms and conditions (except for the requirements of Executive's continued employment) in effect on the date of termination. If at any time after Executive's termination while the Company is obligated hereunder to make such payments of Base Salary or continue such benefits, Executive receives compensation for providing services as an employee or as an independent contractor from any person or entity, then Executive shall immediately notify the Company of such event and the Company's obligation to continue to make such payments to Executive shall be reduced by the gross amount of any such payments and the obligation to continue to provide benefits shall cease at such time as Executive is eligible for health insurance coverage by any successor employer or person or entity, prompt notice of which Executive shall furnish to the Company. Executive shall use good faith and reasonable efforts to find and secure new employment after any such termination. To the extent such coverage cannot be provided under the Company's health or welfare plans without jeopardizing the tax status of such plans, for underwriting reasons or because of the tax impact on Executive, the Company shall pay Executive an amount equal to the amount the Company would have paid for such benefits on behalf of Executive if the benefits were provided to him as an employee. The continuation of health benefits under this subsection shall reduce and count against Executive's rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA").

e) Amounts Payable. The Company reserves the right to set off against amounts payable to Executive hereunder any amounts owed by Executive to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Conditions and Limitations to Severance.** Notwithstanding the foregoing, the Company's obligation to make Severance payments to the Executive shall be subject to the following provisions and conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(i) Release of Claims.** The Company shall commence payment of Severance 30 days after the date of the Executive's termination of employment, <u>provided</u> that the Executive has signed and not revoked a general release and separation agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(ii) Consequences of Breach.** If the Executive materially breaches the Executive's obligations under Section 6 of this Agreement, which specific breach, if curable, is not cured within 20 days after written notice to the Executive thereof or, if cured, recurs in the 6-month period following such cure, the Company may immediately cease payments of Severance and may recover all Severance paid to the Executive after the date of such breach. The cessation and recovery of these payments shall be in addition to, and not as an alternative to, any other remedies at law or in equity available to the Company, including without limitation the right to seek specific performance or an injunction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. Survival.** The provisions of Sections 5 through 24 of this Agreement shall survive the term of this Agreement and the termination of the Executive's employment with the Company, and shall continue thereafter in full force and effect in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12. Enforceability.** This Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision hereof shall be prohibited or invalid under any such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating or nullifying the remainder of such provision or any other provisions of this Agreement. If any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, such provisions shall be construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13. Notices.** All notices, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered in person, by e-mail or fax, by United States mail, certified or registered with return receipt requested, or by a nationally recognized overnight courier service, or otherwise actually delivered: (a) if to the Executive, to the address set forth on the signature page hereof; (b) if to the Company, Chairman, Point Medical Inc., 665 Martinsville Road, Suite 219, Basking Ridge, NJ 07920, with copies (which shall not constitute notice) to CEO, Point Medical Inc. 665 Martinsville Road, Suite 219, Basking Ridge, NJ 07920; or (c) or at such other address as may have been furnished by such person in writing to the other parties. Any such notice, demand or communication shall be deemed given on the date given, if delivered in person, e-mailed or faxed, on the date received, if given by registered or certified mail, return receipt requested or given by overnight delivery service, or three days after the date mailed, if otherwise given by first class mail, postage prepaid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14. Severability.** The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15. Indemnification.** The Company hereby agrees to indemnify Executive and hold him harmless to the fullest extent permitted by law and under the bylaws of the Company against and in respect to any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorney's fees), losses, and damages resulting from Executive's good faith performance of his duties and obligations with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16. Governing Law; Consent to Jurisdiction.** This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its choice of law provisions. Any proceeding arising out of or relating to this Agreement shall be brought in the courts of the State of Delaware, or, if it has or can acquire jurisdiction, in the United States District Court for the District of Delaware. This provision may be filed with any court as written evidence of the knowing and voluntary irrevocable agreement between parties to waive any objections to jurisdiction, venue or convenience of forum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17. Arbitration.** Any dispute or controversy arising under or in connection with this Agreement shall be submitted to arbitration in accordance with the rules of the American Arbitration Association then in effect in Delaware before a panel of three (3) arbitrators who shall be knowledgeable in executive employment law, who shall be independent of, and have no ex parte communications with, the parties or their representatives, and who shall render written findings of fact, conclusions of law and order. In addition to any other inherent powers, arbitrators shall have the express powers to order a party to comply with or desist from breaching any of the terms of this Agreement. The determination of the arbitrators shall be final and binding upon the parties and may be entered as a final judgment in any court of competent jurisdiction. The parties shall equally share the costs of arbitration. Nothing herein, however, shall deprive a party of the right to seek equitable relief from the courts to restrain or enjoin the other from a breach this Agreement pending the empanelling of the arbitrators or their final determination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18. Amendments and Waivers.** This Agreement may be amended or modified only by a written instrument signed by the Company and the Executive. No waiver of this Agreement or any provision hereof shall be binding upon the party against whom enforcement of such waiver is sought unless it is made in writing and signed by or on behalf of such party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19. No Waivers.** The waiver of a breach of any provision of this Agreement shall not be construed as a waiver or a continuing waiver of the same or any subsequent breach of any provision of this Agreement. No delay or omission in exercising any right under this Agreement shall operate as a waiver of that or any other right.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20. Binding Effect.** This Agreement shall be binding on and inure to the benefit of the parties hereto and their respective heirs, executors and administrators, successors and assigns, except that the rights and obligations of the Executive hereunder are personal and may not be assigned without the Company's prior written consent. Any assignment of this Agreement by the Company shall not be considered a termination of the Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21. Entire Agreement.** This Agreement constitutes the final and entire agreement of the parties with respect to the matters covered hereby and replaces and supersedes all other agreements and understandings relating hereto and to the Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22. Counterparts.** This Agreement may be executed in any number of counterparts, including counterpart signature pages or counterpart facsimile signature pages, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23. No Conflicting Agreements.** The Executive represents and warrants to the Company that the Executive is not a party to or bound by any confidentiality, noncompetition, non-solicitation, employment, consulting or other agreement or restriction that could conflict with, or be violated by, the performance of the Executive's duties to the Company or obligations under this Agreement. Executive will not use or misappropriate any intellectual property, trade secrets or confidential information belonging to former employers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24. Interpretation.** The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises under any provision of this Agreement, this Agreement shall be construed as if drafted jointly by the parties thereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authoring any of the provisions of this Agreement. The parties intend for this Agreement to comply with Section 409A of the Internal Revenue Code of 1986, as amended **(the "Code"),** and all provisions of this Agreement will be interpreted and applied accordingly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25. Notification of New Employer.** In the event that the Executive is no longer an employee of the Company, the Executive consents to notification by the Company to the Executive's new employer or its agents regarding the Executive's rights and obligations under Section 6 of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26. Reimbursement of Executive's Legal Expenses.** The Company shall upon presentation of an invoice promptly reimburse the Executive for legal expenses not to exceed $1,000 incurred in connection with the negotiation and drafting of this Agreement and other agreements entered into in connection herewith.

[Remainder of this page intentionally left blank.]

 

This Agreement has been executed and delivered as a sealed instrument as of the date first above written.

---

| | |
|:---|:---|
| COMPANY | COMPANY |
| By: | /s/ Jason Pottinger |
| Print Name: | Jason Pottinger |
| Title: | Director |
| EXECUTIVE | EXECUTIVE |
| ![](ex10-2_001.jpg) | ![](ex10-2_001.jpg) |
| Address: | Address: |
| 125 Douglas Rd, | 125 Douglas Rd, |
| Brick, NJ 08723 | Brick, NJ 08723 |

---

Exhibit A

To Employment Agreement

between Autism Diagnostic Technologies Inc. and Joerg Klaube

<u>Boards and Advisory Boards</u>

## Exhibit 10.3

**Exhibit 10.3**

**Rental Agreement**

This agreement is entered into between Retrieve Medical Inc. ("Retrieve") and NeuroSpectrum Insights, Inc. ("NeuroSpectrum") effective on April 1, 2024.

The parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. Retrieve shall provide suitable office space and use of conference facilities in the premises presently leased by Retrieve at 376
Main Street, Bedminster, NJ, at the price of $2,000 per month.

&nbsp;&nbsp;&nbsp;&nbsp;2. The office space rented to NeuroSpectrum shall be referred to as Suite 105 at the above address.

&nbsp;&nbsp;&nbsp;&nbsp;3. This rental agreement is a month-to-month arrangement.

---

| | | | |
|:---|:---|:---|:---|
| RETRIEVE MEDICAL INC. | RETRIEVE MEDICAL INC. | NEUROSPECTRUM INSIGHTS, INC. | NEUROSPECTRUM INSIGHTS, INC. |
| By: | /s/ Jerry Swon | By: | /s/ Andrew Stewart |
|  | Jerry Swon, CEO |  | Andrew Stewart, CEO |

---

## Exhibit 10.4

**Exhibit 10.4**

**EXCLUSIVE AGREEMENT**

This exclusive license agreement **("Agreement")** is dated and effective as of the date of last signature (the **"Effective Date")** and is made by and between University of Louisville Research Foundation, Inc. **("ULRF")**, a Kentucky 501(c)3 non-profit corporation having an office at 300 East Market Street, Suite 300, Louisville, Kentucky, 40202, as the agent of the University of Louisville **("UofL")** for licensing intellectual property owned and controlled by ULRF on behalf of UofL and Autism Diagnostic Technologies, Inc. **("Licensee")**, a Delaware corporation with a principal place of business at 10422 Monticello Hill Drive, Katy, Texas, 77494. ULRF and Licensee are referred to herein, on occasion, separately as a **"Party"** or together as the **"Parties"**.

**BACKGROUND**

1. ULRF was established by UofL to enter into and administer research
agreements with external funding sources and to own, control, and license intellectual property on behalf of UofL in order to foster
the transfer and development of technology for public benefit.

2. Certain innovations relating to systems, methods and computer program products for classifying a brain,
as described in ULRF Case Nos. 11064, 12063, 13098 and 13011 (collectively, the **"Technology"),** was/were developed during
the course of research conducted at UofL by the individuals hereinafter listed in Section 1.5 **("Creators").** 

3. ULRF has acquired through assignment of all rights, title and interest of the Creators in the Technology
and the related Licensed Patents and Licensed Copyrights, as hereinafter defined.

4. The Parties have entered into a mutual confidentiality agreement effective August 5, 2016 (ULRF Ref. 17037-NDA)
hereinafter the **"Confidentiality Agreement",** for the purpose of allowing ULRF and Licensee to evaluate their respective
interests in entering into this Agreement with respect to the Technology.

5. Licensee has provided ULRF with a commercialization plan for the Technology in order to allow ULRF to
evaluate Licensee's capabilities.

6. Development of the Technology was sponsored in part by the Wallace H. Coulter Foundation's Translational
Research Partnership Program (ULRF Ref. OGMB110749Al) and, as a consequence, this Agreement is subject to certain obligations under the
sponsorship agreement.

7. Development of the Technology was also sponsored in part by the Kentucky Science and Technology Corporation
(KSTC) under Kentucky Commercialization Fund Award Agreement No. KSTC-144-401-13-061 (ULRF Ref. OGMB130263) and, as a consequence, this
Agreement is subject to certain obligations under the sponsorship agreement.

8. ULRF and Licensee desire to have the Technology developed and commercialized so that products and services
resulting therefrom may be available for public use and benefit.

9. Licensee desires to acquire, and ULRF desires to grant, a license under the Licensed Patents to make,
use, sell, offer for sale, and import products, methods, and services in accordance with the terms herein.

Page 1 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

Now, therefore, the Parties agree as follows:

1. DEFINITIONS

1.1 **"Affiliate"** of Licensee (or of a Sublicensee, respectively) means any entity that,
as of the applicable point in time during the term of this Agreement, directly or indirectly controls Licensee (or a Sublicensee, respectively),
is controlled by Licensee (or a Sublicensee, respectively), or is under common control with Licensee (or a Sublicensee, respectively).
For purposes of this definition, "control" means (a) having the actual, present capacity to elect a majority of the directors
of such entity, or (b) having the power to direct at least fifty percent (50%) of the voting rights entitled to elect directors of such
entity.

1.2 **"Change of Control"** means (a) the sale of all or substantially all the assets of a
Party; (b) any merger, consolidation or acquisition of a Party with, by or into another corporation, entity or person; or (c) any change
in the ownership of more than fifty percent (50%) of the voting capital stock of a Party in one or more related transactions.

1.3 **"Field of Use"** means the field of analyzing images of a brain to assess neurological
conditions.

1.4 **"Funds"** means all funds received by Licensee during the term of this Agreement, including
but not limited to any grants, awards, payments in consideration for the issuance of equity or debt securities of Licensee, Net Sales,
Sublicensing Income, or other amounts from any and all sources whatsoever.

1.5 **"Creators"** means: Manuel F. Casanova, M.D., Ayman S. El-Baz, Ph.D., Matthew Nitzken,
Ph.D., and Ahmed Soliman.

1.6 **"Licensed Copyrights"** means the software, computer programs, documentation, algorithms,
or other materials subject to copyright protection listed in Exhibit A, and Modifications thereto developed during the term of this Agreement
and provided to Licensee by UofL or ULRF.

1.7 **"Licensed Patents"** means:
(a) the United States and foreign patents and/or patent applications identified in Exhibit A; (b) any and all patents issuing from the
foregoing; (c) any and all claims of continuation-in-part applications that claim priority to the United States patent applications identified
in Exhibit A, but only where such claims are directed to inventions disclosed in the manner provided in 35 U.S.C. § 112(a) in the
United States patent applications identified in Exhibit A, and such claims in any patents issuing from such continuation-in-part applications;
(d) any and all foreign patent applications, foreign patents or related foreign patent documents that claim priority to the patents and/or
patent applications identified in Exhibit A; and (e) any and all divisionals, continuations, reissues, reexaminations, renewals, substitutions,
and extensions of the foregoing. Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be invalid
by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken.

1.8 **"Licensed Product"** means any method, process,
composition, product, service, or component part thereof that would, the making, use, Sale, offer for Sale, or import of which, absent
the rights granted pursuant to this Agreement, infringes, induces infringement, or contributes to infringement of a Licensed Patent or
a Licensed Copyright.

1.9 **"Licensed Rights"** means all rights granted
to Licensee under Article 2 (Grant of Rights) of this Agreement.

1.10 **"Licensed Technology"** means the Licensed
Patents and Licensed Copyrights identified in Exhibit A.

1.11 **"License Year"** means a year in which this
Agreement is in effect. The first License Year will begin on the Effective Date and run until December 31 of the same calendar year.
Thereafter, each subsequent License Year will mean each subsequent calendar year, beginning January 1 and ending December 31, provided
that the final License Year will end on the date of expiration or termination of this Agreement.

1.12 **"Modifications"** means changes or extensions
introduced into a Licensed Copyright, which include, but are not limited to, corrections of programs errors, translations, and stylistic
restructuring of software, addition or deletion of functions or enhancement of existing functions of a Licensed Copyright, changes or
additions required to integrate software into other applications or to allow software to run under alternative operating systems or computer
hardware configurations, and other adaptations of the software.

Page 2 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

1.13 **"Net Sales"** means the gross amount of any
payments, and the fair market value of any non-cash consideration, received by Licensee, Affiliates or Sublicensees for the use, Sale
or other transfer of Licensed Products, less (a) discounts or rebates actually allowed from billed amounts, (b) credits or allowances
actually allowed upon claims or returns, and (c) taxes or other government charges included in amounts billed. However, in no case will
Net Sales be less than ninety percent (90%) of the gross amounts received in connection with Sales.

1.14 **"Non-Royalty Sublicensing Income"** means the
gross amount of any payments, and the fair market value of all other consideration, received by Licensee for the grant of rights under
a Sublicense, excluding payments made to Licensee as a royalty based on Sales by the Sublicensee.

1.15 **"Sale"** means the act of selling, leasing,
or otherwise transferring or providing Licensed Products for any consideration. Correspondingly, **"Sell"** means to make
or cause to be made a Sale, and **"Sold"** means to have made or cause to be made a Sale.

1.16 **"Sublicense"** means the grant by Licensee
to any third party of any license, option, first right to negotiate, or other right granted under the Licensed Rights, in whole or in
part.

1.17 **"Sublicensee"** means any third party to whom
Licensee has granted a Sublicense.

2. GRANT OF RIGHTS

2.1 **Patent License.** Subject to Licensee's compliance
with the terms and conditions of this Agreement, ULRF hereby grants to Licensee an exclusive, worldwide license under the Licensed Patents
in the Field of Use to make, have made, use, offer for Sale, import, and Sell Licensed Products. Unless otherwise terminated pursuant
to Article 15 (Termination), the term of this patent license will begin on the Effective Date and continue until the expiration of the
last to expire Licensed Patents.

2.2 **Copyright License.** Subject to Licensee's compliance
with the terms and conditions of this Agreement, ULRF hereby grants to Licensee an exclusive, worldwide license to reproduce, display,
perform, distribute and create derivative works of Licensed Copyrights in the Field of Use. Unless this Agreement is otherwise terminated
pursuant to Article 15 (Termination), the term of this copyright license will begin on the Effective Date and will expire upon the latter
to occur of: (a) the 20 year anniversary of the Effective Date, or (b) the expiration of the last to expire Licensed Patents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Transfer.** ULRF will provide Licensee access to the Licensed
Copyright materials by internet transmission (email or ftp), CD-ROM, DVD or other expeditious means within 30 business days after the
Effective Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Grant Forward.** ULRF hereby grants to Licensee a license

the authors of the Licensed Copyrights which are based on the Licensed Copyrights and assigned to ULRF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Grant Back.** Any

to Licensee in the Field of Use and under the same terms and conditions as the Licensed Copyrights. Licensee will deliver to ULRF at
least once per License Year a current copy of the source code and a current copy of the object code (in machine-readable form) for any
derivative work based on the Licensed Copyrights. Upon termination of this Agreement for any reason, Licensee will assign to ULRF the full
copyright rights to any and all such derivative works.

Page 3 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

2.3 **Retained Rights.** ULRF reserves the right, on behalf of
itself and UofL, to do any one or more of the following: (a) publish any information resulting from research relating to the Technology;
(b) practice the Licensed Rights for any not-for-profit purposes, including education, research, teaching, and public service; (c) make,
use, and import the Technology and associated technology for educational and research purposes; and (d) allow other non-profit academic
research institutions to do any one or more of the activities of the preceding clauses (a), (b), and (c) of this Section for educational
and research purposes.

2.4 **Government Rights.** It is understood that if the United
States Government (through any of its agencies or otherwise) has funded research, during the course of or under which any inventions
of the Licensed Patents were conceived or made, the United States Government is entitled, as a right, under the provisions of 35 U.S.C.
§§ 200-212 and applicable regulations of Chapter 37 of the Code of Federal Regulations, to a nonexclusive, nontransferable,
irrevocable, paid-up license to practice or have practiced the invention of such Licensed Patents for governmental purposes. These provisions
also impose the obligation that Licensed Products Sold or produced in the United States be "manufactured substantially in the United
States." Licensee will ensure that all obligations under these provisions are met.

2.6 **Specific Exclusions.** Nothing in this Agreement is or
will be construed as: (a) conferring to Licensee by implication, estoppel, or otherwise any license or rights under any patent applications,
patents or copyrights of ULRF other than the rights expressly granted it in this Agreement under the Licensed Rights; or (b) an obligation
to furnish to Licensee any know-how not provided in the Licensed Patents or Licensed Copyrights.

3. SUBLICENSING

3.1 **Permitted Sublicensing.** Subject to the requirements of
Section 3.3 and for so long as Licensee remains in good standing with all terms and conditions of this Agreement, Licensee may grant
Sublicenses in the Field of Use. For purposes of this Agreement, the operations of any Sublicensee under their respective Sublicense
will be deemed to be the operations of Licensee, for which Licensee will be responsible. Affiliates will have no licenses under the Licensed
Rights except as granted by Licensee in a Sublicense.

3.2 Required Sublicensing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that ULRF and Licensee each own an undivided interest
in any Licensed Patent (a **"Jointly Owned Licensed Patent"),** Licensee will not attempt to separately grant a license
to any third party under its rights in such Jointly Owned Licensed Patent without concurrently granting a Sublicense under ULRF's
rights in the same.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If Licensee licenses patent rights assigned to or otherwise acquired by it **("Licensee's Patent Rights"),** and it believes, in good faith, that the recipient of such license will infringe Licensed Patents in practicing
Licensee's Patent Rights, then Licensee will not separately grant a license to such recipient under Licensee's Patent Rights
without concurrently granting a Sublicense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If Licensee is unable or unwilling to develop potential Licensed Products or to serve a market territory
for which there is an organization willing to be a Sublicensee, Licensee will, at ULRF' s request, negotiate in good faith a Sublicense
with any such potential Sublicensee.

3.3 **Sublicense Requirements.** Any Sublicense: (a) is subject to this Agreement, (b) will not permit
the grant of further sublicenses by the Sublicensee, and (c) will, as a condition of validity, expressly include the provisions of Articles
7, 8 and 10 for the benefit of ULRF and UofL.

3.4 **Notice and Copy of Sublicense.** Within thirty (30) days of execution of each Sublicense, or amendment
thereof, Licensee will notify ULRF of such executed Sublicense or amendment and provide to ULRF an unredacted copy of such Sublicense
or amendment.

3.5 **License Termination.** Upon termination of this Agreement for any reason, all Sublicenses will automatically
terminate, unless ULRF, at its sole discretion, agrees in writing to an assignment to ULRF of any Sublicense. In the event of termination
of this Agreement and if ULRF accepts assignment of any Sublicense, ULRF will not be bound by any grant of rights broader than, and will
not be required to perform any obligation other than, those rights and obligations contained in this Agreement. ULRF will have the sole
right to modify each such assigned Sublicense to include all of the rights of ULRF contained in this Agreement.

Page 4 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

4. DILIGENCE

4.1 **Best Efforts by Licensee.** Licensee will use best efforts to effect introduction of Licensed Products
into the commercial market as soon as possible; thereafter, and until the expiration or tennination of this Agreement, Licensee will keep
Licensed Products reasonably available to the public.

4.2 **Milestones.** In addition to Licensee's obligations under Section 4.1, Licensee will accomplish
the diligence milestones **("Milestones")** set forth in Exhibit C. Licensee agrees that said Milestones are reasonable
and that it will take all reasonable steps to meet its diligence obligations.

4.3 Licensee's failure to perform in accordance with Sections 4.1 or 4.2 will be grounds for ULRF to
terminate this Agreement pursuant to Section 15.3.

5. PAYMENTS AND ACCOUNTING

5.1 **Equity Issuance.** In partial consideration for the rights granted herein, and in accordance with
the Stock Issuance Agreement entered into in conjunction herewith between Licensee and ULRF (attached hereto as Exhibit D), Licensee will
issue to ULRF and to the Inventors, as designees of ULRF, that number of shares of common stock of Licensee that constitute eight percent
(8.0%) total equity on the date of issuance. Total equity will be calculated as the total number of issued and outstanding shares assuming:
(i) the conversion of all issued and outstanding securities into stock; (ii) the exercise of all issued and outstanding warrants or options;
and (iii) the issuance, grant and exercise of all securities reserved for issuance pursuant to any stock option plan then in effect. Licensee
agrees to provide ULRF with a copy of its capitalization table and its bylaws within forty-five (45) days of the Effective Date, as well
as to provide any additional requested information regarding its capitalization to support the share calculation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Licensee acknowledges that in accordance with UotL's Intellectual
Property Policy, certain individuals are to receive a portion of the common stock received as consideration hereunder. Licensee will
issue the shares granted to ULRF under Section 5.1 directly in the names of the individuals and/or entities and in the proportions as
set forth in the Stock Issuance Agreement attached hereto as Exhibit D.

5.2 **Fees and Royalties.** As additional consideration for the rights granted herein, Licensee will pay
to ULRF the fees, royalties and other amounts specified in Exhibit B, and will reimburse ULRF for costs incurred in connection with the
Licensed Patents and Licensed Copyrights as provided in Article 9.

5.3 **Payment Procedures.** All payments due to ULRF will be made in United States currency preferably
by electronic file transfer (EFT), e.g., ACH, wire or book transfer. Bank information will be provided upon request. Alternatively, payments
due to ULRF hereunder may be made by check or money order payable to "University of Louisville Research Foundation, Inc."
with reference to tax identification number 61-1029626, and remitted to the address for ULRF specified in Section 14.1. Licensee or its
Sublicensees will be responsible for payments of any fees associated with the transfer or other delivery of amounts payable to ULRF hereunder.

Page 5 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

5.4 **Calculation and Payment of Royalties.** When Licensed Products are Sold for monies other than United
States dollars, Royalties will first be determined in the foreign currency of the country in which the Sale was made and then converted
into equivalent United States dollars. The exchange rate will be that rate quoted in the Wall Street Journal on the last business day
of the reporting period. Royalties will be paid to the ULRF free and clear of all foreign taxes. If any Licensed Patent, or any claim
thereof, expires or is held invalid by a final decision of a court of competent jurisdiction from which no appeal can be or is taken,
all obligations to pay Royalties based on such Licensed Patent, or claim, will cease as of the date of such expiration or final decision.
Licensee will not, however, be relieved from paying any Royalties that accrued before such expiration or final decision or that are based
on another Licensed Patent, or claim within any Licensed Patent, which is not expired, or which is not held invalid or unpatentable
in such final decision.

5.5 **Books and Records.** Licensee will keep full, true, and accurate books of accounts containing all
particulars that may be necessary for the purpose of showing (a) the amount of Royalties payable to ULRF, and (b) Licensee's compliance
with obligations under this Agreement. For six (6) years following the end of the calendar year to which they pertain, said books and
the supporting data will be open, during normal business hours upon reasonable notice, to inspection and audit by an independent certified
public accountant as well as an internal ULRF auditor for purposes of verifying Licensee's Development and Royalty Reports under
Article 6 and compliance in other respects with this Agreement. Such representatives will be required to hold all information in confidence
except as necessary to communicate Licensee's non-compliance with this Agreement to ULRF. The fees and expenses of the representatives
performing such an examination will be borne by ULRF, provided that if an error in underpaid Royalties or other payments to ULRF of more
than five percent (5%) for any calendar year is discovered, then the fees and expenses of these representatives in conducting such examination
will be borne by Licensee.

5.6 **Self-audit.** Licensee will conduct an independent audit
of Sales and Royalties at least every two (2) years if Net Sales exceed five million dollars ($5,000,000) in any given calendar year.
The audit will address, at a minimum, the amount of Net Sales by or on behalf of Licensee during the audit period, the amount of funds
owed to ULRF under this Agreement, and whether the amount owed has been paid to ULRF and is reflected in Licensee's records. Licensee
will submit the auditor's report promptly to ULRF upon completion. Licensee will pay for the entire cost of the audit.

5.7 **Auditing and Review of Development Records.** ULRF reserves
the right to audit Licensee's records relating to the development of Licensed Products as required hereunder. Such requirements
for Licensee's record keeping and ULRF's audit thereof will be subject to the same procedures and restrictions set forth
in Section 5.5 for audit of financial records of Licensee.

5.8 **Late Payments.** In the event any payment due hereunder
is not made when due, the payment will accrue interest, calculated at the monthly rate of one and one-half percent (1.5%), the interest
being compounded on the last day of each calendar month. Each such payment when made will be accompanied by all interest so accrued.
Said interest and the payment and acceptance thereof will not negate or waive the right of ULRF to seek any other remedy, legal or equitable,
to which it may be entitled because of the delinquency of any payment including, but not limited to, termination of this Agreement as
provided in Article 15.

6. DEVELOPMENT AND ROYALTY REPORTS

6.1 **Development Reports.** Until the first Sale occurs in the United States, Licensee will submit
 to ULRF a semi-annual development report **("Development Report")** within sixty (60) days of each June 30 and
 December 31 following the end of such six (6) month period. Development Reports will cover Licensee's activities related to
 the development and testing of Licensed Products, including efforts related to obtaining necessary government approvals, if any, for
 marketing in the United States and foreign countries. Each Development Report will provide a sufficiently detailed summary of
 activities of Licensee and any Sublicensees so that ULRF may evaluate and determine Licensee's progress in the development of
 Licensed Products, and in meeting Licensee's diligence obligations under Article 4, and include at least the following: (a)
 summary of work completed and in progress; (b) current schedule of anticipated events and milestones, including the diligence
 Milestones under Article 4; (c) anticipated market introduction dates; (d) names and addresses of Sublicensees for any new
 Sublicenses entered into during the reporting period; (e) Sublicensees' activities during the reporting period; and (f)
 description of any Non-Royalty Sublicensing Income received by Licensee. In the Development Report immediately subsequent to the
 first Sale by Licensee or by a Sublicensee, Licensee will report the date of such first Sale.

Page 6 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

6.2 **Royalty Reports.** After the first Sale, within sixty (60)
days of each June 30 and December 31 following the end of such six (6) month period, Licensee will submit to ULRF a semi-annual royalty
report **("Royalty Report"),** accompanied by the corresponding Royalty payment as required in Exhibit B, Section 2. Each
Royalty Report will include at least the following: (a) the volume of Licensed Products Sold (if no Sales have occurred during the report
period, the Royalty Report will contain a statement to this effect); (b) gross amounts of any payments or other consideration received
in connection with Sales, (c) Net Sales pursuant to Section 1.13, and the calculation of Net Sales, including all deductions taken, so
that ULRF can confirm the calculation; (d) total Royalties due to ULRF; (e) description of any Non-Royalty Sublicensing Income received
by Licensee; and (f) names and addresses of Sublicensees for any new Sublicenses entered into during the reporting period.

6.3 **Submission of Development and Royalty Reports.** All Development
and Royalty Reports will be submitted electronically via email with reference to this Agreement (ULRF Ref. 17104-LA) to the UofL Office
of Technology Transfer service account at thinker@louisville.edu.

7. EXCLUSIONS AND NEGATIONS OF WARRANTIES, AND LIMITATION OF LIABILITY

7.1 **Negation of Warranties.** ULRF provides Licensee the rights
granted in this Agreement AS IS and WITH ALL FAULTS. ULRF makes no representations and extends no warranties of any kind, either express
or implied. Among other things, ULRF disclaims any express or implied warranty: (a) of merchantability, or of fitness for a particular
purpose; (b) of non-infringement; or (c) arising out of any course of dealing.

7.2 **Intellectual Property Disclaimers.** ULRF expressly disclaims
any warranties concerning and makes no representations: (a) regarding the validity or scope of protection of any Licensed Patent or Licensed
Copyright; or (b) that the exploitation of the Technology, Licensed Patents, or Licensed Copyrights will be successful.

7.3 **No Warranties to Third Parties.** Licensee will not make
any statements, representations or warranties or accept any liabilities or responsibilities whatsoever to or with regard to any person
or entity that are inconsistent with any disclaimer or limitation included in this Article.

7.4 **Limitation of Liability.** THE ENTIRE RISK AS TO PERFORMANCE
OF LICENSED PRODUCTS AND UNDERLYING RESEARCH IS ASSUMED BY LICENSEE OR ANY SUBLICENSEES. IN NO EVENT WILL ULRF, UOFL, INCLUDING ITS TRUSTEES,
FELLOWS, OFFICERS, EMPLOYEES, STUDENTS AND AGENTS, BE RESPONSIBLE OR LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL
OR OTHER DAMAGES WHATSOEVER, OR LOST PROFITS OR OTHER ECONOMIC LOSS OR DAMAGE WITH RESPECT TO THE PRACTICE OF THE TECHNOLOGY, THE LICENSED
PATENTS OR LICENSED COPYRIGHTS (INCLUDING MAKING, USING, SELLING, OFFERING TO SELL, OR IMPORTING LICENSED PRODUCTS) WHETHER GROUNDED
IN TORT (INCLUDING NEGLIGENCE AND PRODUCT LIABILITY), STRICT LIABILITY, CONTRACT OR OTHERWISE.
THE ABOVE LIMITATIONS ON LIABILITY APPLY EVEN THOUGH ULRF, UOFL, ITS TRUSTEES, FELLOWS, OFFICERS, EMPLOYEES, STUDENTS OR AGENTS MAY HAVE
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

Page 7 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

8. INDEMNITY AND INSURANCE

8.1 **Indemnity.** Licensee will indemnify, hold harmless, and
defend ULRF, UofL, and its trustees, fellows, officers, employees, students, and agents from and against any and all claims, suits, losses,
damage, costs, fees, and expenses (including attorneys' fees) resulting from or arising out of the exercise of the license granted
hereunder, or any Sublicense thereof, by Licensee, Affiliates or Sublicensees. This indemnification will include, but not be limited
to, any product liability.

8.2 **Insurance.** During the Term, Licensee will obtain and maintain at all times and will require
 Affiliates and Sublicensees, and any subcontractors of any of the foregoing, to obtain and maintain (a) insurance for all
 statutory workers' compensation and employers' liability requirements covering any and all employees with respect to
 activities performed under this Agreement; and (b) commercial general liability insurance, with limits of insurance not less than
 $1,000,000 per occurrence and $3,000,000 aggregate, including products liability insurance, written on an occurrence bases, from
 reputable and financially secure insurance carriers (having an AM. Best rating of A IX or above) to cover their respective
 activities. Such insurance will provide an appropriate and standard level of coverage considering the size of the company and for
 the product and industry, and will list ULRF, UofL, its trustees, fellows, officers, employees, students, and agents as additional
 insureds. Such insurance will be written to cover claims resulting from or arising out of the exercise of the licenses granted
 hereunder, or any Sublicense thereof, by Licensee, Affiliates or Sublicensees incurred, discovered, manifested, or made at any time
 during or after the expiration or termination of this Agreement. At ULRF's request, Licensee will furnish a certificate of
 insurance evidencing primary coverage, indicating that ULRF and UofL have been listed as an additional insured under commercial
 general liability, and requiring thirty (30) days prior written notice to ULRF of cancellation or material change. All such
 insurance of Licensee will be primary coverage; the insurance of ULRF will be deemed to be excess and noncontributory. ULRF will
 notify Licensee in writing of any claim brought against ULRF in respect to which ULRF intends to invoke the provisions of this
 Section. Licensee will keep ULRF informed in writing and on a current basis of Licensee's defense(s) of any known claim under
 this Section.

9. PATENT PROSECUTION AND MAINTENANCE

9.1 **Responsibility for Licensed Patents.** ULRF will prosecute
and maintain the Licensed Patents, subject to Licensee's reimbursement of ULRF's Reimbursable Costs under Section 9.2. ULRF
will have sole responsibility for retaining and instructing patent counsel, and will promptly provide Licensee with copies of all official
patent office correspondence. ULRF will seek and consider comments from Licensee prior to taking any substantive prosecution action in
any Licensed Patent, provided that if Licensee has not commented on such prosecution action prior to the deadline for filing a response
with the relevant government patent office, ULRF will be free to respond appropriately without consideration of Licensee's comments.
ULRF will use reasonable efforts to prepare or amend any patent application within the Licensed Patents to include claims reasonably
requested by Licensee to protect the Licensed Products contemplated to be Sold under this Agreement. Licensee will make all reasonable
efforts to advise ULRF and its patent counsel in order to secure the broadest patent protection possible with respect to envisioned Licensed
Products.

Page 8 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

9.2 **Reimbursable Costs.** Subject to Section 9.3, Licensee
will reimburse ULRF for all out-of-pocket costs incurred before, on, or after the Effective Date in connection with preparing, filing,
prosecuting and maintaining Licensed Patents (including, without limitation, the cost of any reexaminations, oppositions, post-grant
review, inter partes review, supplemental examinations, and other patent office administrative proceedings, and their appeals) and any
copyright registration for any Licensed Copyright, which have not been previously reimbursed to ULRF **("Reimbursable Costs").** If, however, one or more Licensed Patents and/or Licensed Copyrights are licensed to parties other than Licensee, any subsequently
incurred Reimbursable Costs will be divided equally among the licensed parties from the effective date of each subsequently granted license
agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Prior Reimbursable Costs.** Licensee will reimburse ULRF
for all Reimbursable Costs incurred prior to the Effective Date in the amount stated in Exhibit B at such time and in such manner as
stated in Exhibit B.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Ongoing Reimbursable Costs.** Licensee will reimburse ULRF for all Reimbursable Costs incurred on
or after the Effective Date within thirty (30) days of receipt by Licensee of invoice from ULRF for the same.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Advances.** ULRF at its sole discretion, may require that Licensee deposit with ULRF a reasonable
amount, as based on patent counsel's estimate or invoice, as an advance against anticipated significant Reimbursable Costs, such
as new patent application filings, maintenance fees, or annuities. Unless otherwise agreed, such funds will be applied against invoices
ULRF receives in connection with such Reimbursable Costs until the funds are depleted. Upon expiration or termination of this Agreement,
or at such time that no additional Reimbursable Costs are reasonably anticipated, the remaining balance, if any, will be returned to Licensee
at Licensee's written request, or at Licensee's election, may be credited against other amounts then due and payable to ULRF
hereunder.

9.3 **Surrender of Rights.** Licensee's obligation to pay Reimbursable Costs will continue for so
long as this Agreement remains in effect, provided that Licensee may terminate Licensee's obligations with respect to any given
patent application or patent within the Licensed Patents in any designated country upon ninety (90) days written notice to ULRF. In the
event of such notice to ULRF, ULRF will undertake to curtail applicable Reimbursable Costs reimbursable by Licensee pursuant to Section
9.2. ULRF may continue prosecution and maintenance of such patent applications or patents at ULRF's sole discretion and expense,
provided that Licensee will have no further rights thereunder.

10. CONTEST OF PATENT VALIDITY

10.1 Licensee and Sublicensees must provide ULRF at least ninety (90) days prior written notice before filing
any action that contests the validity of any Licensed Patent during the Term.

10.2 In the event Licensee, a Sublicensee, or an Affiliate files any action contesting the validity of any
Licensed Patent, the Royalty rate applicable to Sales made during the pendency of such action will be two (2) times the Royalty rate specified
in Exhibit B. Should the outcome of such contest determine that any claim of a Licensed Patent challenged is valid and would be infringed
by Licensee's or a Sublicensee's Sales if not for the license granted by this Agreement, the applicable Royalty rate for Sales
made thereafter and for the remainder of the Term will be three (3) times the Royalty rate specified in Exhibit B. In the event that Licensee,
a Sublicensee, or an Affiliate contests the validity of any Licensed Patent during the Term, Licensee agrees (and will require its Sublicensees
to agree) to pay to ULRF all royalties due under this Agreement during the period of challenge. For the sake of clarity, such amounts
will not be paid into any escrow or other account, but directly to ULRF, and will not be refunded.

11. INFRINGEMENT

11.1 **Infringement Procedure.** Each Party will promptly notify
the other Party if it believes a third party is infringing exclusively Licensed Rights in the Field of Use. During the term of this Agreement,
Licensee may have the right to institute a suit relating to the exclusively Licensed Rights against such third party as provided in Sections
11.2 through 11.6.

Page 9 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

11.2 **ULRF Suit.** ULRF will have the first right to institute
suit, and may name Licensee as a party to such suit for standing purposes. If ULRF decides to institute suit, it will notify Licensee
in writing. If Licensee does not notify ULRF in writing that it desires to jointly prosecute the suit within fifteen (15) days after
the date of the notice, Licensee will assign and hereby does assign to ULRF all rights, causes of action, and damages resulting from
the alleged infringement. ULRF will bear the entire cost of the litigation, and from any recovery or damages derived therefrom, ULRF
will first be reimbursed its out-of-pocket costs and attorney fees, and the remaining sums will be split, with seventy-five percent (75%)
of such sums going to ULRF, and twenty-five percent (25%) of such sums going to Licensee. In the event that a non-cash cross license
is awarded or a non-cash settlement is reached, both Parties agree to negotiate appropriate compensation in good faith.

11.3 **Joint Suit.** If ULRF and Licensee so agree, they may institute suit jointly. If so, they will: (a)
prosecute the suit in both their names; (b) bear the out-of-pocket costs equally; (c) share any recovery or settlement equally; and (d)
agree in a separate written document how they will exercise control over the action. In the event that a non-cash cross license is awarded
or a non-cash settlement is reached, both Parties agree to negotiate appropriate compensation in good faith

11.4 **Licensee Suit.** If ULRF elects to not pursue a suit pursuant to either of Sections 11.2 or 11.3,
Licensee may institute and prosecute a suit so long as it conforms with the requirements of this Article 11 and Licensee is diligently
developing or making Sales of Licensed Products. Licensee will diligently pursue the suit and will bear the entire cost of the litigation,
and will indemnify ULRF for any costs, expenses, and counsel fees incurred by ULRF. Licensee will keep ULRF reasonably apprised of all
developments in the suit, and will seek ULRF's input and approval on any substantive submissions or positions taken in the litigation
regarding the scope, validity and enforceability of the Licensed Patents and/or Licensed Copyrights. Licensee will not prosecute, settle
or otherwise compromise any such suit in a manner that adversely affects the interests of ULRF or UofL without ULRF's prior written
consent. ULRF may be named as a party only if: (a) Licensee's, ULRF's and UofL's respective counsel recommend that such
action is necessary in their reasonable opinion to achieve standing; (b) ULRF is not the first named party in the action; and (c) the
pleadings and any public statements about the action state that Licensee is pursuing the action and that Licensee has the right to join
ULRF as a party plaintiff thereto.

11.5 **Recovery.** If Licensee institutes suit pursuant to Section 11.4, any recovery in excess of any unrecovered
litigation costs and fees will be shared with ULRF as follows: Any recovery will be split, with seventy-five percent (75%) of such sums
going to Licensee, and twenty-five (25%) of such sums going to ULRF. In the event that a non-cash cross license is awarded or a non-cash
settlement is reached, both Parties agree to negotiate appropriate compensation to ULRF in good faith.

11.6 **Abandonment of Suit.** If either ULRF or Licensee commences a suit and thereafter intends to abandon
the suit, it will give timely notice to the other Party. The other Party may continue prosecution of the suit after ULRF and Licensee
agree on the sharing of expenses and any recovery in the suit.

12. DECLARATORY JUDGMENT

12.1 In the event a declaratory judgment action alleging invalidity or noninfringement of any Licensed Patent
or Licensed Copyright is brought against Licensee, then ULRF, at its option and sole discretion, will have the right, within thirty (30)
days after commencement of such action, to intervene and take over the sole defense of the action at its own expense.

Page 10 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

13. CONFIDENTIALITY

13.1 With respect to disclosures by one Party **("Disclosing Party")** to the other Party **("Receiving Party")** under this Agreement or under the Confidentiality Agreement identified in the above Background Section, effective
 August 5, 2016, the Receiving Party will, subject to Sections 13.2 and 13.3, keep any information identified as confidential by the
 Disclosing Party confidential using methods at least as stringent as each Party uses to protect its own confidential information. **"Confidential Information"** will include the negotiated terms of this Agreement as set forth in Exhibits B and C, Licensee's
 Development Reports, Royalty Reports, Sublicenses, the Licensed Patents, the Licensed Copyrights, information regarding any
 prior/on-going/future research or the review of such research and all information concerning them and any other information marked
 confidential or accompanied by correspondence indicating such information is exchanged in confidence between the Parties. Except as
 may be authorized in advance in writing by ULRF, Licensee will grant access to ULRF's Confidential Information only to its own
 employees or agents involved in research relating to the Technology and Licensee will require such employees to be bound by terms of
 confidentiality no less restrictive than those set forth in this Article.

13.2 The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information
disclosed hereunder except to the extent that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the information was already in the Receiving Party's possession
on a non-confidential basis prior to receipt from the Disclosing Party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the information was in the public domain by public use, general knowledge or the like, or after disclosure
hereunder, becomes general or public knowledge through no fault of the Receiving Party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) was properly obtained by the Receiving Party from a third party not under a confidentiality obligation
to the Disclosing Party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) is explicitly approved for release by written authorization of the Disclosing Party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) is independently developed by employees or agents of the Receiving Party who had no knowledge of or access
to the Confidential Information as evidenced by the Receiving Party's business records;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the information is subject to disclosure under ULRF's contract with the Kentucky Science and Technology
Corporation (KSTC Ref. 144-401-13-061; ULRF Ref. OGMB130263), under which the Technology was made or developed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) is required to be disclosed by law, regulation, or order of a court or other governmental authority of
competent jurisdiction, including an opinion issued by the Kentucky Attorney General, which carries the force of law in Kentucky open-records
cases; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) five (5) years have elapsed from the expiration of this Agreement.

13.3 ULRF will be free to release to the Creators, and to ULRF and UofL senior administrators, the terms and
conditions of this Agreement upon their request. If such release if made, ULRF will inform such individuals of the confidentiality obligations
set forth above and will request that such individuals not disclose such terms and conditions to others.

Page 11 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

14. NOTICES AND INVOICES

14.1 **Notices.** All notices required or permitted to be given
hereunder will be effective when given in writing, with reference to this Agreement and when (a) sent by email with receipt confirmed,
(b) sent by registered or certified mail, return receipt requested, or (c) by overnight courier, such as Federal Express or UPS, to the
other Party at its respective address set forth below or to such other address as one Party may designate by written notice from time
to time hereunder. Notices will be deemed effective when received.

If to Licensee: Autism Diagnostic Technologies, Inc.

Attn.: Jason Pottinger, Dir. Business Development

LPH01 – 20 Bruyeres Mews

Toronto, Ontario, M5V-0G8, Canada

Email: pottingerj@hotmail.com

If to ULRF: University of Louisville Technology Transfer

300 East Market Street, Suite 300

Louisville, KY 40202

Email: thinker@louisville.edu

Attn.: Director (with reference to ULRF Ref. 17104-LA)

14.2 **Invoices.** ULRF may submit invoices for any payments due
in electronic from via email sent to the email address supplied by Licensee from time to time. An invoice directed to the last email
address provided by Licensee to ULRF will be deemed received by Licensee when sent by ULRF.

15. TERMINATION

15.1 **End of Term.** This Agreement will expire, unless terminated earlier pursuant to this Article
 15 (Termination), without further action by the Parties, when all Licensed Rights have terminated pursuant to Article 2 (Grant of
 Rights), and all obligations due to ULRF based on the exercise of such Licensed Rights have been fulfilled.

15.2 **Termination by Licensee.** Licensee may terminate this Agreement by providing written notice to
ULRF in accordance with Section 14.1 at least ninety (90) days in advance of the effective date of termination selected by Licensee.

15.3 **Termination by ULRF.** If Licensee should violate or fail to perform any term or provision of this
Agreement, then ULRF may give written notice of such default **("Notice of Default")** to Licensee. If Licensee should
fail to repair such default within thirty (30) days of the effective date of such Notice of Default, ULRF will have the right to terminate
this Agreement by a second written notice **("Notice of Termination")** to Licensee. If a Notice of Termination is sent
to Licensee, this Agreement will automatically terminate on the effective date of such notice. Such termination will not relieve Licensee
of Licensee's obligation to pay any Royalty or fees owing at the time of such termination and will not impair any accrued rights
of ULRF. Notices given under this Section will be subject to Section 14.1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Notwithstanding Section 15.3, ULRF may terminate this Agreement
immediately upon notice to Licensee in the event of: (a) the dissolution or insolvency, by virtue of either a deficit in net worth or
the inability to pay debts as they mature, of Licensee, (b) the making of an assignment by Licensee for the benefit of its creditors,
or an offer of settlement, extension, or composition to its unsecured creditors generally, or (c) the appointment of a trustee, conservator,
receiver, or similar fiduciary for Licensee for substantially all of the assets of Licensee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Notwithstanding Sections 15.3 and 15.3(a), this Agreement will
terminate immediately and without notice from ULRF in the event of the filing of a petition for relief under the United States Bankruptcy
Code by or against Licensee as a debtor or alleged debtor.

15.4 **Consequences of Termination.** Upon termination of this Agreement for any reason, nothing herein
is to be construed to release either Party from any obligation that matured prior to the effective date of such termination. Licensee
may, however, for one (1) year following the date of termination, Sell inventoried Licensed Products, provided that Licensee pays to ULRF
Royalties thereon as required under Article 5 and submits the related reports as required under Article 6. Upon termination, Licensee
will remain obligated to provide, in the form specified in Section 6.2, an accounting for and pay Royalties earned up to the date of termination
and for the one (1) year period thereafter, as specified above, and any Annual Minimums prorated as of the date of termination based on
the number of days elapsed in the applicable License Year. Any such payments or reports due hereunder will be sent to ULRF within thirty
(30) days of termination. In the event of termination, ULRF will have no obligation to refund any royalties, fees, or other amounts paid
to ULRF under this Agreement or any other agreement between the Parties.

15.5 **Surviving Provisions.** Surviving any termination or expiration are: (a) Licensee's obligation
to pay royalties or other amounts accrued or accruable; (b) any claim of Licensee or ULRF, accrued or to accrue, because of any breach
or default by the other Party; and (c) the provisions of Articles 5, 6, 7, 8, 12, 13 and 17, Section 3.5, and any other provision that
by its nature is intended to survive.

Page 12 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

16. ASSIGNMENT

16.1 **Permitted Assignment by Licensee.** Subject to Section 16.3, Licensee may assign this Agreement to
their successor in interest as part of a Change of Control, provided that, if Licensee is in breach of any provision of this Agreement,
Licensee must obtain ULRF's prior written consent to such assignment.

16.2 **Any Other Assignment by Licensee.** Any other attempt to assign this Agreement by Licensee is null
and void.

16.3 **Conditions of Assignment.** Prior to any assignment, the following conditions must be met: (a) Licensee
must give ULRF thirty (30) days prior written notice of the assignment, including the assignee's contact information; and (b) the
assignee must agree in writing to ULRF to be bound by this Agreement.

16.4 **After the Assignment.** Upon a permitted assignment of this Agreement pursuant to this Article, the
term "Licensee" in this Agreement will mean the assignee.

17. MISCELLANEOUS

17.1 **Marking.** To the extent commercially feasible, Licensee
will mark all Licensed Products made, used, offered for Sale, imported, or Sold under this Agreement, or their containers, in accordance
with applicable patent marking laws. Licensee will also retain in the Licensed Copyrights, and in any Modifications, the proprietary
notices and legends as may be provided by ULRF from time to time and, at the request of ULRF, will promptly modify such proprietary notices
and legends to conform with ULRF's reasonable requirements.

17.2 **Use of Names and Trademarks.** Licensee will not, without the prior written consent of ULRF, identify
ULRF, UofL, or any of their affiliated entities in any promotional statement or use the name of any Creator (with the exception of any
Creators who are employed by, partners in, or consultants of Licensee) or any UofL employee or student, or any trademark, service mark,
trade name, or symbol of ULRF or UofL. Notwithstanding the foregoing or anything to the contrary herein, Licensee may state that it is
a licensee of ULRF with respect to the Licensed Patents; likewise, ULRF or UofL may state that the Licensed Patents are licensed to Licensee.

17.3 **Entire Agreement; Amendment.** This Agreement, including the attached Exhibits, constitutes the entire
agreement and the understanding of the Parties with respect to the matter contained herein, and supersedes all prior communications, representations,
or understandings, whether oral or written, between the Parties relating to the same. The Confidentiality Agreement identified in the
above Background Section, effective August 5, 2016, is hereby superseded. This Agreement may be modified only by an instrument duly executed
by authorized officials of the Parties and only if such instrument specifically states that it is an amendment to this Agreement.

17.4 **Severability.** In the event any provision of this Agreement is determined by a court of competent
jurisdiction to be invalid, illegal or unenforceable, that provision will be curtailed, limited or deleted, but only to the extent necessary
to remove such invalidity, illegality or unenforceability, and the remaining provisions are not in any way to be affected or impaired thereby.
In the event such curtailment, limitation or deletion is not allowed by relevant law or if such curtailment, limitation or deletion changes
any essential basis of the bargain set forth in this Agreement, the Parties agree to substitute a new provision as similar in effect to
the deleted provision as may be allowed by relevant law.

Page 13 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

17.5 **Interpretation.** Any reference herein to any defined term includes both the singular and the plural,
whether or not both forms are included in the reference. References to any statutes or regulations mean such statutes or regulations as
amended at the time of interpretation and include any successor legislation or regulations. All references to particular Exhibits, Articles
or Sections mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified. Any Exhibits are hereby incorporated
by reference and deemed a part of this Agreement. Unless the context otherwise requires, capitalized terms used herein will have the respective
meanings specified or referred to in Article 1, or elsewhere herein. Any words not herein defined will have their ordinary meaning.

17.6 **Waiver.** The failure of either Party to assert a right hereunder or to insist upon compliance with
any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any
such term or condition by the other Party. None of the terms and conditions of this Agreement can be waived except by the written consent
of the Party waiving compliance.

17.7 **No Agency.** The relationship between the Parties is that of independent contractors. Neither Party
will be deemed an agent of the other in connection with the exercise of any rights hereunder, nor will either Party have any right or
authority to assume or create any obligation or responsibility on behalf of the other.

17.8 **Governing Law.** This Agreement will be governed solely by the laws of the Commonwealth of Kentucky,
without applying any law that would result in the application of a different body of law; provided that questions affecting the construction
and effect of any patent will be determined by the law of the country in which the patent has been granted. The Parties agree that the
United Nations Convention on Contracts for the International Sale of Goods will not apply to this Agreement.

17.9 **Jurisdiction and Forum.** The state courts located in the Commonwealth of Kentucky will have exclusive
jurisdiction over any claim or dispute concerning or arising out of this Agreement. The Parties hereby irrevocably consent to the exclusive
jurisdiction of such courts and irrevocably waive any claim of inconvenient forum; provided that, notwithstanding the foregoing, either
Party will have the right to seek injunctive relief and the enforcement of judgments in any court of competent jurisdiction, no matter
where located.

17.10 **Compliance with Laws.** This Agreement will be subject to all United States laws and regulations
now or hereafter applicable to the subject matter of this Agreement. Licensee will comply with all applicable international, national,
state, regional, and local laws and regulations in performing its obligations hereunder and in Licensee's use, manufacture, Sale,
offer for Sale, or import of Licensed Products. Without limitation, Licensee will observe all applicable United States and foreign laws
and regulations governing the transfer to other countries of technical data related to Licensed Products, including, without limitation,
the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations (EAR). Licensee will obtain, and will require
Affiliates and Sublicensees to obtain, such written assurances regarding export and re-export of technical data (including Licensed Products
made by use of technical data) as may be required by EAR, and any similar foreign laws or regulations, and Licensee hereby gives such
written assurances as may be required under those Regulations to ULRF.

17.11 **Export Controls.** Licensee understands that ULRF and UofL are subject to United States laws and
regulations (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979) controlling the export of technical
data, computer software, laboratory prototypes, and other commodities, and ULRF's obligations to Licensee under this Agreement are
contingent on and subject to compliance with such laws and regulations. The transfer of certain technical data or commodities may require
a license from an agency of the United States Government or written assurances by Licensee or a Sublicensee that Licensee or a Sublicensee
will not export such technical data or commodities to certain foreign countries without prior approval of such agency. ULRF neither represents
that such a license will not be required nor that, if required, it will be issued.

Page 14 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

Therefore, the Parties have executed this Agreement in duplicate originals by their duly authorized officers or representatives.

---

| | |
|:---|:---|
| **UNIVERSITY OF LOUISVILLE <br> RESEARCH FOUNDATION, INC.** | **AUTISM DIAGNOSTICS TECHNOLOGIES, INC.** |
| **/s/ T. Allen Morris** | **/s/ Jason Pottinger** |
| **Authorized Representative** | **Authorized Representative** |
| **T. Allen Morris, Director** | **Jason Pottinger, Director of Business Strategy** |
| **Name and title – printed or typed** | **Name and title – printed or typed** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Date** | **01/31/ 2017** | **Date** | **01/30/2017** |

---

Attachments: Exhibit A: Licensed Patents and Licensed Copyrights

Exhibit B: Fees and Royalties

Exhibit C: Diligence Milestones

Exhibit D: Stock Issuance Agreement

Page 15 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

**EXHIBIT A – LICENSED PATENTS AND LICENSED COPYRIGHTS**

**<u>Licensed Patents:</u>**

&nbsp;&nbsp;&nbsp;&nbsp;1. U.S. Patent No. 9,230,321, "Computer Aided Diagnostic System Incorporating 3D Shape Analysis of
 the Brain for Identifying Developmental Brain Disorders," issued Jan. 5, 2016 from U.S. Patent App. No. 13/834,231 (ULRF Ref.
 11064-02), which claims priority to U.S. Provisional Patent App. No. 61/617,869, filed Mar. 30, 2012 (ULRF Ref. 11064-01, -02)

&nbsp;&nbsp;&nbsp;&nbsp;2. U.S. Patent App. No. 15/233,671, "Computer Aided Diagnostic System for Mapping of Brain
 Images," filed Jul. 29, 2016 (ULRF Ref. 13098-03), which claims priority to U.S. Provisional Patent App. No. 62/198,169,
 filed Jul. 29, 2015 (ULRF Ref. 13098-02, -03)

**<u>Licensed Copyrights:</u>**

&nbsp;&nbsp;&nbsp;&nbsp;1. U.S. Copyright Registration No. TX-520-124 for "Mesh Diagnostic Software," registered Apr.
6, 2012 (ULRF Ref. 12063-01)

&nbsp;&nbsp;&nbsp;&nbsp;2. U.S. Copyright Office Case No. 1-402120627, "Brain Image Segmentation Software," filed
Sep. 23, 2016 (ULRF Ref. 13100-02)

Page 16 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

**EXHIBIT B – FEES AND ROYALTIES**

**NOTICE:** THIS EXHIBIT B CONTAINS FINANCIAL AND COMMERCIAL INFORMATION DEEMED BUSINESS SENSITIVE AND CONFIDENTIAL. THE PARTIES AGREE NOT TO DISCLOSE THE TERMS OF THIS EXHIBIT TO ANY THIRD PARTY WITHOUT THE WRITTEN CONSENT OF THE OTHER PARTY, EXCEPT AS NECESSARY TO ENABLE THE PARTIES TO PERFORM UNDER THIS AGREEMENT OR AS MAY BE REQUIRED AND CONTEMPLATED IN ARTICLE 13 HEREOF.

1. **License Issue Fee.** In lieu of a license issue fee, Licensee will issue to ULRF shares of common
stock of Licensee as provided in Section 5.1 and in accordance with the terms and conditions of the Stock Issuance Agreement, entered
into by and between Licensee and ULRF on the Effective Date, and attached hereto as Exhibit D.

2. **Royalties.** Licensee will pay to ULRF earned royalties **("Royalties")** at the
rate of five percent (5.0%) of Net Sales for all Licensed Products Sold during the Term by Licensee, Affiliates, Sublicensees or any third
party otherwise authorized by Licensee to Sell Licensed Products. Amounts owed under this Section will be paid and reported on a semi-annual
basis, as described in Section 6.2.

3. **Non-Royalty Sublicensing Income.** With respect to any Sublicenses granted by Licensee under Article
3, Licensee will pay to ULRF thirty percent (30%) of any Non-Royalty Sublicensing Income. Amounts owed under this Section will be paid
to ULRF within thirty (30) days of Licensee's receipt of any Non-Royalty Sublicensing Income. No payments owed under this Section
will be prorated, regardless of whether or not the Sublicense is bundled with other licenses or sublicenses, without ULRF's written
consent.

4. **Annual Minimums.** If total amounts actually paid under Sections 2 and 3 of this Exhibit for any
License Year are less than the applicable minimum amount set forth in the following table (the **"Annual Minimum"),** Licensee
will pay to ULRF an amount for that License Year equal to the shortfall. Such payment will be made within sixty (60) days of the end of
the applicable License Year. If this Agreement expires or terminates for any reason during any year, the Annual Minimum for such License
Year will be reduced pro-rata.

---

| | |
|:---|:---|
| License Year(s) corresponding with calendar year(s) | Annual Minimum |
| 2020 | $25000 |
| 2021-2022 | $75000 |
| 2023 and each License Year thereafter | $150000 |

---

5. **Prior Reimbursable Costs.** Licensee will reimburse ULRF
in the amount of $34,273 for Reimbursable Costs incurred prior to the Effective Date according to the following schedule:

---

| | |
|:---|:---|
| Payment Amount | Payment Due Date |
| $2500 | Upon execution of this Agreement |
| $7929 | August 1, 2017 |
| $7929 | February 1, 2018 |
| $7930 | August 1, 2018 |
| $7985 | February 1, 2019 |

---

Page 17 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

**EXHIBIT C – DILIGENCE MILESTONES**

**NOTICE:** THIS EXHIBIT C CONTAINS COMMERCIAL AND PROPRIETARY INFORMATION DEEMED BUSINESS SENSITIVE AND CONFIDENTIAL. THE PARTIES AGREE NOT TO DISCLOSE THE TERMS OF THIS EXHIBIT TO ANY THIRD PARTY WITHOUT THE WRITTEN CONSENT OF THE OTHER PARTY, EXCEPT AS NECESSARY TO ENABLE THE PARTIES TO PERFORM UNDER THIS AGREEMENT OR AS MAY BE REQUIRED AND CONTEMPLATED IN ARTICLE 13 HEREOF.

1. Within six (6) months of the Effective Date, Licensee will provide
to ULRF documentation outlining any updates to its development plan and a timeline for obtaining any regulatory clearances required to
market and Sell Licensed Products.

2. By October 1, 2017, Licensee will obtain at least fifty thousand
dollars ($50,000) in Funds (as that term is defined in Section 1.4) to support commercial development of the Licensed Rights and/or
efforts toward obtaining regulatory clearances for Licensed Products.

3. By April 1, 2018, Licensee will complete verification and validation
of software for implementation of the Technology in a Licensed Product.

4. By October 1, 2018, Licensee will develop a beta prototype
for demonstration and regulatory purposes.

5. By April 1, 2019, Licensee and/or Sublicenees will invest a
minimum of two-hundred fifty thousand dollars ($250,000) toward commercial development of the Licensed Rights and/or efforts toward obtaining
regulatory clearances for Licensed Products.

6. By October 1, 2019, Licensee will submit an application to the
United States Food and Drug Administration ("FDA") to obtain 510(k), PMA or other clearance to market and sell Licensed
Products in the United States.

7. Within twelve (12) months of obtaining appropriate clearance
from the FDA and by no later than July 1, 2021, whichever occurs first, Licensee or a Sublicensee will make a first Sale in the United
States.

8. After the first Sale, and throughout the remainder of the Term,
Licensee or a Sublicensee will Sell at least one Licensed Product every six (6) months.

Page 18 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

**EXHIBIT D – STOCK ISSUANCE AGREEMENT**

This Stock Issuance Agreement (this "**Agreement**") is made and entered into as of the date of last signature below and is made by and between Autism Diagnostic Technologies, Inc., a Delaware corporation ("**Company**") and University of Louisville Research Foundation, Inc. ("**ULRF**"), a Kentucky 501(c)3 non-profit corporation ("**ULRF**").

This Agreement implements the terms of Section 5.1 of that certain License Agreement by and between the Company and ULRF effective as of even date herewith (the "**License Agreement**"). Capitalized terms in this Agreement will have the meanings ascribed to such terms in the License Agreement unless provided otherwise herein.

As partial consideration for the rights granted to Company under the License Agreement, Company agrees to issue certain Shares (as defined below) to ULRF. In accordance with UofL's Intellectual Property Policy, certain individuals are to receive a portion of the Shares received as consideration hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Issuance of Shares.** Pursuant to Section 5.1 of the License Agreement, the Company will, within sixty (60) days of the Effective Date, issue and deliver certificates representing a total of 4,782,609 shares of common stock in the Company (the "**Shares**"). The Company will issue the Shares granted to ULRF hereunder directly in the name of the following individuals and/or entities and in the proportions and/or amounts set forth in the following table.

---

| | | |
|:---|:---|:---|
| **CERTIFICATE REGISTERED IN THE NAME OF:** | **PERCENT OF DISTRIBUTION<br> OF TOTAL SHARES:** | **NUMBER OF<br> SHARES TO<br> BE ISSUED TO NAMED<br> INDIVIDUAL<br> OR ENTITY:** |
| University of Louisville Research Foundation, Inc. | 50.0% | 2391305 |
| Dr. Manuel F. Casanova | 12.5% | 597826 |
| Dr. Ayman S. El-Baz | 12.5% | 597826 |
| Dr. Matthew Nitzken | 12.5% | 597826 |
| Ahmed Soliman | 12.5% | 597826 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Shares will possess all rights and privileges granted to holders of common stock as provided in the Company's Certificate of incorporation filed with the Delaware Secretary of State on January 19, 2016 (the "**Certificate**"), the Company's bylaws adopted January 25, 2016, and applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Representations and Warranties of the Company.** The Company hereby represents and warrants to URLF as follows as of the date hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Organization; Good Standing; Qualification.</u> The Company is a corporation duly organized and validly existing under, and by virtue of, the law of the State of Delaware and is in good standing under such laws. The company has the requisite corporate power to own and operate its properties and assets, and to carry on its own business as presently conducted and as proposed to be conducted. The Company is in good standing and qualified to do business in a foreign corporation in Kentucky and every other jurisdiction where required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Stock</u>. The Company has 90,000,000 shares of common stock duly authorized, of which 55,000,000 are issued and outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Corporate Power</u>. The Company has all requisite legal and corporate power and authority to enter into this Agreement, to issue and transfer the Shares hereunder and to carry out and perform its obligations under the terms of this Agreement.

Page 19 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Authorization</u>. Issuance of the Shares has been duly authorized and, within sixty (60) days of the Effective Date, will be validly issued, fully paid and nonassessable, and free of any liens, encumbrances, or security interests whatsoever; provided, however, that the Shares may be subject to restrictions on transfer under state and/or federal securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Certificate; Bylaws</u>. Within forty-five days of the Effective Date, Company will provide to ULRF a true and complete copy of the Certificate, including all amendments thereto, along with a copy of its capitalization table and bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Company has the full right, power and authority to enter into this Agreement and to make the representations and warranties contained herein, and this Agreement constitutes the valid and binding obligation of the Company enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) No consent, approval or authorization of, or designation, declaration or filing with, any governmental authority or other person, firm or entity on the part of the Company is required in connection with the valid execution; delivery or performance of this Agreement by Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Representations and Certifications of ULRF.** ULRF hereby represents and certifies to the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Restricted Securities</u>. ULRF understands that the Shares are characterized as "restricted securities" under the 1933 Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under the 1933 Act and applicable regulations thereunder such securities may be resold without registration under the 1933 Act only in certain limited circumstances. In this connection, ULRF represents that ULRF is familiar with Rule 144 of the U.S. Securities and Exchange Commission (the "SEC"), as presently in effect, and understands the resale limitations imposed thereby and by the 1933 Act. ULRF understands that the Company is under no obligation to register any of the securities sold hereunder except as provided herein. ULRF understands that no public market now exists for any of the Shares and that it is uncertain whether a public market will ever exist for the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Further Limitations on Disposition.</u> Without in any way limiting the representations set forth above, ULRF further agrees not to make any disposition of all or any portion of the Shares unless and until: (i) there is then in effect a registration statement under the 1933 Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or (ii) ULRF shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition, and if requested by the Company, ULRF or its transferee shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such securities under the 1933 Act.

Notwithstanding the provisions of paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be required for any transfer of any Shares in compliance with SEC Rule 144 or Rule 144A, or any other exemption from registration under the Securities Act of 1933.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **5. Miscellaneous.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and permitted assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This Agreement constitutes the entire agreement between the Parties with respect to the Company's right to repurchase Restricted Stock, and this Agreement controls over and supersedes any prior understandings, agreements or representations by or between the Parties, written or oral between the Parties with respect to such subject matter and may not be modified except by written instrument executed by the Parties.

[Signature Page Follows]

Page 20 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

IN WITNESS WHEREOF, Company and ULRF have caused this Agreement to be executed by their duly authorized representatives as of the day and year indicated below.

---

| | |
|:---|:---|
| **UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.** | **AUTISM DIAGNOSTICS TECHNOLOGIES, INC.** |
| /s/ T. Allen Morris | /s/ Jason Pottinger |
| Authorized Representative | Authorized Representative |
| T. Allen Morris, Director | Jason Pottinger, Director of Business Strategy |
| Name and title — printed or typed | Name and title — printed or typed |

---

Date 01/31/2017 Date 01/30/2017

Page 21 of 21 ULRF Initials <u>am</u><br> Licensee Initials <u>JP</u>

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

CONSENT AND REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT

We hereby consent to the use in this Registration Statement on Form S-1 of our report dated June 18, 2025, relating to the financial statements of NeuroSpectrum Insights, Inc. (f/k/a Autism Diagnostic Technologies, Inc.) for the years ended December 31, 2024 and 2023, and to the reference to our Firm under the caption "Experts" in the Registration Statement. Our report contains an explanatory paragraph about NeuroSpectrum Insights, Inc.'s ability to continue as a going concern.

/s/ Rosenberg Rich Baker Berman, P.A.

Somerset, New Jersey

June 18, 2025

"RRBB" is the brand name under which Rosenberg Rich Baker Berman, P.A. and RRBB Advisors, LLC, and its subsidiary entities, including CFO Financial Partners LLC, provide professional services. Rosenberg Rich Baker Berman, PA. and RRBB Advisors, LLC (and its subsidiary entities) practice as an alternative practice structure in accordance with the AlCPA Code of Professional Conduct and applicable laws, regulations, and professional standards. Rosenberg Rich Baker Berman, P.A. is a licensed independent CPA firm that provides attest services to its clients, and RRBB Advisors, LLC, and its subsidiary entities provide tax and business consulting services to their clients. RRBB Advisors, LLC, and its subsidiary entities are not licensed CPA firms.

## Ex-Filing

**Exhibit 107**

**CALCULATION OF FILING FEE TABLE**

**FORM S-1**

(Form type)

**NeuroSpectrum Insights, Inc.**

(Exact name of Registrant as specified in its charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br> Type** | **Security <br> Class<br> Title** | **Fee Calculation<br> or Carry<br> Forward<br> Rule** | **Amount<br> Registered** | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Security** | **Maximum<br> Aggregate<br> Offering<br> Price** | **Fee<br> Rate** | **Amount of<br> Registration<br> Fee** |
| Fees to be Paid | Equity | common stock, par value $0.00001 per share | Rule 457(o) | (1) |  | $15000000 | $0.00015310 | $2296.50 |
|  | Total Offering Amount | Total Offering Amount | Total Offering Amount |  |  | $15000000 |  | $2296.50 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  |  |  |
|  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |  |
|  | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  |  | $2296.50 |

---

<sup>(1)</sup> The number or amount of common stock being registered which collectively shall have an aggregate initial offering price not to exceed $15,000,000, estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o).